{"Title": ["BUZZ-U.S. STOCKS ON THE MOVE-Wynn Resorts, Thermogenesis, U.S. Cruise Lines", "Regeneron Begins Human Trials of a Potential COVID-19 Treatment", "Nasdaq 100 Movers: UAL, REGN", "S&P 500 Movers: OKE, REGN", "BUZZ-U.S. STOCKS ON THE MOVE-Amazon, Uber, Moderna, Reata Pharma", "Regeneron begins human testing of COVID-19 antibody cocktail", "BUZZ-U.S. STOCKS ON THE MOVE-Regeneron Pharmaceuticals, Onconova Therapeutics, Nio Inc", "Regeneron Begins Clinical Trial Of Anti-Viral Antibody Cocktail Against COVID-19", "BUZZ-U.S. STOCKS ON THE MOVE-Wynn Resorts, Thermogenesis, U.S. Cruise Lines", "Regeneron begins human testing of COVID-19 antibody cocktail", "Sanofi To Present Strategy For Dupixent In Type 2 Inflammatory Diseases", "Healthcare group Sanofi upbeat on Dupixent opportunities", "Anti-inflammatory and cancer drugs tested in UK as possible COVID-19 therapy", "Regeneron Pharma To Present At Goldman Sachs Global Healthcare Conference; Webcast At 3:00 PM ET", "Noteworthy ETF Outflows: XBI, MRNA, REGN, IMMU", "EXPLAINER-What are antibody therapies and who is developing them for COVID-19?", "Regeneron's (REGN) Resplendent Journey From $60 To $600 In 9 Years", "Here's Why Vir Biotechnology Jumped 12% in May", "Could Gilead's COVID-19 Drug Make $7 Billion Per Year?", "AstraZeneca blood cancer drug shows signs of helping COVID-19 patients", "BUZZ-U.S. STOCKS ON THE MOVE-Genius Brands, Royal Caribbean, Sorrento", "AbbVie Enters the Race to Develop New COVID-19 Treatments", "Wednesday Sector Laggards: Healthcare, Utilities", "Is Momenta Pharmaceuticals' Stock a Buy?", "EXPLAINER-What are antibody therapies and who is developing them for COVID-19?", "Why Editas Medicine Is Now the CRISPR Stock to Really Watch", "Where Will Regeneron Be in 5 Years?", "Eli Lilly Leaps Past Regeneron's COVID-19 Treatment Candidate", "BUZZ-U.S. STOCKS ON THE MOVE-Raytheon, Planet Fitness, Lands End", "BUZZ-U.S. STOCKS ON THE MOVE-Virgin Galactic, Baozun, HollyFrontier", "BUZZ-U.S. STOCKS ON THE MOVE-Digital Ally, Marathon Patent, Aduro Biotech", "BUZZ-U.S. STOCKS ON THE MOVE-Visa, MoneyGram, Trevena, Seadrill", "Better Buy: CRISPR Therapeutics vs. Intellia", "U.S. companies issue shares at fastest rate ever, selling the rally", "BUZZ-U.S. STOCKS ON THE MOVE-Coty, Tesla, Zoom Video, Zynga", "Is Inovio Pharmaceuticals Really Just the Next Theranos?", "Eli Lilly Is Already Testing a COVID-19 Antibody Treatment in Humans", "Here's Why Intellia Therapeutics Gained as Much as 18.0% Today", "Regeneron Expands Existing Collaboration With Intellia - Quick Facts", "GRAPHIC-Take Five: Hong Kong takes centre stage", "NTLA Gains On Amended REGN Deal, GILD Reports SIMPLE Results, MYOV On Watch, NVUS Slumps", "Regeneron Pharmaceuticals Reaches Analyst Target Price", "Thursday Sector Leaders: Utilities, Healthcare", "2 Top Healthcare Stocks to Buy Right Now", "Regeneron Stock Is a Solid Long-Term Buy", "Rising Swiss rivalry as Roche and Novartis target same diseases", "Drugmaker Sanofi to raise over $11 bln via sale of Regeneron shares", "Sanofi : FDA Approves Dupixentas To Treat Moderate-to-severe Atopic Dermatitis", "Regeneron : Data On Libtayo Shows Longer Durability, Higher Complete Response Rates In Skin Cancer", "Tuesday Sector Laggards: Healthcare, Technology & Communications", "Sanofi to Sell Its 20.6% Stake in Regeneron, but Keep Their Collaboration Intact", "Notable Tuesday Option Activity: NVDA, AZO, REGN", "BUZZ-U.S. STOCKS ON THE MOVE-Alliance Data Systems, Alibaba Group, Dexcom, Can Fite Biofarma, U.S. travel firms", "Nasdaq 100 Movers: DXCM, UAL", "S&P 500 Movers: REGN, NCLH", "Stock Alert: Regeneron Pharma Down 4%", "Regeneron Announces Pricing Of Secondary Offering Of Its Stock Held By Sanofi At $515.00/shr", "BUZZ-U.S. STOCKS ON THE MOVE-Novavax, Tuesday Morning, HPE", "Regeneron to buy back $5 billion stake held by Sanofi", "U.S.' Regeneron to buy back $5 bln stake held by Sanofi", "Here's Why Editas Could Beat Intellia to a CRISPR Therapy", "Here's Why Sorrento Therapeutics Dropped 16.6% Today", "Monday Sector Laggards: Healthcare, Technology & Communications", "Why Sorrento Therapeutics Stock Is on Fire Today", "Sanofi shares down despite $13 billion Regeneron payday", "Why Gilead's Remdesivir Might Not Be the Mega-Moneymaker Some Think It Will Be", "Health Care Sector Update for 05/15/2020: OMCL,OCUL,REGN,BPMC", "3 Earnings Stocks to Buy While They Climb Above Everything Else", "Health Care Sector Update for 05/15/2020: ABT, MYO, OCUL, REGN, XLV, IBB", "Abivax Stock Soars After France Approves a Covid-19 Trial", "Notable Wednesday Option Activity: REGN, SPLK, AXP", "Wednesday Sector Leaders: Healthcare, Utilities", "Validea's Top Five Healthcare Stocks Based On Motley Fool - 5/17/2020", "XBI, MRNA, REGN, SGEN: ETF Inflow Alert", "Better Coronavirus Stock: Inovio Pharmaceuticals or Regeneron?", "6 Stocks to Buy and Hold (And 6 Picks to Avoid)", "Here's Why Adverum Biotechnologies Is Soaring Today", "Regeneron Pharmaceuticals (REGN) Q1 2020 Earnings Call Transcript", "Noteworthy Tuesday Option Activity: REGN, PTLA, W", "Wall Street rises as lockdowns ease, healthcare shares jump", "BUZZ-U.S. STOCKS ON THE MOVE-Cornerstone Building, Aerpio Pharma, J.C. Penney", "Health Care Sector Update for 05/05/2020: REGN,PTLA,GNPX,OXFD", "Regeneron Says Its COVID-19 Combo Treatment Could Be Ready for People This Fall", "The Trends are Mostly Friendly for Moderna Stock Investors", "Regeneron Posts Rapid Growth Due to Dupixent", "Tuesday Sector Leaders: Healthcare, Technology & Communications", "Wall Street jumps as healthcare shares rise, lockdowns ease", "BUZZ-U.S. STOCKS ON THE MOVE-Oil and gas stocks, banks, Tesla, tankers", "Wall Street rises as lockdowns ease, healthcare shares jump", "BUZZ-U.S. STOCKS ON THE MOVE-Tesla, banks, Pfizer, Regeneron", "BUZZ-U.S. STOCKS ON THE MOVE-Tesla, banks, Pfizer, Regeneron", "Regeneron Jumps After Earnings Beat Expectations", "Regeneron Pharma beats quarterly estimates on Eylea strength", "Regeneron Pharmaceuticals Q1 adjusted earnings Beat Estimates", "Sanofi: Libtayo Shows Clinically-Meaningful And Durable Responses In Skin Cancer", "Amgen Stock Jumps on Earnings, Covid-19 Trial Announcement", "Wall Street jumps as energy shares rise, lockdowns ease", "Health Care Sector Update for 04/29/2020: CAPR,TORC,LIVN,NVS,REGN,JNJ", "Notable Tuesday Option Activity: FFIV, GD, REGN", "10 Stocks to Buy for an Aging Population", "Better Buy: Inovio Pharmaceuticals vs. GlaxoSmithKline", "Biotech Stocks Facing FDA Decision In May 2020", "Positive Cancer Trial Results Offset a COVID-19 Flop for Regeneron and Sanofi", "BUZZ-U.S. STOCKS ON THE MOVE-Regeneron, Zoom Video, U.S. oil companies, Apple, U.S. insurers", "Here's Why Investors Should Follow Sanofi and GlaxoSmithKline's New Coronavirus Collaboration", "BUZZ-U.S. STOCKS ON THE MOVE-Tanker operators, oil and gas companies, Caterpillar", "Regeneron, Sanofi Say Kevzara Will Now Only Be Tested in Sickest COVID-19 Patients", "Nasdaq 100 Movers: REGN, TSLA", "U.S. stock futures gain as more states prepare to ease lockdown", "Regeneron, Sanofi to treat only 'critical' COVID-19 patients with arthritis drug", "Regeneron, Sanofi To Amend Trial To Enroll Only Critical COVID-19 Patients", "Regeneron, Sanofi: Libtayo Meets Primary Endpoint In Phase 3 Trial", "BUZZ-U.S. STOCKS ON THE MOVE-Kohl's, tanker operators, oil and gas companies, U.S. casinos", "ANALYSIS-Investors bet on testing, treatments for restart of U.S. economy", "ANALYSIS-Investors bet on testing, treatments for restart of U.S. economy", "While Big Pharma Tanked, Gilead Sciences and Regeneron Soared", "Does Regeneron Pharmaceuticals\u2019 Winning Streak Signal Irrational Exuberance?", "BUZZ-U.S. STOCKS ON THE MOVE-Sleep Number, Crocs, Cassava Sciences", "Noteworthy ETF Inflows: IBB, VRTX, BIIB, REGN", "Notable Friday Option Activity: SHAK, REGN, LRCX", "Regeneron, Sanofi to treat only 'critical' COVID-19 patients with arthritis drug", "BUZZ-U.S. STOCKS ON THE MOVE-Schlumberger, Biohaven Pharmaceutical, Spirit AeroSystems", "BUZZ-U.S. STOCKS ON THE MOVE-Schlumberger, Banks, Spirit AeroSystems, State Street", "BTAI On Track To Report SERENITY Data, REGN Hits All-time High, THMO On Watch", "Regeneron Pharma: FDA To Review BLA For REGN-EB3 - Quick Facts", "Stock Alert: Regeneron Touches New High", "Sanofi and GlaxoSmithKline Join Forces to Develop a Coronavirus Vaccine", "Three Reasons to Consider Buying Regeneron Stock", "BUZZ-U.S. STOCKS ON THE MOVE-Netflix, Cutera, Moderna", "Reasons for hope: the drugs, tests and tactics that may conquer coronavirus", "Wall Street Week Ahead-Health, tech, staples could shine through earnings gloom", "25 Blue Chips With Brawny Balance Sheets", "5 Biotech Stocks Winning the Coronavirus Race", "Goldman Sachs: These Are the 5 Best Stocks for an Economic Recovery", "Here's Why Regeneron\u2019s Stock Is Worth More Than Its Coronavirus Work", "Better Coronavirus Stock: Inovio vs. Regeneron", "Moderna Stock Is the Greatest Coronavirus Speculation Play", "BUZZ-U.S. STOCKS ON THE MOVE-Gap Inc, HanesBrands, Kroger, Otis Worldwide", "Could Regeneron Pharmaceuticals Be a Millionaire-Maker Stock?", "Nasdaq 100 Movers: BIDU, AAL", "BUZZ-U.S. STOCKS ON THE MOVE-Youngevity, Party City Holdco, Ellington Financial, Hexo", "Zai Lab To Commercialize REGN1979 In Oncology In Mainland China, Hong Kong", "Novavax to start human trial for novel coronavirus vaccine", "GRAPHIC-Wall St volatility raises fears of another selloff", "Why Regeneron Pharmaceuticals Shares Rose 10% in March?", "Here Are All the Companies Working on COVID-19 Vaccines, Treatments, and Testing", "Doctors embrace drug touted by Trump for COVID-19, without hard evidence it works", "Should You Buy Inovio Pharmaceuticals During the Coronavirus Market Crash?", "Better Coronavirus Stock: Novavax vs. Regeneron", "EMA Recommends Remdesivir for Treatment of COVID-19 Under Compassionate-Use Rules", "Novartis, Incyte join repurposing wave to give Jakavi a trial run in COVID-19", "Regeneron, Sanofi Announce Detailed Positive Results From Dupixent Trial", "Investors await data on coronavirus drugs as market rally builds", "Incyte to Test Its Cancer Drug Jakafi as a Treatment for COVID-19", "REGN May 22nd Options Begin Trading", "Novavax Stock Could Easily Triple in Value", "3 Big Stock Charts for Thursday: Kellogg, Regeneron Pharmaceuticals, Newmont", "Here's Why Sanofi Is An Underappreciated Coronavirus Stock", "Better Buy: Vertex Pharmaceuticals vs. Regeneron Pharmaceuticals", "Is iBio Stock Worth the Risk as Coronavirus Continues to Spread?", "Sanofi and Regeneron's Dupixent shows more encouraging results", "A Market Roadmap Shows the Stimulus Will Save the Economy", "3 Big Stock Charts for Tuesday: Abbott Laboratories, Johnson & Johnson, and Regeneron Pharmaceuticals", "Health Care Sector Update for 03/30/2020: REGN,ATHX,JNJ,BRKR", "Regeneron, Sanofi Begin COVID-19 Clinical Program Outside Of U.S.", "2 Biotech Stocks in the Hunt for New Coronavirus Drugs; Oppenheimer Weighs In", "Noteworthy ETF Outflows: RSP, REGN, GILD, AMD", "For Gilead, Its Coronavirus Treatment Is Icing on the Cake", "5 Hot Stocks for 2020 That Are Soaring While the Market Plunges", "Better Coronavirus Stock: Regeneron or Roche?", "4 Reasons Biotech Stocks Are a Buy Right Now", "Top-Notch Vaccine Technology Makes iBio Stock a Smart Bet", "Nasdaq 100 Movers: REGN, UAL", "S&P 500 Movers: KR, DRI", "3 Biotech Stocks Fighting the Coronavirus; Here\u2019s What to Expect", "Why Consider These 2 Stocks When Markets Are Crashing?", "3 Things to Know if Chloroquine Wins the COVID-19 Treatment Race", "Don\u2019t Forget About Stocks to Buy During the Coronavirus Crisis", "Why Is Everyone Talking About Regeneron?", "Why Sanofi's Coronavirus Vaccine Work Hasn't Helped Its Stock", "All the Drugs Proving Anecdotally Effective Against COVID-19, and the Companies That Make Them", "Nonprofit Group Starts Multiple COVID-19 Clinical Studies", "Better Coronavirus Stock: Inovio Pharmaceuticals or GlaxoSmithKline?", "Is It Too Late to Buy Coronavirus Biotech Stocks?", "Roche Tests Arthritis Drug Actemra for COVID-19 Pneumonia", "Don\u2019t Forget About Stocks to Buy During the Coronavirus Crisis", "Regeneron Stock Rose on COVID-19 Breakthrough", "Better Coronavirus Stock: Gilead Sciences or Regeneron Pharmaceuticals?", "Regeneron Makes Progress in Antibody Program to Treat Coronavirus Pandemic", "BNTX On Fire, QDEL's Coronavirus Test Gets FDA's EUA, CureVac Back In The News", "8 Best Performing Stocks During the 2020\u2019s Market Meltdown", "Why Regeneron Pharmaceuticals Stock Is Bolting Higher Today", "Notable Thursday Option Activity: EXPE, REGN, SBUX", "Regeneron Could Start Testing a Coronavirus Cocktail Therapy by Early Summer", "Nasdaq 100 Movers: ULTA, REGN", "Stock Alert: Regeneron Pharma Rises 10%", "Regeneron Discovers Antibodies For COVID-19 Treatment", "Regeneron and Sanofi Start Human Trials of Arthritis Drug as Possible COVID-19 Treatment", "Focus on iBio\u2019s Tech, Not Its Coronavirus Story", "Sanofi, Regeneron Begin Kevzara Clinical Trial For Severe COVID-19 - Quick Facts", "Stock Market News: Regeneron Looks to Kill Coronavirus; Churchill Downs Postpones the Derby", "Notable Wednesday Option Activity: SBUX, REGN, LYV", "3 Diverse and Critical Stocks to Watch For a Market Bottom", "Its Powerful Pipeline Shows Pfizer Stock Is Undervalued by 15%", "7 Big Pharma Companies Trump Asked to Fight the Coronavirus Outbreak", "3 Profitable Healthcare Stocks That Are Trouncing the Market During the Coronavirus Correction", "Moderna Stock\u2019s Winning Streak Seems Likely to End", "Inovio Pharmaceuticals Rapidly Becoming The Premier Coronavirus Play", "The 12 Best Low-Volatility Stocks of the Market Crash", "Why Regeneron Shares Rose 31.6% in February", "Buy Regeneron Stock for Coronavirus 2.0 and Beyond", "First Week of April 17th Options Trading For Regeneron Pharmaceuticals (REGN)", "Noteworthy Monday Option Activity: UNIT, REGN, BAC", "The 5 Best Stocks (And 5 Worst) of the Coronavirus Correction", "Here's Why Hype Around Companies Working on Coronavirus Treatments Is Overblown", "3 Small-Caps That Are Soaring Because of Coronavirus Panic", "Is iShares Nasdaq Biotechnology Index Fund a Buy?", "Stock Alert: REGN Shares Gain As Coronavirus Outbreak Intensifies", "Momentum Stocks Benefitting From Coronavirus", "Fighting The Deadly Coronavirus", "Nasdaq 100 Movers: GILD, REGN", "REGN Crosses Above Average Analyst Target", "Now That Teva Has Stabilized, Teva Stock Looks Undervalued", "A Stock That Defies Conventions & Corona - Regeneron Pharma", "Traders Are Treating Inovio Like 2018\u2019s Pot Stock Stars", "Noteworthy Friday Option Activity: PTLA, REGN, VMI", "Moderna Will Rebound, But Wait for a Dip Lower to Buy Shares", "Validea's Top Five Healthcare Stocks Based On Kenneth Fisher - 2/16/2020", "Better Buy: bluebird bio vs. Gilead Sciences", "Validea Peter Lynch Strategy Daily Upgrade Report - 2/11/2020", "Sanofi Grows Revenue by 6.8% in Fourth Quarter Boosted by Dupixent", "Regeneron Pharmaceuticals (REGN) Q4 2019 Earnings Call Transcript", "4 Top Stock Trades for Tuesday: SPY, QQQ, MSFT, REGN", "Regeneron Shares Rise on Earnings, Coronavirus Work", "What's Behind Regeneron Pharmaceuticals' Great Q4 Results", "Merck\u2019s Spinoff Plans Place a Big Bet on Cancer-Fighting Keytruda", "Regeneron Pharmaceuticals Q4 19 Earnings Conference Call At 8:00 AM ET", "Regeneron, Sanofi To Restructure Antibody Collaboration For Kevzara, Praluent", "Regeneron Pharmaceuticals Q4 adjusted earnings Beat Estimates", "Notable Monday Option Activity: REGN, UNH, ISRG", "Alnylam Beats Revenue Estimates, but Misses on Earnings", "Regeneron, Sanofi: FDA To Review SBLA For Dupixent - Quick Facts", "Noteworthy Friday Option Activity: CSII, ISRG, REGN", "Regeneron Pharmaceuticals is Now Oversold (REGN)", "A Tale of 3 Healthcare Stocks \u2013 2 to Buy, and 1 to Sell", "First Week of March 20th Options Trading For Regeneron Pharmaceuticals (REGN)", "2 Biotechs Battling Immune Diseases", "Noteworthy Friday Option Activity: SO, LH, REGN", "FDA Agrees to Review Regeneron's Dupixent for Use by Younger Children", "Regeneron Pharmaceuticals Reaches Analyst Target Price", "Nasdaq 100 Movers: ALGN, REGN", "Regeneron Pharma To Present At J.P. Morgan Conference; Webcast At 1:30 PM ET", "Eli Lilly to Boost Its Dermatology Pipeline with $1.1 Billion Dermira Acquisition", "FEX, CXO, REGN, URI: Large Inflows Detected at ETF", "Why Has Vertex Pharmaceuticals' Stock Gained 30% In The Last Quarter?", "Noteworthy Thursday Option Activity: REGN, APPN, RUN", "Thursday Sector Laggards: Healthcare, Energy", "Interesting REGN Put And Call Options For August 21st", "Noteworthy Thursday Option Activity: BLK, REGN, TMUS", "3 Biotech Stocks That Crushed It in 2019", "iShares Nasdaq Biotechnology ETF Experiences Big Outflow", "Why 2020 Should Be the Biggest Year Yet for CRISPR Gene-Editing Stocks", "Here's Why Inovio Pharmaceuticals Jumped Higher Today", "Nasdaq 100 Movers: REGN, NTES", "Why the FDA's Decision on Aimmune's Peanut Allergy Drug Is Crucial for the Company -- and Patients", "Why BridgeBio Pharma Is Currently Trading At 2x Its IPO Price", "Here's Why Dermira Stock Popped Today", "Is bluebird bio a Buy?", "Noteworthy Monday Option Activity: FCX, ALGN, REGN", "Can Cannabis 2.0 Kickstart Marijuana Stocks?", "Here's Why Apellis Pharmaceuticals Fell Today", "Celgene Gave This Tech Back to Editas Medicine, but It Could Prove Valuable", "Noteworthy Tuesday Option Activity: ISRG, LLY, REGN", "Regeneron Pharma To Present At Piper Jaffray Conference; Webcast At 8:00 AM ET", "Why Novartis's $9.7 Billion Purchase of The Medicines Company Is Bad News for Amgen", "Is Inovio Pharmaceuticals a Buy?", "Understanding Why Regeneron Pharmaceuticals' Stock Has Gained 25% In 2 Months", "Understanding Why Regeneron Pharmaceuticals' Stock Has Gained 25% In 2 Months", "Better Buy: Novavax vs. Inovio Pharmaceuticals", "A 45% Premium: Here's Why The Medicines Company Is Worth More to Novartis Than It Was to You", "Regeneron Pharma Announces Positive Phase 2 Results In Rare Blood Disorder", "Noteworthy Friday Option Activity: COST, REGN, DIS", "Thursday Sector Leaders: Energy, Healthcare", "Here\u2019s Why The Medicines Company Jumped Higher Again Today", "Here's Why The Medicines Company Moved Higher Today", "3 Biotech Stock Rockets With More Fuel in the Tank", "Regeneron Pharma To Present At Guggenheim Healthcare Forum; Webcast At 11:15 AM", "Noteworthy Thursday Option Activity: REGN, XNCR, EBIX", "Why The Medicines Company Stock Is Soaring Today", "Friday Sector Leaders: Healthcare, Technology & Communications", "Here's Why Dermira Stock Is Soaring Today", "Noteworthy Thursday Option Activity: REGN, NLSN, DLR", "December 27th Options Now Available For Regeneron Pharmaceuticals (REGN)", "3 Big Stock Charts for Thursday: Kraft Heinz, Wabtec, and Regeneron Pharmaceuticals", "Regeneron, Vyriad To Collaborate On New Oncolytic Virus Treatments For Cancer", "Regeneron Pharmaceuticals (REGN) Q3 2019 Earnings Call Transcript", "Thursday Sector Laggards: Consumer Products, Healthcare", "REGN Makes Bullish Cross Above Critical Moving Average", "Nasdaq 100 Movers: SYMC, REGN", "Health Care Sector Update for 11/05/2019: BDX, REGN, ZBH, JNJ, PFE, ABT, MRK, AMGN", "Daily Markets: Potential US-China Trade Progress Lifts Global Equities", "Why This Just Might Be the Biggest Week for CARA Stock", "Regeneron Pharma Q3 19 Earnings Conference Call At 8:30 AM ET", "Regeneron Pharmaceuticals Board Approves $1 Bln Share Buyback - Quick Facts", "Tuesday's ETF with Unusual Volume: QQEW", "Notable Thursday Option Activity: REGN, IRM, CI", "Regeneron, Sanofi: European Commission Approves New Indication For Dupixent", "2 Under-the-Radar Biotech Stocks That Could Make You Rich", "5 Top Healthcare ETFs", "First Week of REGN December 20th Options Trading", "Analysts Forecast 11% Gains Ahead For IWF", "Noteworthy Wednesday Option Activity: REGN, CVM, CI", "Regeneron Pharmaceuticals Q3 adjusted earnings Beat Estimates", "Here's Why Dermira Stock Is Rocketing Higher Today", "Are These 3 Beaten-Down Biotech Stocks Bargains Now?", "Notable Wednesday Option Activity: REGN, LMT, HON", "3 Undervalued Stocks to Buy According to Goldman Sachs", "Noteworthy Tuesday Option Activity: REGN, XNCR, DE", "3 Cancer-Fighting Drug Stocks to Buy Right Now", "Notable Tuesday Option Activity: REGN, CAT, GPC", "Is AnaptysBio a Buy?", "XBI, MRTX, SGEN, REGN: Large Inflows Detected at ETF", "Interesting REGN Put And Call Options For May 2020", "Add Up The Parts: QLD Could Be Worth $109", "Health Care Sector Update for 09/20/2019: NSPR,REGN,SNY,ALGN,ZBH,ACB,ACB.TO", "Health Care Sector Update for 09/20/2019: REGN,ALGN,ZBH,ACB", "6 September Healthcare IPOs Investors Should Take Stock Of", "Regeneron And Sanofi Say CHMP Adopts Positive Opinion For Dupixent", "The Medicines Company Is Up 161% Year to Date, but Here's a Better Way to Play the Drugmaker's Success", "Nasdaq 100 Movers: AMGN, NFLX", "S&P 500 Movers: AMGN, LB", "Regeneron Pharma To Present At Morgan Stanley Conference; Webcast At 8:10 AM ET", "Notable Friday Option Activity: WDAY, LKQ, REGN", "REGN October 11th Options Begin Trading", "Noteworthy Thursday Option Activity: SRE, REGN, MCD", "3 Biotech Stocks That Show The Good, The Bad and the Ugly Side of This Sector", "8 Biotech Stocks to Watch After the Q2 Earnings Season", "Interesting REGN Put And Call Options For October 18th", "Noteworthy Wednesday Option Activity: MS, REGN, ANTM", "5 Reasons Novartis Shareholders Aren't Shaken", "AnaptysBio Prepares for a Potential Gear Shift", "Noteworthy Wednesday Option Activity: REGN, CAT, MMM", "Regeneron Pharmaceuticals (REGN) Q2 2019 Earnings Call Transcript", "Here's Why AnaptysBio Shares Are Slipping Today", "Regeneron Pharma Q2 19 Earnings Conference Call At 8:30 AM ET", "Is Intellia Therapeutics a Buy?", "Noteworthy Tuesday Option Activity: REGN, TENB, TWOU", "Notable Tuesday Option Activity: NVDA, BA, REGN", "Look Under The Hood: QQXT Has 10% Upside", "8 More Big Pharma Events in 2019 You Don't Want to Miss", "Monday Sector Leaders: Utilities, Healthcare", "Regeneron Pharmaceuticals Reports Marked Improvement in Q2", "Nasdaq 100 Movers: FAST, NVDA", "Noteworthy Monday Option Activity: NFLX, PEP, REGN", "3 Top Biotech Stocks to Add to Your Watchlist", "Noteworthy Friday Option Activity: TTD, SHAK, REGN", "Interesting REGN Put And Call Options For August 9th", "Interesting REGN Put And Call Options For February 2020", "The 10 Biggest Biotech Stocks", "Interesting REGN Put And Call Options For August 30th", "Nasdaq 100 Movers: FAST, NVDA", "3 Drugs Under FDA Review With Blockbuster Potential", "Nasdaq 100 Movers: UAL, REGN", "S&P 500 Movers: CCL, ORCL", "Analysts Anticipate IVE To Hit $128", "Notable Thursday Option Activity: REGN, BIIB, GRMN", "Here's Why Regeneron Pharmaceuticals Tumbled 12% in May", "Here's Why AnaptysBio Shares Are Sliding Today", "Noteworthy Friday Option Activity: NVDA, TGT, REGN", "Biotech Stocks Facing FDA Decision In June 2019", "5 Growthy Biotech Stocks to Buy Despite the Scrutiny", "Friday Sector Laggards: Healthcare, Technology & Communications", "Noteworthy Thursday Option Activity: EGHT, REGN, SGMO", "Health Care Sector Update for 05/07/2019: PINC,CPRX,HSIC,REGN,SNY", "Health Care Sector Update for 05/07/2019: CPRX,HSIC,REGN,SNY", "Why Inovio Pharmaceuticals Stock Is Sinking Today", "Regeneron Pharmaceuticals Q1 19 Earnings Conference Call At 8:30 AM ET", "Regeneron Pharmaceuticals Q1 adjusted earnings Miss Estimates", "Why Are Investors Passing on Teva Pharmaceutical Industries?", "Noteworthy Thursday Option Activity: FLR, ALGN, REGN", "Can Alnylam Pharmaceuticals Stock Start Climbing Again?", "3 Things You Might Not Know About Zoetis", "5 Biotech Stocks for a Long-Lived Portfolio", "Regeneron & Sanofi: Dupixent Approved For Severe Asthma Indication In EU", "Biotech Stocks Facing FDA Decision In May 2019", "Why Investors Should Buy the Dip in MRK Stock", "This Is Why You Shouldn\u2019t Count Regeneron Stock Out", "Regeneron Pharmaceuticals Becomes Oversold (REGN)", "Is Alnylam Pharmaceuticals a Buy Now?", "Alnylam Initiates Phase III ILLUMINATE-B Study on Lumasiran", "Notable Monday Option Activity: REGN, XEC, IFF", "Sanofi: FDA Approves Praluent To Prevent Heart Attack, Stroke, Unstable Angina", "Alnylam (ALNY) Reports Phase III ENVISION Data on Givosiran", "Notable Monday Option Activity: REGN, XEC, IFF", "REGN Makes Notable Cross Below Critical Moving Average", "Friday Sector Laggards: Healthcare, Utilities", "REGN Makes Notable Cross Below Critical Moving Average", "Friday Sector Laggards: Healthcare, Utilities", "Thursday Sector Laggards: Healthcare, Energy", "Interesting REGN Put Options For May 31st", "Thursday Sector Laggards: Healthcare, Energy", "Market Close Report: NASDAQ Composite index closes at 7,964.24 up 54.96 points", "Regeneron, Alnylam Extend Collaboration for RNAi Therapeutics", "Here's Why Dermira Shot Up 62% in March", "Here's Why Dermira Shot Up 62% in March", "Regeneron To Invest $800 Mln In Alnylam; To Jointly Develop RNAi Therapeutics", "Noteworthy Friday Option Activity: REGN, T, APC", "4 Drug/Biotech Stocks Making a Mark in RNAi Therapeutics", "Better Buy: Vertex Pharmaceuticals vs. Regeneron Pharmaceuticals", "Notable Thursday Option Activity: BA, REGN, EA", "Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?", "Can Dermira Stock Keep Soaring?", "Inovio's Early/Mid-Stage Vaccine Pipeline Exhibits Growth", "Regeneron, Sanofi Get EC Nod for Label Expansion of Praluent", "After Berkshire Bought Teva Pharmaceutical Stock, Should Others Follow Suit?", "Noteworthy Friday Option Activity: REGN, T, APC", "Nasdaq 100 Movers: REGN, MELI", "S&P 500 Movers: REGN, BR", "Inovio (INO) Misses on Q4 Earnings & Revenues, Shares Down", "NASDAQ Composite Index closes up 32.97 points for the week, rising for the 3rd straight day", "Notable Wednesday Option Activity: KSU, DE, REGN", "Regeneron/Sanofi's Dupixent Gets FDA Nod for Label Expansion", "April 26th Options Now Available For Regeneron Pharmaceuticals (REGN)", "Biotech Stock Roundup: REGN Gets FDA Nod for Dupixent & Other Pipeline News", "Regeneron/Sanofi wins U.S. approval for expanded use of skin drug", "Regeneron/Sanofi skin disease drug cleared for use in U.S. teens", "PWB, PWC: Big ETF Outflows", "Regeneron (REGN) Up 0.8% Since Last Earnings Report: Can It Continue?", "Biotech Stock Roundup: BIIB to Acquire Nightstar, Other Pipeline News & More", "Noteworthy Tuesday Option Activity: RGR, KMX, REGN", "Regeneron-Sanofi Get CHMP Nod for Dupixent Label Expansion", "Sanofi's Dupixent Gets FDA Priority Status for Nasal Polyps", "Sanofi/Regeneron Disagree With Jury Verdict in Amgen's Favor", "With a Stocked War Chest, bluebird bio Presses On", "Noteworthy Monday Option Activity: QCOM, PBYI, REGN", "bluebird (BLUE) Q4 Earnings Beat Estimates, Revenues Up Y/Y", "Pfizer & Lilly's Pain Candidate Succeeds in Back Pain Study", "Validea's Top Five Healthcare Stocks Based On Martin Zweig - 2/17/2019", "3 Most Profitable Drugmakers in the S&P 500 -- Are They Buys?", "Biotech Stock Roundup: ONCE, CMTA Soar on Merger News, Other Pipeline Updates", "Biotech Stock Roundup: Regeneron Impresses in Q4, Gilead Slumps, MacroGenics Soars", "Is Regeneron Pharmaceuticals (REGN) Stock Outpacing Its Medical Peers This Year?", "Sanofi/Regeneron Cut Price of PCSK9 Inhibitor Praluent by 60%", "The Zacks Analyst Blog Highlights: Chevron, CSX, Regeneron, Capital One and Canadian National", "Sanofi (SNY) Q4 Earnings Top, Genzyme Unit Drives Sales Growth", "Notable Thursday Option Activity: WDAY, ENS, REGN", "Regeneron (REGN) Q4 Earnings and Revenues Surpass Estimates", "Notable ETF Outflow Detected - IBB, BIIB, ILMN, REGN", "Regeneron Pharmaceuticals Q4 adjusted earnings Beat Estimates", "Regeneron Pharmaceuticals Inc (REGN) Q4 2018 Earnings Conference Call Transcript", "Regeneron Q4 Earnings & Sales Beat on Strong Dupixent, Eylea", "Sanofi's Myeloma Candidate Meets Goal in Phase III Study", "Pre-Market Earnings Report for February 6, 2019 : LLY, GM, BSX, REGN, HUM, CTSH, CMI, GSK, FDC, TTWO, BIP, JEC", "3 Biotech Stocks That Pay Solid Dividends", "Regeneron (REGN) to Report Q4 Earnings: Is a Beat in Store?", "Regeneron Pharmaceuticals Q4 18 Earnings Conference Call At 8:30 AM ET", "Alexion (ALXN) to Report Q4 Earnings: What's in the Cards?", "Noteworthy Thursday Option Activity: GE, REGN, MA", "Lilly/Pfizer's Osteoarthritis Pain Drug Succeeds in 2nd Study", "3 Top Biotech Stocks to Buy Right Now", "Amgen (AMGN) to Report Q4 Earnings: What's in the Cards?", "The Zacks Analyst Blog Highlights: Celgene, Regeneron Pharmaceuticals, Amgen, Alnylam Pharmaceuticals and bluebird bio", "Is a Beat in Store for AbbVie (ABBV) This Earnings Season?", "4 Healthcare Stocks Likely to Beat Estimates in Q4", "Notable Tuesday Option Activity: TXT, REGN, MCD", "3 Healthcare Stocks Hitting 52-Week Highs: Are They Buys?", "Aerie's (AERI) Eye Care Candidate to Enter Clinical Studies", "J&J (JNJ) to Commence Pharma Q4 Earnings: What to Expect", "Notable ETF Outflow Detected - IBB, AMGN, ILMN, REGN", "Can Regeneron (REGN) Keep the Earnings Surprise Streak Alive?", "3 of the Top Big Pharma Stocks to Buy Now", "7 Best Stocks to Buy Until the Next Seismic Shift", "Biotech Stock Roundup: LOXO, CELG Gain, J.P. Morgan Healthcare Conference in Focus", "Market Leadership\u2019s Odd Couple: Wingstop and Regeneron", "Regeneron, Sanofi Restructure Immuno-Oncology Collaboration", "Sanofi to pay Regeneron $462 mln in revised immuno-oncology deal", "Sanofi to pay Regeneron $580 mln in revised immuno-oncology deal", "Drugmakers Sanofi, Regeneron restructure immuno-oncology deal", "Regeneron, Sanofi Select Two Clinical-stage Antibodies For Ongoing Collaboration", "REGN Crosses Above Average Analyst Target", "The 3 Best Stocks to Buy At the End of the Bear Market", "Stocks Seeing Further Upside After Initial Jump - U.S. Commentary", "Strong Jobs Data, Powell Comments Lead To Rally On Wall Street - U.S. Commentary", "Noteworthy Friday Option Activity: ARNC, REGN, CRM", "Regeneron Posting Strong Gain On Upgrade By Guggenheim", "Value Investors Should Buy into the Teva Stock Dip", "Biotech Stocks Made Big Progress Toward Preventing Heart Attacks in 2018", "Stocks Rallying On Strong Jobs Data, Powell Comments - U.S. Commentary", "Validea's Top Five Healthcare Stocks Based On Martin Zweig - 12/16/2018", "Nasdaq 100 Movers: COST, REGN", "The Zacks Analyst Blog Highlights: Gilead Sciences, Alexion Pharmaceuticals, Regeneron Pharmaceutical and Biogen", "Moderna Stock Ushers In the Next Wave of Biotech", "4 Biotech Stocks Investors Can Add to Their Portfolio in 2019", "Noteworthy Friday Option Activity: FB, AVGO, REGN", "Is It Too Late to Get In on This Millionaire-Maker Stock?", "3 Top Stocks After #ASH18", "S&P 500 Movers: DG, AZO", "Better Buy: Vertex Pharmaceuticals vs. Regeneron Pharmaceuticals", "10 Stocks That Could Tank, According to Morgan Stanley", "Galapagos' Osteoarthritis Candidate Gets Fast Track Status", "Noteworthy Wednesday Option Activity: PYPL, REGN, WMT", "The Implied Analyst 12-Month Target For XLV", "Why Is Regeneron (REGN) Up 2.4% Since Last Earnings Report?", "Glaxo Seeks Label Expansion of Nucala in Pediatric Patients", "Validea's Top Five Healthcare Stocks Based On Martin Zweig - 11/18/2018", "Validea's Top Five Healthcare Stocks Based On Peter Lynch - 11/18/2018", "The Zacks Analyst Blog Highlights: PetroChina, NextEra, Eni, Dr Pepper and Regeneron", "Regeneron (REGN) Rides on Eylea and Dupixent's Performance", "Biotech Stock Roundup: Gilead, Regeneron Present Data, Cocrystal Pharma Surges", "7 Best Stocks to Buy Until the Next Seismic Shift", "Pfizer Stock Has Multiple Positive Catalysts", "Wall Street Dives Deeper Ahead of Opening Bell on Veterans Day", "US Futures Cautiously Lower as Traders Pause on Veterans Day", "Inovio (INO) Q3 Loss Narrower Than Expected, Revenues Meet", "Waiting for bluebird bio to Sing at ASH", "Sanofi Eczema Drug Dupixent's sBLA Gets Priority Review", "September JOLTS Report In Spotlight", "Regeneron (REGN) Q3 Earnings and Revenues Beat Estimates", "What's in the Cards for Bayer (BAYRY) This Earnings Season?", "Regeneron Pharmaceuticals Inc (REGN) Q3 2018 Earnings Conference Call Transcript", "Will Stocks Gain After the Elections? & Earnings from CVS, LLY, HEAR", "Nasdaq 100 Movers: ATVI, KHC", "Why Regeneron (REGN) Might Surprise This Earnings Season", "5 Drug/Biotech Stocks Set to Trump Estimates in Q3 Earnings", "Pre-Market Earnings Report for November 6, 2018 : LLY, CVS, BDX, EMR, REGN, APD, TRI, ADM, ABC, TDG, BR, HSIC", "Biogen Stock Rebounds After Impressive Q3 Earnings", "Regeneron (REGN) Q3 Earnings Beat Estimates, Revenues In Line", "Eli Lilly (LLY) to Report Q3 Earnings: What's in the Cards?", "The Zacks Analyst Blog Highlights: Gilead Sciences, Amgen, Vertex Pharmaceuticals, Celgene and Regeneron Pharmaceuticals", "Regeneron (REGN) to Report Q3 Earnings: Is a Beat in Store?", "What's in the Cards for Novavax (NVAX) This Earnings Season?", "Sanofi's (SNY) Q3 Earnings and Sales Surpass Estimates", "Biotech Stock Roundup: Celgene, Amgen, Vertex Impress in Q3, DRNA Soars on LLY Deal", "What's in the Cards for AbbVie (ABBV) This Earnings Season?", "bluebird (BLUE) Q3 Loss Narrower Than Expected, Revenues Beat", "7 Rising Healthcare Stocks to Consider", "The Zacks Analyst Blog Highlights: Allergan, Regeneron Pharmaceuticals, Amgen, Alnylam Pharmaceuticals and AMAG Pharmaceuticals", "The Math Shows SPLG Can Go To $38", "5 Drug/Biotech Stocks Likely to Beat Estimates in Q3 Earnings", "Can Amgen (AMGN) Keep the Earnings Streak Alive in Q3?", "Regeneron Pharmaceuticals is Now Oversold (REGN)", "REGN Crosses Below Key Moving Average Level", "Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?", "7 Rising Healthcare Stocks to Consider", "Is a Beat in the Cards for Allergan (AGN) in Q3 Earnings?", "Biotech Stock Roundup: BIIB Tops, MACK Plunges, REGN's Asthma Drug Gets FDA Nod", "Noteworthy Wednesday Option Activity: REGN, RMD, DISH", "What's in Store for Celgene Corp. (CELG) Q3 Earnings?", "What's in Store for Anika Therapeutics (ANIK) in Q3 Earnings?", "Will Gilead (GILD) HIV Sales Offset HCV Sales Decline in Q3?", "Nasdaq 100 Movers: ALGN, XLNX", "4 Strong Stocks to Buy That Double As Big Takeover Targets", "Tuesday Sector Leaders: Healthcare, Technology & Communications", "Health Care Sector Update for 10/16/2018: REGN,SNY,PRPO,PSTI,JNJ", "5 Healthcare Stocks to Buy for Complete Portfolio Wellness", "ARWR Stock Sinks After Signing a Big Collaboration Deal", "3 Top Biotech Stocks to Buy in October", "Noteworthy Monday Option Activity: REGN, GOOG, CPB", "Regeneron's Dupixent Meets Goals in Nasal Polyps Studies", "Health Care Sector Update for 10/01/2018: TLRY,MNTA,TARO,ABBV,REGN,MYL", "Notable Friday Option Activity: EVRI, REGN, GOOG", "Is Regeneron Pharmaceuticals (REGN) Outperforming Other Medical Stocks This Year?", "Market Close Report: NASDAQ Composite Index closes above 8000; up 51.6 points at 8,041.97", "My Favorite Large-Cap Biotech Stock to Buy Now", "XBI, ICPT, SRPT, REGN: ETF Outflow Alert", "FDA Lifts Clinical Hold on Epizyme's Lead Candidate's Study", "Sanofi/Regeneron's Cemiplimab Wins FDA Nod for Skin Cancer", "Health Care Sector Update for 10/01/2018: TLRY,MNTA,TARO,ABBV,REGN,MYL", "CHMP Reconfirms Negative Opinion for Sarepta's Exondys", "Novartis Gets Positive CHMP Opinion for Drugs, Biosimilar", "FDA Confirms Positive Safety Profile of Acadia's Nuplazid", "Notable Friday Option Activity: GWW, T, REGN", "Zacks.com highlights: G-III Apparel Group, Target, Regeneron Pharmaceuticals, AMETEK and Xilinx", "The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Celgene, Sanofi and Gilead Sciences", "FDA Lifts Clinical Hold on Sarepta's DMD Gene Therapy Program", "5 Stocks Near 52-Week High With Scope for Further Upside", "Regeneron Gains on Eylea, Dupixent and Pipeline Progress", "XBI, ICPT, SRPT, REGN: Large Outflows Detected at ETF", "Regeneron-Sanofi Report Data on Dupixent in Atopic Dermatitis", "Time to Focus on Regeneron Pharmaceuticals (REGN) for Strong Earnings Growth Potential", "Notable Thursday Option Activity: REGN, UNH, FIS", "3 Top Value Stocks to Buy Right Now", "Biotech Stock Roundup: CELG, REGN Present Data, VKTX Soars on Drug's Success", "5 Stocks Near 52-Week High With Scope for Further Upside", "Regeneron Gains on Eylea, Dupixent and Pipeline Progress", "Inovio's Early/Mid-Stage Vaccine Pipeline Exhibits Growth", "Inovio Initiates Dosing in Phase I/IIa Study on MERS Vaccine", "Arrowhead Stock Is Not Done Rallying After Its 38% Jump", "IBB, GILD, CELG, REGN: Large Outflows Detected at ETF", "Noteworthy Wednesday Option Activity: TTD, REGN, EXPE", "Biotech Stock Roundup: GILD's Arthritis Drug Successful in Phase III, PRQR Soars", "Is Regeneron Pharmaceuticals (REGN) Stock Outpacing Its Medical Peers This Year?", "The Zacks Analyst Blog Highlights: Oracle, Intuit, Regeneron, Macy's and Deere", "Wednesday Sector Leaders: Energy, Healthcare", "Noteworthy Wednesday Option Activity: IT, BKNG, REGN", "Top Stock Reports for Oracle, Intuit & Regeneron Pharmaceuticals", "4 Biotech Stocks Investors Can Bet on Post Solid Q2 Earnings", "Top-Ranked Stocks That Crushed S&P 500 in Longest Bull Run", "Inovio (INO) Initiates Phase I Study on Hepatitis C Vaccine", "5 Low-Cost Biotech Stocks With High Levels of Growth", "Notable Tuesday Option Activity: C, HAIN, REGN", "Regeneron's Eylea Gets FDA Nod for Wet AMD as a 12-Week Dose", "Validea's Top Five Healthcare Stocks Based On Peter Lynch - 8/19/2018", "Nasdaq 100 Movers: AMAT, PCAR", "Regeneron, Teva Announce Positive Data on Osteoarthritis Drug", "Inovio Pharmaceuticals Initiates Dosing in HIV Vaccine Study", "Biotech Stock Roundup: Label Expansion of Regeneron's Eylea, Vertex's Kalydeco", "Health Care Sector Update for 08/16/2018: TEVA, REGN, PFE, MDT, SNY", "Health Care Sector Update for 08/16/2018: TEVA,REGN,PFE,MDT", "Regeneron's 12-Week Eylea Dose Gets CRL From FDA for Wet AMD", "Time to Focus on Regeneron Pharmaceuticals (REGN) for Strong Earnings Growth Potential", "XBI, ICPT, REGN, HRTX: Large Outflows Detected at ETF", "Notable Monday Option Activity: IGT, SYY, REGN", "Momenta (MNTA) Earnings and Revenues Lag Estimates in Q2", "Why Warren Buffett's Still Gobbling Up Shares in This Generic Drugmaker", "Sarepta (SRPT) Q2 Loss Narrows, Exondys 51 Drives Sales", "Inovio (INO) Q2 Loss Narrows, Revenues Surpass Estimates", "Nasdaq 100 Movers: MYL, QRTEA", "Biotech Stock Roundup: Regeneron Shines, BLUE Surges, ONCE Plunges", "Market Close Report: NASDAQ Composite index closes at 7,888.33 up 4.67 points", "Why Is Bluebird Bio (BLUE) Stock Gaining Today?", "Morning Movers: Intel Drops, Qualcomm Rises, Bluebird Flies", "Carl Icahn Fires Shots at Express Scripts", "Company News For Aug 3, 2018", "Regeneron Pharmaceuticals (REGN) Jumps: Stock Rises 7%", "Noteworthy Friday Option Activity: CTRL, REGN, MED", "Regeneron (REGN) Q2 Earnings Beat on Strong Dupixent Sales", "XBI, HRTX, ICPT, REGN: Large Inflows Detected at ETF", "Ophthotech (OPHT) Q2 Loss Narrows, Zimura Progress On Track", "Zoetis (ZTS) Beats on Q2 Earnings & Sales, Updates '18 View", "T-Mobile-Sprint, Pepsi CEO Departs, Jamie Dimon's Latest Wisdom, & More | Free Lunch", "Company News For Aug 3, 2018", "Why Sanofi Stock Should Run Higher Despite Mixed Earnings", "Sanofi's (SNY) Q2 Earnings Surpass Estimates, Sales Miss", "Zoetis (ZTS) Gears Up for Q2 Earnings: What's in Store?", "Regeneron (REGN) to Report Q2 Earnings: What's in the Cards?", "7 Rebounding Stocks That Are Coming Back From The Dead", "Drug Stock Q2 Earnings Releases on Aug 2: ZTS, REGN & More", "What\u2019s Next for Pfizer Stock After Being Called Out by President Trump", "Pfizer & Lilly's Pain Candidate Succeeds in Phase III Study", "Noteworthy Thursday Option Activity: IDCC, FND, REGN", "GlaxoSmithKline Is More Than Just a 5% Dividend Income Play", "Better Know Biotech: Regenxbio Inc.", "Notable Monday Option Activity: TDG, TWTR, REGN", "5 Pharmaceutical and Biotech Stocks to Consider for July", "Noteworthy Friday Option Activity: JNJ, STZ, REGN", "Bullish Two Hundred Day Moving Average Cross - REGN", "3 Big Stock Charts for Friday: Sherwin-Williams, Regeneron and Allstate", "Notable Friday Option Activity: REGN, JACK, SSYS", "Nasdaq 100 Movers: CTRP, REGN", "Market Close Report: NASDAQ Composite index closes at 7,445.09 down -116.54 points", "Amgen's Repatha Reduces Bad Cholestrol in Type II Diabetes", "Venture Capital Deals Of The Week: Tencent Bets On Online Education", "3 Top Biotech Stocks to Buy in July", "Bullish Two Hundred Day Moving Average Cross - REGN", "Notable Thursday Option Activity: AGIO, PBYI, REGN", "Biotech Stock Roundup: AXON Soars, Amgen Drugs Get FDA, EC Nod", "Should CRISPR Stock Investors Worry About Cancer?", "Alnylam Reports Positive Data on Lumasiran in Renal Disease", "The Bull Case for Regeneron Pharmaceuticals Inc Couldn\u2019t Be More Clear", "Noteworthy Friday Option Activity: GPC, KMX, REGN", "Biotech Stock Roundup: Regeneron, Celgene, Amgen Impress at ASCO", "Mylan (MYL) Gets FDA Approval for Biosimilar of Neulasta", "Why Is Regeneron Pharmaceuticals (REGN) Up 2.7% Since Its Last Earnings Report?", "REGN July 13th Options Begin Trading", "Noteworthy Wednesday Option Activity: BOX, IGT, REGN", "Is Genome Editing the Next Biotech Breakthrough?", "Biotech Stock Roundup: FDA Gives Nod to Amgen's Drugs, EU Approves Exelixis' Cabometyx", "Noteworthy Thursday Option Activity: REGN, QCOM, CME", "Amgen's (AMGN) Repatha Gains EU Nod to Include Outcomes Data", "Sanofi Eczema Drug Dupixent Succeeds in Adolescents Study", "Nasdaq 100 Movers: IDXX, MU", "Better Buy: Amgen Inc. vs. Biogen Inc.", "Will Trump's Surprise Drug Pricing Plan Boost Pharma Stocks?", "S&P 500 Movers: SYMC, REGN", "Nasdaq 100 Movers: SYMC, REGN", "Noteworthy Friday Option Activity: REGN, TROX, CB", "Why The Trade Desk, Noodles & Co., and Regeneron Pharmaceuticals Jumped Today", "Friday Sector Leaders: Utilities, Healthcare", "Notable Friday Option Activity: BKNG, HD, REGN", "Friday's ETF Movers: PJP, CIBR", "Inovio's (INO) Q1 Loss Wider than Expected, Shares Down", "Ophthotech's (OPHT) Q1 Loss Narrows Y/Y, Zimura in Focus", "Is Esperion Therapeutics Inc. a Buy on the Dip?", "Market Close Report: NASDAQ Composite index closes at 7,402.88 down -2.09 points", "Why The Trade Desk, Noodles & Co., and Regeneron Pharmaceuticals Jumped Today", "Friday Sector Leaders: Utilities, Healthcare", "Are These Disappointing Drugs Back on Track to Billions?", "This Clinical-Stage Biotech's Tackling a Huge Health Issue, but It Has to Overcome Pessimistic Investors First", "Regeneron (REGN) Q1 Earnings Top, Sales Lag, Updates View", "Pfizer Inc. Is Stuck in a Trading Range \u2013 for Now", "Regeneron (REGN) Beats on Q1 Earnings", "Oversold Conditions For Regeneron Pharmaceuticals (REGN)", "Health Care Sector Update for 05/03/2018: CAH,TDOC,REGN,AKAO", "Health Care Sector Update for 05/03/2018: TDOC,REGN,AKAO", "Biotech Stock Roundup: ALXN, VRTX Post Solid Results, GILD Disappoints in Q1", "Pre-Market Earnings Report for May 3, 2018 : BDX, CNQ, ICE, CI, BCE, REGN, PCG, K, PPL, CAH, GGP, GPN", "Is a Beat in Store for Adverum (ADVM) This Earnings Season?", "Allergan plc Stock Becomes a Buy as It Bottoms Out", "What's in the Offing for Regeneron (REGN) in Q1 Earnings?", "Notable Thursday Option Activity: PAH, REGN, ODFL", "Nasdaq 100 Movers: CHTR, EXPE", "S&P 500 Movers: CHTR, SIVB", "Friday Sector Leaders: Healthcare, Financial", "Notable Thursday Option Activity: BKNG, EVHC, REGN", "Amgen (AMGN) Earnings Beat Estimates in Q1, Revenues Up Y/Y", "First Week of June 2019 Options Trading For Regeneron Pharmaceuticals (REGN)", "AbbVie Inc. Is a Clear Value Play in Biotech Stocks", "Sanofi's (SNY) Earnings Beat Estimates in Q1, Sales Miss Mark", "Validea's Top Five Healthcare Stocks Based On Martin Zweig - 4/15/2018", "Validea's Top Five Healthcare Stocks Based On Peter Lynch - 4/15/2018", "FDA Restricts Sale of Bayer's Essure Birth Control Device", "FDA Okays Label Expansion of Pacira's Exparel's, Stock Up", "Sonoma Up on FDA Approval of Antimicrobial Post-Therapy Gel", "Emergent (EBS) Gains 86.1% in a Year's Time: Here's Why", "Novo Nordisk Obtains Licence for Sickle Cell Disease Program", "Noteworthy Tuesday Option Activity: AMWD, PYPL, REGN", "Catalyst (CPRX) Up on New Drug Application for Firdapse", "Thursday Sector Laggards: Technology & Communications, Healthcare", "Bio-Path Leukemia Combo Study Shows Positive Early Data", "Biotech Stock Roundup: EDGE Falls, ALKS Down, FDA OK's AMGN Drug Label Expansion", "Rigel (RIGL) Sinks on Failure of Mid-Stage Study on Lead Drug", "Celgene (CELG) President and COO to Step Down: What's Ahead?", "EMA Accepts Regeneron/Sanofi's application for Dupixent", "Notable Friday Option Activity: INCY, NFLX, REGN", "Sanofi's (SNY) Skin Cancer Candidate Filing Accepted in EU", "Alkermes Sinks as FDA Refuses Depression Drug Review", "Edge Therapeutics Loses Edge on Failure of Late-Stage Study", "Alnylam Falls on Pfizer's Rare Disease Drug Success", "Monday Sector Laggards: Energy, Healthcare", "Celgene (CELG) Up on Deal With bluebird For CAR-T Candidate", "BioMarin's MAA for Phenylketonuria Candidate Gains EU Nod", "Amgen's (AMGN) Xgeva Gets EU Approval for Expanded Label", "Noteworthy Thursday Option Activity: JPM, CAT, REGN", "Celgene Loses 17.8% in 3 Months: Time to Reshuffle Portfolio?", "Tread Very Carefully When Investing in AnaptysBio Inc", "Wall Street Has Given Up on These 3 Stocks, and That's a Huge Mistake", "Results Renew Optimism for Esperion Therapeutics", "Amgen's Repatha Gains CHMP Nod to Include Outcomes Data", "Exelixis Cabometyx Gets Positive CHMP Opinion in Europe", "Is Regeneron Pharmaceuticals, Inc. a Buy?", "Noteworthy Thursday Option Activity: JPM, CAT, REGN", "Expect a Slow and Steady Climb Ahead for Mylan NV", "Celgene Corporation Looks Cheap, Considering Its Potential", "Radius Health Down on Negative CHMP Opinion for Lead Drug", "Regeneron Collaborates With Alnylam to Develop NASH Treatment", "Roche's (RHHBY) Lucentis 0.3 mg PFS Receives FDA Approval", "Valeant (VRX) Stock Declines 21% YTD: What Lies Ahead?", "Roche's Tecentriq Combo Study Meets Co-Primary Endpoint", "Biotech Stock RoundUp: ALXN & ARNA Up on Study Data, PRTA Teams Up With Celgene", "Novo Nordisk Poised on Strong Pipeline Amid Competition", "Prothena Rallies on Multi-Year Collaboration With Celgene", "Ignore Trump's Pricing Rhetoric With These 5 Biotech Picks", "Regeneron Eylea Hits 24-Week Primary Endpoint in Study", "Roche Tecentriq Phase III Combo Study Meets Primary Endpoint", "Arena Pharmaceuticals (ARNA) in Focus: Stock Moves 10.7% Higher", "Health Care Sector Update for 03/19/2018: MDWD, REGN, CDTX, GERN", "3 Top Biotech Stocks to Buy Right Now", "Health Care Sector Update for 03/19/2018: CDTX,MDWD,GERN,REGN", "Health Care Sector Update for 03/19/2018: MDWD,GERN,REGN", "Validea's Top Five Healthcare Stocks Based On Martin Zweig - 3/18/2018", "Agenus (AGEN) Q4 Loss Wider Than Expected, Revenues Miss", "Alexion (ALXN) Gains On Positive Date From Lead Candidate", "Radius Health Announces Positive Data on Lead Drug Tymlos", "Catalyst (CPRX) Posts In-Line Q4 Loss, Pipeline in Progress", "Immune Design (IMDZ) Posts Narrower-Than-Expected Loss in Q4", "Inovio's (INO) Q4 Loss Narrower than Expected, Revenues Beat", "Arena Pharmaceuticals (ARNA) Q4 Earnings Beat, Sales Down Y/Y", "Solid Biosciences (SLDB) Hit by Clinical Hold on Lead Drug", "Why Intellia Therapeutics Is Plunging Today", "Epizyme (EPZM) Reports Narrower-than-Expected Loss in Q4", "Infinity (INFI) Reports Narrower-than-Expected Loss in Q4", "Biotech Stock Roundup: REGN Cuts Praluent Price, OREX to File for Bankruptcy", "IBB, AMGN, GILD, REGN: ETF Outflow Alert", "Regeneron Pharmaceuticals, Caesarstone, Qualcomm, Broadcom and Exxon Mobil highlighted as Zacks Bull and Bear of the Day", "Bull of the Day: Regeneron (REGN)", "Sarepta to Seek Rapid Approval for Second DMD Drug, Stock Up", "3 Biotech Stocks With Rising Earnings Estimates Post Q4", "Merrimack (MACK) Incurs Narrower-Than-Expected Loss in Q4", "AbbVie's Uterine Fibroids Candidate Succeeds in Phase III", "Wall Street Stays Buoyant After Uplifting February Jobs Report", "Regeneron Takes Aim at Amgen and Esperion Therapeutics", "Regeneron and Sanofi Announce Positive Data on Praluent", "Health Care Sector Update for 03/12/2018: SVRA, SRPT, ALNY, REGN, SNY, BIIB, PFE", "Pfizer Gets FDA Panel Backing for New Indication for Xeljanz", "Notable Friday Option Activity: PRTY, PAY, REGN", "Conatus (CNAT) Loss Narrower Than Expected in Q4, Sales Miss", "Aradigm Files MAA for Bronchiectasis Candidate in the EU", "How The Pieces Add Up: QQEW Targets $68", "Biotech Stock Round Up: Regeneron Submits sBLA, Biogen to Withdraw Zinbryta", "Corcept Plans Korlym Label Expansion, Pipeline in Progress", "Bristol-Myers' Opdivo gets FDA Nod for Every Four Week Dosing", "Lilly, Boehringer to Expand Jardiance Heart Failure Program", "Bayer, BASF in Talks for Vegetable Seeds Business Sell-Off", "M&A, Innovation & New Drugs to Drive Pharma Stocks", "Looking for a Growth Stock? Why It is Time to Focus on Regeneron (REGN)", "Dermira's Acne Candidate Fails in Pivotal Trials, Shares Sink", "What's in the Cards for Inovio (INO) This Earnings Season?", "Gilead Announces Positive Data on New HIV Therapy Biktarvy", "AstraZeneca's Forxiga Label Expansion Filing Accepted in EU", "Here's What Weighed on Regeneron Pharmaceuticals Inc. Down in February", "Why Clearside Biomedical Jumped Higher Today", "Spectrum (SPPI) Q4 Loss Widens Y/Y, Sales Miss, Stock Falls", "Valeant (VRX) Down on Q4 Earnings Miss, Issues Drab '18 View", "FDA Accepts Regeneron/Sanofi's Dupixent sBLA for Asthma", "Perrigo (PRGO) Surpassed Earnings in Q4, Revenues Down Y/Y", "Puma (PBYI) Q4 Loss Narrower Than Expected, Shares Down", "Radius (RDUS) Q4 Loss Wider Than Expected on Higher Expenses", "Impax (IPXL) Q4 Earnings & Revenues Miss Estimates, Fall Y/Y", "Pacira (PCRX) Posts Earnings in Q4, Revenues in Line", "Aduro (ADRO) Q4 Loss Narrower Than Expected, Revenues Miss", "Bayer (BAYRY) Q4 Earnings Beat Estimates, Sales Down Y/Y", "Endo (ENDP) Surpasses Earnings, Revenue Estimates in Q4", "IBB, REGN, VRTX, ALXN: Large Outflows Detected at ETF", "Jazz Pharmaceuticals (JAZZ) Q4 Earnings Miss, Sales Up Y/Y", "Theravance Biopharma (TBPH) Q4 Loss Wider, Sales Drop Y/Y", "AMAG Pharma (AMAG) Beats on Q4 Earnings, Misses on Revenues", "Ophthotech (OPHT) Q4 Earnings Beat, Gene Therapy in Focus", "Sarepta (SRPT) Narrows Q4 Loss, Exondys 51 Sales Impress", "Perrigo (PRGO) Postpones Q4 Earnings Results, Shares Down", "Endocyte (ECYT) Reports Wider-Than-Estimated Loss in Q4", "Is a Beat in Store for Adverum (ADVM) This Earnings Season?", "BioMarin (BMRN) Q4 Loss Wider Than Expected, Sales Beat", "Corcept's (CORT) Earnings and Sales Meet Estimates in Q4", "IBB, BIIB, CELG, REGN: ETF Inflow Alert", "Novavax (NVAX) in Focus: Stock Moves 8.3% Higher", "Mallinckrodt (MNK) Up on Earnings and Revenues Beat in Q4", "Top Research Reports for Novo Nordisk, TJX Companies & Cigna", "Notable Friday Option Activity: QCOM, REGN, WYNN", "Nasdaq 100 Movers: REGN, BIDU", "Here's What Pushed Intellia Therapeutics Inc. Up 33.7% in January", "Regeneron (REGN) Q4 Earnings & Revenues Top, Eylea Sales Grow", "iShares Nasdaq Biotechnology ETF Experiences Big Outflow", "Regeneron (REGN) Tops Q4 Earnings & Sales", "The Zacks Analyst Blog Highlights: Nordisk, TJX, Cigna, Regeneron and ArcelorMittal", "Commit To Buy Regeneron Pharmaceuticals At $200, Earn 4.5% Using Options", "Sanofi (SNY) Q4 Earnings Lag on Weak Diabetes/Vaccines Sales", "REGN vs. ALXN: Which Stock is Poised for Better Q4 Earnings?", "Here's Why AnaptysBio, Inc. Stock Surged on Wednesday", "Pre-Market Earnings Report for February 8, 2018 : PM, CVS, TMUS, BCE, REGN, TRI, YUM, ALXN, K, TSN, TU, WLTW", "10 Stocks to Ride Out the Market Storm", "Will Regeneron (REGN) Disappoint Investors in Q4 Earnings?", "Noteworthy Thursday Option Activity: REGN, TTWO, NYLD", "Noteworthy Thursday Option Activity: BBY, REGN, PX", "iShares Nasdaq Biotechnology ETF Experiences Big Outflow", "Vertex (VRTX) & Other Drug Stocks with FDA Catalysts this February", "Regeneron's Dupixent Receives MHLW Nod for Label Expansion", "Notable Tuesday Option Activity: MLM, ADBE, REGN", "Why 2017 Was a Year to Forget for Regeneron Pharmaceuticals, Inc.", "Ophthotech Begins Phase II Zimura Study in Stargardt Disease", "How The Pieces Add Up: QQQ Targets $181", "Noteworthy Thursday Option Activity: BBY, REGN, PX", "iShares Nasdaq Biotechnology ETF Experiences Big Outflow", "Notable ETF Outflow Detected - IBB, REGN, VRTX, ILMN", "Biotech Stock Roundup: Celgene to Acquire Impact, J.P. Morgan Healthcare Conference in Focus", "Regeneron, Sanofi Expand Investment in Cemiplimab & Dupilumab", "FDA Approvals Surge in 2017: Here's a Look at the Numbers", "AbbVie's Upadacitinib Gains Breakthrough Therapy Designation", "Validea Martin Zweig Strategy Daily Upgrade Report - 11/7/2018", "Why This Former Biotech Winner Is Now A Short-Sale Opportunity", "Monday Sector Laggards: Healthcare, Services", "Momenta & Mylan to Initiate Trial on Biosimilar of Eylea", "Generalists On Biotech Sidelines As Tax Reform Sweeps The U.S.", "U.S. Novel Drug Approvals Rocket Higher, But Overall Numbers Slide", "Analysts Expect XLV Will Reach $91", "3 Top Value Stocks to Buy in 2018", "Momenta Reports Positive Top-Line Data on Antibody M281", "Does Regeneron Pharma Have A Potential Blockbuster In 2018?", "Market Close Report: NASDAQ Composite index closes at 6,936.25 down -23.71 points", "Biotech Stock Roundup: Label Expansion for Exelixis's Cabometyx, FDA Nod for Spark's Gene Therapy", "Regeneron in Strategic Immuno-Oncology Collaboration With ISA", "The Zacks Analyst Blog Highlights: Disney, Kraft Heinz, Caterpillar, Humana and Regeneron", "Top Research Reports for Disney, Kraft Heinz & Caterpillar", "Beware: Price Wars For Big Pharma, Biotech Companies On Horizon", "iShares Nasdaq Biotechnology ETF Experiences Big Outflow", "Will This Drug Kick-Start Regeneron Pharmaceuticals Shares?", "Biotech Stock Roundup: ASH Data in Focus, Gilead to Buy Cell Design Labs", "Regeneron, Sanofi Report Positive Top Line Skin Cancer Data", "Regeneron's sBLA for Eylea Accepted by FDA, Action Date Set", "FDA Accepts Regeneron's Supplemental Biologics License Application for Eylea; Shares Edge Lower Pre Bell", "Regeneron (REGN) Down 8.3% Since Earnings Report: Can It Rebound?", "The Zacks Analyst Blog Highlights: Netflix, Stamps.com, Constellation Brands and Regeneron Pharmaceuticals", "Cancer Space Update: Roche, Pfizer & Regeneron Make Data Presentations", "Will This Drug Kick-Start Regeneron Pharmaceuticals Shares?", "This Double Whammy Caused Regeneron Pharmaceuticals Inc. to Fall 10% in November", "Amgen's PCSK9 Inhibitor Gets FDA Nod for Stroke Prevention", "Amgen, Regeneron Prep For Battle In 2018 Over Cholesterol Drugs", "Nasdaq 100 Movers: ULTA, MYL", "Here's What's Unusual About Regeneron Pharmaceuticals' Latest Deal", "Biotech Stock Roundup: Regeneron Down on Eylea Data, Biogen-Alkermes in MS Deal", "Notable Friday Option Activity: REGN, MON, PZZA", "How The Parts Add Up: XLV Headed For $90", "Notable Monday Option Activity: HUM, DVN, REGN", "Regeneron Dips To 7-Month Low After Drug Combo With Bayer Fails", "Regeneron Pharmaceuticals is Now Oversold (REGN)", "Lagoda Investment Management, L.P. Buys Cimarex Energy Co, Tesla Inc, T2 Biosystems Inc, Sells ...", "Noteworthy Thursday Option Activity: ULTA, REGN, SJM", "Nasdaq 100 Movers: DISCA, HAS", "Regeneron's Stock Falls as Mid-Stage Eye Disease Studies Fail", "Inovio (INO) Q3 Loss Wider Than Expected, Revenues Miss", "Ophthotech (OPHT) Q3 Earnings & Sales Beat, Zimura in Focus", "Biotech Stock Roundup: Regeneron Delivers Strong Q3 Results, Cellectis Clinical Hold Lifted", "Regeneron (REGN) Beats on Q3 Earnings & Sales, Shares Up", "Nasdaq 100 Movers: CTXS, ATVI", "S&P 500 Movers: DVA, REGN", "Regeneron Jumps After Issuing Street-Topping Revenue, Earnings", "Market Close Report: NASDAQ Composite index closes at 6,757.60 up 6.66 points", "Here's Why Regeneron Pharmaceuticals Inc. Slipped 10% in October", "Pre-Market Earnings Report for November 8, 2017 : REGN, HUM, ROK, MGM, GIB, ECA, HII, BR, SEE, VER, STWD, EGN", "Inovio (INO) Q3 Earnings: Is a Beat in Store for the Stock?", "Chart School: Using Regeneron's Five-Year Rally to Study Support", "Will Regeneron Pharma (REGN) Disappoint in Q3 Earnings?", "What's in the Cards for Adverum (ADVM) This Earnings Season?", "Sanofi (SNY) Q3 Earnings In Line, Sales Lag, Diabetes Weak", "Regeneron (REGN) Q3 Earnings Beat Estimates", "Relative Strength Alert For Regeneron Pharmaceuticals", "Amgen (AMGN) Q3 Earnings Top, Sales Decline Y/Y, Stock Falls", "Analysts See 11% Gains Ahead For QQEW", "Notable Wednesday Option Activity: AGN, REGN, BK", "Is Regeneron Pharmaceuticals, Inc. Stock a Buy?", "REGN Crosses Below Key Moving Average Level", "Nasdaq 100 Movers: CELG, PYPL", "Noteworthy Wednesday Option Activity: SEAS, TSLA, REGN", "Notable Wednesday Option Activity: AGN, REGN, ABBV", "Sanofi/Regeneron's Dupixent Succeeds in Phase II Study", "IBD Biotech Innovator Awards", "6 Top Biotech Companies In Innovation Earn Recognition In New Awards", "Regeneron Advances Science To Attack Arthritis, Eye Disease, More", "Health Care Sector Update for 10/16/2017: AIMI,REGN,SNY,EXEL,TGTX", "Why These Biotech Players Look Poised To Crush Earnings Views", "Biotech Stock Roundup: Exelixis Soars on Priority Review, FDA Panel Supports Spark Drug", "Dow's Merck Bails On Cholesterol Drug, Prodding Shares Down", "Notable Wednesday Option Activity: ABBV, AGN, REGN", "This Biotech Hit Record High; Could Undercut Regeneron In Eczema", "Regeneron and Sanofi Get Favorable Ruling Against Amgen", "Why Regeneron's Patent Win Is Worse For Amgen Than You Think", "Regeneron Pops After Judge Tosses Ban On Amgen-Rivaling Med", "Why Regeneron Pharmaceuticals Dropped 11.3% in September", "Biotech Stock Roundup: Amgen's Imlygic Data Promising, Regeneron Scores Win in PCSK9 Lawsuit", "Mallinckrodt, NeuroproteXeon Team Up for Inhalation Therapy", "Allergan's sNDA for Anti-Infective Avycaz Accepted by FDA", "Seattle Genetics' Adcetris Gets Breakthrough Therapy Status", "3 Top-Ranked Big Biotech Stocks to Buy Now", "FDA Accepts Roche's (RHHBY) Application for Adjuvant Perjeta", "Endocyte Inks Deal For Prostate Cancer Candidate, Shares Up", "Novo Nordisk's Fiasp Gets FDA Nod for Diabetes in Adults", "Biotech Stock Roundup: Endocyte Shoots up on Deal, Amgen-AbbVie Settle Humira Litigation", "Mallinckrodt, NeuroproteXeon Team Up for Inhalation Therapy", "4 Biotech Stocks (and 1 ETF) to Buy As They Bolt Higher", "Notable Monday Option Activity: TSLA, REGN, GWW", "Friday Sector Leaders: Healthcare, Consumer Products", "3 Stocks That Turned $7,000 Into $130,200", "Galapagos Pops After Eczema Drug Shows Promise Vs. Regeneron", "Infinity/ Bristol-Myers Adds TNBC Patients to Clinical Deal", "Lilly (LLY) Makes Leadership Changes to Executive Positions", "Notable Monday Option Activity: REGN, WHR, QRVO", "The Medicines Co. Continues to Focus on Pipeline Development", "Bayer (BAYRY) Focuses on Pipeline Development & Acquisitions", "Alnylam/Sanofi's RNAi Drug Meets Endpoint in Study, Stock Up", "How is the Age-Related Macular Degeneration Space Faring Now?", "5 Top Stocks With Impressive Sales Growth Worth Betting On", "Teva/Nuvelution to Speed Up Development of Austedo in US", "Abbvie/Bristol-Myers Inks Deal to Develop Therapeutic Cancer", "Alkermes' ARISTADA Shows Better Results to Treat Schizophrenia", "Pluristem's Ischemia Candidate Gets Fast Track Designation", "Zacks.com featured highlights include include Hasbro, Regeneron Pharmaceuticals, Applied Materials, Vantiv, and CBRE Group", "Glaxo's Triple Therapy COPD Inhaler Gets CHMP Nod in the EU", "5 Top Stocks with Impressive Sales Growth Worth Betting On", "Notable Monday Option Activity: JPM, NOC, REGN", "IBB, BIIB, REGN, ALXN: ETF Inflow Alert", "ProQR's Genetic Disorder Candidate Gets Orphan Drug Status", "Lilly/Incyte's Baricitinib Meets Endpoint in Eczema Study", "Glaxo's Shingles Candidate Gets Positive FDA Committee Vote", "3 High-Risk, High-Reward Naked Puts", "Alexion (ALXN) Reports Interim Results for Soliris Study", "Oversold Conditions For Regeneron Pharmaceuticals (REGN)", "Biotech Stock Roundup: Alexion to Cut Jobs, Streamline Operations, Kura Up on Cancer Data", "Regeneron's Dupixent Takes Another Step Toward Blockbuster Status", "Pfizer Xtandi Succeeds in Early Stage Prostate Cancer Study", "Achillion's HCV Partnership with J&J Terminated, Stock Falls", "AstraZeneca's Asthma Candidate Shows Promising Results", "Pfizer Lung Cancer Drug's Overall Survival Data Unfavorable", "3 Soaring Healthcare Stocks With Very Bullish News Sentiment", "5 Things Regeneron's CEO Said as the Biotech Stock Sank", "Top Ranked Momentum Stocks to Buy for September 11th", "Nasdaq 100 Movers: REGN, MELI", "Alexion to Restructure Operations, to Lower Headcount by 20%", "Roche's Ophthalmology Drug Fails to Meet Primary Endpoint", "5 Top-Ranked Biotech Stocks to Buy Right Now", "Market Close Report: NASDAQ Composite index closes at 6,432.26 up 72.07 points", "Why Equifax, Regeneron Pharmaceuticals, and AngloGold Ashanti Slumped Today", "AstraZeneca's Lung Cancer Study Data Promising, Shares Spike", "Regeneron/Sanofi's Dupixent Asthma Study Meets Endpoints", "Lilly to Cut 3,500 Jobs to Invest in New Drugs and Growth", "S&P 500 Movers: REGN, RE", "Regeneron's Cemiplimab Gains Breakthrough Therapy Status", "Noteworthy Friday Option Activity: REGN, FNHC, AXON", "4 Biotech Stocks to Improve Your Portfolio\u2019s Health", "Nasdaq 100 Movers: REGN, CERN", "AstraZeneca's COPD Candidate Duaklir Reports Positive Data", "S&P 500 Movers: LEG, MA", "REGN Crosses Above Average Analyst Target", "AbbVie's Upadacitinib Meets Primary Endpoint in Phase IIb", "Nasdaq 100 Biotechnology: Beyond Pure Tech; Still Pure Innovation", "Why Regeneron (REGN) Could Be Positioned for a Surge", "ProQR's QRX-421 Gets Orphan Drug Designation from FDA and EMA", "VIVUS Gives Rights to Alvogen in Korea for Anti-Obesity Drug", "The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Activision Blizzard, Intuit, Alexion Pharmaceuticals and Gilead Sciences", "Biotech Stocks Back in Favor: Will the Rally Continue?", "4 Biotech Stocks to Improve Your Portfolio's Health", "AbbVie Scores 2 Wins: 1 Threatens Regeneron", "Nasdaq 100 Biotechnology: Beyond Pure Tech; Still Pure Innovation", "Why Regeneron (REGN) Could Be Positioned for a Surge", "AMAG's Filing for Feraheme's Label Expansion Accepted by FDA", "Teva Austedo Gets FDA Nod for Label Expansion in Dyskinesia", "Lilly/Incyte to Re-File Baricitinib NDA Faster Than Expected", "Roche's (RHHBY) Actemra Gets FDA Nod for Label Expansion", "BioMarin's Pegvaliase BLA Granted Priority Review by the FDA", "Why Is Regeneron (REGN) Up 7.9% Since the Last Earnings Report?", "Amgen Presents New Repatha Analysis from FOURIER Study", "The Zacks Analyst Blog Highlights: Toyota Motor, NVIDIA and Regeneron", "Strength Seen in Adaptimmune Therapeutics (ADAP): Stock Soars 15.2%", "Advanced Accelerator Gets Action Date for Lutathera from FDA", "Novo Nordisk's Tresiba Gets Canadian Nod", "Kamada (KMDA) Gets FDA Approval for Rabies Vaccine", "Time for the Facts: Global Week Ahead", "5 Biotech Stocks That Are Breaking Higher", "Amgen Presents New Repatha Analysis from FOURIER Study", "Vertex's Cystic Fibrosis Combo Gets Priority Review in U.S.", "Will Endo (ENDP) Continue to Disappoint Investors in 2017?", "Pfizer's Ibrance in First-Line Combo Breast Cancer Study", "Are Glaxo's Successful New Drugs Enough to Drive Growth?", "Alkermes Initiates Rolling Submission of Depression Drug", "4 Biotech Stocks to Add to your Portfolio Post Q2 Earnings", "AstraZeneca's Faslodex Gets FDA Nod in First-Line Setting", "Why Regeneron Pharmaceuticals, Inc. (REGN) Might Be a Diamond in the Rough", "What's the Most Important Drug in Regeneron Pharmaceuticals' Pipeline?", "What Will Drive Regeneron Pharmaceuticals' Growth Higher From Here?", "Why Eylea Is Still Regeneron Pharmaceuticals' Most Important Drug", "3 Large-Cap Biotech Stocks to Scrape From the Selloff", "Pfizer's (PFE) Besponsa Gets FDA Nod with a Boxed Warning", "Is Regeneron Pharmaceuticals the Best Biotech Stock to Buy?", "Alexion's (ALXN) Soliris' Label Expansion Approved in Europe", "Why Regeneron Pharmaceuticals, Inc. (REGN) Might Be a Diamond in the Rough", "Ophthotech's Fovista Combo Regimen Disappoints in Phase III", "Biotech Stock Roundup: Regeneron Drops RSV Antibody, Gilead HIV Drug Gets Priority Review", "Regeneron's (REGN) RSV Drug Suptavumab Fails NURSERY Trial", "Spectrum (SPPI) Initiates Phase II Study for Cancer Drug", "3 Stocks That Could Make You Rich", "Regeneron vs. Alexion: Which Stock is a Better Pick Post Q2 Earnings?", "Seattle Genetics' Adcetris Granted Priority Review by FDA", "Puma (PBYI) Q2 Loss Narrower than Expected, Nerlynx in Focus", "Geron (GERN) Q2 Loss Narrows, Sales Miss Estimates, Stock Up", "Inovio (INO) Q2 Loss Narrower Than Expected, Revenues Beat", "Biotech Stock Roundup: Q2 Earnings from Regeneron, Kite & More, FibroGen Up on IPF Data", "The Zacks Analyst Blog Highlights: ExxonMobil, MasterCard, Shell, Regeneron and BP", "Ray Gerald L & Associates Ltd Buys Norfolk Southern Corp, Splunk Inc, ONEOK Inc, Sells ...", "Top Research Reports for ExxonMobil, MasterCard & Shell", "Forget Teva (TEVA), Buy These 4 Drug Stocks Instead", "Puma (PBYI) Q2 Loss Narrower than Expected, Nerlynx in Focus", "Regeneron (REGN) Q2 Earnings Beat Estimates", "Regeneron (REGN) Beats on Q2 Earnings & Sales, Raises View", "Pre-Market Earnings Report for August 3, 2017 : AGN, DUK, EPD, AET, SHPG, REGN, BDX, BCE, CTSH, ICE, ENB, CNQ", "Notable Tuesday Option Activity: CIA, REGN, TSLA", "What's in the Cards for Adverum (ADVM) this Earnings Season?", "Sanofi (SNY) Q2 Earnings In Line, Sales Lag,'17 View Raised", "Vertex Pharmaceuticals vs. Regeneron Pharmaceuticals: Which Company Reported Better Earnings", "Regeneron Pharmaceuticals Reaches Analyst Target Price", "Can Regeneron Pharma (REGN) Pull a Surprise in Q2 Earnings?", "3 Large-Cap Biotech Stocks to Buy Now", "Notable Monday Option Activity: VC, REGN, RYAM", "Tesla Moves Up In Market Cap Rank, Passing Regeneron Pharmaceuticals", "3 Big Stock Charts for Thursday: Tripadvisor Inc (TRIP), Regeneron Pharmaceuticals Inc (REGN) and Lam Research Corporation (LRCX)", "7 Stocks to Buy That Wall Street Analysts Hate", "Agree To Buy Regeneron Pharmaceuticals At $370, Earn 6.4% Using Options", "5 Top Multibagger Biotech Stocks to Buy in the 2nd Half", "BIB, BIIB, REGN, VRTX: ETF Outflow Alert", "Sanofi Versus AstraZeneca: Large Cap Pharma Stock Faceoff", "Noteworthy Thursday Option Activity: CDNS, REGN, BAC", "3 Best Fidelity Funds to Finish 2017", "Tech Takes the Lead...but for How Long?", "Thursday Sector Leaders: Healthcare, Utilities", "Apple CEO Tim Cook Blows Away Other CEOs with 2016 Salary", "BioMarin Files BLA for Phenylketonuria Candidate Pegvaliase", "Roche (RHHBY) Launches Cobas Test for Bacterial Infections", "Marinus' (MRNS) Ganaxolone Gets Orphan Drug Status in US", "Amgen's Colorectal Cancer Drug Gets FDA Nod to Expand Label", "Acorda Files NDA for Parkinson's Disease Candidate Inbrija", "Zacks.com featured highlights: Principal Financial Group, Regeneron Pharmaceuticals, Zebra Technologies, United Technologies and T. Rowe Price Group", "Apple's Tim Cook earns $145M in 2016, Tops S&P 500 CEOs", "Apple CEO Tim Cook Blows Away Other CEOs with 2016 Salary", "BioMarin Files BLA for Phenylketonuria Candidate Pegvaliase", "Robust 1H for Pharma/Biotech Sector, 3 Big Stocks to Buy", "Biotech Stock Roundup: EU Nod for Regeneron RA Drug, Portola Soars on FDA Nod", "5 Top-Ranked Stocks with Impressive Sales Growth to Buy Now", "Noteworthy Thursday Option Activity: SIG, MET, REGN", "Esperion's Combo Cholesterol Candidate Enters Phase III", "Health Care Sector Update for 06/30/2017: REGN,SNY,SKLN,CARA", "Strongbridge (SBBP) Shows Strength: Stock Moves Up 10.1%", "Neothetics' Fat Reduction Candidate Fails in Phase II Study", "5 Biomedical Stocks That Are Expected To Surge", "Agios/Celgene's Leukemia Candidate Positive in Phase I/II", "Sanofi/Regeneron's Kevzara Gets Marketing Approval in EU", "Amgen Gets Positive CHMP Opinion for Mimpara Label Expansion", "Conatus's PSC Candidate Gets Orphan Designation in the U.S.", "Teva/Xenon Nerve Pain Candidate Fails in Phase II Study", "Novartis Cardiovascular Drug Positive, NSCLC Drug Approved", "Mid-Day Market Update: Bed Bath & Beyond Drops Following Disappointing Earnings; Synchronoss Technologies Shares Surge", "Nasdaq 100 Movers: REGN, MNST", "Mid-Morning Market Update: Markets Mostly Flat; BlackBerry Sales Miss Views", "Kamada Withdraws Inhaled AAT Marketing Application in EU", "Here's Why Investors Are Glued to Vertex Pharma (VRTX) Stock", "Regeneron (REGN) Stock on Fire: What's Behind the Surge?", "Will AbbVie Outsmart Biosimilars, and Can Clovis Win the PARP Race?", "2 Key Stock Index Plays In Buy Range As Biotechs Surge Again", "Here's Why Geron (GERN) is a Good Stock to Invest in Now", "Nasdaq 100 Movers: CA, REGN", "BioDelivery Inks New Contract with CVS/Caremark, Shares Up", "Indivor's Opioid Use Disorder Drug Meets Primary Endpoint", "AveXis (AVXS) Jumps: Stock Rises 7.1%", "Strength Seen in Arena Pharmaceuticals (ARNA): Stock Up 5.4%", "Friday Sector Laggards: Services, Healthcare", "Novartis Migraine Drug Accepted, AMD Positive in Phase III", "Fresh Capital to Be Injected into Biotech Stocks: 5 Must-Buys", "Vanda Pharmaceuticals (VNDA) Worth a Look: Stock Jumps 8%", "Biotech Stock Roundup: Clovis Soars on Rubraca Data, Seattle Hit by Study Halt", "5 Biotech Stocks That Are Roaring Back to Life", "Wednesday Sector Leaders: Healthcare, Technology & Communications", "J&J-AbbVie's Imbruvica Positive in Follow-up Lymphoma Study", "If Esperion Wants to Market the Next Big Cholesterol Drug, It Will Take Strategy", "Amgen's Xgeva Myeloma Label Expansion sBLA Accepted by FDA", "Merrimack Completes Enrollment in Phase II Study for MM-141", "Nasdaq 100 Movers: LILA, REGN", "CAI International, Kroger, Broadcom, Regeneron and Vodafone Group highlighted as Zacks Bull and Bear of the Day", "Market Close Report: NASDAQ trading volume joins the top ten ranking for the year. NASDAQ Composite Index closes at 6,188.03", "Novartis Takes Aim at Regeneron Pharmaceuticals' Eylea", "Regeneron Pharmaceuticals Inc (REGN) Stock Looks Good Despite the Backdrop", "Rigel Pharmaceuticals' NDA for Tavalisse Accepted by FDA", "GlaxoSmithKline's Benlysta Positive in Continuation Trial", "A Lazy, Unfocused Summer Is Here: Global Week Ahead", "3 Biotech Trades to Diversify Your Portfolio", "Pfizer & Lilly Get Fast Track Designation for Pain Candidate", "Zacks.com featured highlights: Regeneron Pharmaceuticals, Raymond James Financial, Dollar General, Xcel Energy and Morgan Stanley", "Notable Wednesday Option Activity: ISRG, UNH, REGN", "GTx's (GTXI) Enobosarm Positive in Phase II Study; Shares Up", "Tuesday's ETF with Unusual Volume: URTH", "Lilly Plans New Outcomes Study to Expand Jardiance Label", "Sanofi/Regeneron's Praluent Cuts Bad Cholesterol in Studies", "J&J Announces EU Regulatory Approval for Actelion Deal", "Midday Update: Averages Set Record Highs After Event Risk Fades", "Regeneron (REGN) Up 7.3% Since Earnings Report: Can It Continue?", "AstraZeneca (AZN) Divests Migraine Drug Rights Beyond Japan", "Pfizer's (PFE) Tafamidis Gets Fast Track Status in the U.S.", "5 Stocks with Solid Sales Growth Catching Eyeballs", "Amgen Files for Repatha in the U.S., EU for Expanded Use", "Notable Tuesday Option Activity: KSU, REGN, MON", "Regeneron Announces Positive Data on Carcinoma Candidate", "Don't Be Rip Van Winkle: Global Week Ahead", "Why Regeneron Is Quickly Becoming My Top Biotech Stock Pick", "3 Biotech Stocks to Buy If You've Never Bought a Biotech Stock", "BioMarin's (BMRN) Brineura Approved by European Commission", "Acorda Presents Phase III Data on PD Candidate CVT-301", "Universal Display, Hewlett Packard, Regeneron Pharmaceuticals, Sangamo Therapeutics and Puma Biotechnology highlighted as Zacks Bull and Bear of the Day", "What's Behind Regeneron's Big 15% Bounce in May?", "Friday Sector Leaders: Healthcare, Industrial", "Noteworthy ETF Outflows: XBI, VRTX, EXAS, REGN", "3 Hot Biotech Stocks to Buy in June", "Teva's Migraine Candidate TEV-48125 Positive in Phase III", "Eli Lilly's (LLY) Cancer Drug Cyramza Positive in Phase III", "SDS, PBE: Big ETF Inflows", "Universal Display, Hewlett Packard, Regeneron Pharmaceuticals, Sangamo Therapeutics and Puma Biotechnology highlighted as Zacks Bull and Bear of the Day", "What's Behind Regeneron's Big 15% Bounce in May?", "Friday Sector Leaders: Healthcare, Industrial", "Will Regeneron's (REGN) Newly Approved Drugs Drive Growth?", "Sanofi (SNY) Stock Continues to Gain on Key Drug Approvals", "Noteworthy Tuesday Option Activity: ADI, REGN, WDC", "Regeneron Presents Positive Phase II Data on HoFH Candidate", "Pfizer's Trumenba Vaccine Approved by European Commission", "Theravance/Mylan Presents Phase III Data on COPD Candidate", "Biotech Stock Roundup: FDA Nod for Regeneron RA Drug, Amgen Hit by Study Data", "Sanofi/Regeneron's Kevzara Gets FDA Approval for Arthritis", "Merck Presents Phase II Data on Chronic Cough Candidate", "Merck's HIV Drug Gets Positive CHMP Opinion for Higher Dose", "Compugen (CGEN) Worth a Look: Stock Adds 10.4% in Session", "XBI, VRTX, REGN, EXAS: Large Inflows Detected at ETF", "The Zacks Analyst Blog Highlights: Regeneron, Amgen and Celgene", "Biotech Stock Roundup: Biogen Inks Deal to Boost Pipeline, Sangamo Soars on Pfizer Deal", "Bull of the Day: Regeneron (REGN)", "TransEnterix (TRXC) Reports Wider-than-Expected Loss in Q1", "Bear of the Day: AMAG Pharmaceuticals (AMAG)", "Notable Monday Option Activity: XON, REGN, NFLX", "Wsfs Capital Management, Llc Buys Regeneron Pharmaceuticals Inc, Williams Inc, BB&T Corp, ...", "Is Regeneron Pharmaceuticals Stock Still a Buy After Its Big Bounce?", "Regeneron, Nuance Communications, Waste Management, Waste Connections and Republic Services highlighted as Zacks Bull and Bear of the Day", "Biotech Stock Roundup: Biogen Inks Deal to Boost Pipeline, Sangamo Soars on Pfizer Deal", "STERIS (STE) Grapples with Headwinds: Should You Dump?", "Hologic (HOLX) Tops Q2 Earnings & Sales, Raises 2017 View", "Genomic Health (GHDX) Misses Q1 Earnings & Sales Estimates", "Dull Q1 Earnings & Tough Industry Spell Trouble for BioScrip", "Inovio (INO) Q1 Loss Narrower Than Expected, Revenues Beat", "Biotech Stock Roundup: Regeneron, BioMarin Report Q1, Kite Down on Patient Death", "Masimo (MASI) Beats on Q1 Earnings and Revenues, Guides Up", "Regeneron Pharmaceuticals (REGN) Shares March Higher, Can It Continue?", "7 Stocks to Buy Now for BIG Summer Outperformance", "Regeneron Pharmaceuticals Reaches Analyst Target Price", "Zacks Investment Ideas feature highlights: Regeneron, Edwards Lifesciences, Alexion Pharmaceuticals, Align Technology and Centene", "Go Long Regeneron Pharmaceuticals Inc (REGN) Stock at a Discount", "Nasdaq 100 Movers: TSLA, REGN", "Ophthotech (OPHT) Q1 Loss Narrower than Expected, Sales Miss", "I Still Can't Believe Gilead Sciences, Inc. Spent $14.8 Billion on Shareholder Rewards", "5 Healthcare Innovators I'm Still Buying", "Market Close Report: NASDAQ Composite index closes at 6,075.34 up 2.79 points", "Regeneron (REGN) Q1 Earnings Miss, Revenues Beat Estimates", "Thursday Sector Leaders: Healthcare, Consumer Products", "4 Biotech Stocks That Could Be Rocked and Rolled This Month", "Drug Stock Q1 Earnings Releases on May 4: ZTS, REGN & More", "Biotech Stock Roundup: Amgen, Gilead, Celgene Q1 Earnings, Sunesis Down on Vosaroxin Update", "Regeneron (REGN) Q1 Earnings Misses Estimates", "Pre-Market Earnings Report for May 4, 2017 : D, OXY, REGN, CNQ, ZTS, PPL, K, INCY, APA, CCE, WLTW, ABC", "After Gilead Earnings, Buy These Biotech Stocks", "Notable ETF Outflow Detected - BIB, BIIB, REGN, ILMN", "6 FDA Events to Watch Out for in May 2017", "5 Big Drugmakers With Important Catalysts in May", "Is Regeneron (Finally) Getting Back on Track?", "Regeneron Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish for REGN", "What's in Store for Adverum (ADVM) in Q1 Earnings?", "Nasdaq 100 Movers: BIDU, CERN", "Seattle Genetics (SGEN) Q1 Loss Widens, Sales Top Estimates", "Sanofi (SNY) Q1 Earnings Top, Sales Rise Y/Y, Shares Up", "Regeneron (REGN) to Post Q1 Earnings: What's in the Cards?", "Noteworthy Friday Option Activity: REGN, AMBC, LSI", "Friday Sector Leaders: Healthcare, Energy", "Amgen (AMGN) Q1 Earnings Top, Sales Miss, Shares Decline", "Sarepta (SRPT) Q1 Loss Narrows, Exondys 51 Sales Pick Up", "Biotech Stock Roundup: Biogen Gains on Strong Q1, NASH Data on Gilead Drug", "Agree To Buy Regeneron Pharmaceuticals At $270, Earn 7.2% Using Options", "Noteworthy Friday Option Activity: BAC, REGN, MHK", "Lilly and Incyte's Loss Is AbbVie and Regeneron's Gain", "3 Big Reasons to Be Bullish on Biotech Stocks", "Analysts Predict 11% Gains Ahead For The Holdings of IYH", "5 Reasons Why Sanofi (SNY) is a Good Stock to Buy Now", "Amgen's Q1 Results Highlight the Need for an Acquisition", "Notable Monday Option Activity: EXPE, REGN, SWFT", "3 Big Biotech Stocks With Big-Time Catalysts", "Regeneron's Evinacumab Gets Breakthrough Therapy by FDA", "REGN Makes Notable Cross Below Critical Moving Average", "4 FDA Decisions to Watch Out for in Apr 2017", "Could Pfizer Buy Esperion Therapeutics?", "Regeneron's Game-Changing New Eczema Drug Could Be a Blockbuster", "Biotech Stock Roundup: Geron Gains on Interim Data, OncoMed Slumps on Pipeline Setback", "Notable Monday Option Activity: EXPE, REGN, SWFT", "Regeneron & Sanofi's Atopic Dermatitis Drug Gets FDA Nod", "Biotech Stock Roundup: Regeneron, Tesaro Drugs Approved, Vertex Scores Big in Study", "Noteworthy Tuesday Option Activity: KMX, REGN, DRI", "3 Top Biotech Stocks to Buy in 2017", "How This Company Is Taking on Amgen", "Biotech Stock Roundup: Amgen Down on Repatha Data, Nektar Surges on Pain Results", "The 3 Best Cholesterol Drug Stocks to Buy in 2017", "Nasdaq 100 Movers: AMGN, ADBE", "S&P 500 Movers: AMGN, ADBE", "What are Sanofi's (SNY) Strengths and Challenges in 2017?", "Noteworthy ETF Outflows: IBB, BIIB, REGN, INCY", "Biotech Stock Roundup: Amgen's Data on Repatha, Catalyst Soars on Firdapse Data", "Amgen's Repatha Meets Primary Endpoint in Phase III Study", "3 Growth Stocks I'd Buy Right Now", "Amgen (AMGN): Repatha Outcomes Data Disappoint, Shares Drop", "Noteworthy Friday Option Activity: ALB, PH, REGN", "REGN Crosses Above Key Moving Average Level", "Nasdaq 100 Movers: STX, REGN", "A Trip to 8-Year Bull Run: What's Up, What's Down", "Market Close Report: NASDAQ Composite index closes at 5,838.81 up 1.26 points", "Thursday Sector Leaders: Healthcare, Utilities", "Stock Market News for March 08, 2017", "Why Amgen (AMGN) Stock Rallied After Q4 Earnings Release?", "5 FDA Decisions to Watch Out for in Mar 2017", "Analysts Expect BBH Will Reach $134", "Noteworthy Thursday Option Activity: LGND, LXRX, REGN", "Ophthotech (OPHT) Q4 Loss Wider than Expected, Sales Miss", "IBB, REGN, ILMN, ALXN: Large Outflows Detected at ETF", "Adverum (ADVM) to Post Q4 Earnings: What's in the Cards?", "Notable Thursday Option Activity: CMG, REGN, LVLT", "Better Buy: Regeneron Pharmaceuticals, Inc. vs. Novartis", "Drug Stocks Q4 Earnings Slated for Feb 16: ALXN, ZTS & More", "Amgen Looking to Broaden Leukemia Drug Blincyto's Label", "Biotech Stock Roundup: Regeneron's Praluent to Remain on Market for Now, GILD Presents HIV Data", "Bullish Two Hundred Day Moving Average Cross - REGN", "BIB, BIIB, REGN, ILMN: Large Outflows Detected at ETF", "Nasdaq 100 Movers: TMUS, TSLA", "Market Close Report: Historical high reached as NASDAQ Composite Index closes at 5,763.96.", "Why Amgen's Becoming One of My Top Dividend Stocks to Buy", "Regeneron (REGN) Misses on Q4 Earnings & Sales, View Bleak", "Regeneron (REGN) Q4 Earnings Misses Estimates", "Sanofi (SNY) Q4 Earnings In Line; Can Sell Praulent for Now", "Biotech Stock Roundup: Amgen, Gilead Report 4Q Results, ARIAD Seeks EU Nod for Brigatinib", "Regeneron (REGN) Q4 Earnings: Will the Stock Disappoint?", "Pre-Market Earnings Report for February 9, 2017 : KO, CVS, OXY, MFC, REGN, K, CMI, YUM, TU, ROP, DTE, WLTW", "7 High-Risk, High-Reward Stocks to Buy Now", "3 Beaten-Down Stocks Ready to Bounce Back", "Why Morgan Stanley, Amgen, and Tableau Software Jumped Today", "Biotech Stock Roundup: Celgene, Biogen, ABBV Post Q4 Results, Catabasis Falls on DMD Data", "Amgen, Inc. (AMGN) Q4 Earnings Preview", "SanofiRegeneron Sarilumab Approved in Canada for Arthritis", "Nasdaq 100 Movers: PCAR, MYL", "Analysts Forecast 15% Upside For The Holdings of XLV", "Amgen, Inc. (AMGN) Stock Is a Bet on Fatter Yields", "Amgen (AMGN) Q4 Earnings Top; Repatha Positive in CV Study", "Why Morgan Stanley, Amgen, and Tableau Software Jumped Today", "Lagoda Investment Management, L.P. Buys Texas Pacific Land Trust, Microsoft Corp, Coca-Cola Co, ...", "Top Biotech Stocks to Buy in 2017", "ProShares UltraPro QQQ Experiences Big Outflow", "5 Biotech Stocks You'll Want to Watch in the 1st Quarter", "Noteworthy Wednesday Option Activity: JPM, REGN, AFSI", "Key FDA Events to Watch Out for in Q1", "3 Top Biotech Stocks You Can Still Buy With the Dow at 20,000", "Stock Market News for January 11, 2017", "Should You Buy Amgen Inc. (AMGN) Stock? 3 Pros, 3 Cons", "Biotech Stock Roundup: ARIAD to be Acquired for $5.2B, Vertex Outlook Falls Short", "Notable ETF Inflow Detected - IBB, REGN, ALXN, INCY", "The Zacks Analyst Blog Highlights: Clovis Oncology, Pfizer, Roche's, Sanofi and Regeneron Pharmaceuticals", "Amgen Inks Multiple Deals, Offers Update on Repatha Lawsuit", "Biotech Resolutions: More Innovation, Better Execution, and Fewer Price Hikes", "Why Regeneron Pharmaceuticals, Inc. Stock Slipped 32.4% in 2016", "Company News for January 09, 2017", "The FDA Approved Fewer Drugs in 2016: Here's Why", "2 Top Stocks in Biotech", "The 10 Worst Stocks in the Nasdaq in 2016", "The 3 Best Mutual Funds for a January Correction", "Noteworthy Monday Option Activity: REGN, GOOG, ANTM", "Why Biotech Titans Are Clashing Over Cholesterol", "Nasdaq 100 Movers: VOD, INCY", "Better Buy: Regeneron Pharmaceuticals, Inc. vs. Pfizer", "Nasdaq 100 Movers: REGN, AMGN", "S&P 500 Movers: REGN, AMGN", "Health Care Sector Update for 01/06/2017: MDCO, SNY, REGN, JNJ, PFE, ABT, MRK, AMGN", "Pre-Market Most Active for Jan 6, 2017 : JCP, NOK, TEVA, BAC, SUM, FCAU, TLT, TVIX, OREX, QQQ, XIV, REGN", "Amgen's Repatha Wins Over Sanofi & Regeneron's Praluent", "Why Regeneron Pharmaceuticals, Sears Holdings, and Shake Shack Slumped Today", "Top Stocks to Buy in 2017", "Roche's (RHHBY) Lucentis Gets FDA Nod for Fifth Indication", "Healthcare Stocks to Buy for 2017: Less Risky, More Risky, and Most Risky", "3 Stocks to Watch on Wednesday: Tesla Motors Inc (TSLA), Agile Therapeutics Inc (AGRX) and Regeneron Pharmaceuticals Inc (REGN)", "Health Care Sector Update for 01/04/2017: SNY,AMGN,REGN,CBAY,AGRX", "Biotech Stocks: What to Watch in 2017", "Notable Friday Option Activity: FEYE, REGN, FDX", "Regeneron vs. Vertex: Which Stock is a Better Pick?", "Market Close Report: Historical high reached as NASDAQ Composite Index closes at 5,521.06.", "The Zacks Analyst Blog Highlights: Alexion Pharmaceuticals, Celgene, Incyte, Eli Lilly, Regeneron Pharmaceuticals and Ophthotech", "Stock Market News for December 27, 2016", "Forget Alexion (ALXN), Buy These 3 Biotech Stocks Instead", "Bad News Bashes Biotech Investors... Again", "5 Steps To Buying Biotech Stocks", "Fovista Flops: What's Next?", "Noteworthy ETF Inflows: IBB, REGN, MYL, ALXN", "4 Biotech Stocks with Bright Prospects in 2017", "7 Top Stocks We're Excited About Headed Into 2017", "7 Stocks to Buy with Impressive Interest Coverage Ratio", "4 Growth Stocks to Buy Amid Obamacare Repeal Talks", "The Zacks Analyst Blog Highlights: Celgene, Regeneron Pharmaceuticals, Ophthotech and Exelixis", "Biotech Stock Roundup: Ophthotech Slumps on Fovista Results, Achaogen Skyrockets on Data", "Ophthotech Hits 52-Week Low on Unfavorable Fovista Data", "3 Great Stocks to Beat the Biotech Blues", "Zacks.com featured highlights: EnerSys, Monarch Casino & Resort, Grand Canyon Education, Ingredion and Regeneron Pharmaceuticals", "REGN Crosses Above Key Moving Average Level", "Nasdaq 100 Movers: ALXN, REGN", "S&P 500 Movers: ALXN, REGN", "Market Close Report: NASDAQ Composite index closes at 5,412.54 down -31.96 points", "Monday's ETF with Unusual Volume: SPYG", "Verizon Communications Inc. (VZ) Stock Is a Keeper", "The Boost in Basic Materials Is Just the Beginning", "Regeneron Pharmaceuticals Inc (REGN) Stock Gains on Opthotech\u2019s Loss", "Cohen's Point72 Bets Big Ahead of Ophthotech Corp. Trial Results", "Should Biotech Investors Worry About Donald Trump?", "The Zacks Analyst Blog Highlights: Booz Allen Hamilton Holding, McDonald's, Regions Financial and Regeneron Pharmaceuticals", "Play the Trump Factor with these 4 Large-Cap Stocks", "Buy 7 Stocks with Impressive Interest Coverage Ratio", "5 Top Performing Biotechnology Stocks of November", "NVIDIA, Sotheby's Holdings, Celgene, Regeneron Pharmaceuticals and Sanofi highlighted as Zacks Bull and Bear of the Day", "Think Sanofi SA (ADR) (SNY) Stock When You Think Big Pharma", "Biotech Stock Roundup: Acorda Stops Ampyra PSWD Development, CRL for Spectrum's Qapzola", "3 Biotechs That Don't Pay Dividends -- but Could", "Attention, Biotech Investors: Black Friday Is Already Here", "Buy Regeneron Pharmaceuticals Inc (REGN) Now, Don\u2019t Fold", "Regeneron/Sanofi's Praluent CV Outcomes Study to Continue", "Sanofi/Regeneron Present Sarilumab Data at ACR Meeting", "Aegerion's Juxtapid Gets Pricing Authorization in Japan", "Celgene vs. Regeneron: Which Stock is a Better Pick?", "Nasdaq 100 Movers: CSCO, NTAP", "Mid-Morning Market Update: Markets Edge Higher; Wal-Mart Posts Mixed Q3 Results", "Biotech Stock Roundup: Biotech Stocks Soar on Election Results, Gilead HBV Drug Approved", "IBB, REGN, ALXN, VRTX: ETF Inflow Alert", "Market Close Report: NASDAQ Composite index closes at 5,275.62 up 57.22 points", "Notable Monday Option Activity: PBYI, OCUL, REGN", "3 Biotech Stocks You MUST Buy for Donald Trump\u2019s Presidency", "Better Buy: Regeneron Pharmaceuticals, Inc. vs. Novartis", "Nasdaq 100 Movers: CSCO, NTAP", "Mid-Morning Market Update: Markets Edge Higher; Wal-Mart Posts Mixed Q3 Results", "Biotech Stock Roundup: Ionis Soars on Spinraza Data, Regeneron's Q3 Results Mixed", "NASDAQ Composite Index closes up 27.32 points for the week, rising for the 3rd straight day", "Regeneron Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish for REGN", "Adverum (ADVM) Q3 Earnings Preview: What's in the Cards?", "Regeneron Pharmaceuticals, Inc. Dropped 14.3% in October -- Here's Why", "Drug Stocks Surge on Trump Win: 5 Stocks to Buy Now", "Market Close Report: NASDAQ Composite index closes at 5,166.17 up 119.80 points", "Regeneron Pharmaceuticals Inc (REGN) Stock Pops on Mixed Q3 Results", "SPY ETF Tests A Key Level As Every S&P Sector Posts A Weekly Loss", "The Zacks Analyst Blog Highlights: Allergan, Gilead Sciences, Pfizer, Regeneron Pharmaceuticals and Lion Biotechnologies", "Regeneron (REGN) Q3 Earnings Top Estimates, Sales Miss", "Notable Friday Option Activity: REGN, WIFI, DNKN", "3 Things You Really Need to Know About Regeneron Pharmaceuticals' Q3 Results", "Top Research Reports for Exxon, Duke & Gilead", "Biotech Stock Roundup: Amgen Down on Enbrel Sales, Regeneron's Sarilumab Faces Delay", "Pre-Market Earnings Report for November 4, 2016 : DUK, REGN, PCG, HUM, TU, WLTW, FE, XRAY, AEE, CNP, BIP, AES", "Pfizer's Surprising News Upends the Market for Next-Gen Cholesterol Busters", "10 Best Stocks of the Bull Market", "Regeneron (REGN) Q3 Earnings: Will the Stock Surprise?", "3 Things You Really Need to Know About Pfizer's Q3 Results", "Nasdaq 100 Movers: SHPG, CHKP", "Drug Stocks to Watch for Earnings on Nov 4; REGN & More", "Will This Trend Cost Biotech Stock Investors Lots of Money?", "3 Big-Money Naked Puts to Trade: AMZN, REGN, GOOGL", "Exactly How Bad Is Regeneron's Latest News?", "3 Key Questions for Amgen Inc. in Q3", "iShares Nasdaq Biotechnology ETF Experiences Big Outflow", "Biotech Stock Roundup: ARIAD Down on Drug Pricing Tweet, Regeneron Study on Clinical Hold", "Regeneron & Teva Hit by Clinical Hold on Chronic Pain Study", "Sanofi (SNY) Beats Earnings, Revenues Rise Y/Y; Ups View", "Midday Update: Wall Street Spooked by Downbeat Chinese Trade Data", "Mid-Day Market Update: Ocular Therapeutix Surges Following Collaboration Deal With Regeneron; Flex Pharma Shares Slide", "Mid-Morning Market Update: Markets Open Lower; Delta Air Lines Profit Beats Estimates", "Stock Futures Turn Defensive as China Trade Disappoints, Initial Claims Fall to 43-Year Low", "Close Update: Downbeat Chinese Trade Data Weighs on Wall Street", "Mid-Afternoon Market Update: Lindsay Gains Following Q4 Results; Fluidigm Shares Drop", "Better Buy: Regeneron Pharmaceuticals, Inc. vs. Roche Holding AG", "Ocular's (OCUL) Stock Jumps on Collaboration with Regeneron", "Sanofi Vaccines Unit Riding High on BARDA Zika Funding", "Is Another Blockbuster Drug on the Way for Regeneron Pharmaceuticals, Inc.?", "10 Hot Stocks That Made Millionaires in 10 Years", "Noteworthy Monday Option Activity: PVH, REGN, EQIX", "The Big Reason You Shouldn't Give Up on Big-Cap Biotech", "Here's Why Ophtotech Corporation Dropped 16.5% in September", "Biotech Stock Roundup: Summit Soars on Sarepta Deal, Regeneron Presents Data", "Wednesday Sector Laggards: Healthcare, Energy", "Regeneron's Eylea/Rinucumab Combination Data Disappoints", "Marketplace Roundtable: The State Of Biotech", "Here's Why Ophthotech Corporation Is Dropping Today", "Nasdaq 100 Movers: CTSH, NXPI", "Exelixis, Inc. (EXEL) Crushed on CaboNivo Drug Trial Results", "A \u201cDon\u2019t Blink\u201d Opportunity In Regeneron Pharmaceuticals Inc (REGN)", "Why Cognizant Technology Solutions, Pier 1 Imports, and Ophthotech Slumped Today", "In Your 40s? 3 Stocks You Should Consider Buying", "Regeneron's Eylea/Rinucumab Combination Data Disappoints", "Marketplace Roundtable: The State Of Biotech", "Here's Why Ophthotech Corporation Is Dropping Today", "3 Critical FDA Decisions You Can't Afford to Miss", "Market Close Report: NASDAQ Composite index closes at 5,305.71 up 48.22 points", "5 Stocks with Impressive Sales Growth to Bet On", "Regeneron, Sanofi Skin Disease Drug Under Priority Review", "Why Investors Are Paying a Premium for Regeneron Pharmaceuticals, Inc.", "Regeneron Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish for REGN", "Biotech Stock Roundup: Tobira Soars on Acquisition Deal, FDA Says Yes to Sarepta DMD Drug", "Regeneron, Teva Collaborate to Develop Chronic Pain Drug", "This Crazy Stock Market Is Creating Crazy Discounts", "Notable ETF Outflow Detected - PBE, INCY, BMRN, REGN", "3 Large-Cap Stocks to Buy in September", "3 Biotech Stocks to Buy in September", "3 Growth Stocks You Can Buy Cheap Right Now", "The Medicines Co. Offers Update on Dyslipidemia Programs", "3 Beaten-Up Biotech Stocks: Are They Bargains?", "Regeneron/Sanofi Present Positive Phase III Praluent Data", "These Next-Generation Cholesterol Drugs Could Raise U.S. Healthcare Costs by $119 Billion a Year", "Buy Chesapeake Energy Corporation (CHK) If You\u2019ve Got Some Guts", "Merck & Co., Inc. (MRK) Preps for a Healthy Breakout", "Biotech Stock Roundup: Gilead in Patent Infringement Lawsuit, Enbrel Biosimilar Approved", "Why Barrick Gold Corporation (USA) (ABX), Express, Inc. (EXPR) and Garmin Ltd. (GRMN) Are 3 of Today\u2019s Worst Stocks", "Biotech Stock Roundup: Medivation to Pfizer, Clovis Priority Review", "Regeneron Stock Up on BARDA Deal for MERS Antibodies", "S&P 500 Movers: MRO, REGN", "J&J (JNJ) Remicade Patent Invalid, Pfizer to Launch Inflectra?", "Another Endorsement for Biotech ETFs", "Regeneron Pharmaceuticals Inc: Profit In REGN Stock\u2019s Pullback", "Regeneron Pharmaceuticals Inc (REGN) Just Reached a Critical Fork in the Road", "Adverum (ADVM) Reports Narrower-than-Expected Q2 Loss", "Biotech Stock Roundup: Earnings in Focus, AbbVie Takes Steps to Block Humira Copycat", "Regeneron Pharmaceuticals Inc.'s Q2 Earnings -- It's Still All About Eylea, but Not for Too Much Longer", "What's in Store for Adverum (ADVM) this Earnings Season?", "Regeneron (REGN) Tops Q2 Earnings, Keeps '16 Eylea View", "Regeneron (REGN) Beats on Q2 Earnings, Retains Eylea View", "3 of Frank Sands' Top 5 Transactions in 2nd Quarter Were Reductions", "Health Care Sector Update for 08/04/2016: REGN,CHEK,SGMO", "3 Big Stock Charts for Wednesday: Regeneron Pharmaceuticals Inc (REGN), Biogen Inc (BIIB) and Dun & Bradstreet Corp (DNB)", "IBB: Significantly Overbought - Sharp Declines Imminent", "5 Drug Stocks to Watch for Earnings on Aug 4: BMRN & More", "Pre-Market Earnings Report for August 4, 2016 : PCLN, DUK, REGN, EOG, BCE, BDX, CNQ, MNST, K, SRE, APA, PH", "Regeneron (REGN) Q2 Earnings: Can the Stock Surprise?", "Better Buy: Regeneron Pharmaceuticals vs. Pfizer", "Earnings Reaction History: Regeneron Pharmaceuticals, 18.2% Follow-Through Indicator, 3.2% Sensitive", "Noteworthy ETF Outflows: BIB, BIIB, REGN, MYL", "Why I Bought Shares of Regeneron Pharmaceuticals Inc. Last Week", "3 Biotech Stocks to Buy and Hold", "Noteworthy Monday Option Activity: MAC, GPC, REGN", "Pfizer Publishes Final Data from Atopic Dermatitis Studies", "Here's Why Regeneron Pharmaceuticals, Inc. Dropped Another 12% in June", "Amgen's Repatha Gains FDA Approval for New Dosing Option", "Notable Wednesday Option Activity: FTK, REGN, HES", "Stock Market News for July 07, 2016", "Sanofi Starts Olipudase Alfa Study, Praluent Ok'd in Japan", "3 Top Healthcare Stocks to Buy Now", "Here's Why Regeneron Pharmaceuticals Inc Is Down 35% This Year", "Pfizer's PCSK9 Inhibitor Tops Two Additional Phase III Studies", "Esperion Therapeutics Inc Sinks After FDA Says, \"Ask Us in 2019\"", "Instant Analysis: Amgen's Latest Approval Raises the Bar Yet Again on Regeneron Pharmaceuticals Inc and Sanofi SA (ADR)", "Implied QQXT Analyst Target Price: $46", "Warren Buffett's Favorite High-Yield Dividend Stock", "3 Biotech Stocks to Buy Now: CELG, REGN and BIIB", "3 Biotech Stocks to Buy If the Market Crashes", "The Zacks Analyst Blog Highlights: iShares Nasdaq Biotechnology, Biogen, Alexion Pharma, BioMarin Pharma and Regeneron", "5 Top Stocks to Buy in June", "4 Stocks That Crushed the Biotechnology ETF (IBB) This Week", "3 Biotech Stocks to Buy Now for the Long Haul", "Biotech Stock Roundup: Biogen Slips on MS Results, ASCO Data in Focus", "Regeneron, Sanofi Report Positive Dupilumab Phase III Data", "3 Biotechs Expecting Market-Moving Trial Results Soon", "Regeneron Reports Interim Data on Cholesterol Lowering Drug", "Better Buy: Regeneron Pharmaceuticals, Inc. vs. Roche", "10 Highest-Paid CEOs in 2015", "Pfizer's Buyout of Anacor Pharmaceuticals for $5.2 Billion Is a Bad Move -- Here's Why", "Why Ophthotech Corp. Shares Soared 14.9% in May", "3 Bullish Stock Picks in a Soft Market: REGN, RTEC, TIS", "Nasdaq 100 Movers: CHTR, BIDU", "5 Toxic Stocks to Discard from Your Portfolio", "Avalanche (AAVL) Reports Wider-than-Expected Q1 Loss", "Look Under The Hood: CSM Has 12% Upside", "Regeneron (REGN) Tops Q1 Earnings, Ups 2016 Eylea View", "Regeneron (REGN) Beats on Q1 Earnings and Revenues", "The 10 Best Healthcare Stocks to Buy Now", "Pre-Market Earnings Report for May 5, 2016 : MRK, BABA, OXY, EOG, REGN, BDX, CNQ, K, APA, TU, ABC, MGA", "Noteworthy Wednesday Option Activity: TUMI, REGN, MTCH", "Biotech Stock Roundup: Amgen Impresses, Gilead Disappoints in Q1, Biogen to Spin Off Hemophilia", "Biotech Stocks Earnings Preview: REGN, LGND, ECYT & More", "Regeneron Pharmaceuticals Inc Has a Lot to Prove on May 5", "Vanguard Boosts Stake in Incyte in \u2013st Quarter", "Regeneron (REGN) Q1 Earnings: Stock Likely to Disappoint", "Regeneron (REGN) Misses on Q1 Earnings, Beats on Revenues", "Pre-Market Earnings Report for May 5, 2016 : MRK, BABA, OXY, EOG, REGN, BDX, CNQ, K, APA, TU, ABC, MGA", "Noteworthy Wednesday Option Activity: TUMI, REGN, MTCH", "3 Stocks to Buy in a Crashing Market", "IBB, REGN, ILMN, ALXN: ETF Outflow Alert", "Nasdaq 100 Movers: CHKP, BMRN", "3 Stocks Analysts Think Could Roar 25% Higher (Citigroup, DAL, LNKD)", "3 Stocks Analysts Think Could CRATER 35% (GPRO, U.S. Steel, MBLY)", "Aside From 1 Eyesore, Amgen Delivers Another Solid Quarter", "3 Biotech Stocks That Could Endure Hillary Clinton", "3 Big-Money Covered Calls \u2014 GOOG PCLN REGN", "Better Buy: MannKind Corporation vs. Sanofi", "3 Biotech Stocks to Buy in April", "Regeneron, Intellia Strike Deal for CRISPR/Cas Platform", "Regeneron's Bold Bet on the Future of Medicine", "Shares of Regeneron Pharmaceuticals, Inc. Struggled in March -- Here's Why", "Illumina, Inc. (ILMN) Takes a 25% Hit \u2013 What Now?", "3 Biotech Stocks That Could Endure Hillary Clinton", "The Zacks Analyst Blog Highlights: Gilead, Regeneron, Medivation and Intercept", "9 Stocks to Buy With Rip-Roaring Growth Potential", "Biotech Stock Roundup: Gilead's HIV Drug Approved, Regeneron Up on Positive Data", "Allergan, Pfizer Inc. Fall Prey to Tax-Inversion Hawks (AGN, PFE)", "General Electric Company Downgraded \u2013 Who Cares? (GE)", "IBB, REGN, ILMN, MYL: Large Inflows Detected at ETF", "S&P 500 Sputters Through Broad-Based Weekly Decline; Energy, Health Care Stocks Lone Winners This Week", "Wall Street Hits Snag on Strength in Treasuries", "This Amgen News Could Be a Game-Changer in its Fight Against Sanofi and Regeneron Pharmaceuticals", "3 Biotech Stocks on the Verge of an Overdue Run (AMGN, GILD, REGN)", "Better Buy: Regeneron Pharmaceuticals, Inc. vs. Amgen", "Pfizer's PCSK9 Inhibitor Positive in Second Phase III Study", "Regeneron, Sanofi Up, Eczema Drug Tops Phase III Studies", "Regeneron Pharmaceuticals Inc Is THE Biotech Stock to Buy! (REGN)", "S&P 500 Movers: CRC, REGN", "Why Regeneron Pharmaceuticals, Tronox, and Office Depot Jumped Today", "Regeneron Pharmaceuticals Inc Jumps on Positive Clinical Data", "Regeneron Delivers A 'Blockbuster' Win In Eczema", "Friday Sector Leaders: Healthcare, Financial", "Mid-Afternoon Market Update: Crude Oil Down 3.5%; Tesla Shares Rise Following Model 3 Launch", "Friday's ETF Movers: IBB, FXN", "Nasdaq 100 Movers: MAR, TSLA", "S&P 500 Movers: CRC, REGN", "Gilead & Biogen's Patent Woes, Amgen Scores Win in Patent Litigation", "Amgen, Inc.: AMGN Stock Looking to Break Out", "Do You Own Any Of These Top Sector Funds?", "3 Biotech Stocks to Buy in March", "Winners and Losers: 5 Stocks You Can Buy Now", "Friday Sector Leaders: Drugs, Biotechnology Stocks", "The Zacks Analyst Blog Highlights: Gilead, Amgen, Regeneron, Ionis and Biogen", "The Zacks Analyst Blog Highlights: GW Pharma, Orexigen, Gilead and Regeneron", "Amgen Wins PCSK9 Lawsuit, Sanofi and Regeneron to Appeal", "Biotech Stock Roundup: GW Pharma Soars on Epidiolex Data, Gilead's Zydelig in Trouble?", "Why Investors Should Sell These Biotech Stocks & Buy Gilead Instead", "Regeneron/Sanofi Report Positive Sarilumab Phase III Data", "Instant Analysis: Regeneron Pharmaceuticals and Sanofi's Experimental Drug Bests an AbbVie Blockbust", "3 Biotech Stocks That Are Ripe for a Fall", "Nasdaq 100 Movers: REGN, WDC", "Regeneron Pharmaceuticals Inc: REGN Suffers Amid the Biotech Rout", "Biotech Stock Roundup: AbbVie's Imbruvica Label Expanded, Celldex Slumps on Study Update", "3 Stocks to Own for the Next 10 Years", "The Zacks Analyst Blog Highlights: Valeant Pharmaceuticals International, Gilead Sciences, Biogen, Amgen and Regeneron Pharmaceuticals", "4 Top Stocks We're Excited About", "Repligen Corporation Jumped 14.6% in February -- Here's Why", "Biotech Investing Guide: 3 Stocks to Buy and 3 to Avoid", "Avalanche (AAVL) Reports Wider-than-Expected Loss in Q4", "These 3 Biotechs Are Growing Fast -- Which Is the Best Buy Today?", "What's in Store for Avalanche (AAVL) This Earnings Season?", "5 Must-See Comments From Amgen's Top Executives", "Better Buy: Regeneron Pharmaceuticals Inc. vs. Pfizer", "Can Biotech Stocks Bounce Back?", "4 Funds to Buy on Healthy Medical Sector Earnings", "What Does Trump's Healthcare Plan Mean for Investors?", "Bouncing Biotech? Here Are 3 Stocks to Buy", "Eylea's Slowing Sales Growth Sends Regeneron Pharmaceutical Inc.'s Shares Lower", "The Zacks Analyst Blog Highlights: Regeneron, Alexion, CTI BioPharma, BioCryst and Sarepta", "Sanofi Tops Q4 Earnings, Revenues Fall Y/Y, Gives 2016 View", "Biotech Stock Roundup: Alexion, Regeneron Miss Estimates; Setback for CTI BioPharma", "Regeneron Q4 Earnings Lag, Gives 2016 View for Eylea Sales", "Noteworthy Tuesday Option Activity: CERS, REGN, CTCT", "Biotech Stock Roundup: Incyte Down on Jakafi Update, Is Intercept a Buyout Target?", "Pre-Market Earnings Report for February 9, 2016 : KO, CVS, REGN, OMC, HCP, FIS, VIAB, IR, AGU, TDG, SNY, MAS", "Why Ophthotech Corporation Shares Tumbled 31% in January", "EWT, PTH: Big ETF Outflows", "3 Things to Look for in Regeneron Pharmaceuticals Inc.'s Earnings", "Regeneron (REGN) to Report Q4 Earnings: What's in Store?", "Biotech Stock Roundup: Biogen, Amgen Top Estimates; Zika Virus Grabs Attention", "Ignore Regeneron Pharmaceuticals, Inc: Here Are 3 Better Buys Right Now", "Regeneron (REGN) Misses on Q4 Earnings and Revenues", "Avalanche (AAVL) Set to Acquire Annapurna Therapeutics", "Nasdaq 100 Movers: INCY, SBAC", "Regeneron Pharmaceuticals Inc. Stock: Bargain or Rip-Off?", "Health Care Sector Update for 01/20/2016: ONCY, REGN", "The Best Healthcare Stocks for 2016", "5 Slides That Tell You Everything You Need to Know About Amgen", "Biotech Stock Roundup: Baxalta - Shire to Combine, JPM Healthcare Conference in Focus", "Why Regeneron Pharmaceuticals Shares Fell 23% in January", "Nasdaq 100 Movers: REGN, AKAM", "Sanofi Inks Multiple Deals, Sarilumab under FDA Review", "Why Opthotech Corporation Shares Skyrocketed by 75% in 2015", "Why Regeneron Pharmaceuticals Shares Jumped 32% in 2015", "Will 2016 Be Regeneron Pharmaceuticals Inc.'s Best Year Yet?", "Biotech Stock Roundup: MannKind Tanks on Deal Termination, Speedy Review for Gilead Drug", "DoctoRx Positions For 2016: My No. 1 Risk Factor Is The Flood Of Money Into Biotech", "Biotech ETFs Snap Back After Undercutting Sept. Lows", "Agree To Purchase Regeneron Pharmaceuticals At $380, Earn 9.2% Using Options", "Will Amgen Inc. Raise Its Dividend in 2016?", "5 Companies We Wish We'd Bought in 2015", "What Happened in Biotech in 2015?", "The Worst Regeneron Pharmaceuticals, Inc. Headlines in 2015", "Biotech Industry Could Offer Early Profit in 2016", "The Best 3 Biotech Stocks for 2016", "3 Stocks To Buy In A Market Crash", "Agree To Purchase Regeneron Pharmaceuticals At $380, Earn 9.2% Using Options", "Will Amgen Inc. Raise Its Dividend in 2016?", "The Zacks Analyst Blog Highlights: Amgen, ARIAD, Clovis Oncology, Regeneron and Akebia Therapeutics", "Big Biotech Amgen Facing Pivotal Year In 2016", "Biotech Stock Roundup: Amgen Hikes First Quarter Dividend, ARIAD Lowers Iclusig Outlook", "Did CVS Health Just Make a Huge Mistake?", "This May Be The Fastest-Growing Biotech Stock Next Year (Hint: It's Not Gilead Sciences)", "Why Aegerion Pharmaceuticals' Stock Bolted Higher Today", "IBB, AMGN, REGN, BIIB: Large Outflows Detected at ETF", "Aegerion Pharmaceuticals Lost a Third of Its Value in November: Time to Buy?", "Why Ophthotech Corporation Shares Soared Higher Last Month", "Noteworthy Friday Option Activity: KMI, CVX, REGN", "Noteworthy ETF Outflows: IBB, REGN, BIIB, ALXN", "Stock Market News for December 01, 2015", "CVS Health Plays Favorites with New Cholesterol Drugs", "Top FDA Drug Approvals in 2015: High Cholesterol", "3 Stocks to Buy and Hold for the Next Decade", "5 Things Amgen, Inc. Wants You to Know", "Sanofi and Regeneron Hit Another Bullseye", "These 2 Companies Could Revolutionize Heart Disease Prevention", "IBB, REGN, AMGN, CELG: ETF Outflow Alert", "Why Aegerion Pharmaceuticals Is Crashing Today", "Avalanche (AAVL) Reports Wider-than-Expected Loss in Q3", "Monday Sector Laggards: Healthcare, Services", "Health Care Sector Update for 11/04/2015: CRL, SCMP, REGN", "Regeneron (REGN) Misses on Q3 Earnings, Revenues In Line", "Earnings Reaction History: Regeneron Pharmaceuticals, 30.0% Follow-Through Indicator, 2.7% Sensitive", "Regeneron Misses on Q3 Earnings, Eylea 2015 View Upped", "5 Exciting Biotech Stocks to Buy on November Upswing", "Pre-Market Earnings Report for November 4, 2015 : AGN, TWX, REGN, CTSH, FOXA, BDX, FOX, SE, WEC, HSIC, SEP, MSI", "Zoetis Tops Q3 Earnings, Ups 2015 Bottom-Line Guidance", "IBB, CELG, REGN, AMGN: Large Inflows Detected at ETF", "Noteworthy ETF Inflows: IBB, AMGN, CELG, REGN", "Aegerion (AEGR) Q3 Earnings Preview: What's in the Cards?", "Will Express Scripts (ESRX) Surprise Q3 Earnings Estimates?", "Stock Market News for October 21, 2015", "Stock Market News for October 20, 2015", "Eli Lilly's Failure Is a Success for These Companies", "3 Biotechs Growing Faster Than Apple", "What's in Store for Regeneron (REGN) This Earnings Season?", "Nasdaq 100 Movers: INCY, REGN", "S&P 500 Movers: LLY, REGN", "Winners and Losers of Eli Lilly's CETP Drug Failure", "Stock Market News for October 08, 2015", "The Zacks Analyst Blog Highlights: Amgen, Regeneron, Acorda, Amicus and AbbVie", "Cholesterol Busters Will Be Cheaper but Remain Top Sellers", "Stock Market News for October 14, 2015", "Nasdaq 100 Movers: ADBE, WYNN", "Stock Market News for October 07, 2015", "Express Scripts Includes Praluent and Repatha in Formulary", "Biotech Stock Roundup: PBM Lists Both Amgen & Regeneron PCSK9 Inhibitors, FOLD Plunges on NDA Delay", "Illumina (ILMN) Shares Tumble on Weak Outlook for Sales", "Would an Ebola Vaccine Move Regeneron Pharmaceuticals' Bottom Line?", "Merck's (MRK) Keytruda Gains FDA Nod for Label Expansion", "Commit To Buy Regeneron Pharmaceuticals At $320, Earn 6.6% Using Options", "Illumina Poised on Product Innovation, Global Expansion", "DBV Technologies Reveals Positive Data on Viaskin Peanut", "Sanofi Opts into Alnylam's ALN-AT3 Hemophilia Program", "BioMarin (BMRN) to Acquire Rights to Phenylketonuria Drugs", "Bristol-Myers' Melanoma Combo Opdivo/Yervoy Gets FDA Nod", "Sarepta Unveils New Phase IIb Eteplirsen Data, Shares Soar", "Illumina Downgraded by Leerink, Shares Plummet Over 10%", "Gilead's Letairis Gets FDA Nod in Combination with Adcirca", "Jazz's Defibrotide under FDA Priority Review, Shares Up", "Stock Market News for October 01, 2015", "The Zacks Analyst Blog Highlights: Regeneron, Vertex, Gilead, Biogen and Celgene", "Chiasma (CHMA) Jumps: Stock Adds 5.6% in Session", "Infinity (INFI) Up, Set to Get Duvelisib Milestone Payment", "Revance's Botulinum Toxin Type A in Cervical Dystonia Study", "OXiGENE (OXGN) to Initiate Two Phase II/III Studies on CA4P", "Integra (IART) Hopeful on Spine Spin-Off amid Global Woes", "Clovis' Rociletinib under Review in U.S., EU for Lung Cancer", "Novavax's Respiratory Vaccine Study Data Fail to Impress", "Regeneron Pharmaceuticals and Sanofi Grab Another Important Win", "Sanofi, Eli Lilly Agree to Settle Lantus Patent Litigation", "Endo Completes $8.05B Par Pharma Acquisition, Updates View", "Alnylam's Extension Study on Patisiran Reveals Positive Data", "Esperion Plunges on FDA Advice for Cardiovascular Study", "Regeneron Pharmaceuticals (REGN) Shares Cross Below 200 DMA", "Stock Market News for September 28, 2015", "Regeneron/Sanofi's PCSK9 Inhibitor Praluent Approved in EU", "The Price War for New Cholesterol Drugs Is Heating Up", "Stock Market News for September 25, 2015", "KemPharm (KMPH) Updates on Abuse-Deterrent Opioid Drug", "Bellerophon Presents Positive Interim Data on INOpulse", "Allergan (AGN) Projects Revenues to Surpass $8B in 2H15", "Orexigen Receives $22M Milestone Payment for Contrave", "Conatus Reports Promising Phase II Data on Emricasan", "Biotech Stock Roundup: Clinton's Tweet Shakes Biotech Stocks, Amgen In Pipeline-Boosting Deals", "Heron's (HRTX) Post-Operative Pain Candidate Encourages", "AcelRx's Pain Treatment Drug Zalviso Approved in Europe", "Pfizer's Xeljanz Tops Phase III Ulcerative Colitis Studies", "Inovio Gets Grant for Ebola Drugs, Regeneron Inks Deal", "BioMed Realty Trust REIT Looks For A Buyer", "5 Biotech Stocks Hit Hard by Hillary Clinton's Tweet", "The Zacks Analyst Blog Highlights: Medivation, Gilead Sciences, Regeneron Pharmaceuticals and Anthera Pharmaceuticals", "Merck Reports Encouraging Phase III Data on Bezlotoxumab", "Trevena Hits a 52-Week High on Positive Phase II Data", "TRACON Skyrockets on Positive Choriocarcinoma Study Data", "BioDelivery Up, Opioid Dependence Treatments in Focus", "BioMarin-Dr. Reddy's Agree to Settle Kuvan Patent Litigation", "Gilead Unveils Encouraging HCV Data on Sovaldi/Velpatasvir", "Yellen Doesn't Raise Rates: 4 Biotech Stocks to Buy", "Allergan/Gedeon's Vraylar Gets FDA Nod for Mental Disorders", "Inovio Presents Positive Data on Cervical Neoplasia Drug", "Aerie Reported Positive Phase III Data on Rhopressa", "Novo Nordisk's Victoza Fares Better than Sanofi's Lyxumia", "Intra-Cellular Up on Positive Data from Schizophrenia Study", "XenoPort Hits 52-Week Low on Preliminary Psoriasis Data", "3 Stocks Battling Heart Disease: 2 to Buy, 1 to Sell", "Illumina in Partnership with Memorial Sloan to Develop ctDNA", "The Zacks Analyst Blog Highlights: VIVUS, Regeneron Pharmaceuticals, Gilead Sciences, Repligen and Affymetrix", "Alnylam Reports Positive Initial Phase I Data on ALN-AS1", "InSite Vision Terminates QLT Deal in Favor of Sun Pharma", "GW Pharmaceuticals Up on Encouraging Schizophrenia Data", "Biotech Poised to Rebound: 5 Growth Picks", "Raptor Crushed by Liver Disease Data, Hits 52-Week Low", "Bristol-Myers Up, Opdivo Gets Breakthrough Therapy Status", "Amgen Seeks FDA Approval for Repatha's New Dosing Option", "Sanofi's (SNY) LixiLan Positive in Phase III Diabetes Study", "Better Buy: Amgen, Inc or Regeneron Pharmaceuticals Inc?", "AbbVie's Humira Gains FDA Approval for Label Expansion", "Why is Gilead (GILD) Raising a Whopping $10 Billion?", "Revance's Botulinum Toxin Type A Gel in Phase II Study", "Biogen (BIIB) in Autoimmune Disease Deal Worth Up To $544M", "Collegium's Xtampza Supported for Approval by FDA Panels", "Marinus' End-of-Phase II Meeting Positive for Ganaxolone", "Protalix's Phase I/II Fabry Disease Study Interim Data Positive", "Integra Faces Multiple Headwinds, SeaSpine Spin-off Strong", "Biotech Stock Roundup: Biosimilar Competition for Amgen, Tetraphase Hit By Disappointing Data", "The Zacks Analyst Blog Highlights: Gilead, Regeneron Pharmaceuticals, Thermo Fisher Scientific and Cyberonics", "Impax Hayward Facility Gets FDA Clearance, Shares Rise", "BioDelivery Up on Striking Deal with TennCare for Bunavail", "The Zacks Analyst Blog Highlights: SolarEdge Technologies, Comfort Systems USA, Universal Insurance Holdings, Regeneron Pharmaceuticals and Lawson Products", "Nasdaq 100 Movers: GMCR, JD", "Healthcare Boom a Bubble? 4 Stocks to Buy Anyway", "Bristol-Myers' Opdivo Encourages in Lung Cancer Study", "Is Another Amendment of QLT-InSite Vision Deal Coming Up?", "Alexion's Kanuma FDA Action Date Delayed by Three Months", "AstraZeneca, Starpharma Ink Drug Delivery Technology Deal", "4 Low-Volatility Stocks to Sail Through Market Mayhem", "5 Low-Debt Stocks to Brave the Impact of Rate Hike", "Roche's Hemophilia A Drug Gets Breakthrough Status in U.S.", "Allergan (AGN) to Buy Eye Care Device Company AqueSys", "AstraZeneca's Brilinta Gains FDA Nod for Label Expansion", "Dicerna Files IND Application for Primary Hyperoxaluria Drug", "The Zacks Analyst Blog Highlights: Google, Gilead Sciences, Regeneron Pharmaceuticals, Intuitive Surgical and Amazon.com", "Why Regeneron Pharmaceuticals (REGN) Could Be a Potential Winner", "3 Stocks We're Watching In The Third Quarter", "PCSK9 Drugs Are Here (and Way Over There)", "The Zacks Analyst Blog Highlights: Amazon.com, Skyworks Solutions, Regeneron Pharmaceuticals and Universal Health Services", "Amgen's Next-Generation Cholesterol Drug Is Approved, but Pricing Is a Huge Concern", "Regeneron and Sanofi Present Encouraging Praluent Data", "Illumina Acquires GenoLogics, Boosts Genomic Sequencing", "4 Winning Stocks with the Potential to Beat the Market", "Intercept's (ICPT) OCA Under Priority Review in the U.S.", "Amicus (FOLD) Signs Agreement to Acquire Scioderm", "4 Google-Beating Stocks that Still Hold Promise", "Applied Genetic Meets Enrolment Milestone in XLRS Study", "Noteworthy ETF Inflows: IXJ, MCK, REGN, ANTM", "Amgen's PCSK9 Inhibitor, Repatha, Approved in the U.S.", "Pfizer (PFE) Gains on Label Expansion Efforts for Ibrance", "Exelixis Up on Swiss Approval of Advanced Melanoma Drug", "Oncolytics' Reolysin Phase II Lung Cancer Study Enrolled", "J&J to Sell Sugar Substitute Splenda to Heartland Food", "Trevena's Postoperative Pain Drug Positive in Phase IIb Study", "Bouncing Biotech? 3 Stocks To Buy", "Seres (MCRB) Up on Orphan Drug Status for Lead Candidate", "Alkermes' (ALKS) Aristada Review Date Postponed by FDA", "Bull Or Bear? Biotech's Post-Earnings Buys and Sells", "Vascular (VBLT) Starts Patient Dosing in Glioblastoma Study", "Pfizer's (PFE) Breast Cancer Drug Ibrance Under EU Review", "Raptor (RPTP) to Buy Quinsair, Boost Rare Disease Portfolio", "Sarepta's DMD Drug Eteplirsen Gains FDA Priority Review", "This Is a Concern That Amgen Investors Shouldn't Take Lightly", "Google's 11-Year Dream Run: From IPO to Alphabet", "Esperion Updates on its Cholesterol Management Candidate", "Walgreens Boots Plans to Eliminate 370 Employees to Cut Cost", "Is Esperion's Good News Actually Bad?", "Kite Pharma Provides Update, Death Not Related to KTE-C19", "BioLineRx Up on Phase IIb Study Initiation on Leukemia Drug", "Why Eli Lilly (LLY) was a Bright Spot in the Market on Thursday", "CVS Health Draws a Line in the Sand", "Avalanche Biotechnologies (AAVL) Q2 Loss Narrows Y/Y", "Closing Update: Afternoon Recovery Erases Early Decline Following Above-Consensus Rise in Producer Prices, Factory Use", "Health Care Sector Update for 08/14/2015: ONTX, PBMD, EBIO, NVS, REGN", "Emergent BioSolutions Gets $44M CDC Contract for VIGIV", "Juno Therapeutics Posts In-Line 2Q Loss, Pipeline in Focus", "Looking for a Top Growth Stock? 3 Reasons Why Regeneron Pharmaceuticals (REGN) Is an Impressive Choice", "Are the 3 Best-Performing Big-Cap Biotech Stocks of 2015 Still Worth Buying?", "CVS Health Draws a Line in the Sand", "Avalanche Biotechnologies (AAVL) Q2 Loss Narrows Y/Y", "Bull of the Day: Regeneron Pharma (REGN)", "Pluristem (PSTI) Provides Update on PLX-PAD Cells in Japan", "Repros Incurs Narrower Y/Y Loss in Q2, Pipeline in Focus - Analyst Blog", "TrovaGene Q2 Loss Widens on Higher Expenses, Shares Fall - Analyst Blog", "Sanofi Inks Deals, Diabetes and Immuno-Oncology in Focus - Analyst Blog", "Teva's Chorea in Huntington Disease Treatment under Review", "Is CVS Health's Anti-Tobacco Strategy Paying Off?", "The Zacks Analyst Blog Highlights: Amgen, Vertex, Regeneron, Baxalta and VIVUS - Press Releases", "Aegerion's Loss Narrower than Expected, View Maintained - Analyst Blog", "Biotech Stock Roundup: Baxalta Rejects Shire Bid, Amgen's Beat & Raise Quarter - Analyst Blog", "Will Regeneron's New Drug Break The Bank?", "Top-Rated Stock Picks and Most-Read Stories at Nasdaq.com: July 26 - August 1", "Nasdaq 100 Movers: AVGO, REGN", "3 Top Biotech Stocks for High-Risk Investors", "Health Care Sector Update for 08/04/2015: ELGX, CPHR, REGN", "Regeneron (REGN) Beats on Q2 Earnings, Updates 2015 View - Tale of the Tape", "Top Mutual Funds Pile In Celgene Other Leading Stocks", "Regeneron's Knock-out Quarter Could Be Just The Beginning", "Pre-Market Earnings Report for August 4, 2015 : CVS, REGN, AET, EMR, ADM, SRE, ZTS, HCN, K, CHTR, INCY, HCP", "Sanofi Tops Q2 Earnings, Revenues Grow Y/Y, Maintains View - Analyst Blog", "S&P 500 Movers: ALL, BXLT", "Regeneron Beats on Q2 Earnings, Eylea 2015 View Upped - Analyst Blog", "Biotech Stock Roundup: Biogen Down on Tecfidera Issues, Regeneron's Praluent Gets FDA Nod - Analyst Blog", "Sanofi & Regeneron Enter Immuno-Oncology Collaboration - Analyst Blog", "The Zacks Analyst Blog Highlights: Biogen, Ligand Pharmaceuticals, bluebird bio, Regeneron Pharmaceuticals and Exelixis - Press Releases", "Forget Biogen, Buy These Promising Biotech Stocks Instead - Analyst Blog", "Stock Market News for July 27, 2015 - Market News", "Regeneron Pharmaceuticals and Sanofi Grab a Blockbuster FDA Approval", "Will Regeneron (REGN) Earnings Surprise on Eylea Sales? - Analyst Blog", "Biotech Stock Roundup: Amgen PCSK9 Inhibitor First to Gain Approval, Exelixis Up on Positive Data - Analyst Blog", "Amgen's Repatha Gains EU Nod; First PCSK9 Drug Approved - Analyst Blog", "Monday's ETF Movers: PDP, GDX", "Notable Monday Option Activity: ESRX, WHR, REGN", "8 Biotech Stocks to Buy", "Ohr Pharmaceutical Jumps on Positive Eye Drug Study Data - Analyst Blog", "Sanofi Unveils Restructuring Plans, Prunes Business Units - Analyst Blog", "The Zacks Analyst Blog Highlights: Amgen, Exelixis, Regeneron, Five Prime Therapeutics and AbbVie - Press Releases", "Biotech Stock Roundup: Amgen PCSK9 Inhibitor First to Gain Approval, Exelixis Up on Positive Data - Analyst Blog", "Why July Will Be an Exciting Month for Regeneron Pharmaceuticals", "Regeneron and Sanofi Report Positive Data on Praluent - Analyst Blog", "Health Care Sector Update for 07/09/2015: MYL, REGN, AZN", "Commit To Buy Regeneron Pharmaceuticals At $370, Earn 6.2% Using Options", "IBB, CELG, AMGN, REGN: Large Inflows Detected at ETF", "What Is Beyond Vision-Loss Blockbuster For Regeneron?", "Anacor Hits 52-Week High on Positive Atopic Dermatitis Data - Analyst Blog", "Stock Market News for June 19, 2015 - Market News", "Why Avalanche Biotechnologies, Inc. Stock Collapsed Today", "Health Care Sector Update for 06/15/2015: REGN, INNL, ORPN", "The Zacks Analyst Blog Highlights: Regeneron, Vertex, Celgene, Seattle Genetics and SAGE Therapeutics - Press Releases", "How Big of an Impact Could Praluent Have on Regeneron Pharmaceuticals Inc.?", "Cholesterol Drug Blues: Why Esperion Therapeutics' Stock Is Getting Crushed Today", "Biotech Stock Roundup: FDA Panel Recommends Regeneron's Praluent, SAGE Gains on Data - Analyst Blog", "Regeneron/Bayer's Eylea Gets Label Expansion in Japan - Analyst Blog", "S&P 500 Movers: REGN, TLN", "Mid-Morning Market Update: Markets Open Higher; Oxford Industries Beats Q1 Expectations", "Regeneron/Sanofi's Praluent Gets Positive FDA Panel Vote - Analyst Blog", "Mid-Day Market Update: Sigma Designs Surges On Upbeat Results; Boulder Brands Shares Drop", "Amgen's Repatha Briefing Document Gives Mixed Review - Analyst Blog", "Regeneron/Sanofi's PCSK9 Drug Praluent Set for FDA Panel - Analyst Blog", "Stock Market News for June 08, 2015 - Market News", "Nasdaq 100 Movers: REGN, NFLX", "Biotech Stock Roundup: ImmunoGen Soars on ASCO Data, Amgen Collaborates with Roche - Analyst Blog", "Top Mutual Funds Add To Medical Holdings", "The Highest Paid CEOs in Biotech", "Amgen's PCSK9 Inhibitor a Step Closer to EU Approval - Analyst Blog", "Ampio Pharmaceuticals Shoots up on Positive Optina Data - Analyst Blog", "Regeneron-Sanofi's Sarilumab Meets Endpoints in Phase III - Analyst Blog", "Stock Market News for May 21, 2015 - Market News", "Cholesterol Drugs: 3 Stocks to Watch This Week", "Biotech Stock Roundup: Eleven Bio Slumps on Eye Drug Data, Achillion Signs Deal with J&J - Analyst Blog", "Stock Market News for May 19, 2015 - Market News", "Regeneron/Sanofi Announce Positive Data on Dupilumab - Analyst Blog", "Regeneron Earnings Shine, but All Eyes Are on the Pipeline", "Regeneron (REGN) Beats on Q1 Earnings, Updates 2015 View - Tale of the Tape", "Regeneron Beats on Q1 Earnings, Eylea 2015 View Upped - Analyst Blog", "Pre-Market Earnings Report for May 7, 2015 : PCLN, REGN, CNQ, MFC, BDX, APA, MGA, PPL, TU, SIAL, TAP, CPG", "Health Care Sector Update for 05/21/2015: CALA, DRNA, REGN", "Beyond Pharma: 3 Healthcare Choices - Analyst Blog", "Will Eylea Sales Drive Regeneron (REGN) Q1 Earnings? - Analyst Blog", "The 3 Best Stocks for Investing in Cholesterol Drugs", "3 Potential Blockbuster Drugs That Could Be Approved Before Year's End", "Nasdaq 100 Movers: VIAB, REGN", "Following Gilead Sciences, Inc., Which Biotech Will Pay a Dividend Next?", "Stock Market News for April 01, 2015 - Market News", "Nasdaq 100 Movers: VRTX, NFLX", "Ohr Pharmaceutical Crashes on Disappointing Eye Drug Data - Analyst Blog", "Regeneron's Eylea Gets FDA Approval for Label Expansion - Analyst Blog", "Biotech Stock Roundup: Biogen Soars on Alzheimer's Data, Gilead HCV Drugs Label Update - Analyst Blog", "Biotech ETF Performance Shows Rally Is Not A Fluke", "The Zacks Analyst Blog Highlights: Amgen, Regeneron, Nektar, ACADIA and Pharmacyclics - Press Releases", "Regeneron Hits a 52-Week High on Positive Praluent Data - Analyst Blog", "Biotech Stock Roundup: Amgen & Regeneron Shine at ACC, Nektar Drug Disappoints - Analyst Blog", "Biotech Stock Roundup: Horizon to Buy Hyperion, Conatus Up on Liver Disease Data - Analyst Blog", "Regeneron/Sanofi's PCSK9 Drug Praluent Data Published - Analyst Blog", "Amgen Presents Encouraging PCSK9 Inhibitor Repatha Data - Analyst Blog", "Bayer Seeks Eylea Label Expansion in the EU, Provides View - Analyst Blog", "Biotech Stock Roundup: AbbVie to Buy Pharmacyclics, FDA Approves First Biosimilar - Analyst Blog", "Nasdaq 100 Movers: WYNN, MNST", "Biotech Stock Roundup: Pharmacyclics Up on Buyout Rumors, Celgene Drug Label Expanded - Analyst Blog", "Billions on the Line in the Next Drug Pricing War", "Esperion Soars on Positive Phase IIb Data on ETC-1002 - Analyst Blog", "Thursday's ETF Movers: PBE, ICF", "Nasdaq 100 Movers: VIP, PCLN", "3 Upcoming FDA Decisions We're Most Excited About", "Forget Gilead Sciences: Here Are 3 Better Biotech Stocks", "Biotech Stock Roundup: Achillion Impresses with HCV Data, Regeneron 4Q Results Top Estimates - Analyst Blog", "Health Care Sector Update for 02/11/2015: CVS, CASM, REGN", "Regeneron Pharmaceuticals Inc. Earnings: All Eyes on Eylea", "Regeneron's Eylea Tops Diabetic Macular Edema Study - Analyst Blog", "Regeneron Beats on Q4 Earnings Driven by Eylea Sales - Analyst Blog", "Health Care Sector Update for 02/10/2015: MRGE, ISIS, REGN", "Regeneron (REGN) Beats on Q4 Earnings, Provides 2015 View - Tale of the Tape", "Roche's Lucentis Gets FDA Nod for Diabetic Retinopathy - Analyst Blog", "Pre-Market Earnings Report for February 10, 2015 : KO, CVS, REGN, RAI, PCG, HCP, OMC, HOT, TAP, KKR, WYN, SEE", "Will Regeneron (REGN) Beat Q4 Earnings on Eylea Sales? - Analyst Blog", "Will Avalanche (AAVL) Miss This Earnings on Higher Costs? - Analyst Blog", "Stock Market News for February 10, 2015 - Market News", "Biotech Stock Roundup: Biogen Impresses with 4Q Results, Gilead & AbbVie HCV Drugs in Focus - Analyst Blog", "Nasdaq 100 Movers: AAL, SPLS", "Energy Stocks Lead Mutual Funds' Dive Into Red In Jan.", "Will Perrigo (PRGO) Disappoint This Earnings Season? - Analyst Blog", "Will Teva (TEVA) Earnings Surprise on Higher Sales? - Analyst Blog", "This Tiny Biotech Hopes to Capture a Share of This $6 Billion Market", "Will Pacific Biosciences (PACB) Surprise on Earnings in Q4? - Analyst Blog", "Sanofi Misses on Q4 Earnings, Maintains Diabetes Guidance - Analyst Blog", "Regeneron/Sanofi's PCSK9 Drug Gets FDA Priority Review - Analyst Blog", "Can Celgene (CELG) Beat Earnings on Strong Product Sales? - Analyst Blog", "Will Alexion's (ALXN) Soliris Drive Q4 Earnings Beat? - Analyst Blog", "Health Care Sector Update for 01/23/2015: REGN, ASPX, CELG", "Biotech Stock Roundup: Shire to Acquire NPSP, Celgene & Pharmacyclics Give Strong Outlook - Analyst Blog", "Aegerion Reveals Preliminary 2014 Results and 2015 Outlook - Analyst Blog", "Nasdaq 100 Movers: SNDK, CELG", "Will GW Pharmaceuticals (GWPH) Miss this Earnings Season? - Analyst Blog", "Agree To Purchase Regeneron Pharmaceuticals At $240, Earn 6.3% Using Options", "S&P 500 Movers: DNR, LUV", "Nasdaq 100 Movers: VIP, REGN", "DoctoRx Positions For 2015: I Have Cut Back On My Exposure To All Biotech Substantially", "Nasdaq 100 Movers: REGN, GILD", "IBB, GILD, REGN, BMRN: Large Inflows Detected at ETF", "Nasdaq 100 Movers: CELG, WYNN", "Regeneron/Sanofi Seek PCSK9 Drug Praluent Approval in EU - Analyst Blog", "The Best Healthcare Stocks of 2014: Which Is Our Favorite for 2015?", "Top Healthcare Stocks for 2014", "Billionaires Are Dumping These 3 Stocks", "Can Pfizer\u2019s Cholesterol Drug Catch Up To The Competition?", "3 Biotech Stocks to Buy in December", "5 Biotech Stocks to Buy for 2015", "Regeneron at 52-Week High on Eylea Priority Review Status - Analyst Blog", "Nasdaq 100 Movers: GILD, VIP", "Stock Market News for December 03, 2014 - Market News", "Regeneron/Bayer's Eylea to be Reviewed on a Priority Basis - Analyst Blog", "Gilead Sciences Inc. Just Paid $125 Million for Something It Can't Use for a Year", "Can New Launches Offset Sanofi's Soft Diabetes Business? - Analyst Blog", "Regeneron & Sanofi Present Positive Data on PCSK9 Drug - Analyst Blog", "Gilead to Buy Knight Therapeutics' Priority Review Voucher - Analyst Blog", "Biotech Stock Roundup: Geron Soars on $935M J&J Deal, Gilead's Harvoni Approved in the EU - Analyst Blog", "Biotech Stock Roundup: Avanir to be Acquired by Japanese Firm, Biogen Scores in Alzheimer's Study - Analyst Blog", "Nasdaq 100 Movers: VIP, MYL", "Biotech: And Yet We've Just Begun...", "Why Novartis and Regeneron Care About This Tiny Biotech Stock", "Regeneron/Sanofi Announce Positive Dupilumab Study Data - Analyst Blog", "Biotech Stock Roundup: Gilead, AbbVie Score at Liver Meeting, Dendreon Files for Bankruptcy - Analyst Blog", "3 Crashing Stocks: Is 1 a Buy?", "Biotech Stock Roundup: Regeneron's Eylea Stumbles, Geron Up on Lifting of Clinical Hold - Analyst Blog", "Merck IMPROVEs-IT Causing These Biotechs' Stock Prices to Improve Too", "Sector Update: Health Care", "Regeneron Pharmaceuticals Inc. Earnings: Eylea's Roller-Coaster Ride", "Regeneron Q3 Earnings Up Y/Y, Narrows Eylea Guidance - Analyst Blog", "Pre-Market Earnings Report for November 4, 2014 : CVS, PCLN, EOG, EMR, REGN, TRP, ADM, SRE, VLO, BDX, ICE, PPL", "Aegerion Q3 Loss Wider than Expected, 2014 View Lowered - Analyst Blog", "Will Regeneron (REGN) Q3 Earnings be Hit by Higher Costs? - Analyst Blog", "Alnylam Pharmaceuticals, Inc. Has This Ratio Right", "AstraZeneca's Lynparza a Step Closer to European Approval - Analyst Blog", "Biotech Stock Roundup: AbbVie Calls off Shire Acquisition, Will Amgen Consider Breakup? - Analyst Blog", "Regeneron Pharmaceuticals (REGN) Jumps: Stock Up 8.5% - Tale of the Tape", "Sanofi and Regeneron Dose Patients in Dupilumab Study - Analyst Blog", "Amgen Sues Sanofi and Regeneron over PCSK9 Candidate - Analyst Blog", "Nasdaq 100 Movers: NFLX, XLNX", "Sanofi Beats on Q3 Earnings but Lantus Outlook Disappoints - Analyst Blog", "Friday's ETF Movers: BBH, GDX", "S&P 500 Analyst Moves: REGN", "Ohr Pharmaceutical's OHR-102 to Enter Phase III in 1H15 - Analyst Blog", "Bristol-Myers Collaborates for Opdivo-Imbruvica Combo - Analyst Blog", "Celgene's Otezla Encourages in Plaque Psoriasis at EADV - Analyst Blog", "Amgen's Data on Evolocumab Published in The Lancet - Analyst Blog", "Biotech Stock Roundup: Sunesis Tanks on Study Results, Chimerix Up on Ebola Update - Analyst Blog", "Pharmacyclics, Roche Ink Deal for Cancer Combo Therapy - Analyst Blog", "Should Pfizer Inc. Buy This Surprisingly Competitive Biotech Stock?", "Regeneron's Eye Drug Eylea Wins Another FDA Approval - Analyst Blog", "Regeneron-Sanofi's Dupilumab Meets All Endpoints - Analyst Blog", "Sector Update: Health-Care Shares Mixed Pre-Market", "Sector Update: Health Care", "Sector Update: Health Care Shares Flat in Pre-Market Trade", "Sector Update: Health Care", "Bristol-Myers Gives Up on US Approval of 2-Drug HCV Combo - Analyst Blog", "Should Pfizer Inc. Buy This Surprisingly Competitive Biotech Stock?", "Anacor's Kerydin Launched in the US for Onychomycosis - Analyst Blog", "Bayer/Regeneron Successfully Expand Eylea Label in Japan - Analyst Blog", "Sector Update: Health-Care Shares Mixed Pre-Market", "Sector Update: Health Care", "Regeneron Gets Breakthrough Therapy Status for Eylea - Analyst Blog", "Why I'd Avoid Pfizer Inc. Stock Despite the Dividend", "Biotech Stock Roundup: Auxilium an Acquisition Target, Amgen Submits another BLA - Analyst Blog", "3 Reasons Sanofi's Stock Could Fall", "Bayer/Regeneron Looking for Eylea Label Expansion in Japan - Analyst Blog", "Nasdaq 100 Movers: SPLS, FAST", "5 Stocks to Buy for September", "Amgen Seeks EU Approval for PCSK9 Inhibitor Evolocumab - Analyst Blog", "Biotech Stock Roundup: United Therapeutics Up on Court Ruling, Amgen Files PCSK9 Inhibitor - Analyst Blog", "S&P 500 Movers: WYNN, SPLS", "Nasdaq 100 Movers: REGN, YHOO", "Great Cholesterol Drug Data From Regeneron Pharmaceuticals Inc. and Sanofi SA, but Read the Fine Pri", "Regeneron/Sanofi Presents Encouraging Alirocumab Data - Analyst Blog", "Regeneron Pharmaceuticals' Pipeline Progress Raises Costs - Analyst Blog", "Amgen Submits Regulatory Application for PCSK9 Inhibitor - Analyst Blog", "Regeneron (REGN) is in Overbought Territory: What's Next? - Tale of the Tape", "7 Things Regeneron Pharmaceuticals Inc.'s Management Wants You to Know", "Nasdaq 100 Movers: INTU, GILD", "Nasdaq 100 Movers: WYNN, SPLS", "Biotech Stock Roundup: Amgen Plans Job Cuts, Regeneron's Eylea Continues to Impress - Analyst Blog", "Nasdaq 100 Movers: EXPD, WFM", "Sector Update: Health Care Stocks Weighed in Pre-Market Trade", "Sector Update: Health Care", "Regeneron Misses on Earnings in Q2, Eylea Drives Sales Beat - Analyst Blog", "Pre-Market Earnings Report for August 5, 2014 : CVS, EMR, ACT, REGN, ADM, HCP, MMP, ZTS, MSI, FE, MGM, IEP", "BioMarin Q2 Loss Narrower than Expected, Revenue Guidance Up - Analyst Blog", "Regeneron's Eye Drug Eylea Cleared in the EU for DME - Analyst Blog", "Nasdaq 100 Movers: GRMN, REGN", "Regeneron's Eylea Gets FDA Nod for Diabetic Macular Edema - Analyst Blog", "Bayer/Regeneron Continue to Progress with Eylea - Analyst Blog", "Sector Update: Health Care Shares Mixed Pre-Market", "Sector Update: Health Care", "Notable Two Hundred Day Moving Average Cross - REGN", "Biotech Stock Roundup: AbbVie Woos Shire with Revised Offer, Sarepta Slips on Eteplirsen Data - Analyst Blog", "S&P 500 Movers: GNW, EW", "Anacor's Kerydin Gets FDA Nod for Onychomycosis - Analyst Blog", "Nasdaq 100 Movers: GRMN, ORLY", "Biotech Stock Roundup: Regado Plunges on Study Update, Jazz Gains on Product Acquisition Deal - Analyst Blog", "Sanofi buys big chunk of Regeneron shares", "Nasdaq 100 Movers: BIDU, STX", "Glaxo/Theravance Drug Gets Japanese Approval - Analyst Blog", "Nasdaq 100 Movers: WYNN, REGN", "Sanofi/Regeneron Announce Encouraging Dupilumab Data - Analyst Blog", "Regado Slumps on Revolixys Study Halt - Analyst Blog", "Spectrum Pharmaceuticals Gains U.S. Approval of Beleodaq - Analyst Blog", "Insys Therapeutics' Epilepsy Therapy Gains FDA Orphan Drug Status - Analyst Blog", "RedHill Acquires Mesupron from Wilex - Analyst Blog", "Nasdaq 100 Movers: PAYX, LMCA", "Roche Acquires Seragon Pharma - Analyst Blog", "Regeneron Shares Jump as Sanofi Increases Stake - Analyst Blog", "Hospira Completes Orchid Facility Buy - Analyst Blog", "GlycoMimetics Up on FDA Agreement on Rivipansel Study - Analyst Blog", "Roche Launches cobas 6500 Testing System - Analyst Blog", "S&P 500 Movers: URBN, NFLX", "Glaxo/Theravance Seek to Expand Breo Ellipta's Label - Analyst Blog", "NPS Pharmaceuticals' Gattex Gets Updated Label - Analyst Blog", "Amicus Up on Migalastat Study Update - Analyst Blog", "Allergan Slides as Migraine Drug Fails to Win Approval - Analyst Blog", "Biotech Stock Roundup: Vertex Jumps on Phase III Data, MannKind Scores FDA Approval - Analyst Blog", "Nasdaq 100 Movers: SBAC, NFLX", "CHMP Positive on Bristol-Myers/Pfizer's Eliquis for New Indication - Analyst Blog", "AmerisourceBergen Acquires Minority Stake In Profarma - Analyst Blog", "Glaxo's Label Expansion Plans Marred as Arzerra Disappoints - Analyst Blog", "Gilead Seeks Japanese Approval for Sovaldi - Analyst Blog", "Roche's Avastin Receives Positive Opinion from CHMP - Analyst Blog", "AbbVie's Oncology Candidate Progresses - Analyst Blog", "Synageva's Sebelipase Alfa Meets Primary Endpoint in ARISE - Analyst Blog", "MannKind's Afrezza Approval a Key Milestone - Analyst Blog", "Eli Lilly & Boehringer's Insulin Copy Gets Positive EU Opinion - Analyst Blog", "Vertex Pharmaceuticals' Kalydeco Wins Positive EU Opinion - Analyst Blog", "Nasdaq 100 Movers: REGN, GMCR", "Coronado Falls on TSO Study Results - Analyst Blog", "BioDelivery Progresses with Clonidine Late-Stage Study - Analyst Blog", "AstraZeneca's Olaparib Fails to Impress FDA Panel - Analyst Blog", "Bayer Drugs Get Positive CHMP Recommendation - Analyst Blog", "McKesson Reiterates FY15 Earnings Guidance - Analyst Blog", "Hyperion's Ravicti Submission Accepted in EU - Analyst Blog", "Auxilium/Sobi's Xiapex Filed for Label Expansion - Analyst Blog", "Shire Snubs AbbVie Offer Again, Favorable Ruling for Vyvanse - Analyst Blog", "Vertex Pharma Skyrockets on Cystic Fibrosis Drug Trial Results - Analyst Blog", "Bayer Inks Hemophilia Deal with Dimension Therapeutics - Analyst Blog", "Clovis Oncology Initiates Study on CO-1686 - Analyst Blog", "Bristol-Myers Up on Nivolumab News - Analyst Blog", "XenoPort's XP23829 in Phase II Study - Analyst Blog", "AbbVie Raises Outlook amidst Shire Takeover Attempts - Analyst Blog", "RegeneRx and Lee's Pharmaceutical Dry Eye Drug Progresses - Analyst Blog", "Perrigo Settles Patent Dispute with Teva - Analyst Blog", "Merrimack Falls Steeply as Sanofi Returns Oncology Drug Rights - Analyst Blog", "Nasdaq 100 Movers: WFM, DISH", "Celgene Rises on Yet Another Stock Split - Analyst Blog", "Forest Laboratories Reports Positive Data on Viibryd - Analyst Blog", "Alnylam-TAP Collaborate for AAT Candidate - Analyst Blog", "Alkermes' Aripiprazole Lauroxil Looks Promising - Analyst Blog", "BioLineRx to Commence BL-8040 Study - Analyst Blog", "Insmed Soars on Arikayce's Breakthrough Designation - Analyst Blog", "Alexion's Soliris Gets Orphan Drug Status for New Indication - Analyst Blog", "Vertex Pharmaceuticals Crumbles on Analyst Worries - Analyst Blog", "Celgene's Pomalyst Data at European Hematology Association Shows Promise - Analyst Blog", "Cubist Gets Priority Review from FDA for Antibiotic Candidate - Analyst Blog", "Celgene's Vidaza Disappoints in Phase III Study - Analyst Blog", "Bristol-Myers Suffers a Legal Setback - Analyst Blog", "Sanofi/ Regeneron Present Postive Data on Sarilumab - Analyst Blog", "Exelon Moves Up In Market Cap Rank, Passing Regeneron Pharmaceuticals", "Vertex Pharmaceuticals' New Kalydeco Data Out - Analyst Blog", "Geron Gains as FDA Lifts Partial Hold on Imetelstat Study - Analyst Blog", "Encouraging Long-Term Data on Celgene's Otezla - Analyst Blog", "Gilead's HCV Combination Therapy Data Looks Promising - Analyst Blog", "Eli Lilly's Cyramza Misses Primary Goal in Liver Cancer Study - Analyst Blog", "Bayer Looking to Expand Eylea's Label - Analyst Blog", "Alkermes Progresses with its Late Stage Candidate - Analyst Blog", "NPS Pharma's Natpara Likely to be Reviewed in September - Analyst Blog", "Immunomedics' IMMU-132 Gets Orphan Drug Status - Analyst Blog", "Cubist Pharma's Antibiotics Portfolio Holds Promise - Analyst Blog", "GW Pharma Gets Fast-Track Designation for Epidiolex - Analyst Blog", "Orexigen Slumps as Obesity Drug Approval Delayed - Analyst Blog", "Biogen's Eloctate Approved in the U.S. - Analyst Blog", "REGN Makes Notable Cross Below Critical Moving Average", "XLF, PTH: Big ETF Outflows", "Nasdaq 100 Movers: REGN, GMCR", "Earnings Up at Jazz Pharma, Guidance Reiterated - Analyst Blog", "Regeneron Beats on Earnings, Revenues in Q1 - Analyst Blog", "Will Regeneron (REGN) Disappoint in Q1 Earnings? - Analyst Blog", "Orexigen's Upcoming Pipeline Catalyst - Analyst Blog", "Regeneron Inks Ophthalmology Deal - Analyst Blog", "Sanofi Misses on Q1 Earnings, Lackluster Revs - Analyst Blog", "Amicus Therapeutics (FOLD) Jumps: Stock Up 20.7% - Tale of the Tape", "GTX Inc. (GTXI) Jumps: Stock Up 14.4% - Tale of the Tape", "Amicus Up on Positive Data - Analyst Blog", "Regeneron Pharmaceuticals (REGN) Shares Cross Above 200 DMA", "Hyperion Set to Acquire Andromeda - Analyst Blog", "Pre-Market Earnings Report for May 8, 2014 : PCLN, VRX, PCP, APA, REGN, MGA, MPEL, HCN, ICE, DISH, LMCA, LINTA", "Progenics Finishes Patient Enrollment - Analyst Blog", "Johnson & Johnson Boosts Dividend 6.1% - Analyst Blog", "Emergent's BioThrax Gets Orphan Drug Status - Analyst Blog", "Alexion Posts Strong Earnings in Q1 - Analyst Blog", "Celgene Earnings Grow Year Over Year in Q1 - Analyst Blog", "Strong Q1 Earnings at Gilead on Stellar Sovaldi Sales - Analyst Blog", "Cubist Pharma Posts Weak Earnings on Soft Cubicin Sales - Analyst Blog", "Wider-than-Expected Q1 Loss at AMAG - Analyst Blog", "Biogen's Q1 Earnings Soar Y/Y on Tecfidera Sales - Analyst Blog", "Sarepta Soars on Eteplirsen Submission Plans - Analyst Blog", "Nasdaq 100 Movers: LLTC, YHOO", "Ambit Biosciences Slumps: AMBI Falls 13.0% in Session - Tale of the Tape", "Good News for BioMarin - Analyst Blog", "Bristol-Myers Seeks Approval for HIV Combo Drug - Analyst Blog", "Repros Completes Enrollment for Androxal Study - Analyst Blog", "Bristol-Myers, Samsung BioLogics Extend Ties - Analyst Blog", "FDA Nod for Merck's Grastek - Analyst Blog", "Portola's Betrixaban Study Design Published - Analyst Blog", "Another Earnings Beat from J&J, View Up - Analyst Blog", "Nasdaq 100 Movers: ISRG, REGN", "REGN Makes Notable Cross Below Critical Moving Average", "Anacor Enrolls First Patient in Study - Analyst Blog", "Aegerion Pharmaceuticals' Viability Threatened As Regulatory, Legal And Market Forces Close In", "Encouraging Results from Lexicon Candidate - Analyst Blog", "FDA Nod for Merck's Grastek - Analyst Blog", "Portola's Betrixaban Study Design Published - Analyst Blog", "Healthcare Stocks Slipping Near Final Bell; Regeneron, Sanofi Sink After Warning of FDA Probe", "Sector Update: Healthcare", "Update on Bayer/Regeneron's Eylea - Analyst Blog", "S&P 500 Movers: DRI, NEM", "Nasdaq 100 Movers: VIP, REGN", "IBB, BIIB, AMGN, REGN: ETF Outflow Alert", "Sanofi/Ardelyx Ink Deal - Analyst Blog", "Nasdaq 100 Movers: CHTR, INTU", "Regeneron Pharmaceuticals, Inc. (REGN): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report", "Weekly Insider Sells Highlight: MSFT, REGN, ATVI, MAA", "Sector Update: Healthcare Shares Flat Pre-Market; Regeneron Rises 2% on Q4 Beat", "Sector Update: Healthcare", "Market Wrap For February 11: Yellen Re-assures Markets & Wakes Up The Sleeping Bulls", "No Looking Back for Regeneron's Eylea - Analyst Blog", "Sector Update: Healthcare Shares Flat Pre-Market; Regeneron Rises 4% on Phase 3 Trial of Eylea", "Sector Update: Healthcare", "Will Regeneron (REGN) Disappoint in Q4? - Analyst Blog", "Pre-Market Earnings Report for February 11, 2014 : CVS, S, REGN, RAI, MMC, OMC, PCG, HCP, IR, ICE, ETR, HSIC", "Healthcare Stocks Still Adding to Late Gains; Regeneron Pharma Rises After Positive 2-Year Data for Eyesight Drug", "Sector Update: Healthcare", "Sanofi's Q4 Earnings Beat Overcast by Weak Guidance - Analyst Blog", "Regeneron Beats on Earnings, Revenues - Analyst Blog", "Regeneron Rises on Upbeat Eylea Q4 Outlook - Analyst Blog", "Update on Sanofi/REGN's Alirocumab - Analyst Blog", "Update on Eylea - Analyst Blog", "Bayer Files for Another Eylea Indication - Analyst Blog", "Bayer Progresses with Eylea - Analyst Blog", "Positive Data on Sanofi/REGN's Sarilumab - Analyst Blog", "European Shares Mostly Advance After Strong German Business Confidence Data", "LinkedIn, TripAdvisor, Google: Top Manager's Ideas", "Sector Update: Healthcare", "Bayer's Eye Drug Impresses - Analyst Blog", "Sector Update: Healthcare Shares Flat Pre-Market; Regeneron up 1% on Q3 Earnings", "Sector Update: Healthcare", "Trade the Earnings: Regeneron Pharmaceuticals", "Regeneron Beats Both Earnings and Revs - Analyst Blog", "Pre-Market Earnings Report for November 5, 2013 : CVS, EMR, D, DTV, TRP, REGN, CTSH, SRE, HCA, BDX, HCN, MPEL", "Sector Update: Healthcare Shares Mixed Pre-Market; Isis Up 1% on Plans to Investigate Muscular Atrophy Treatment", "Will AmerisourceBergen (ABC) Disappoint on Earnings? - Analyst Blog", "Is Mylan (MYL) Poised to Beat Earnings Estimates? - Analyst Blog", "Will Gilead (GILD) Disappoint in Q3? - Analyst Blog", "pSivida: Thoughts In The Aftermath Of The Complete Response Letter On Iluvien", "Positive Data on REGN/Sanofi's Drug - Analyst Blog", "Top Biotechnology ETF in Focus: PBE - ETF News And Commentary", "New Stock Coverage: Exciting New Chapter for Facebook", "Sanofi Misses on Q3 Earnings - Analyst Blog", "Market Close Report: NASDAQ Composite index closes at 3,722.18 up 6.21 points", "Orphan Drug Status for AEGR's Juxtapid in Japan - Analyst Blog", "New Stock Coverage: Bill Still to Come Due for JC Penney", "Market Close Report: NASDAQ Composite index closes at 3,612.61 up 22.74 points", "Sector Update: Healthcare Shares Higher; Pharmacyclics To Get $75 Mln Milestone Payment", "Sector Update: Healthcare", "Good News for Regeneron on Eylea - Analyst Blog", "Stock Upgrades: Tilly's Is a Teenage Dream", "Earnings Beat at Regeneron in Q2 - Analyst Blog", "Earnings Down, Outlook Lowered at Sanofi - Analyst Blog", "Sector Update: Healthcare Shares Flat Pre-Market; Endo Health'S Q2 Earnings Top Street Consensus", "Sector Update: Healthcare", "Pre-Market Earnings Report for August 6, 2013 : CVS, EMR, D, REGN, ADM, SE, CTSH, SRE, HCN, FE, PH, KORS", "Best Stocks: Isis, Gilead, Celgene, and Regeneron Take Over the Top Ranks", "Will Amgen (AMGN) Beat Earnings? - Analyst Blog", "Merrimack: Undervalued Because Of Misunderstanding And Miscommunication?", "Evenly Poised on Regeneron - Analyst Blog", "Market Close Report: NASDAQ Composite index closes at 3,443.20 down -38.98 points", "Market Close Report: NASDAQ Composite index closes at 3,482.18 up 30.05 points", "Stock Upgrades: France Likes What It Sees in Lululemon", "Positive Data on Bayer/REGN's Eye Drug - Analyst Blog", "OPKO Looks Lucrative As Acquired HGH-CTP Moves Into Phase III Trials", "Biogen Idec Inc. (BIIB): Today's Most Compelling Stock Buy", "Weekly Top Insider Sells: REGN", "The Panic Button: When to Hit It ... and Why", "Market Close Report: NASDAQ Composite index closes at 3,459.42 down -3.88 points", "Sanofi/REGN's Dupilumab Data Published - Analyst Blog", "Sanofi/REGN Commence Enrollment - Analyst Blog", "Stock Upgrades: Make a Mint (Julep) in Jim Beam Ahead of Kentucky Derby", "Market Close Report: NASDAQ Composite index closes at 3,378.63 up 38.01 points", "Market Close Report: NASDAQ Composite index closes at 3,424.05 up 22.57 points", "ECB Cuts Rates, Jobless Claims Hit New Five-Year Low", "Pre-Market Earnings Report for May 3, 2013 : DUK, ADP, REGN, SE, MCO, HST, SWN, IEP, NWL, PNW, BPL, LNT", "Market Close Report: NASDAQ Composite index closes at 3,299.13 down -29.66 points", "Market Wrap for Wednesday, May 1: Stocks Fall as Employment Data Weakens in April", "After Hours Most Active for Apr 30, 2013 : PCS, REGN, ORCL, FRAN, QQQ, EXP, S, MSFT, VOD, BAC, DDR, GE", "Minyanville's T3 Morning Market Call: Bulls and Bears Both Have Valid Arguments", "Eylea Drives Earnings at Regeneron - Analyst Blog", "Regeneron Touches 52-Week High - Analyst Blog", "Regeneron Rated Neutral Again - Analyst Blog", "Regeneron Aims HQ Expansion - Analyst Blog", "Regeneron Pharmaceuticals Inc (REGN): Today's Most Compelling Buy", "Regeneron to Earn More Royalty - Analyst Blog", "Sanofi/REGN Present Dupilumab Data - Analyst Blog", "Sanofi's Vaccine Backed by CHMP - Analyst Blog", "Market Close Report: NASDAQ Composite index closes at 3,264.63 up 48.14 points", "Eylea Drives Regeneron - Analyst Blog", "Pre-Market Earnings Report for February 14, 2013 : PEP, GM, APA, ABX, DTV, CVE, PPL, ALXN, SLF, WM, REGN, ECA", "Sanofi Shows Interest in Regeneron - Analyst Blog", "Sanofi's Diabetes Drug Gets EU Nod - Analyst Blog", "SNY/REGN's Zaltrap Approved in EU - Analyst Blog", "Safety Data on Omeros' OMS302 - Analyst Blog", "REGN Predicts Eylea Growth in 2013 - Analyst Blog", "Pipeline Progress at Bayer/Regeneron - Analyst Blog", "The Stock Market Teaches Bad Behavior", "European Approval for Eye-Drug Eylea - Analyst Blog", "Weekly Top Insider Sells: GOOG, ISRG, DG, and AAPL", "CHMP in Favor of Sanofi's Zaltrap - Analyst Blog", "Italy Lifts Ban on Novartis Vaccines - Analyst Blog", "Edward Owens' Vanguard Health Care Fund Does More Shedding Than Adding in Third Quarter", "Allergan Beats on EPS, Updates View - Analyst Blog", "Back to Neutral on Bayer - Analyst Blog", "Back to Neutral on Regeneron - Analyst Blog", "Detailed Data on Sanofi's Zaltrap - Analyst Blog", "Active Investment Management", "Regeneron Pharma on a High - Analyst Blog", "52-Week High Companies: ZMH, CVX, V, REGN, DFS", "Regeneron Pharmaceuticals: Continuous loss making company delivers 2-year 600% gain in share price", "Disciplined Columbia Fund Rallies From Mediocre 2011", "Strong Quarter at Regeneron - Analyst Blog", "Back to Neutral on Regeneron - Analyst Blog", "Good News for Regeneron/Sanofi - Analyst Blog", "Top-Performing Funds Latch On To Biotech And Discount Retail Stocks", "Regeneron Gets CRL - Analyst Blog", "Biotechs In Motion As New Drug Pipeline Brims", "Regeneron Tops, Lifts Eylea View - Analyst Blog", "Allergan-Molecular Extend Contracts - Analyst Blog", "52-Week High Companies: BAM, REGN, TRV, WFC", "S&P: Not All Mid-Cap ETFs Created Equal (MDY, VO)", "Eylea Drives Regeneron to Profit - Analyst Blog", "Priority Review for Zaltrap - Analyst Blog", "Still Neutral on Ardea Biosciences - Analyst Blog", "The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Sanofi, Pfizer, Bayer and Toyota Motor - Press Releases", "Pipeline Progress at Regeneron - Analyst Blog", "Regeneron Pharmaceuticals (REGN) - Bull of the Day", "Encouraging Data on Amgen Candidate - Analyst Blog", "Australian Clearance for Eye-Drug Eylea - Analyst Blog", "Regeneron Treads the Neutral Path - Analyst Blog", "Look To Mid Caps For Market-Beating Returns", "REGN Projects Strong Q4 Eylea Sales - Analyst Blog", "Regeneron Settles Dispute - Analyst Blog", "Regeneron's Eylea Data Unimpressive - Analyst Blog", "The Zacks Analyst Blog Highlights: Amgen, Sanofi, Regeneron, Alnylam and Coach - Press Releases", "Regeneron/Bayer Initiate Study - Analyst Blog", "Regeneron Seeks Label Expansion - Analyst Blog", "Regeneron Drug Cleared in the US - Analyst Blog", "Investing 101: Momentum Stocks with Insider Buying", "FDA Watch: 6 Biotechs Awaiting FDA Drug Approvals in 2011", "Hearty Profits: Companies Racing to Develop the Next Big Cholesterol Drug", "Investing 101: Finding Rallying Stocks Still Undervalued to Analyst Estimates", "Company News for December 6, 2011 - Corporate Summary", "Reporting This Week: Billion Dollar Companies With Insider Buying", "How Regeneron trade provides protection", "5 Rallying Biotech Stocks Being Snapped Up By Insiders", "U.S. Stock Indexes Lower on China's Surprise Interest Rate Hike; East Coast Storm Snarls Air Traffic", "Mid-Day Update: Stocks Lower as China's Interest Rate Move, East Coast Blizzard Drive Lackluster Session", "Stocks Mixed at Mid-Day as Investors Seek Direction in Shortened Trading Week", "Mid-Day Update: Stocks Mixed as Optimism from Tax Cut Fades, Euro Debt Weighs", "Top 10 list of unusual option activity", "Mid-Day Update: Stocks Trending Lower; Ireland Remains Investor Focus Through Session's First Half", "Amgen, Celgene and Novartis in the Fight Against Pancreatic Cancer", "Bull extends Regeneron position", "Stocks Lower on Ireland Worries, Wall Street Insider Trading Probe"], "Elapsed Time": ["2 DAYS AGO", "2 DAYS AGO", "2 DAYS AGO", "2 DAYS AGO", "2 DAYS AGO", "2 DAYS AGO", "2 DAYS AGO", "2 DAYS AGO", "2 DAYS AGO", "3 DAYS AGO", "3 DAYS AGO", "3 DAYS AGO", "4 DAYS AGO", "4 DAYS AGO", "4 DAYS AGO", "5 DAYS AGO", "3 DAYS AGO", "5 DAYS AGO", "JUN 7, 2020", "JUN 5, 2020", "JUN 5, 2020", "JUN 5, 2020", "JUN 3, 2020", "JUN 3, 2020", "5 DAYS AGO", "JUN 3, 2020", "JUN 3, 2020", "JUN 3, 2020", "JUN 2, 2020", "JUN 2, 2020", "JUN 2, 2020", "JUN 2, 2020", "JUN 3, 2020", "JUN 1, 2020", "JUN 1, 2020", "JUN 1, 2020", "JUN 1, 2020", "JUN 1, 2020", "JUN 1, 2020", "MAY 29, 2020", "JUN 2, 2020", "MAY 29, 2020", "MAY 28, 2020", "MAY 28, 2020", "MAY 27, 2020", "MAY 27, 2020", "MAY 27, 2020", "MAY 26, 2020", "MAY 29, 2020", "MAY 26, 2020", "MAY 26, 2020", "MAY 26, 2020", "MAY 26, 2020", "MAY 26, 2020", "MAY 26, 2020", "MAY 26, 2020", "MAY 26, 2020", "MAY 26, 2020", "MAY 25, 2020", "MAY 25, 2020", "MAY 22, 2020", "MAY 19, 2020", "MAY 18, 2020", "MAY 18, 2020", "MAY 26, 2020", "MAY 17, 2020", "MAY 15, 2020", "MAY 15, 2020", "MAY 15, 2020", "MAY 14, 2020", "MAY 13, 2020", "MAY 13, 2020", "MAY 17, 2020", "MAY 13, 2020", "MAY 10, 2020", "MAY 7, 2020", "MAY 6, 2020", "MAY 5, 2020", "MAY 5, 2020", "MAY 5, 2020", "MAY 13, 2020", "MAY 5, 2020", "MAY 5, 2020", "MAY 5, 2020", "MAY 5, 2020", "MAY 5, 2020", "MAY 5, 2020", "MAY 5, 2020", "MAY 5, 2020", "MAY 5, 2020", "MAY 5, 2020", "MAY 5, 2020", "MAY 5, 2020", "MAY 5, 2020", "MAY 5, 2020", "APR 30, 2020", "MAY 5, 2020", "APR 29, 2020", "APR 28, 2020", "APR 28, 2020", "APR 28, 2020", "APR 27, 2020", "APR 27, 2020", "APR 27, 2020", "APR 30, 2020", "APR 27, 2020", "APR 27, 2020", "APR 27, 2020", "APR 27, 2020", "APR 27, 2020", "APR 27, 2020", "APR 27, 2020", "APR 27, 2020", "APR 27, 2020", "APR 26, 2020", "APR 25, 2020", "APR 24, 2020", "APR 23, 2020", "APR 22, 2020", "APR 17, 2020", "APR 27, 2020", "APR 17, 2020", "APR 17, 2020", "APR 17, 2020", "APR 16, 2020", "APR 16, 2020", "APR 14, 2020", "APR 14, 2020", "APR 17, 2020", "APR 13, 2020", "APR 13, 2020", "APR 13, 2020", "APR 11, 2020", "APR 9, 2020", "APR 9, 2020", "APR 9, 2020", "APR 14, 2020", "APR 8, 2020", "APR 8, 2020", "APR 8, 2020", "APR 8, 2020", "APR 8, 2020", "APR 8, 2020", "APR 7, 2020", "APR 8, 2020", "APR 7, 2020", "APR 6, 2020", "APR 5, 2020", "APR 4, 2020", "APR 3, 2020", "APR 3, 2020", "APR 3, 2020", "APR 7, 2020", "APR 2, 2020", "APR 2, 2020", "APR 2, 2020", "APR 2, 2020", "APR 1, 2020", "APR 1, 2020", "MAR 31, 2020", "APR 3, 2020", "MAR 31, 2020", "MAR 31, 2020", "MAR 30, 2020", "MAR 30, 2020", "MAR 29, 2020", "MAR 27, 2020", "MAR 27, 2020", "MAR 31, 2020", "MAR 25, 2020", "MAR 25, 2020", "MAR 24, 2020", "MAR 24, 2020", "MAR 24, 2020", "MAR 24, 2020", "MAR 24, 2020", "MAR 27, 2020", "MAR 23, 2020", "MAR 22, 2020", "MAR 21, 2020", "MAR 21, 2020", "MAR 21, 2020", "MAR 20, 2020", "MAR 20, 2020", "MAR 23, 2020", "MAR 19, 2020", "MAR 19, 2020", "MAR 19, 2020", "MAR 18, 2020", "MAR 18, 2020", "MAR 17, 2020", "MAR 17, 2020", "MAR 19, 2020", "MAR 17, 2020", "MAR 17, 2020", "MAR 17, 2020", "MAR 17, 2020", "MAR 16, 2020", "MAR 16, 2020", "MAR 16, 2020", "MAR 17, 2020", "MAR 11, 2020", "MAR 11, 2020", "MAR 10, 2020", "MAR 10, 2020", "MAR 10, 2020", "MAR 9, 2020", "MAR 5, 2020", "MAR 13, 2020", "MAR 5, 2020", "MAR 4, 2020", "MAR 3, 2020", "MAR 2, 2020", "MAR 2, 2020", "FEB 29, 2020", "FEB 28, 2020", "MAR 5, 2020", "FEB 27, 2020", "FEB 27, 2020", "FEB 27, 2020", "FEB 25, 2020", "FEB 25, 2020", "FEB 25, 2020", "FEB 25, 2020", "FEB 28, 2020", "FEB 21, 2020", "FEB 18, 2020", "FEB 16, 2020", "FEB 12, 2020", "FEB 11, 2020", "FEB 6, 2020", "FEB 6, 2020", "FEB 24, 2020", "FEB 6, 2020", "FEB 6, 2020", "FEB 6, 2020", "FEB 6, 2020", "FEB 6, 2020", "FEB 6, 2020", "FEB 3, 2020", "FEB 6, 2020", "JAN 28, 2020", "JAN 24, 2020", "JAN 24, 2020", "JAN 23, 2020", "JAN 22, 2020", "JAN 19, 2020", "JAN 17, 2020", "JAN 28, 2020", "JAN 16, 2020", "JAN 15, 2020", "JAN 13, 2020", "JAN 10, 2020", "JAN 10, 2020", "JAN 9, 2020", "JAN 9, 2020", "JAN 16, 2020", "JAN 3, 2020", "JAN 2, 2020", "DEC 28, 2019", "DEC 24, 2019", "DEC 22, 2019", "DEC 19, 2019", "DEC 19, 2019", "JAN 9, 2020", "DEC 12, 2019", "DEC 10, 2019", "DEC 10, 2019", "DEC 9, 2019", "DEC 6, 2019", "DEC 5, 2019", "DEC 5, 2019", "DEC 17, 2019", "DEC 3, 2019", "DEC 2, 2019", "NOV 27, 2019", "NOV 26, 2019", "NOV 26, 2019", "NOV 26, 2019", "NOV 25, 2019", "DEC 5, 2019", "NOV 22, 2019", "NOV 21, 2019", "NOV 19, 2019", "NOV 18, 2019", "NOV 18, 2019", "NOV 18, 2019", "NOV 14, 2019", "NOV 25, 2019", "NOV 8, 2019", "NOV 8, 2019", "NOV 7, 2019", "NOV 7, 2019", "NOV 7, 2019", "NOV 6, 2019", "NOV 5, 2019", "NOV 14, 2019", "NOV 5, 2019", "NOV 5, 2019", "NOV 5, 2019", "NOV 5, 2019", "NOV 5, 2019", "NOV 5, 2019", "NOV 5, 2019", "NOV 5, 2019", "OCT 31, 2019", "OCT 29, 2019", "OCT 28, 2019", "OCT 26, 2019", "OCT 25, 2019", "OCT 24, 2019", "OCT 23, 2019", "NOV 5, 2019", "OCT 18, 2019", "OCT 17, 2019", "OCT 16, 2019", "OCT 14, 2019", "OCT 8, 2019", "OCT 3, 2019", "OCT 1, 2019", "OCT 23, 2019", "SEP 30, 2019", "SEP 24, 2019", "SEP 23, 2019", "SEP 20, 2019", "SEP 20, 2019", "SEP 20, 2019", "SEP 20, 2019", "OCT 1, 2019", "SEP 9, 2019", "SEP 9, 2019", "SEP 9, 2019", "SEP 6, 2019", "SEP 3, 2019", "AUG 22, 2019", "SEP 14, 2019", "AUG 20, 2019", "AUG 20, 2019", "AUG 14, 2019", "AUG 11, 2019", "AUG 10, 2019", "AUG 7, 2019", "AUG 6, 2019", "AUG 20, 2019", "AUG 6, 2019", "JUL 31, 2019", "JUL 30, 2019", "JUL 23, 2019", "JUL 22, 2019", "JUL 20, 2019", "JUL 15, 2019", "AUG 6, 2019", "JUL 11, 2019", "JUL 8, 2019", "JUN 30, 2019", "JUN 28, 2019", "JUN 27, 2019", "JUN 26, 2019", "JUN 25, 2019", "JUL 15, 2019", "JUN 21, 2019", "JUN 20, 2019", "JUN 20, 2019", "JUN 20, 2019", "JUN 20, 2019", "JUN 13, 2019", "JUN 10, 2019", "JUN 21, 2019", "MAY 30, 2019", "MAY 24, 2019", "MAY 13, 2019", "MAY 10, 2019", "MAY 9, 2019", "MAY 7, 2019", "MAY 7, 2019", "MAY 31, 2019", "MAY 7, 2019", "MAY 7, 2019", "MAY 5, 2019", "MAY 2, 2019", "MAY 2, 2019", "MAY 1, 2019", "APR 30, 2019", "MAY 7, 2019", "APR 25, 2019", "APR 24, 2019", "APR 22, 2019", "APR 16, 2019", "APR 16, 2019", "APR 16, 2019", "APR 15, 2019", "APR 28, 2019", "APR 15, 2019", "APR 15, 2019", "APR 12, 2019", "APR 12, 2019", "APR 12, 2019", "APR 12, 2019", "APR 11, 2019", "APR 15, 2019", "APR 11, 2019", "APR 10, 2019", "APR 9, 2019", "APR 8, 2019", "APR 8, 2019", "APR 8, 2019", "APR 5, 2019", "APR 11, 2019", "MAR 24, 2019", "MAR 21, 2019", "MAR 20, 2019", "MAR 19, 2019", "MAR 18, 2019", "MAR 18, 2019", "MAR 15, 2019", "APR 5, 2019", "MAR 13, 2019", "MAR 13, 2019", "MAR 13, 2019", "MAR 13, 2019", "MAR 13, 2019", "MAR 12, 2019", "MAR 11, 2019", "MAR 13, 2019", "MAR 11, 2019", "MAR 11, 2019", "MAR 8, 2019", "MAR 8, 2019", "MAR 6, 2019", "MAR 5, 2019", "MAR 4, 2019", "MAR 11, 2019", "FEB 26, 2019", "FEB 26, 2019", "FEB 25, 2019", "FEB 22, 2019", "FEB 20, 2019", "FEB 17, 2019", "FEB 17, 2019", "FEB 27, 2019", "FEB 13, 2019", "FEB 12, 2019", "FEB 12, 2019", "FEB 8, 2019", "FEB 7, 2019", "FEB 7, 2019", "FEB 6, 2019", "FEB 14, 2019", "FEB 6, 2019", "FEB 6, 2019", "FEB 6, 2019", "FEB 5, 2019", "FEB 5, 2019", "FEB 5, 2019", "FEB 4, 2019", "FEB 6, 2019", "JAN 31, 2019", "JAN 31, 2019", "JAN 30, 2019", "JAN 29, 2019", "JAN 28, 2019", "JAN 24, 2019", "JAN 23, 2019", "JAN 31, 2019", "JAN 22, 2019", "JAN 20, 2019", "JAN 18, 2019", "JAN 17, 2019", "JAN 16, 2019", "JAN 15, 2019", "JAN 15, 2019", "JAN 23, 2019", "JAN 9, 2019", "JAN 9, 2019", "JAN 7, 2019", "JAN 7, 2019", "JAN 7, 2019", "JAN 7, 2019", "JAN 7, 2019", "JAN 11, 2019", "JAN 4, 2019", "JAN 4, 2019", "JAN 4, 2019", "JAN 4, 2019", "JAN 4, 2019", "DEC 26, 2018", "DEC 18, 2018", "JAN 4, 2019", "DEC 16, 2018", "DEC 14, 2018", "DEC 12, 2018", "DEC 11, 2018", "DEC 11, 2018", "DEC 7, 2018", "DEC 17, 2018", "DEC 6, 2018", "DEC 4, 2018", "DEC 1, 2018", "NOV 30, 2018", "NOV 28, 2018", "NOV 28, 2018", "NOV 26, 2018", "DEC 6, 2018", "NOV 20, 2018", "NOV 18, 2018", "NOV 18, 2018", "NOV 16, 2018", "NOV 16, 2018", "NOV 14, 2018", "NOV 12, 2018", "NOV 21, 2018", "NOV 12, 2018", "NOV 12, 2018", "NOV 9, 2018", "NOV 9, 2018", "NOV 7, 2018", "NOV 6, 2018", "NOV 6, 2018", "NOV 12, 2018", "NOV 6, 2018", "NOV 6, 2018", "NOV 5, 2018", "NOV 5, 2018", "NOV 5, 2018", "NOV 5, 2018", "NOV 5, 2018", "NOV 6, 2018", "NOV 1, 2018", "NOV 1, 2018", "NOV 1, 2018", "OCT 31, 2018", "OCT 31, 2018", "OCT 31, 2018", "OCT 30, 2018", "NOV 2, 2018", "OCT 29, 2018", "OCT 29, 2018", "OCT 26, 2018", "OCT 26, 2018", "OCT 25, 2018", "OCT 25, 2018", "OCT 25, 2018", "OCT 30, 2018", "OCT 24, 2018", "OCT 24, 2018", "OCT 24, 2018", "OCT 24, 2018", "OCT 23, 2018", "OCT 22, 2018", "OCT 22, 2018", "OCT 25, 2018", "OCT 16, 2018", "OCT 16, 2018", "OCT 16, 2018", "OCT 10, 2018", "OCT 9, 2018", "OCT 8, 2018", "OCT 8, 2018", "OCT 17, 2018", "OCT 1, 2018", "SEP 28, 2018", "SEP 27, 2018", "SEP 27, 2018", "SEP 26, 2018", "SEP 25, 2018", "SEP 25, 2018", "OCT 1, 2018", "SEP 25, 2018", "SEP 24, 2018", "SEP 24, 2018", "SEP 21, 2018", "SEP 21, 2018", "SEP 20, 2018", "SEP 20, 2018", "SEP 25, 2018", "SEP 19, 2018", "SEP 18, 2018", "SEP 17, 2018", "SEP 17, 2018", "SEP 17, 2018", "SEP 13, 2018", "SEP 12, 2018", "SEP 19, 2018", "SEP 19, 2018", "SEP 12, 2018", "SEP 10, 2018", "SEP 7, 2018", "SEP 7, 2018", "SEP 6, 2018", "SEP 5, 2018", "SEP 12, 2018", "AUG 30, 2018", "AUG 29, 2018", "AUG 29, 2018", "AUG 29, 2018", "AUG 28, 2018", "AUG 23, 2018", "AUG 23, 2018", "SEP 4, 2018", "AUG 21, 2018", "AUG 21, 2018", "AUG 20, 2018", "AUG 19, 2018", "AUG 17, 2018", "AUG 17, 2018", "AUG 16, 2018", "AUG 22, 2018", "AUG 16, 2018", "AUG 16, 2018", "AUG 14, 2018", "AUG 14, 2018", "AUG 13, 2018", "AUG 13, 2018", "AUG 10, 2018", "AUG 16, 2018", "AUG 9, 2018", "AUG 8, 2018", "AUG 8, 2018", "AUG 8, 2018", "AUG 8, 2018", "AUG 6, 2018", "AUG 6, 2018", "AUG 9, 2018", "AUG 3, 2018", "AUG 3, 2018", "AUG 3, 2018", "AUG 2, 2018", "AUG 2, 2018", "AUG 2, 2018", "AUG 2, 2018", "AUG 6, 2018", "AUG 3, 2018", "JUL 31, 2018", "JUL 31, 2018", "JUL 31, 2018", "JUL 30, 2018", "JUL 27, 2018", "AUG 1, 2018", "JUL 23, 2018", "JUL 19, 2018", "JUL 19, 2018", "JUL 17, 2018", "JUL 13, 2018", "JUL 9, 2018", "JUL 6, 2018", "JUL 27, 2018", "JUL 5, 2018", "JUN 29, 2018", "JUN 29, 2018", "JUN 27, 2018", "JUN 27, 2018", "JUN 25, 2018", "JUN 23, 2018", "JUL 6, 2018", "JUL 5, 2018", "JUN 14, 2018", "JUN 13, 2018", "JUN 13, 2018", "JUN 11, 2018", "JUN 7, 2018", "JUN 22, 2018", "JUN 6, 2018", "JUN 5, 2018", "JUN 4, 2018", "MAY 31, 2018", "MAY 30, 2018", "MAY 24, 2018", "MAY 23, 2018", "JUN 7, 2018", "MAY 17, 2018", "MAY 16, 2018", "MAY 16, 2018", "MAY 15, 2018", "MAY 14, 2018", "MAY 11, 2018", "MAY 11, 2018", "MAY 18, 2018", "MAY 11, 2018", "MAY 11, 2018", "MAY 11, 2018", "MAY 11, 2018", "MAY 10, 2018", "MAY 10, 2018", "MAY 8, 2018", "MAY 11, 2018", "MAY 11, 2018", "MAY 11, 2018", "MAY 5, 2018", "MAY 4, 2018", "MAY 3, 2018", "MAY 3, 2018", "MAY 3, 2018", "MAY 7, 2018", "MAY 3, 2018", "MAY 3, 2018", "MAY 2, 2018", "MAY 2, 2018", "MAY 1, 2018", "MAY 1, 2018", "APR 30, 2018", "MAY 3, 2018", "APR 27, 2018", "APR 27, 2018", "APR 27, 2018", "APR 26, 2018", "APR 25, 2018", "APR 25, 2018", "APR 17, 2018", "APR 27, 2018", "APR 15, 2018", "APR 15, 2018", "APR 10, 2018", "APR 9, 2018", "APR 6, 2018", "APR 6, 2018", "APR 6, 2018", "APR 17, 2018", "APR 5, 2018", "APR 5, 2018", "APR 4, 2018", "APR 4, 2018", "APR 4, 2018", "APR 3, 2018", "APR 3, 2018", "APR 6, 2018", "APR 3, 2018", "APR 3, 2018", "APR 2, 2018", "APR 2, 2018", "APR 2, 2018", "MAR 29, 2018", "MAR 29, 2018", "APR 3, 2018", "MAR 29, 2018", "MAR 28, 2018", "MAR 28, 2018", "MAR 27, 2018", "MAR 27, 2018", "MAR 26, 2018", "MAR 26, 2018", "MAR 29, 2018", "MAR 24, 2018", "MAR 23, 2018", "MAR 23, 2018", "MAR 23, 2018", "MAR 22, 2018", "MAR 22, 2018", "MAR 22, 2018", "MAR 26, 2018", "MAR 21, 2018", "MAR 21, 2018", "MAR 21, 2018", "MAR 21, 2018", "MAR 20, 2018", "MAR 20, 2018", "MAR 22, 2018", "MAR 19, 2018", "MAR 19, 2018", "MAR 19, 2018", "MAR 19, 2018", "MAR 18, 2018", "MAR 16, 2018", "MAR 16, 2018", "MAR 19, 2018", "MAR 15, 2018", "MAR 15, 2018", "MAR 15, 2018", "MAR 15, 2018", "MAR 15, 2018", "MAR 14, 2018", "MAR 14, 2018", "MAR 16, 2018", "MAR 14, 2018", "MAR 14, 2018", "MAR 14, 2018", "MAR 14, 2018", "MAR 13, 2018", "MAR 13, 2018", "MAR 13, 2018", "MAR 14, 2018", "MAR 12, 2018", "MAR 12, 2018", "MAR 12, 2018", "MAR 12, 2018", "MAR 9, 2018", "MAR 9, 2018", "MAR 8, 2018", "MAR 12, 2018", "MAR 8, 2018", "MAR 8, 2018", "MAR 8, 2018", "MAR 8, 2018", "MAR 8, 2018", "MAR 8, 2018", "MAR 8, 2018", "MAR 8, 2018", "MAR 6, 2018", "MAR 6, 2018", "MAR 6, 2018", "MAR 6, 2018", "MAR 6, 2018", "MAR 6, 2018", "MAR 7, 2018", "MAR 5, 2018", "MAR 5, 2018", "MAR 2, 2018", "MAR 2, 2018", "MAR 2, 2018", "MAR 2, 2018", "MAR 2, 2018", "MAR 5, 2018", "MAR 1, 2018", "FEB 28, 2018", "FEB 28, 2018", "FEB 28, 2018", "FEB 28, 2018", "FEB 28, 2018", "FEB 28, 2018", "MAR 2, 2018", "FEB 27, 2018", "FEB 27, 2018", "FEB 26, 2018", "FEB 23, 2018", "FEB 23, 2018", "FEB 20, 2018", "FEB 20, 2018", "FEB 28, 2018", "FEB 16, 2018", "FEB 16, 2018", "FEB 14, 2018", "FEB 8, 2018", "FEB 8, 2018", "FEB 8, 2018", "FEB 8, 2018", "FEB 20, 2018", "FEB 8, 2018", "FEB 7, 2018", "FEB 7, 2018", "FEB 7, 2018", "FEB 7, 2018", "FEB 6, 2018", "FEB 5, 2018", "FEB 8, 2018", "FEB 1, 2018", "JAN 31, 2018", "JAN 31, 2018", "JAN 23, 2018", "JAN 23, 2018", "JAN 22, 2018", "JAN 17, 2018", "FEB 5, 2018", "FEB 1, 2018", "JAN 31, 2018", "JAN 10, 2018", "JAN 10, 2018", "JAN 9, 2018", "JAN 9, 2018", "JAN 9, 2018", "JAN 17, 2018", "JAN 8, 2018", "JAN 8, 2018", "JAN 4, 2018", "JAN 3, 2018", "JAN 2, 2018", "JAN 1, 2018", "DEC 31, 2017", "JAN 8, 2018", "DEC 28, 2017", "DEC 26, 2017", "DEC 20, 2017", "DEC 19, 2017", "DEC 19, 2017", "DEC 18, 2017", "DEC 15, 2017", "DEC 29, 2017", "DEC 13, 2017", "DEC 13, 2017", "DEC 13, 2017", "DEC 12, 2017", "DEC 11, 2017", "DEC 11, 2017", "DEC 8, 2017", "DEC 15, 2017", "DEC 13, 2017", "DEC 6, 2017", "DEC 4, 2017", "DEC 4, 2017", "DEC 1, 2017", "NOV 30, 2017", "NOV 29, 2017", "DEC 8, 2017", "NOV 27, 2017", "NOV 27, 2017", "NOV 27, 2017", "NOV 20, 2017", "NOV 16, 2017", "NOV 16, 2017", "NOV 13, 2017", "NOV 28, 2017", "NOV 9, 2017", "NOV 9, 2017", "NOV 9, 2017", "NOV 8, 2017", "NOV 8, 2017", "NOV 8, 2017", "NOV 8, 2017", "NOV 13, 2017", "NOV 7, 2017", "NOV 7, 2017", "NOV 6, 2017", "NOV 3, 2017", "NOV 3, 2017", "NOV 3, 2017", "NOV 2, 2017", "NOV 8, 2017", "OCT 26, 2017", "OCT 26, 2017", "OCT 26, 2017", "OCT 25, 2017", "OCT 24, 2017", "OCT 20, 2017", "OCT 20, 2017", "NOV 1, 2017", "OCT 18, 2017", "OCT 17, 2017", "OCT 16, 2017", "OCT 16, 2017", "OCT 16, 2017", "OCT 16, 2017", "OCT 13, 2017", "OCT 18, 2017", "OCT 11, 2017", "OCT 11, 2017", "OCT 10, 2017", "OCT 6, 2017", "OCT 6, 2017", "OCT 5, 2017", "OCT 5, 2017", "OCT 11, 2017", "OCT 3, 2017", "OCT 3, 2017", "OCT 3, 2017", "OCT 3, 2017", "OCT 3, 2017", "OCT 3, 2017", "OCT 2, 2017", "OCT 4, 2017", "OCT 3, 2017", "OCT 2, 2017", "OCT 2, 2017", "SEP 29, 2017", "SEP 28, 2017", "SEP 27, 2017", "SEP 26, 2017", "OCT 2, 2017", "SEP 25, 2017", "SEP 22, 2017", "SEP 22, 2017", "SEP 21, 2017", "SEP 21, 2017", "SEP 21, 2017", "SEP 20, 2017", "SEP 25, 2017", "SEP 19, 2017", "SEP 19, 2017", "SEP 19, 2017", "SEP 18, 2017", "SEP 18, 2017", "SEP 18, 2017", "SEP 15, 2017", "SEP 20, 2017", "SEP 15, 2017", "SEP 14, 2017", "SEP 14, 2017", "SEP 14, 2017", "SEP 13, 2017", "SEP 13, 2017", "SEP 13, 2017", "SEP 15, 2017", "SEP 12, 2017", "SEP 12, 2017", "SEP 12, 2017", "SEP 12, 2017", "SEP 12, 2017", "SEP 11, 2017", "SEP 11, 2017", "SEP 13, 2017", "SEP 11, 2017", "SEP 11, 2017", "SEP 11, 2017", "SEP 11, 2017", "SEP 11, 2017", "SEP 11, 2017", "SEP 8, 2017", "SEP 11, 2017", "SEP 8, 2017", "SEP 8, 2017", "SEP 8, 2017", "SEP 7, 2017", "SEP 7, 2017", "SEP 7, 2017", "SEP 7, 2017", "SEP 8, 2017", "SEP 6, 2017", "SEP 6, 2017", "SEP 6, 2017", "SEP 6, 2017", "SEP 5, 2017", "SEP 5, 2017", "SEP 5, 2017", "SEP 7, 2017", "SEP 6, 2017", "SEP 1, 2017", "SEP 1, 2017", "AUG 31, 2017", "AUG 31, 2017", "AUG 31, 2017", "AUG 30, 2017", "SEP 4, 2017", "AUG 29, 2017", "AUG 29, 2017", "AUG 29, 2017", "AUG 29, 2017", "AUG 29, 2017", "AUG 28, 2017", "AUG 28, 2017", "AUG 30, 2017", "AUG 29, 2017", "AUG 25, 2017", "AUG 25, 2017", "AUG 23, 2017", "AUG 23, 2017", "AUG 22, 2017", "AUG 22, 2017", "AUG 28, 2017", "AUG 22, 2017", "AUG 22, 2017", "AUG 22, 2017", "AUG 22, 2017", "AUG 21, 2017", "AUG 18, 2017", "AUG 17, 2017", "AUG 22, 2017", "AUG 22, 2017", "AUG 16, 2017", "AUG 16, 2017", "AUG 16, 2017", "AUG 16, 2017", "AUG 15, 2017", "AUG 14, 2017", "AUG 17, 2017", "AUG 10, 2017", "AUG 10, 2017", "AUG 9, 2017", "AUG 9, 2017", "AUG 8, 2017", "AUG 8, 2017", "AUG 7, 2017", "AUG 11, 2017", "AUG 10, 2017", "AUG 3, 2017", "AUG 3, 2017", "AUG 2, 2017", "AUG 1, 2017", "AUG 1, 2017", "JUL 31, 2017", "AUG 4, 2017", "AUG 3, 2017", "JUL 26, 2017", "JUL 24, 2017", "JUL 24, 2017", "JUL 21, 2017", "JUL 20, 2017", "JUL 20, 2017", "JUL 28, 2017", "JUL 11, 2017", "JUL 10, 2017", "JUL 6, 2017", "JUL 6, 2017", "JUL 6, 2017", "JUL 6, 2017", "JUL 20, 2017", "JUL 5, 2017", "JUL 3, 2017", "JUL 3, 2017", "JUN 30, 2017", "JUN 30, 2017", "JUN 30, 2017", "JUN 30, 2017", "JUL 5, 2017", "JUL 5, 2017", "JUN 29, 2017", "JUN 29, 2017", "JUN 29, 2017", "JUN 29, 2017", "JUN 29, 2017", "JUN 28, 2017", "JUN 30, 2017", "JUN 28, 2017", "JUN 28, 2017", "JUN 27, 2017", "JUN 27, 2017", "JUN 27, 2017", "JUN 27, 2017", "JUN 27, 2017", "JUN 28, 2017", "JUN 26, 2017", "JUN 23, 2017", "JUN 23, 2017", "JUN 23, 2017", "JUN 23, 2017", "JUN 23, 2017", "JUN 23, 2017", "JUN 27, 2017", "JUN 22, 2017", "JUN 22, 2017", "JUN 22, 2017", "JUN 22, 2017", "JUN 22, 2017", "JUN 22, 2017", "JUN 22, 2017", "JUN 23, 2017", "JUN 21, 2017", "JUN 21, 2017", "JUN 21, 2017", "JUN 21, 2017", "JUN 21, 2017", "JUN 21, 2017", "JUN 20, 2017", "JUN 22, 2017", "JUN 20, 2017", "JUN 20, 2017", "JUN 20, 2017", "JUN 20, 2017", "JUN 20, 2017", "JUN 20, 2017", "JUN 20, 2017", "JUN 20, 2017", "JUN 19, 2017", "JUN 19, 2017", "JUN 16, 2017", "JUN 14, 2017", "JUN 14, 2017", "JUN 14, 2017", "JUN 13, 2017", "JUN 20, 2017", "JUN 13, 2017", "JUN 12, 2017", "JUN 12, 2017", "JUN 9, 2017", "JUN 9, 2017", "JUN 8, 2017", "JUN 7, 2017", "JUN 13, 2017", "JUN 6, 2017", "JUN 6, 2017", "JUN 5, 2017", "JUN 5, 2017", "JUN 5, 2017", "JUN 4, 2017", "JUN 2, 2017", "JUN 7, 2017", "JUN 2, 2017", "JUN 2, 2017", "JUN 2, 2017", "JUN 1, 2017", "JUN 1, 2017", "JUN 1, 2017", "JUN 1, 2017", "JUN 2, 2017", "JUN 2, 2017", "JUN 2, 2017", "MAY 31, 2017", "MAY 30, 2017", "MAY 30, 2017", "MAY 30, 2017", "MAY 25, 2017", "MAY 31, 2017", "MAY 24, 2017", "MAY 24, 2017", "MAY 23, 2017", "MAY 23, 2017", "MAY 22, 2017", "MAY 22, 2017", "MAY 19, 2017", "MAY 25, 2017", "MAY 17, 2017", "MAY 17, 2017", "MAY 15, 2017", "MAY 15, 2017", "MAY 15, 2017", "MAY 12, 2017", "MAY 12, 2017", "MAY 17, 2017", "MAY 17, 2017", "MAY 12, 2017", "MAY 11, 2017", "MAY 11, 2017", "MAY 11, 2017", "MAY 11, 2017", "MAY 10, 2017", "MAY 12, 2017", "MAY 9, 2017", "MAY 9, 2017", "MAY 5, 2017", "MAY 5, 2017", "MAY 4, 2017", "MAY 4, 2017", "MAY 4, 2017", "MAY 9, 2017", "MAY 4, 2017", "MAY 4, 2017", "MAY 4, 2017", "MAY 4, 2017", "MAY 4, 2017", "MAY 3, 2017", "MAY 3, 2017", "MAY 4, 2017", "MAY 3, 2017", "MAY 3, 2017", "MAY 2, 2017", "MAY 1, 2017", "APR 30, 2017", "APR 29, 2017", "APR 28, 2017", "MAY 3, 2017", "APR 28, 2017", "APR 28, 2017", "APR 28, 2017", "APR 28, 2017", "APR 28, 2017", "APR 28, 2017", "APR 27, 2017", "APR 28, 2017", "APR 26, 2017", "APR 24, 2017", "APR 21, 2017", "APR 17, 2017", "APR 16, 2017", "APR 12, 2017", "APR 12, 2017", "APR 27, 2017", "APR 10, 2017", "APR 8, 2017", "APR 7, 2017", "APR 4, 2017", "APR 3, 2017", "MAR 31, 2017", "MAR 30, 2017", "APR 12, 2017", "MAR 29, 2017", "MAR 29, 2017", "MAR 29, 2017", "MAR 28, 2017", "MAR 26, 2017", "MAR 23, 2017", "MAR 22, 2017", "MAR 30, 2017", "MAR 17, 2017", "MAR 17, 2017", "MAR 17, 2017", "MAR 16, 2017", "MAR 16, 2017", "MAR 14, 2017", "MAR 11, 2017", "MAR 20, 2017", "MAR 10, 2017", "MAR 9, 2017", "MAR 9, 2017", "MAR 9, 2017", "MAR 9, 2017", "MAR 9, 2017", "MAR 8, 2017", "MAR 10, 2017", "MAR 6, 2017", "MAR 2, 2017", "MAR 2, 2017", "MAR 1, 2017", "FEB 27, 2017", "FEB 27, 2017", "FEB 23, 2017", "MAR 7, 2017", "FEB 15, 2017", "FEB 15, 2017", "FEB 15, 2017", "FEB 15, 2017", "FEB 13, 2017", "FEB 13, 2017", "FEB 13, 2017", "FEB 16, 2017", "FEB 9, 2017", "FEB 9, 2017", "FEB 9, 2017", "FEB 8, 2017", "FEB 8, 2017", "FEB 8, 2017", "FEB 8, 2017", "FEB 10, 2017", "FEB 3, 2017", "FEB 2, 2017", "FEB 1, 2017", "FEB 1, 2017", "JAN 31, 2017", "JAN 30, 2017", "JAN 27, 2017", "FEB 3, 2017", "FEB 3, 2017", "JAN 24, 2017", "JAN 22, 2017", "JAN 20, 2017", "JAN 18, 2017", "JAN 18, 2017", "JAN 17, 2017", "JAN 26, 2017", "JAN 11, 2017", "JAN 11, 2017", "JAN 11, 2017", "JAN 10, 2017", "JAN 10, 2017", "JAN 10, 2017", "JAN 10, 2017", "JAN 15, 2017", "JAN 9, 2017", "JAN 9, 2017", "JAN 9, 2017", "JAN 9, 2017", "JAN 9, 2017", "JAN 9, 2017", "JAN 8, 2017", "JAN 9, 2017", "JAN 7, 2017", "JAN 6, 2017", "JAN 6, 2017", "JAN 6, 2017", "JAN 6, 2017", "JAN 6, 2017", "JAN 6, 2017", "JAN 7, 2017", "JAN 6, 2017", "JAN 5, 2017", "JAN 4, 2017", "JAN 4, 2017", "JAN 1, 2017", "DEC 30, 2016", "DEC 29, 2016", "JAN 6, 2017", "DEC 28, 2016", "DEC 27, 2016", "DEC 27, 2016", "DEC 21, 2016", "DEC 21, 2016", "DEC 19, 2016", "DEC 19, 2016", "DEC 29, 2016", "DEC 19, 2016", "DEC 16, 2016", "DEC 15, 2016", "DEC 14, 2016", "DEC 14, 2016", "DEC 13, 2016", "DEC 13, 2016", "DEC 19, 2016", "DEC 12, 2016", "DEC 12, 2016", "DEC 12, 2016", "DEC 12, 2016", "DEC 12, 2016", "DEC 12, 2016", "DEC 12, 2016", "DEC 12, 2016", "DEC 9, 2016", "DEC 8, 2016", "DEC 7, 2016", "DEC 6, 2016", "DEC 1, 2016", "DEC 1, 2016", "NOV 30, 2016", "DEC 9, 2016", "NOV 23, 2016", "NOV 22, 2016", "NOV 21, 2016", "NOV 18, 2016", "NOV 18, 2016", "NOV 18, 2016", "NOV 18, 2016", "NOV 29, 2016", "NOV 17, 2016", "NOV 17, 2016", "NOV 16, 2016", "NOV 15, 2016", "NOV 15, 2016", "NOV 14, 2016", "NOV 10, 2016", "NOV 18, 2016", "NOV 17, 2016", "NOV 9, 2016", "NOV 9, 2016", "NOV 9, 2016", "NOV 9, 2016", "NOV 8, 2016", "NOV 8, 2016", "NOV 10, 2016", "NOV 7, 2016", "NOV 4, 2016", "NOV 4, 2016", "NOV 4, 2016", "NOV 4, 2016", "NOV 4, 2016", "NOV 4, 2016", "NOV 7, 2016", "NOV 3, 2016", "NOV 3, 2016", "NOV 1, 2016", "NOV 1, 2016", "NOV 1, 2016", "NOV 1, 2016", "OCT 31, 2016", "NOV 3, 2016", "OCT 30, 2016", "OCT 27, 2016", "OCT 26, 2016", "OCT 25, 2016", "OCT 24, 2016", "OCT 19, 2016", "OCT 18, 2016", "OCT 31, 2016", "OCT 13, 2016", "OCT 13, 2016", "OCT 13, 2016", "OCT 13, 2016", "OCT 13, 2016", "OCT 13, 2016", "OCT 12, 2016", "OCT 14, 2016", "OCT 11, 2016", "OCT 10, 2016", "OCT 10, 2016", "OCT 10, 2016", "OCT 8, 2016", "OCT 8, 2016", "OCT 5, 2016", "OCT 12, 2016", "OCT 3, 2016", "OCT 1, 2016", "SEP 30, 2016", "SEP 30, 2016", "SEP 30, 2016", "SEP 30, 2016", "SEP 30, 2016", "OCT 5, 2016", "OCT 3, 2016", "OCT 1, 2016", "SEP 30, 2016", "SEP 27, 2016", "SEP 27, 2016", "SEP 26, 2016", "SEP 26, 2016", "SEP 29, 2016", "SEP 23, 2016", "SEP 21, 2016", "SEP 21, 2016", "SEP 14, 2016", "SEP 8, 2016", "SEP 2, 2016", "SEP 2, 2016", "SEP 26, 2016", "AUG 31, 2016", "AUG 31, 2016", "AUG 29, 2016", "AUG 27, 2016", "AUG 24, 2016", "AUG 24, 2016", "SEP 1, 2016", "AUG 24, 2016", "AUG 24, 2016", "AUG 23, 2016", "AUG 22, 2016", "AUG 18, 2016", "AUG 16, 2016", "AUG 15, 2016", "AUG 24, 2016", "AUG 11, 2016", "AUG 11, 2016", "AUG 10, 2016", "AUG 8, 2016", "AUG 4, 2016", "AUG 4, 2016", "AUG 14, 2016", "AUG 4, 2016", "AUG 3, 2016", "AUG 3, 2016", "AUG 3, 2016", "AUG 3, 2016", "AUG 1, 2016", "JUL 29, 2016", "AUG 4, 2016", "JUL 21, 2016", "JUL 20, 2016", "JUL 19, 2016", "JUL 18, 2016", "JUL 14, 2016", "JUL 13, 2016", "JUL 12, 2016", "JUL 27, 2016", "JUL 7, 2016", "JUL 7, 2016", "JUL 4, 2016", "JUL 1, 2016", "JUN 29, 2016", "JUN 29, 2016", "JUL 12, 2016", "JUN 23, 2016", "JUN 22, 2016", "JUN 21, 2016", "JUN 14, 2016", "JUN 13, 2016", "JUN 13, 2016", "JUN 10, 2016", "JUN 25, 2016", "JUN 8, 2016", "JUN 6, 2016", "JUN 4, 2016", "JUN 1, 2016", "MAY 27, 2016", "MAY 27, 2016", "MAY 24, 2016", "JUN 9, 2016", "MAY 19, 2016", "MAY 16, 2016", "MAY 9, 2016", "MAY 9, 2016", "MAY 9, 2016", "MAY 5, 2016", "MAY 5, 2016", "MAY 24, 2016", "MAY 4, 2016", "MAY 4, 2016", "MAY 4, 2016", "MAY 3, 2016", "MAY 3, 2016", "MAY 3, 2016", "MAY 2, 2016", "MAY 5, 2016", "MAY 4, 2016", "APR 27, 2016", "APR 22, 2016", "APR 21, 2016", "APR 20, 2016", "APR 20, 2016", "APR 20, 2016", "MAY 2, 2016", "APR 19, 2016", "APR 14, 2016", "APR 14, 2016", "APR 12, 2016", "APR 12, 2016", "APR 12, 2016", "APR 11, 2016", "APR 19, 2016", "APR 19, 2016", "APR 7, 2016", "APR 7, 2016", "APR 6, 2016", "APR 5, 2016", "APR 5, 2016", "APR 11, 2016", "APR 5, 2016", "APR 5, 2016", "APR 5, 2016", "APR 4, 2016", "APR 4, 2016", "APR 4, 2016", "APR 4, 2016", "APR 5, 2016", "APR 1, 2016", "APR 1, 2016", "APR 1, 2016", "APR 1, 2016", "APR 1, 2016", "APR 1, 2016", "APR 1, 2016", "APR 1, 2016", "APR 1, 2016", "MAR 24, 2016", "MAR 18, 2016", "MAR 18, 2016", "MAR 18, 2016", "MAR 18, 2016", "APR 1, 2016", "MAR 28, 2016", "MAR 17, 2016", "MAR 17, 2016", "MAR 16, 2016", "MAR 15, 2016", "MAR 14, 2016", "MAR 11, 2016", "MAR 17, 2016", "MAR 9, 2016", "MAR 9, 2016", "MAR 9, 2016", "MAR 8, 2016", "MAR 7, 2016", "MAR 6, 2016", "MAR 6, 2016", "MAR 11, 2016", "MAR 4, 2016", "MAR 3, 2016", "MAR 2, 2016", "FEB 23, 2016", "FEB 22, 2016", "FEB 19, 2016", "FEB 18, 2016", "MAR 4, 2016", "FEB 17, 2016", "FEB 12, 2016", "FEB 11, 2016", "FEB 10, 2016", "FEB 10, 2016", "FEB 9, 2016", "FEB 9, 2016", "FEB 17, 2016", "FEB 8, 2016", "FEB 6, 2016", "FEB 5, 2016", "FEB 5, 2016", "FEB 5, 2016", "FEB 3, 2016", "FEB 2, 2016", "FEB 9, 2016", "FEB 2, 2016", "JAN 26, 2016", "JAN 21, 2016", "JAN 20, 2016", "JAN 15, 2016", "JAN 13, 2016", "JAN 13, 2016", "FEB 2, 2016", "JAN 12, 2016", "JAN 11, 2016", "JAN 10, 2016", "JAN 9, 2016", "JAN 6, 2016", "JAN 6, 2016", "JAN 6, 2016", "JAN 12, 2016", "DEC 31, 2015", "DEC 31, 2015", "DEC 30, 2015", "DEC 28, 2015", "DEC 26, 2015", "DEC 24, 2015", "DEC 22, 2015", "JAN 4, 2016", "DEC 31, 2015", "DEC 17, 2015", "DEC 17, 2015", "DEC 17, 2015", "DEC 16, 2015", "DEC 15, 2015", "DEC 14, 2015", "DEC 21, 2015", "DEC 11, 2015", "DEC 9, 2015", "DEC 4, 2015", "DEC 4, 2015", "DEC 3, 2015", "DEC 1, 2015", "DEC 1, 2015", "DEC 12, 2015", "NOV 23, 2015", "NOV 21, 2015", "NOV 18, 2015", "NOV 14, 2015", "NOV 13, 2015", "NOV 10, 2015", "NOV 10, 2015", "NOV 30, 2015", "NOV 4, 2015", "NOV 4, 2015", "NOV 4, 2015", "NOV 4, 2015", "NOV 3, 2015", "NOV 3, 2015", "NOV 3, 2015", "NOV 5, 2015", "OCT 29, 2015", "OCT 27, 2015", "OCT 26, 2015", "OCT 21, 2015", "OCT 20, 2015", "OCT 19, 2015", "OCT 18, 2015", "NOV 2, 2015", "OCT 12, 2015", "OCT 12, 2015", "OCT 12, 2015", "OCT 8, 2015", "OCT 8, 2015", "OCT 7, 2015", "OCT 14, 2015", "OCT 7, 2015", "OCT 7, 2015", "OCT 7, 2015", "OCT 7, 2015", "OCT 6, 2015", "OCT 6, 2015", "OCT 5, 2015", "OCT 7, 2015", "OCT 5, 2015", "OCT 5, 2015", "OCT 2, 2015", "OCT 2, 2015", "OCT 2, 2015", "OCT 2, 2015", "OCT 2, 2015", "OCT 5, 2015", "OCT 1, 2015", "OCT 1, 2015", "OCT 1, 2015", "OCT 1, 2015", "OCT 1, 2015", "SEP 30, 2015", "SEP 30, 2015", "OCT 2, 2015", "SEP 30, 2015", "SEP 30, 2015", "SEP 29, 2015", "SEP 29, 2015", "SEP 29, 2015", "SEP 29, 2015", "SEP 30, 2015", "SEP 28, 2015", "SEP 28, 2015", "SEP 28, 2015", "SEP 25, 2015", "SEP 25, 2015", "SEP 25, 2015", "SEP 25, 2015", "SEP 29, 2015", "SEP 24, 2015", "SEP 24, 2015", "SEP 23, 2015", "SEP 23, 2015", "SEP 23, 2015", "SEP 22, 2015", "SEP 22, 2015", "SEP 24, 2015", "SEP 22, 2015", "SEP 21, 2015", "SEP 21, 2015", "SEP 21, 2015", "SEP 21, 2015", "SEP 21, 2015", "SEP 21, 2015", "SEP 22, 2015", "SEP 18, 2015", "SEP 18, 2015", "SEP 18, 2015", "SEP 17, 2015", "SEP 17, 2015", "SEP 17, 2015", "SEP 17, 2015", "SEP 20, 2015", "SEP 17, 2015", "SEP 16, 2015", "SEP 16, 2015", "SEP 16, 2015", "SEP 16, 2015", "SEP 15, 2015", "SEP 15, 2015", "SEP 17, 2015", "SEP 14, 2015", "SEP 14, 2015", "SEP 11, 2015", "SEP 11, 2015", "SEP 11, 2015", "SEP 11, 2015", "SEP 10, 2015", "SEP 14, 2015", "SEP 10, 2015", "SEP 10, 2015", "SEP 10, 2015", "SEP 9, 2015", "SEP 9, 2015", "SEP 9, 2015", "SEP 9, 2015", "SEP 10, 2015", "SEP 8, 2015", "SEP 8, 2015", "SEP 8, 2015", "SEP 8, 2015", "SEP 7, 2015", "SEP 7, 2015", "SEP 4, 2015", "SEP 9, 2015", "SEP 4, 2015", "SEP 4, 2015", "SEP 4, 2015", "SEP 4, 2015", "SEP 3, 2015", "SEP 3, 2015", "SEP 3, 2015", "SEP 4, 2015", "SEP 2, 2015", "SEP 2, 2015", "SEP 2, 2015", "SEP 2, 2015", "SEP 1, 2015", "SEP 1, 2015", "SEP 1, 2015", "SEP 2, 2015", "AUG 31, 2015", "AUG 28, 2015", "AUG 28, 2015", "AUG 28, 2015", "AUG 28, 2015", "AUG 27, 2015", "AUG 26, 2015", "SEP 1, 2015", "AUG 25, 2015", "AUG 24, 2015", "AUG 24, 2015", "AUG 23, 2015", "AUG 21, 2015", "AUG 21, 2015", "AUG 21, 2015", "AUG 26, 2015", "AUG 20, 2015", "AUG 20, 2015", "AUG 19, 2015", "AUG 19, 2015", "AUG 19, 2015", "AUG 18, 2015", "AUG 18, 2015", "AUG 21, 2015", "AUG 15, 2015", "AUG 14, 2015", "AUG 14, 2015", "AUG 14, 2015", "AUG 14, 2015", "AUG 13, 2015", "AUG 13, 2015", "AUG 17, 2015", "AUG 15, 2015", "AUG 12, 2015", "AUG 12, 2015", "AUG 12, 2015", "AUG 11, 2015", "AUG 11, 2015", "AUG 10, 2015", "AUG 13, 2015", "AUG 8, 2015", "AUG 6, 2015", "AUG 6, 2015", "AUG 5, 2015", "AUG 5, 2015", "AUG 4, 2015", "AUG 4, 2015", "AUG 8, 2015", "AUG 4, 2015", "AUG 4, 2015", "AUG 4, 2015", "AUG 4, 2015", "AUG 3, 2015", "JUL 31, 2015", "AUG 4, 2015", "JUL 30, 2015", "JUL 29, 2015", "JUL 29, 2015", "JUL 28, 2015", "JUL 27, 2015", "JUL 27, 2015", "JUL 27, 2015", "JUL 31, 2015", "JUL 22, 2015", "JUL 22, 2015", "JUL 20, 2015", "JUL 20, 2015", "JUL 16, 2015", "JUL 16, 2015", "JUL 16, 2015", "JUL 23, 2015", "JUL 22, 2015", "JUL 11, 2015", "JUL 9, 2015", "JUL 9, 2015", "JUL 8, 2015", "JUL 2, 2015", "JUL 1, 2015", "JUL 14, 2015", "JUN 19, 2015", "JUN 16, 2015", "JUN 15, 2015", "JUN 11, 2015", "JUN 10, 2015", "JUN 10, 2015", "JUN 10, 2015", "JUN 29, 2015", "JUN 10, 2015", "JUN 10, 2015", "JUN 10, 2015", "JUN 10, 2015", "JUN 9, 2015", "JUN 8, 2015", "JUN 8, 2015", "JUN 10, 2015", "JUN 3, 2015", "JUN 2, 2015", "MAY 30, 2015", "MAY 25, 2015", "MAY 22, 2015", "MAY 21, 2015", "MAY 21, 2015", "JUN 8, 2015", "MAY 20, 2015", "MAY 19, 2015", "MAY 19, 2015", "MAY 8, 2015", "MAY 7, 2015", "MAY 7, 2015", "MAY 6, 2015", "MAY 21, 2015", "MAY 5, 2015", "MAY 5, 2015", "APR 18, 2015", "APR 16, 2015", "APR 7, 2015", "APR 4, 2015", "APR 1, 2015", "MAY 5, 2015", "MAR 30, 2015", "MAR 26, 2015", "MAR 25, 2015", "MAR 20, 2015", "MAR 19, 2015", "MAR 18, 2015", "MAR 18, 2015", "APR 1, 2015", "MAR 16, 2015", "MAR 16, 2015", "MAR 12, 2015", "MAR 11, 2015", "MAR 9, 2015", "FEB 26, 2015", "FEB 24, 2015", "MAR 18, 2015", "FEB 19, 2015", "FEB 19, 2015", "FEB 16, 2015", "FEB 12, 2015", "FEB 11, 2015", "FEB 11, 2015", "FEB 10, 2015", "FEB 19, 2015", "FEB 10, 2015", "FEB 10, 2015", "FEB 10, 2015", "FEB 9, 2015", "FEB 9, 2015", "FEB 9, 2015", "FEB 9, 2015", "FEB 10, 2015", "FEB 4, 2015", "FEB 3, 2015", "FEB 3, 2015", "FEB 3, 2015", "FEB 3, 2015", "FEB 2, 2015", "FEB 2, 2015", "FEB 6, 2015", "JAN 27, 2015", "JAN 27, 2015", "JAN 27, 2015", "JAN 23, 2015", "JAN 14, 2015", "JAN 13, 2015", "JAN 12, 2015", "FEB 2, 2015", "JAN 9, 2015", "DEC 31, 2014", "DEC 31, 2014", "DEC 30, 2014", "DEC 29, 2014", "DEC 29, 2014", "DEC 23, 2014", "JAN 12, 2015", "DEC 19, 2014", "DEC 14, 2014", "DEC 13, 2014", "DEC 11, 2014", "DEC 10, 2014", "DEC 9, 2014", "DEC 4, 2014", "DEC 22, 2014", "DEC 3, 2014", "DEC 2, 2014", "NOV 24, 2014", "NOV 21, 2014", "NOV 20, 2014", "NOV 20, 2014", "NOV 19, 2014", "DEC 3, 2014", "NOV 17, 2014", "NOV 14, 2014", "NOV 14, 2014", "NOV 12, 2014", "NOV 12, 2014", "NOV 9, 2014", "NOV 5, 2014", "NOV 18, 2014", "NOV 4, 2014", "NOV 4, 2014", "NOV 4, 2014", "NOV 3, 2014", "OCT 31, 2014", "OCT 30, 2014", "NOV 5, 2014", "OCT 27, 2014", "OCT 22, 2014", "OCT 20, 2014", "OCT 20, 2014", "OCT 20, 2014", "OCT 17, 2014", "OCT 30, 2014", "OCT 17, 2014", "OCT 17, 2014", "OCT 16, 2014", "OCT 14, 2014", "OCT 13, 2014", "OCT 8, 2014", "OCT 8, 2014", "OCT 17, 2014", "OCT 7, 2014", "OCT 7, 2014", "OCT 3, 2014", "OCT 1, 2014", "OCT 1, 2014", "SEP 30, 2014", "SEP 30, 2014", "OCT 8, 2014", "SEP 23, 2014", "SEP 23, 2014", "SEP 23, 2014", "SEP 22, 2014", "SEP 22, 2014", "SEP 17, 2014", "SEP 11, 2014", "SEP 24, 2014", "SEP 8, 2014", "SEP 8, 2014", "SEP 4, 2014", "SEP 4, 2014", "SEP 4, 2014", "SEP 3, 2014", "SEP 2, 2014", "SEP 8, 2014", "SEP 2, 2014", "SEP 2, 2014", "AUG 29, 2014", "AUG 29, 2014", "AUG 27, 2014", "AUG 26, 2014", "AUG 25, 2014", "SEP 2, 2014", "AUG 6, 2014", "AUG 5, 2014", "AUG 5, 2014", "AUG 5, 2014", "AUG 5, 2014", "AUG 4, 2014", "JUL 31, 2014", "AUG 12, 2014", "JUL 30, 2014", "JUL 30, 2014", "JUL 22, 2014", "JUL 18, 2014", "JUL 18, 2014", "JUL 17, 2014", "JUL 16, 2014", "JUL 30, 2014", "JUL 9, 2014", "JUL 9, 2014", "JUL 9, 2014", "JUL 9, 2014", "JUL 8, 2014", "JUL 7, 2014", "JUL 7, 2014", "JUL 10, 2014", "JUL 7, 2014", "JUL 7, 2014", "JUL 3, 2014", "JUL 3, 2014", "JUL 2, 2014", "JUL 2, 2014", "JUL 2, 2014", "JUL 7, 2014", "JUL 2, 2014", "JUL 1, 2014", "JUL 1, 2014", "JUL 1, 2014", "JUL 1, 2014", "JUL 1, 2014", "JUL 1, 2014", "JUL 2, 2014", "JUL 1, 2014", "JUN 30, 2014", "JUN 30, 2014", "JUN 30, 2014", "JUN 30, 2014", "JUN 30, 2014", "JUN 30, 2014", "JUL 1, 2014", "JUN 30, 2014", "JUN 30, 2014", "JUN 30, 2014", "JUN 27, 2014", "JUN 27, 2014", "JUN 27, 2014", "JUN 26, 2014", "JUN 30, 2014", "JUN 26, 2014", "JUN 26, 2014", "JUN 26, 2014", "JUN 26, 2014", "JUN 25, 2014", "JUN 25, 2014", "JUN 24, 2014", "JUN 26, 2014", "JUN 24, 2014", "JUN 24, 2014", "JUN 23, 2014", "JUN 23, 2014", "JUN 23, 2014", "JUN 20, 2014", "JUN 20, 2014", "JUN 24, 2014", "JUN 20, 2014", "JUN 19, 2014", "JUN 19, 2014", "JUN 19, 2014", "JUN 18, 2014", "JUN 17, 2014", "JUN 17, 2014", "JUN 20, 2014", "JUN 16, 2014", "JUN 13, 2014", "JUN 13, 2014", "JUN 13, 2014", "JUN 13, 2014", "JUN 13, 2014", "JUN 12, 2014", "JUN 16, 2014", "JUN 12, 2014", "JUN 12, 2014", "JUN 11, 2014", "JUN 11, 2014", "JUN 10, 2014", "JUN 10, 2014", "JUN 9, 2014", "JUN 12, 2014", "JUN 9, 2014", "MAY 21, 2014", "MAY 16, 2014", "MAY 13, 2014", "MAY 9, 2014", "MAY 8, 2014", "MAY 7, 2014", "JUN 9, 2014", "MAY 6, 2014", "APR 30, 2014", "APR 30, 2014", "APR 30, 2014", "APR 30, 2014", "APR 29, 2014", "APR 29, 2014", "MAY 7, 2014", "APR 25, 2014", "APR 25, 2014", "APR 24, 2014", "APR 24, 2014", "APR 24, 2014", "APR 23, 2014", "APR 23, 2014", "APR 25, 2014", "APR 23, 2014", "APR 22, 2014", "APR 16, 2014", "APR 15, 2014", "APR 15, 2014", "APR 15, 2014", "APR 15, 2014", "APR 23, 2014", "APR 15, 2014", "APR 15, 2014", "APR 15, 2014", "APR 9, 2014", "APR 7, 2014", "MAR 31, 2014", "MAR 28, 2014", "APR 15, 2014", "APR 15, 2014", "MAR 10, 2014", "MAR 7, 2014", "MAR 7, 2014", "MAR 5, 2014", "MAR 3, 2014", "MAR 3, 2014", "MAR 26, 2014", "FEB 25, 2014", "FEB 21, 2014", "FEB 21, 2014", "FEB 17, 2014", "FEB 11, 2014", "FEB 11, 2014", "FEB 11, 2014", "FEB 25, 2014", "FEB 10, 2014", "FEB 10, 2014", "FEB 10, 2014", "FEB 10, 2014", "FEB 10, 2014", "FEB 10, 2014", "FEB 7, 2014", "FEB 11, 2014", "JAN 15, 2014", "DEC 23, 2013", "DEC 23, 2013", "NOV 29, 2013", "NOV 26, 2013", "NOV 25, 2013", "NOV 22, 2013", "FEB 4, 2014", "NOV 22, 2013", "NOV 20, 2013", "NOV 5, 2013", "NOV 5, 2013", "NOV 5, 2013", "NOV 5, 2013", "NOV 4, 2013", "NOV 22, 2013", "OCT 30, 2013", "OCT 29, 2013", "OCT 28, 2013", "OCT 20, 2013", "OCT 16, 2013", "OCT 4, 2013", "SEP 19, 2013", "OCT 31, 2013", "SEP 13, 2013", "SEP 10, 2013", "SEP 4, 2013", "SEP 3, 2013", "AUG 29, 2013", "AUG 29, 2013", "AUG 29, 2013", "SEP 18, 2013", "AUG 6, 2013", "AUG 6, 2013", "AUG 6, 2013", "AUG 6, 2013", "AUG 5, 2013", "JUL 29, 2013", "JUL 29, 2013", "AUG 15, 2013", "JUN 25, 2013", "JUN 19, 2013", "JUN 18, 2013", "JUN 7, 2013", "JUN 7, 2013", "JUN 6, 2013", "JUL 11, 2013", "MAY 27, 2013", "MAY 24, 2013", "MAY 23, 2013", "MAY 22, 2013", "MAY 15, 2013", "MAY 3, 2013", "MAY 3, 2013", "JUN 6, 2013", "MAY 2, 2013", "MAY 2, 2013", "MAY 1, 2013", "MAY 1, 2013", "APR 30, 2013", "APR 23, 2013", "MAY 3, 2013", "APR 11, 2013", "APR 10, 2013", "APR 8, 2013", "MAR 14, 2013", "MAR 5, 2013", "MAR 4, 2013", "FEB 26, 2013", "APR 16, 2013", "FEB 15, 2013", "FEB 13, 2013", "FEB 12, 2013", "FEB 7, 2013", "FEB 6, 2013", "JAN 23, 2013", "JAN 9, 2013", "FEB 19, 2013", "DEC 6, 2012", "DEC 4, 2012", "DEC 3, 2012", "NOV 20, 2012", "NOV 16, 2012", "NOV 1, 2012", "OCT 30, 2012", "DEC 26, 2012", "OCT 11, 2012", "OCT 10, 2012", "SEP 27, 2012", "SEP 24, 2012", "SEP 10, 2012", "SEP 8, 2012", "SEP 5, 2012", "OCT 29, 2012", "OCT 11, 2012", "AUG 6, 2012", "AUG 2, 2012", "JUL 31, 2012", "JUL 27, 2012", "JUL 26, 2012", "AUG 23, 2012", "AUG 20, 2012", "JUL 5, 2012", "APR 27, 2012", "APR 5, 2012", "APR 4, 2012", "MAR 30, 2012", "MAR 29, 2012", "JUL 24, 2012", "MAR 27, 2012", "MAR 9, 2012", "FEB 22, 2012", "FEB 20, 2012", "JAN 13, 2012", "JAN 4, 2012", "DEC 7, 2011", "MAR 28, 2012", "NOV 28, 2011", "NOV 25, 2011", "NOV 21, 2011", "SEP 20, 2011", "SEP 8, 2011", "AUG 30, 2011", "AUG 17, 2011", "DEC 6, 2011", "JUL 26, 2011", "JUL 25, 2011", "FEB 24, 2011", "DEC 27, 2010", "DEC 27, 2010", "DEC 20, 2010", "DEC 20, 2010", "AUG 16, 2011", "NOV 22, 2010", "OCT 26, 2010", "OCT 26, 2010", "NOV 22, 2010"], "Published Date": [], "Link": ["https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-wynn-resorts-thermogenesis-u.s.-cruise-lines-2020-06-11", "https://www.nasdaq.com/articles/regeneron-begins-human-trials-of-a-potential-covid-19-treatment-2020-06-11", "https://www.nasdaq.com/articles/nasdaq-100-movers%3A-ual-regn-2020-06-11", "https://www.nasdaq.com/articles/sp-500-movers%3A-oke-regn-2020-06-11", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-amazon-uber-moderna-reata-pharma-2020-06-11", "https://www.nasdaq.com/articles/regeneron-begins-human-testing-of-covid-19-antibody-cocktail-2020-06-11-0", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-regeneron-pharmaceuticals-onconova-therapeutics-nio-inc-2020", "https://www.nasdaq.com/articles/regeneron-begins-clinical-trial-of-anti-viral-antibody-cocktail-against-covid-19-2020-06", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-wynn-resorts-thermogenesis-u.s.-cruise-lines-2020-06-11", "https://www.nasdaq.com/articles/regeneron-begins-human-testing-of-covid-19-antibody-cocktail-2020-06-11", "https://www.nasdaq.com/articles/sanofi-to-present-strategy-for-dupixent-in-type-2-inflammatory-diseases-2020-06-11", "https://www.nasdaq.com/articles/healthcare-group-sanofi-upbeat-on-dupixent-opportunities-2020-06-11", "https://www.nasdaq.com/articles/anti-inflammatory-and-cancer-drugs-tested-in-uk-as-possible-covid-19-therapy-2020-06-10", "https://www.nasdaq.com/articles/regeneron-pharma-to-present-at-goldman-sachs-global-healthcare-conference-webcast-at-3%3A00", "https://www.nasdaq.com/articles/noteworthy-etf-outflows%3A-xbi-mrna-regn-immu-2020-06-09", "https://www.nasdaq.com/articles/explainer-what-are-antibody-therapies-and-who-is-developing-them-for-covid-19-2020-06-09-0", "https://www.nasdaq.com/articles/regenerons-regn-resplendent-journey-from-%2460-to-%24600-in-9-years-2020-06-11", "https://www.nasdaq.com/articles/heres-why-vir-biotechnology-jumped-12-in-may-2020-06-08", "https://www.nasdaq.com/articles/could-gileads-covid-19-drug-make-%247-billion-per-year-2020-06-07", "https://www.nasdaq.com/articles/astrazeneca-blood-cancer-drug-shows-signs-of-helping-covid-19-patients-2020-06-05", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-genius-brands-royal-caribbean-sorrento-2020-06-05", "https://www.nasdaq.com/articles/abbvie-enters-the-race-to-develop-new-covid-19-treatments-2020-06-05", "https://www.nasdaq.com/articles/wednesday-sector-laggards%3A-healthcare-utilities-2020-06-03", "https://www.nasdaq.com/articles/is-momenta-pharmaceuticals-stock-a-buy-2020-06-03", "https://www.nasdaq.com/articles/explainer-what-are-antibody-therapies-and-who-is-developing-them-for-covid-19-2020-06-09", "https://www.nasdaq.com/articles/why-editas-medicine-is-now-the-crispr-stock-to-really-watch-2020-06-03", "https://www.nasdaq.com/articles/where-will-regeneron-be-in-5-years-2020-06-03", "https://www.nasdaq.com/articles/eli-lilly-leaps-past-regenerons-covid-19-treatment-candidate-2020-06-03", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-raytheon-planet-fitness-lands-end-2020-06-02", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-virgin-galactic-baozun-hollyfrontier-2020-06-02", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-digital-ally-marathon-patent-aduro-biotech-2020-06-02", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-visa-moneygram-trevena-seadrill-2020-06-02", "https://www.nasdaq.com/articles/better-buy%3A-crispr-therapeutics-vs.-intellia-2020-06-03", "https://www.nasdaq.com/articles/u.s.-companies-issue-shares-at-fastest-rate-ever-selling-the-rally-2020-06-01", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-coty-tesla-zoom-video-zynga-2020-06-01", "https://www.nasdaq.com/articles/is-inovio-pharmaceuticals-really-just-the-next-theranos-2020-06-01", "https://www.nasdaq.com/articles/eli-lilly-is-already-testing-a-covid-19-antibody-treatment-in-humans-2020-06-01", "https://www.nasdaq.com/articles/heres-why-intellia-therapeutics-gained-as-much-as-18.0-today-2020-06-01", "https://www.nasdaq.com/articles/regeneron-expands-existing-collaboration-with-intellia-quick-facts-2020-06-01", "https://www.nasdaq.com/articles/graphic-take-five%3A-hong-kong-takes-centre-stage-2020-05-29", "https://www.nasdaq.com/articles/ntla-gains-on-amended-regn-deal-gild-reports-simple-results-myov-on-watch-nvus-slumps-2020", "https://www.nasdaq.com/articles/regeneron-pharmaceuticals-reaches-analyst-target-price-2020-05-29", "https://www.nasdaq.com/articles/thursday-sector-leaders%3A-utilities-healthcare-2020-05-28", "https://www.nasdaq.com/articles/2-top-healthcare-stocks-to-buy-right-now-2020-05-28", "https://www.nasdaq.com/articles/regeneron-stock-is-a-solid-long-term-buy-2020-05-27", "https://www.nasdaq.com/articles/rising-swiss-rivalry-as-roche-and-novartis-target-same-diseases-2020-05-27", "https://www.nasdaq.com/articles/drugmaker-sanofi-to-raise-over-%2411-bln-via-sale-of-regeneron-shares-2020-05-27", "https://www.nasdaq.com/articles/sanofi-%3A-fda-approves-dupixentas-to-treat-moderate-to-severe-atopic-dermatitis-2020-05-26", "https://www.nasdaq.com/articles/regeneron-%3A-data-on-libtayo-shows-longer-durability-higher-complete-response-rates-in-skin", "https://www.nasdaq.com/articles/tuesday-sector-laggards%3A-healthcare-technology-communications-2020-05-26", "https://www.nasdaq.com/articles/sanofi-to-sell-its-20.6-stake-in-regeneron-but-keep-their-collaboration-intact-2020-05-26", "https://www.nasdaq.com/articles/notable-tuesday-option-activity%3A-nvda-azo-regn-2020-05-26", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-alliance-data-systems-alibaba-group-dexcom-can-fite-biofarma", "https://www.nasdaq.com/articles/nasdaq-100-movers%3A-dxcm-ual-2020-05-26", "https://www.nasdaq.com/articles/sp-500-movers%3A-regn-nclh-2020-05-26", "https://www.nasdaq.com/articles/stock-alert%3A-regeneron-pharma-down-4-2020-05-26", "https://www.nasdaq.com/articles/regeneron-announces-pricing-of-secondary-offering-of-its-stock-held-by-sanofi-at-%24515.00", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-novavax-tuesday-morning-hpe-2020-05-26", "https://www.nasdaq.com/articles/regeneron-to-buy-back-%245-billion-stake-held-by-sanofi-2020-05-25", "https://www.nasdaq.com/articles/u.s.-regeneron-to-buy-back-%245-bln-stake-held-by-sanofi-2020-05-25", "https://www.nasdaq.com/articles/heres-why-editas-could-beat-intellia-to-a-crispr-therapy-2020-05-22", "https://www.nasdaq.com/articles/heres-why-sorrento-therapeutics-dropped-16.6-today-2020-05-19", "https://www.nasdaq.com/articles/monday-sector-laggards%3A-healthcare-technology-communications-2020-05-18", "https://www.nasdaq.com/articles/why-sorrento-therapeutics-stock-is-on-fire-today-2020-05-18", "https://www.nasdaq.com/articles/sanofi-shares-down-despite-%2413-billion-regeneron-payday-2020-05-26", "https://www.nasdaq.com/articles/why-gileads-remdesivir-might-not-be-the-mega-moneymaker-some-think-it-will-be-2020-05-17", "https://www.nasdaq.com/articles/health-care-sector-update-for-05-15-2020%3A-omcloculregnbpmc-2020-05-15", "https://www.nasdaq.com/articles/3-earnings-stocks-to-buy-while-they-climb-above-everything-else-2020-05-15", "https://www.nasdaq.com/articles/health-care-sector-update-for-05-15-2020%3A-abt-myo-ocul-regn-xlv-ibb-2020-05-15", "https://www.nasdaq.com/articles/abivax-stock-soars-after-france-approves-a-covid-19-trial-2020-05-14", "https://www.nasdaq.com/articles/notable-wednesday-option-activity%3A-regn-splk-axp-2020-05-13", "https://www.nasdaq.com/articles/wednesday-sector-leaders%3A-healthcare-utilities-2020-05-13", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-motley-fool-5-17-2020-2020-05-17", "https://www.nasdaq.com/articles/xbi-mrna-regn-sgen%3A-etf-inflow-alert-2020-05-13", "https://www.nasdaq.com/articles/better-coronavirus-stock%3A-inovio-pharmaceuticals-or-regeneron-2020-05-10", "https://www.nasdaq.com/articles/6-stocks-to-buy-and-hold-and-6-picks-to-avoid-2020-05-08", "https://www.nasdaq.com/articles/heres-why-adverum-biotechnologies-is-soaring-today-2020-05-06", "https://www.nasdaq.com/articles/regeneron-pharmaceuticals-regn-q1-2020-earnings-call-transcript-2020-05-06", "https://www.nasdaq.com/articles/noteworthy-tuesday-option-activity%3A-regn-ptla-w-2020-05-05", "https://www.nasdaq.com/articles/wall-street-rises-as-lockdowns-ease-healthcare-shares-jump-2020-05-05-0", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-cornerstone-building-aerpio-pharma-j.c.-penney-2020-05-13", "https://www.nasdaq.com/articles/health-care-sector-update-for-05-05-2020%3A-regnptlagnpxoxfd-2020-05-05", "https://www.nasdaq.com/articles/regeneron-says-its-covid-19-combo-treatment-could-be-ready-for-people-this-fall-2020-05-05", "https://www.nasdaq.com/articles/the-trends-are-mostly-friendly-for-moderna-stock-investors-2020-05-05", "https://www.nasdaq.com/articles/regeneron-posts-rapid-growth-due-to-dupixent-2020-05-05", "https://www.nasdaq.com/articles/tuesday-sector-leaders%3A-healthcare-technology-communications-2020-05-05", "https://www.nasdaq.com/articles/wall-street-jumps-as-healthcare-shares-rise-lockdowns-ease-2020-05-05", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-oil-and-gas-stocks-banks-tesla-tankers-2020-05-05", "https://www.nasdaq.com/articles/wall-street-rises-as-lockdowns-ease-healthcare-shares-jump-2020-05-05", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-tesla-banks-pfizer-regeneron-2020-05-05-0", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-tesla-banks-pfizer-regeneron-2020-05-05", "https://www.nasdaq.com/articles/regeneron-jumps-after-earnings-beat-expectations-2020-05-05", "https://www.nasdaq.com/articles/regeneron-pharma-beats-quarterly-estimates-on-eylea-strength-2020-05-05", "https://www.nasdaq.com/articles/regeneron-pharmaceuticals-q1-adjusted-earnings-beat-estimates-2020-05-05", "https://www.nasdaq.com/articles/sanofi%3A-libtayo-shows-clinically-meaningful-and-durable-responses-in-skin-cancer-2020-05", "https://www.nasdaq.com/articles/amgen-stock-jumps-on-earnings-covid-19-trial-announcement-2020-04-30", "https://www.nasdaq.com/articles/wall-street-jumps-as-energy-shares-rise-lockdowns-ease-2020-05-05", "https://www.nasdaq.com/articles/health-care-sector-update-for-04-29-2020%3A-caprtorclivnnvsregnjnj-2020-04-29", "https://www.nasdaq.com/articles/notable-tuesday-option-activity%3A-ffiv-gd-regn-2020-04-28", "https://www.nasdaq.com/articles/10-stocks-to-buy-for-an-aging-population-2020-04-28", "https://www.nasdaq.com/articles/better-buy%3A-inovio-pharmaceuticals-vs.-glaxosmithkline-2020-04-28", "https://www.nasdaq.com/articles/biotech-stocks-facing-fda-decision-in-may-2020-2020-04-27", "https://www.nasdaq.com/articles/positive-cancer-trial-results-offset-a-covid-19-flop-for-regeneron-and-sanofi-2020-04-27", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-regeneron-zoom-video-u.s.-oil-companies-apple-u.s.-insurers", "https://www.nasdaq.com/articles/heres-why-investors-should-follow-sanofi-and-glaxosmithklines-new-coronavirus", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-tanker-operators-oil-and-gas-companies-caterpillar-2020-04-27", "https://www.nasdaq.com/articles/regeneron-sanofi-say-kevzara-will-now-only-be-tested-in-sickest-covid-19-patients-2020-04", "https://www.nasdaq.com/articles/nasdaq-100-movers%3A-regn-tsla-2020-04-27", "https://www.nasdaq.com/articles/u.s.-stock-futures-gain-as-more-states-prepare-to-ease-lockdown-2020-04-27", "https://www.nasdaq.com/articles/regeneron-sanofi-to-treat-only-critical-covid-19-patients-with-arthritis-drug-2020-04-27-0", "https://www.nasdaq.com/articles/regeneron-sanofi-to-amend-trial-to-enroll-only-critical-covid-19-patients-2020-04-27", "https://www.nasdaq.com/articles/regeneron-sanofi%3A-libtayo-meets-primary-endpoint-in-phase-3-trial-2020-04-27", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-kohls-tanker-operators-oil-and-gas-companies-u.s.-casinos", "https://www.nasdaq.com/articles/analysis-investors-bet-on-testing-treatments-for-restart-of-u.s.-economy-2020-04-27", "https://www.nasdaq.com/articles/analysis-investors-bet-on-testing-treatments-for-restart-of-u.s.-economy-2020-04-26", "https://www.nasdaq.com/articles/while-big-pharma-tanked-gilead-sciences-and-regeneron-soared-2020-04-25", "https://www.nasdaq.com/articles/does-regeneron-pharmaceuticals-winning-streak-signal-irrational-exuberance-2020-04-24", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-sleep-number-crocs-cassava-sciences-2020-04-23", "https://www.nasdaq.com/articles/noteworthy-etf-inflows%3A-ibb-vrtx-biib-regn-2020-04-22", "https://www.nasdaq.com/articles/notable-friday-option-activity%3A-shak-regn-lrcx-2020-04-17", "https://www.nasdaq.com/articles/regeneron-sanofi-to-treat-only-critical-covid-19-patients-with-arthritis-drug-2020-04-27", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-schlumberger-biohaven-pharmaceutical-spirit-aerosystems-2020", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-schlumberger-banks-spirit-aerosystems-state-street-2020-04-17", "https://www.nasdaq.com/articles/btai-on-track-to-report-serenity-data-regn-hits-all-time-high-thmo-on-watch-2020-04-17", "https://www.nasdaq.com/articles/regeneron-pharma%3A-fda-to-review-bla-for-regn-eb3-quick-facts-2020-04-16", "https://www.nasdaq.com/articles/stock-alert%3A-regeneron-touches-new-high-2020-04-16", "https://www.nasdaq.com/articles/sanofi-and-glaxosmithkline-join-forces-to-develop-a-coronavirus-vaccine-2020-04-14", "https://www.nasdaq.com/articles/three-reasons-to-consider-buying-regeneron-stock-2020-04-14", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-netflix-cutera-moderna-2020-04-17", "https://www.nasdaq.com/articles/reasons-for-hope%3A-the-drugs-tests-and-tactics-that-may-conquer-coronavirus-2020-04-13", "https://www.nasdaq.com/articles/wall-street-week-ahead-health-tech-staples-could-shine-through-earnings-gloom-2020-04-13", "https://www.nasdaq.com/articles/25-blue-chips-with-brawny-balance-sheets-2020-04-13", "https://www.nasdaq.com/articles/5-biotech-stocks-winning-the-coronavirus-race-2020-04-11", "https://www.nasdaq.com/articles/goldman-sachs%3A-these-are-the-5-best-stocks-for-an-economic-recovery-2020-04-09", "https://www.nasdaq.com/articles/heres-why-regenerons-stock-is-worth-more-than-its-coronavirus-work-2020-04-09", "https://www.nasdaq.com/articles/better-coronavirus-stock%3A-inovio-vs.-regeneron-2020-04-09", "https://www.nasdaq.com/articles/moderna-stock-is-the-greatest-coronavirus-speculation-play-2020-04-14", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-gap-inc-hanesbrands-kroger-otis-worldwide-2020-04-08", "https://www.nasdaq.com/articles/could-regeneron-pharmaceuticals-be-a-millionaire-maker-stock-2020-04-08", "https://www.nasdaq.com/articles/nasdaq-100-movers%3A-bidu-aal-2020-04-08", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-youngevity-party-city-holdco-ellington-financial-hexo-2020-04", "https://www.nasdaq.com/articles/zai-lab-to-commercialize-regn1979-in-oncology-in-mainland-china-hong-kong-2020-04-08", "https://www.nasdaq.com/articles/novavax-to-start-human-trial-for-novel-coronavirus-vaccine-2020-04-08", "https://www.nasdaq.com/articles/graphic-wall-st-volatility-raises-fears-of-another-selloff-2020-04-07", "https://www.nasdaq.com/articles/why-regeneron-pharmaceuticals-shares-rose-10-in-march-2020-04-08", "https://www.nasdaq.com/articles/here-are-all-the-companies-working-on-covid-19-vaccines-treatments-and-testing-2020-04-07", "https://www.nasdaq.com/articles/doctors-embrace-drug-touted-by-trump-for-covid-19-without-hard-evidence-it-works-2020-04", "https://www.nasdaq.com/articles/should-you-buy-inovio-pharmaceuticals-during-the-coronavirus-market-crash-2020-04-05", "https://www.nasdaq.com/articles/better-coronavirus-stock%3A-novavax-vs.-regeneron-2020-04-04", "https://www.nasdaq.com/articles/ema-recommends-remdesivir-for-treatment-of-covid-19-under-compassionate-use-rules-2020-04", "https://www.nasdaq.com/articles/novartis-incyte-join-repurposing-wave-to-give-jakavi-a-trial-run-in-covid-19-2020-04-03", "https://www.nasdaq.com/articles/regeneron-sanofi-announce-detailed-positive-results-from-dupixent-trial-2020-04-03", "https://www.nasdaq.com/articles/investors-await-data-on-coronavirus-drugs-as-market-rally-builds-2020-04-07", "https://www.nasdaq.com/articles/incyte-to-test-its-cancer-drug-jakafi-as-a-treatment-for-covid-19-2020-04-03", "https://www.nasdaq.com/articles/regn-may-22nd-options-begin-trading-2020-04-02", "https://www.nasdaq.com/articles/novavax-stock-could-easily-triple-in-value-2020-04-02", "https://www.nasdaq.com/articles/3-big-stock-charts-for-thursday%3A-kellogg-regeneron-pharmaceuticals-newmont-2020-04-02", "https://www.nasdaq.com/articles/heres-why-sanofi-is-an-underappreciated-coronavirus-stock-2020-04-01", "https://www.nasdaq.com/articles/better-buy%3A-vertex-pharmaceuticals-vs.-regeneron-pharmaceuticals-2020-04-01", "https://www.nasdaq.com/articles/is-ibio-stock-worth-the-risk-as-coronavirus-continues-to-spread-2020-03-31", "https://www.nasdaq.com/articles/sanofi-and-regenerons-dupixent-shows-more-encouraging-results-2020-04-03", "https://www.nasdaq.com/articles/a-market-roadmap-shows-the-stimulus-will-save-the-economy-2020-03-31", "https://www.nasdaq.com/articles/3-big-stock-charts-for-tuesday%3A-abbott-laboratories-johnson-johnson-and-regeneron", "https://www.nasdaq.com/articles/health-care-sector-update-for-03-30-2020%3A-regnathxjnjbrkr-2020-03-30", "https://www.nasdaq.com/articles/regeneron-sanofi-begin-covid-19-clinical-program-outside-of-u.s.-2020-03-30", "https://www.nasdaq.com/articles/2-biotech-stocks-in-the-hunt-for-new-coronavirus-drugs-oppenheimer-weighs-in-2020-03-29", "https://www.nasdaq.com/articles/noteworthy-etf-outflows%3A-rsp-regn-gild-amd-2020-03-27", "https://www.nasdaq.com/articles/for-gilead-its-coronavirus-treatment-is-icing-on-the-cake-2020-03-27", "https://www.nasdaq.com/articles/5-hot-stocks-for-2020-that-are-soaring-while-the-market-plunges-2020-03-31", "https://www.nasdaq.com/articles/better-coronavirus-stock%3A-regeneron-or-roche-2020-03-25", "https://www.nasdaq.com/articles/4-reasons-biotech-stocks-are-a-buy-right-now-2020-03-25", "https://www.nasdaq.com/articles/top-notch-vaccine-technology-makes-ibio-stock-a-smart-bet-2020-03-24", "https://www.nasdaq.com/articles/nasdaq-100-movers%3A-regn-ual-2020-03-24", "https://www.nasdaq.com/articles/sp-500-movers%3A-kr-dri-2020-03-24", "https://www.nasdaq.com/articles/3-biotech-stocks-fighting-the-coronavirus-heres-what-to-expect-2020-03-24", "https://www.nasdaq.com/articles/why-consider-these-2-stocks-when-markets-are-crashing-2020-03-24", "https://www.nasdaq.com/articles/3-things-to-know-if-chloroquine-wins-the-covid-19-treatment-race-2020-03-27", "https://www.nasdaq.com/articles/dont-forget-about-stocks-to-buy-during-the-coronavirus-crisis-2020-03-23", "https://www.nasdaq.com/articles/why-is-everyone-talking-about-regeneron-2020-03-22", "https://www.nasdaq.com/articles/why-sanofis-coronavirus-vaccine-work-hasnt-helped-its-stock-2020-03-21", "https://www.nasdaq.com/articles/all-the-drugs-proving-anecdotally-effective-against-covid-19-and-the-companies-that-make", "https://www.nasdaq.com/articles/nonprofit-group-starts-multiple-covid-19-clinical-studies-2020-03-21", "https://www.nasdaq.com/articles/better-coronavirus-stock%3A-inovio-pharmaceuticals-or-glaxosmithkline-2020-03-20", "https://www.nasdaq.com/articles/is-it-too-late-to-buy-coronavirus-biotech-stocks-2020-03-20", "https://www.nasdaq.com/articles/roche-tests-arthritis-drug-actemra-for-covid-19-pneumonia-2020-03-23", "https://www.nasdaq.com/articles/coronavirus-fighting-tech-makes-ibio-stock-an-interesting-play-2020-03-19", "https://www.nasdaq.com/articles/regeneron-stock-rose-on-covid-19-breakthrough-2020-03-19", "https://www.nasdaq.com/articles/better-coronavirus-stock%3A-gilead-sciences-or-regeneron-pharmaceuticals-2020-03-19", "https://www.nasdaq.com/articles/regeneron-makes-progress-in-antibody-program-to-treat-coronavirus-pandemic-2020-03-18", "https://www.nasdaq.com/articles/bntx-on-fire-qdels-coronavirus-test-gets-fdas-eua-curevac-back-in-the-news-2020-03-18", "https://www.nasdaq.com/articles/8-best-performing-stocks-during-the-2020s-market-meltdown-2020-03-17", "https://www.nasdaq.com/articles/why-regeneron-pharmaceuticals-stock-is-bolting-higher-today-2020-03-17", "https://www.nasdaq.com/articles/notable-thursday-option-activity%3A-expe-regn-sbux-2020-03-19", "https://www.nasdaq.com/articles/regeneron-could-start-testing-a-coronavirus-cocktail-therapy-by-early-summer-2020-03-17", "https://www.nasdaq.com/articles/nasdaq-100-movers%3A-ulta-regn-2020-03-17", "https://www.nasdaq.com/articles/stock-alert%3A-regeneron-pharma-rises-10-2020-03-17", "https://www.nasdaq.com/articles/regeneron-discovers-antibodies-for-covid-19-treatment-2020-03-17", "https://www.nasdaq.com/articles/regeneron-and-sanofi-start-human-trials-of-arthritis-drug-as-possible-covid-19-treatment", "https://www.nasdaq.com/articles/focus-on-ibios-tech-not-its-coronavirus-story-2020-03-16", "https://www.nasdaq.com/articles/sanofi-regeneron-begin-kevzara-clinical-trial-for-severe-covid-19-quick-facts-2020-03-16", "https://www.nasdaq.com/articles/stock-market-news%3A-regeneron-looks-to-kill-coronavirus-churchill-downs-postpones-the-derby", "https://www.nasdaq.com/articles/notable-wednesday-option-activity%3A-sbux-regn-lyv-2020-03-11", "https://www.nasdaq.com/articles/3-diverse-and-critical-stocks-to-watch-for-a-market-bottom-2020-03-11", "https://www.nasdaq.com/articles/its-powerful-pipeline-shows-pfizer-stock-is-undervalued-by-15-2020-03-10", "https://www.nasdaq.com/articles/7-big-pharma-companies-trump-asked-to-fight-the-coronavirus-outbreak-2020-03-10", "https://www.nasdaq.com/articles/3-profitable-healthcare-stocks-that-are-trouncing-the-market-during-the-coronavirus", "https://www.nasdaq.com/articles/moderna-stocks-winning-streak-seems-likely-to-end-2020-03-09", "https://www.nasdaq.com/articles/inovio-pharmaceuticals-rapidly-becoming-the-premier-coronavirus-play-2020-03-05", "https://www.nasdaq.com/articles/the-12-best-low-volatility-stocks-of-the-market-crash-2020-03-13", "https://www.nasdaq.com/articles/why-regeneron-shares-rose-31.6-in-february-2020-03-05", "https://www.nasdaq.com/articles/buy-regeneron-stock-for-coronavirus-2.0-and-beyond-2020-03-04", "https://www.nasdaq.com/articles/first-week-of-april-17th-options-trading-for-regeneron-pharmaceuticals-regn-2020-03-03", "https://www.nasdaq.com/articles/noteworthy-monday-option-activity%3A-unit-regn-bac-2020-03-02", "https://www.nasdaq.com/articles/the-5-best-stocks-and-5-worst-of-the-coronavirus-correction-2020-03-02", "https://www.nasdaq.com/articles/heres-why-hype-around-companies-working-on-coronavirus-treatments-is-overblown-2020-02-29", "https://www.nasdaq.com/articles/3-small-caps-that-are-soaring-because-of-coronavirus-panic-2020-02-29", "https://www.nasdaq.com/articles/is-ishares-nasdaq-biotechnology-index-fund-a-buy-2020-03-05", "https://www.nasdaq.com/articles/stock-alert%3A-regn-shares-gain-as-coronavirus-outbreak-intensifies-2020-02-27", "https://www.nasdaq.com/articles/momentum-stocks-benefitting-from-coronavirus-2020-02-27", "https://www.nasdaq.com/articles/fighting-the-deadly-coronavirus-2020-02-27", "https://www.nasdaq.com/articles/nasdaq-100-movers%3A-gild-regn-2020-02-25", "https://www.nasdaq.com/articles/regn-crosses-above-average-analyst-target-2020-02-25", "https://www.nasdaq.com/articles/now-that-teva-has-stabilized-teva-stock-looks-undervalued-2020-02-25", "https://www.nasdaq.com/articles/a-stock-that-defies-conventions-corona-regeneron-pharma-2020-02-25", "https://www.nasdaq.com/articles/traders-are-treating-inovio-like-2018s-pot-stock-stars-2020-02-28", "https://www.nasdaq.com/articles/noteworthy-friday-option-activity%3A-ptla-regn-vmi-2020-02-21", "https://www.nasdaq.com/articles/moderna-will-rebound-but-wait-for-a-dip-lower-to-buy-shares-2020-02-18", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-kenneth-fisher-2-16-2020-2020-02-16", "https://www.nasdaq.com/articles/better-buy%3A-bluebird-bio-vs.-gilead-sciences-2020-02-12", "https://www.nasdaq.com/articles/validea-peter-lynch-strategy-daily-upgrade-report-2-11-2020-2020-02-11", "https://www.nasdaq.com/articles/sanofi-grows-revenue-by-6.8-in-fourth-quarter-boosted-by-dupixent-2020-02-06", "https://www.nasdaq.com/articles/regeneron-pharmaceuticals-regn-q4-2019-earnings-call-transcript-2020-02-06", "https://www.nasdaq.com/articles/4-top-stock-trades-for-tuesday%3A-spy-qqq-msft-regn-2020-02-24", "https://www.nasdaq.com/articles/regeneron-shares-rise-on-earnings-coronavirus-work-2020-02-06", "https://www.nasdaq.com/articles/whats-behind-regeneron-pharmaceuticals-great-q4-results-2020-02-06", "https://www.nasdaq.com/articles/mercks-spinoff-plans-place-a-big-bet-on-cancer-fighting-keytruda-2020-02-06", "https://www.nasdaq.com/articles/regeneron-pharmaceuticals-q4-19-earnings-conference-call-at-8%3A00-am-et-2020-02-06", "https://www.nasdaq.com/articles/regeneron-sanofi-to-restructure-antibody-collaboration-for-kevzara-praluent-2020-02-06", "https://www.nasdaq.com/articles/regeneron-pharmaceuticals-q4-adjusted-earnings-beat-estimates-2020-02-06", "https://www.nasdaq.com/articles/notable-monday-option-activity%3A-regn-unh-isrg-2020-02-03", "https://www.nasdaq.com/articles/alnylam-beats-revenue-estimates-but-misses-on-earnings-2020-02-06", "https://www.nasdaq.com/articles/regeneron-sanofi%3A-fda-to-review-sbla-for-dupixent-quick-facts-2020-01-28", "https://www.nasdaq.com/articles/noteworthy-friday-option-activity%3A-csii-isrg-regn-2020-01-24", "https://www.nasdaq.com/articles/regeneron-pharmaceuticals-is-now-oversold-regn-2020-01-24", "https://www.nasdaq.com/articles/a-tale-of-3-healthcare-stocks-2-to-buy-and-1-to-sell-2020-01-23", "https://www.nasdaq.com/articles/first-week-of-march-20th-options-trading-for-regeneron-pharmaceuticals-regn-2020-01-22", "https://www.nasdaq.com/articles/2-biotechs-battling-immune-diseases-2020-01-19", "https://www.nasdaq.com/articles/noteworthy-friday-option-activity%3A-so-lh-regn-2020-01-17", "https://www.nasdaq.com/articles/fda-agrees-to-review-regenerons-dupixent-for-use-by-younger-children-2020-01-28", "https://www.nasdaq.com/articles/regeneron-pharmaceuticals-reaches-analyst-target-price-2020-01-16", "https://www.nasdaq.com/articles/nasdaq-100-movers%3A-algn-regn-2020-01-15", "https://www.nasdaq.com/articles/regeneron-pharma-to-present-at-j.p.-morgan-conference-webcast-at-1%3A30-pm-et-2020-01-13", "https://www.nasdaq.com/articles/eli-lilly-to-boost-its-dermatology-pipeline-with-%241.1-billion-dermira-acquisition-2020-01", "https://www.nasdaq.com/articles/fex-cxo-regn-uri%3A-large-inflows-detected-at-etf-2020-01-10", "https://www.nasdaq.com/articles/why-has-vertex-pharmaceuticals-stock-gained-30-in-the-last-quarter-2020-01-10", "https://www.nasdaq.com/articles/noteworthy-thursday-option-activity%3A-regn-appn-run-2020-01-09", "https://www.nasdaq.com/articles/thursday-sector-laggards%3A-healthcare-energy-2020-01-16", "https://www.nasdaq.com/articles/interesting-regn-put-and-call-options-for-august-21st-2020-01-03", "https://www.nasdaq.com/articles/noteworthy-thursday-option-activity%3A-blk-regn-tmus-2020-01-02", "https://www.nasdaq.com/articles/3-biotech-stocks-that-crushed-it-in-2019-2019-12-28", "https://www.nasdaq.com/articles/ishares-nasdaq-biotechnology-etf-experiences-big-outflow-2019-12-24", "https://www.nasdaq.com/articles/why-2020-should-be-the-biggest-year-yet-for-crispr-gene-editing-stocks-2019-12-22", "https://www.nasdaq.com/articles/heres-why-inovio-pharmaceuticals-jumped-higher-today-2019-12-19", "https://www.nasdaq.com/articles/nasdaq-100-movers%3A-regn-ntes-2019-12-19", "https://www.nasdaq.com/articles/why-the-fdas-decision-on-aimmunes-peanut-allergy-drug-is-crucial-for-the-company-and", "https://www.nasdaq.com/articles/why-bridgebio-pharma-is-currently-trading-at-2x-its-ipo-price-2019-12-12", "https://www.nasdaq.com/articles/heres-why-dermira-stock-popped-today-2019-12-10", "https://www.nasdaq.com/articles/is-bluebird-bio-a-buy-2019-12-10", "https://www.nasdaq.com/articles/noteworthy-monday-option-activity%3A-fcx-algn-regn-2019-12-09", "https://www.nasdaq.com/articles/can-cannabis-2.0-kickstart-marijuana-stocks-2019-12-06", "https://www.nasdaq.com/articles/heres-why-apellis-pharmaceuticals-fell-today-2019-12-05", "https://www.nasdaq.com/articles/celgene-gave-this-tech-back-to-editas-medicine-but-it-could-prove-valuable-2019-12-05", "https://www.nasdaq.com/articles/noteworthy-tuesday-option-activity%3A-isrg-lly-regn-2019-12-17", "https://www.nasdaq.com/articles/regeneron-pharma-to-present-at-piper-jaffray-conference-webcast-at-8%3A00-am-et-2019-12-03", "https://www.nasdaq.com/articles/why-novartiss-%249.7-billion-purchase-of-the-medicines-company-is-bad-news-for-amgen-2019-12", "https://www.nasdaq.com/articles/is-inovio-pharmaceuticals-a-buy-2019-11-27", "https://www.nasdaq.com/articles/understanding-why-regeneron-pharmaceuticals-stock-has-gained-25-in-2-months-2019-11-27-0", "https://www.nasdaq.com/articles/understanding-why-regeneron-pharmaceuticals-stock-has-gained-25-in-2-months-2019-11-27", "https://www.nasdaq.com/articles/better-buy%3A-novavax-vs.-inovio-pharmaceuticals-2019-11-26", "https://www.nasdaq.com/articles/a-45-premium%3A-heres-why-the-medicines-company-is-worth-more-to-novartis-than-it-was-to-you", "https://www.nasdaq.com/articles/regeneron-pharma-announces-positive-phase-2-results-in-rare-blood-disorder-2019-12-05", "https://www.nasdaq.com/articles/noteworthy-friday-option-activity%3A-cost-regn-dis-2019-11-22", "https://www.nasdaq.com/articles/thursday-sector-leaders%3A-energy-healthcare-2019-11-21", "https://www.nasdaq.com/articles/heres-why-the-medicines-company-jumped-higher-again-today-2019-11-19", "https://www.nasdaq.com/articles/heres-why-the-medicines-company-moved-higher-today-2019-11-18", "https://www.nasdaq.com/articles/3-biotech-stock-rockets-with-more-fuel-in-the-tank-2019-11-18", "https://www.nasdaq.com/articles/regeneron-pharma-to-present-at-guggenheim-healthcare-forum-webcast-at-11%3A15-am-2019-11-18", "https://www.nasdaq.com/articles/noteworthy-thursday-option-activity%3A-regn-xncr-ebix-2019-11-14", "https://www.nasdaq.com/articles/why-the-medicines-company-stock-is-soaring-today-2019-11-25", "https://www.nasdaq.com/articles/friday-sector-leaders%3A-healthcare-technology-communications-2019-11-08", "https://www.nasdaq.com/articles/heres-why-dermira-stock-is-soaring-today-2019-11-08", "https://www.nasdaq.com/articles/noteworthy-thursday-option-activity%3A-regn-nlsn-dlr-2019-11-07", "https://www.nasdaq.com/articles/december-27th-options-now-available-for-regeneron-pharmaceuticals-regn-2019-11-07", "https://www.nasdaq.com/articles/3-big-stock-charts-for-thursday%3A-kraft-heinz-wabtec-and-regeneron-pharmaceuticals-2019-11", "https://www.nasdaq.com/articles/regeneron-vyriad-to-collaborate-on-new-oncolytic-virus-treatments-for-cancer-2019-11-06", "https://www.nasdaq.com/articles/regeneron-pharmaceuticals-regn-q3-2019-earnings-call-transcript-2019-11-06", "https://www.nasdaq.com/articles/thursday-sector-laggards%3A-consumer-products-healthcare-2019-11-14", "https://www.nasdaq.com/articles/regn-makes-bullish-cross-above-critical-moving-average-2019-11-05", "https://www.nasdaq.com/articles/nasdaq-100-movers%3A-symc-regn-2019-11-05", "https://www.nasdaq.com/articles/health-care-sector-update-for-11-05-2019%3A-bdx-regn-zbh-jnj-pfe-abt-mrk-amgn-2019-11-05", "https://www.nasdaq.com/articles/daily-markets%3A-potential-us-china-trade-progress-lifts-global-equities-2019-11-05", "https://www.nasdaq.com/articles/why-this-just-might-be-the-biggest-week-for-cara-stock-2019-11-05", "https://www.nasdaq.com/articles/regeneron-pharma-q3-19-earnings-conference-call-at-8%3A30-am-et-2019-11-05", "https://www.nasdaq.com/articles/regeneron-pharmaceuticals-board-approves-%241-bln-share-buyback-quick-facts-2019-11-05", "https://www.nasdaq.com/articles/tuesdays-etf-with-unusual-volume%3A-qqew-2019-11-05", "https://www.nasdaq.com/articles/notable-thursday-option-activity%3A-regn-irm-ci-2019-10-31", "https://www.nasdaq.com/articles/regeneron-sanofi%3A-european-commission-approves-new-indication-for-dupixent-2019-10-29", "https://www.nasdaq.com/articles/2-under-the-radar-biotech-stocks-that-could-make-you-rich-2019-10-28", "https://www.nasdaq.com/articles/5-top-healthcare-etfs-2019-10-26", "https://www.nasdaq.com/articles/first-week-of-regn-december-20th-options-trading-2019-10-25", "https://www.nasdaq.com/articles/analysts-forecast-11-gains-ahead-for-iwf-2019-10-24", "https://www.nasdaq.com/articles/noteworthy-wednesday-option-activity%3A-regn-cvm-ci-2019-10-23", "https://www.nasdaq.com/articles/regeneron-pharmaceuticals-q3-adjusted-earnings-beat-estimates-2019-11-05", "https://www.nasdaq.com/articles/heres-why-dermira-stock-is-rocketing-higher-today-2019-10-18", "https://www.nasdaq.com/articles/are-these-3-beaten-down-biotech-stocks-bargains-now-2019-10-17", "https://www.nasdaq.com/articles/notable-wednesday-option-activity%3A-regn-lmt-hon-2019-10-16", "https://www.nasdaq.com/articles/3-undervalued-stocks-to-buy-according-to-goldman-sachs-2019-10-14", "https://www.nasdaq.com/articles/noteworthy-tuesday-option-activity%3A-regn-xncr-de-2019-10-08", "https://www.nasdaq.com/articles/3-cancer-fighting-drug-stocks-to-buy-right-now-2019-10-03", "https://www.nasdaq.com/articles/notable-tuesday-option-activity%3A-regn-cat-gpc-2019-10-01", "https://www.nasdaq.com/articles/is-anaptysbio-a-buy-2019-10-23", "https://www.nasdaq.com/articles/xbi-mrtx-sgen-regn%3A-large-inflows-detected-at-etf-2019-09-30", "https://www.nasdaq.com/articles/interesting-regn-put-and-call-options-for-may-2020-2019-09-24", "https://www.nasdaq.com/articles/add-up-the-parts%3A-qld-could-be-worth-%24109-2019-09-23", "https://www.nasdaq.com/articles/health-care-sector-update-for-09-20-2019%3A-nsprregnsnyalgnzbhacbacb.to-2019-09-20", "https://www.nasdaq.com/articles/health-care-sector-update-for-09-20-2019%3A-regnalgnzbhacb-2019-09-20", "https://www.nasdaq.com/articles/6-september-healthcare-ipos-investors-should-take-stock-of-2019-09-20", "https://www.nasdaq.com/articles/regeneron-and-sanofi-say-chmp-adopts-positive-opinion-for-dupixent-2019-09-20", "https://www.nasdaq.com/articles/the-medicines-company-is-up-161-year-to-date-but-heres-a-better-way-to-play-the-drugmakers", "https://www.nasdaq.com/articles/nasdaq-100-movers%3A-amgn-nflx-2019-09-09", "https://www.nasdaq.com/articles/sp-500-movers%3A-amgn-lb-2019-09-09", "https://www.nasdaq.com/articles/regeneron-pharma-to-present-at-morgan-stanley-conference-webcast-at-8%3A10-am-et-2019-09-09", "https://www.nasdaq.com/articles/notable-friday-option-activity%3A-wday-lkq-regn-2019-09-06", "https://www.nasdaq.com/articles/regn-october-11th-options-begin-trading-2019-09-03", "https://www.nasdaq.com/articles/noteworthy-thursday-option-activity%3A-sre-regn-mcd-2019-08-22", "https://www.nasdaq.com/articles/3-biotech-stocks-that-show-the-good-the-bad-and-the-ugly-side-of-this-sector-2019-09-14", "https://www.nasdaq.com/articles/8-biotech-stocks-to-watch-after-the-q2-earnings-season-2019-08-20", "https://www.nasdaq.com/articles/interesting-regn-put-and-call-options-for-october-18th-2019-08-20", "https://www.nasdaq.com/articles/noteworthy-wednesday-option-activity%3A-ms-regn-antm-2019-08-14", "https://www.nasdaq.com/articles/5-reasons-novartis-shareholders-arent-shaken-2019-08-11", "https://www.nasdaq.com/articles/anaptysbio-prepares-for-a-potential-gear-shift-2019-08-10", "https://www.nasdaq.com/articles/noteworthy-wednesday-option-activity%3A-regn-cat-mmm-2019-08-07", "https://www.nasdaq.com/articles/regeneron-pharmaceuticals-regn-q2-2019-earnings-call-transcript-2019-08-07", "https://www.nasdaq.com/articles/heres-why-anaptysbio-shares-are-slipping-today-2019-08-20", "https://www.nasdaq.com/articles/regeneron-pharma-q2-19-earnings-conference-call-at-8%3A30-am-et-2019-08-06", "https://www.nasdaq.com/articles/is-intellia-therapeutics-a-buy-2019-07-31", "https://www.nasdaq.com/articles/noteworthy-tuesday-option-activity%3A-regn-tenb-twou-2019-07-30", "https://www.nasdaq.com/articles/notable-tuesday-option-activity%3A-nvda-ba-regn-2019-07-23", "https://www.nasdaq.com/articles/look-under-the-hood%3A-qqxt-has-10-upside-2019-07-22", "https://www.nasdaq.com/articles/8-more-big-pharma-events-in-2019-you-dont-want-to-miss-2019-07-20", "https://www.nasdaq.com/articles/monday-sector-leaders%3A-utilities-healthcare-2019-07-15", "https://www.nasdaq.com/articles/regeneron-pharmaceuticals-reports-marked-improvement-in-q2-2019-08-06", "https://www.nasdaq.com/articles/nasdaq-100-movers%3A-fast-nvda-2019-07-11", "https://www.nasdaq.com/articles/noteworthy-monday-option-activity%3A-nflx-pep-regn-2019-07-08", "https://www.nasdaq.com/articles/3-top-biotech-stocks-to-add-to-your-watchlist-2019-06-30", "https://www.nasdaq.com/articles/noteworthy-friday-option-activity%3A-ttd-shak-regn-2019-06-28", "https://www.nasdaq.com/articles/interesting-regn-put-and-call-options-for-august-9th-2019-06-27", "https://www.nasdaq.com/articles/interesting-regn-put-and-call-options-for-february-2020-2019-06-26", "https://www.nasdaq.com/articles/the-10-biggest-biotech-stocks-2019-06-25", "https://www.nasdaq.com/articles/interesting-regn-put-and-call-options-for-august-30th-2019-07-15", "https://www.nasdaq.com/articles/noteworthy-friday-option-activity%3A-nvda-tgt-regn-2019-06-21", "https://www.nasdaq.com/articles/3-drugs-under-fda-review-with-blockbuster-potential-2019-06-20", "https://www.nasdaq.com/articles/nasdaq-100-movers%3A-ual-regn-2019-06-20", "https://www.nasdaq.com/articles/sp-500-movers%3A-ccl-orcl-2019-06-20", "https://www.nasdaq.com/articles/analysts-anticipate-ive-to-hit-%24128-2019-06-20", "https://www.nasdaq.com/articles/notable-thursday-option-activity%3A-regn-biib-grmn-2019-06-13", "https://www.nasdaq.com/articles/heres-why-regeneron-pharmaceuticals-tumbled-12-may-2019-06-10", "https://www.nasdaq.com/articles/heres-why-anaptysbio-shares-are-sliding-today-2019-06-21", "https://www.nasdaq.com/articles/11-biotech-stocks-put-your-radar-soon-2019-05-30", "https://www.nasdaq.com/articles/biotech-stocks-facing-fda-decision-june-2019-2019-05-24", "https://www.nasdaq.com/articles/5-growthy-biotech-stocks-to-buy-despite-the-scrutiny-2019-05-13", "https://www.nasdaq.com/articles/friday-sector-laggards%3A-healthcare-technology-communications-2019-05-10", "https://www.nasdaq.com/articles/noteworthy-thursday-option-activity%3A-eght-regn-sgmo-2019-05-09", "https://www.nasdaq.com/articles/health-care-sector-update-for-05-07-2019%3A-pinccprxhsicregnsny-2019-05-07", "https://www.nasdaq.com/articles/health-care-sector-update-for-05-07-2019%3A-cprxhsicregnsny-2019-05-07", "https://www.nasdaq.com/articles/why-inovio-pharmaceuticals-stock-sinking-today-2019-05-31", "https://www.nasdaq.com/articles/regeneron-pharmaceuticals-q1-19-earnings-conference-call-8%3A30-am-et-2019-05-07", "https://www.nasdaq.com/articles/regeneron-pharmaceuticals-q1-adjusted-earnings-miss-estimates-2019-05-07", "https://www.nasdaq.com/articles/why-are-investors-passing-teva-pharmaceutical-industries-2019-05-05", "https://www.nasdaq.com/articles/noteworthy-thursday-option-activity%3A-flr-algn-regn-2019-05-02", "https://www.nasdaq.com/articles/can-alnylam-pharmaceuticals-stock-start-climbing-again-2019-05-02", "https://www.nasdaq.com/articles/3-things-you-might-not-know-about-zoetis-2019-05-01", "https://www.nasdaq.com/articles/5-biotech-stocks-for-a-long-lived-portfolio-2019-04-30", "https://www.nasdaq.com/articles/regeneron-sanofi%3A-dupixent-approved-severe-asthma-indication-eu-2019-05-07", "https://www.nasdaq.com/articles/biotech-stocks-facing-fda-decision-may-2019-2019-04-26", "https://www.nasdaq.com/articles/why-investors-should-buy-dip-mrk-stock-2019-04-24", "https://www.nasdaq.com/articles/why-you-shouldnt-count-regeneron-stock-out-2019-04-22", "https://www.nasdaq.com/articles/regeneron-pharmaceuticals-becomes-oversold-regn-2019-04-16", "https://www.nasdaq.com/articles/alnylam-pharmaceuticals-buy-now-2019-04-16", "https://www.nasdaq.com/articles/alnylam-initiates-phase-iii-illuminate-b-study-on-lumasiran-2019-04-16-0", "https://www.nasdaq.com/articles/notable-monday-option-activity-regn-xec-iff-2019-04-15", "https://www.nasdaq.com/articles/sanofi%3A-fda-approves-praluent-prevent-heart-attack-stroke-unstable-angina-2019-04-29", "https://www.nasdaq.com/articles/alnylam-alny-reports-phase-iii-envision-data-on-givosiran-2019-04-15-0", "https://www.nasdaq.com/articles/notable-monday-option-activity-regn-xec-iff-2019-04-15-0", "https://www.nasdaq.com/articles/regn-makes-notable-cross-below-critical-moving-average-2019-04-12", "https://www.nasdaq.com/articles/friday-sector-laggards-healthcare-utilities-2019-04-12", "https://www.nasdaq.com/articles/regn-makes-notable-cross-below-critical-moving-average-2019-04-12-0", "https://www.nasdaq.com/articles/friday-sector-laggards-healthcare-utilities-2019-04-12-0", "https://www.nasdaq.com/articles/thursday-sector-laggards-healthcare-energy-2019-04-11", "https://www.nasdaq.com/articles/interesting-regn-put-options-may-31st-2019-04-15", "https://www.nasdaq.com/articles/thursday-sector-laggards-healthcare-energy-2019-04-11-0", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-796424-5496-points-2019-04-10", "https://www.nasdaq.com/articles/regeneron-alnylam-extend-collaboration-for-rnai-therapeutics-2019-04-09", "https://www.nasdaq.com/articles/heres-why-dermira-shot-62-march-2019-04-08", "https://www.nasdaq.com/articles/heres-why-dermira-shot-62-march-2019-04-08-0", "https://www.nasdaq.com/articles/regeneron-invest-%24800-mln-alnylam-jointly-develop-rnai-therapeutics-2019-04-08", "https://www.nasdaq.com/articles/noteworthy-friday-option-activity-regn-t-apc-2019-04-05", "https://www.nasdaq.com/articles/4-drugbiotech-stocks-making-mark-rnai-therapeutics-2019-04-11-0", "https://www.nasdaq.com/articles/better-buy-vertex-pharmaceuticals-vs-regeneron-pharmaceuticals-2019-03-24", "https://www.nasdaq.com/articles/notable-thursday-option-activity-ba-regn-ea-2019-03-21", "https://www.nasdaq.com/articles/should-you-invest-in-the-invesco-dynamic-biotechnology-genome-etf-pbe-2019-03-20", "https://www.nasdaq.com/articles/can-dermira-stock-keep-soaring-2019-03-19", "https://www.nasdaq.com/articles/inovios-early-mid-stage-vaccine-pipeline-exhibits-growth-2019-03-18", "https://www.nasdaq.com/articles/regeneron-sanofi-get-ec-nod-for-label-expansion-of-praluent-2019-03-18", "https://www.nasdaq.com/articles/after-berkshire-bought-teva-pharmaceutical-stock-should-others-follow-suit-2019-03-15", "https://www.nasdaq.com/articles/noteworthy-friday-option-activity-regn-t-apc-2019-04-05-0", "https://www.nasdaq.com/articles/nasdaq-100-movers-regn-meli-2019-03-13", "https://www.nasdaq.com/articles/sp-500-movers-regn-br-2019-03-13", "https://www.nasdaq.com/articles/inovio-ino-misses-on-q4-earnings-revenues-shares-down-2019-03-13", "https://www.nasdaq.com/articles/nasdaq-composite-index-closes-3297-points-week-rising-3rd-straight-day-2019-03-13", "https://www.nasdaq.com/articles/notable-wednesday-option-activity-ksu-de-regn-2019-03-13", "https://www.nasdaq.com/articles/regeneron-sanofis-dupixent-gets-fda-nod-for-label-expansion-2019-03-12", "https://www.nasdaq.com/articles/april-26th-options-now-available-regeneron-pharmaceuticals-regn-2019-03-11", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-regn-gets-fda-nod-for-dupixent-other-pipeline-news-2019-03-13", "https://www.nasdaq.com/articles/regeneronsanofi-wins-us-approval-expanded-use-skin-drug-2019-03-11", "https://www.nasdaq.com/articles/regeneronsanofi-skin-disease-drug-cleared-use-us-teens-2019-03-11", "https://www.nasdaq.com/articles/pwb-pwc-big-etf-outflows-2019-03-08", "https://www.nasdaq.com/articles/regeneron-regn-up-0.8-since-last-earnings-report%3A-can-it-continue-2019-03-08", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-biib-to-acquire-nightstar-other-pipeline-news-more-2019-03-06", "https://www.nasdaq.com/articles/noteworthy-tuesday-option-activity-rgr-kmx-regn-2019-03-05", "https://www.nasdaq.com/articles/regeneron-sanofi-get-chmp-nod-for-dupixent-label-expansion-2019-03-04", "https://www.nasdaq.com/articles/sanofis-dupixent-gets-fda-priority-status-for-nasal-polyps-2019-03-11", "https://www.nasdaq.com/articles/sanofi-regeneron-disagree-with-jury-verdict-in-amgens-favor-2019-02-26", "https://www.nasdaq.com/articles/stocked-war-chest-bluebird-bio-presses-2019-02-26", "https://www.nasdaq.com/articles/noteworthy-monday-option-activity-qcom-pbyi-regn-2019-02-25", "https://www.nasdaq.com/articles/bluebird-blue-q4-earnings-beat-estimates-revenues-up-y-y-2019-02-22", "https://www.nasdaq.com/articles/pfizer-lillys-pain-candidate-succeeds-in-back-pain-study-2019-02-20", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-martin-zweig-2172019-2019-02-17", "https://www.nasdaq.com/articles/3-most-profitable-drugmakers-sp-500-are-they-buys-2019-02-17", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-once-cmta-soar-on-merger-news-other-pipeline-updates-2019-02-27", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-regeneron-impresses-in-q4-gilead-slumps-macrogenics-soars-2019-02", "https://www.nasdaq.com/articles/is-regeneron-pharmaceuticals-regn-stock-outpacing-its-medical-peers-this-year-2019-02-12", "https://www.nasdaq.com/articles/sanofi-regeneron-cut-price-of-pcsk9-inhibitor-praluent-by-60-2019-02-12", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-chevron-csx-regeneron-capital-one-and-canadian-national", "https://www.nasdaq.com/articles/sanofi-sny-q4-earnings-top-genzyme-unit-drives-sales-growth-2019-02-07", "https://www.nasdaq.com/articles/notable-thursday-option-activity-wday-ens-regn-2019-02-07", "https://www.nasdaq.com/articles/regeneron-regn-q4-earnings-and-revenues-surpass-estimates-2019-02-06", "https://www.nasdaq.com/articles/notable-etf-outflow-detected-ibb-biib-ilmn-regn-2019-02-14", "https://www.nasdaq.com/articles/regeneron-pharmaceuticals-q4-adjusted-earnings-beat-estimates-2019-02-06", "https://www.nasdaq.com/articles/regeneron-pharmaceuticals-inc-regn-q4-2018-earnings-conference-call-transcript-2019-02-06", "https://www.nasdaq.com/articles/regeneron-q4-earnings-sales-beat-on-strong-dupixent-eylea-2019-02-06", "https://www.nasdaq.com/articles/sanofis-myeloma-candidate-meets-goal-in-phase-iii-study-2019-02-05", "https://www.nasdaq.com/articles/pre-market-earnings-report-february-6-2019-lly-gm-bsx-regn-hum-ctsh-cmi-gsk-fdc-ttwo-bip", "https://www.nasdaq.com/articles/3-biotech-stocks-that-pay-solid-dividends-2019-02-05", "https://www.nasdaq.com/articles/regeneron-regn-to-report-q4-earnings%3A-is-a-beat-in-store-2019-02-04", "https://www.nasdaq.com/articles/regeneron-pharmaceuticals-q4-18-earnings-conference-call-830-am-et-2019-02-06", "https://www.nasdaq.com/articles/alexion-alxn-to-report-q4-earnings%3A-whats-in-the-cards-2019-01-31", "https://www.nasdaq.com/articles/noteworthy-thursday-option-activity-ge-regn-ma-2019-01-31", "https://www.nasdaq.com/articles/lilly-pfizers-osteoarthritis-pain-drug-succeeds-in-2nd-study-2019-01-30", "https://www.nasdaq.com/articles/3-top-biotech-stocks-buy-right-now-2019-01-29", "https://www.nasdaq.com/articles/amgen-amgn-to-report-q4-earnings%3A-whats-in-the-cards-2019-01-28", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-celgene-regeneron-pharmaceuticals-amgen-alnylam", "https://www.nasdaq.com/articles/is-a-beat-in-store-for-abbvie-abbv-this-earnings-season-2019-01-23", "https://www.nasdaq.com/articles/4-healthcare-stocks-likely-to-beat-estimates-in-q4-2019-01-31", "https://www.nasdaq.com/articles/notable-tuesday-option-activity-txt-regn-mcd-2019-01-22", "https://www.nasdaq.com/articles/3-healthcare-stocks-hitting-52-week-highs-are-they-buys-2019-01-20", "https://www.nasdaq.com/articles/aeries-aeri-eye-care-candidate-to-enter-clinical-studies-2019-01-18", "https://www.nasdaq.com/articles/jj-jnj-to-commence-pharma-q4-earnings%3A-what-to-expect-2019-01-17", "https://www.nasdaq.com/articles/notable-etf-outflow-detected-ibb-amgn-ilmn-regn-2019-01-16", "https://www.nasdaq.com/articles/can-regeneron-regn-keep-the-earnings-surprise-streak-alive-2019-01-15", "https://www.nasdaq.com/articles/3-top-big-pharma-stocks-buy-now-2019-01-15", "https://www.nasdaq.com/articles/7-best-stocks-to-buy-until-the-next-seismic-shift-2019-01-23", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-loxo-celg-gain-j.p.-morgan-healthcare-conference-in-focus-2019-01", "https://www.nasdaq.com/articles/market-leaderships-odd-couple-wingstop-and-regeneron-2019-01-09", "https://www.nasdaq.com/articles/regeneron-sanofi-restructure-immuno-oncology-collaboration-2019-01-07", "https://www.nasdaq.com/articles/sanofi-pay-regeneron-462-mln-revised-immuno-oncology-deal-2019-01-07", "https://www.nasdaq.com/articles/sanofi-pay-regeneron-580-mln-revised-immuno-oncology-deal-2019-01-07", "https://www.nasdaq.com/articles/drugmakers-sanofi-regeneron-restructure-immuno-oncology-deal-2019-01-07", "https://www.nasdaq.com/articles/regeneron-sanofi-select-two-clinical-stage-antibodies-ongoing-collaboration-2019-01-07", "https://www.nasdaq.com/articles/regn-crosses-above-average-analyst-target-2019-01-11", "https://www.nasdaq.com/articles/the-3-best-stocks-to-buy-at-the-end-of-the-bear-market-2019-01-04", "https://www.nasdaq.com/articles/stocks-seeing-further-upside-after-initial-jump-us-commentary-2019-01-04", "https://www.nasdaq.com/articles/strong-jobs-data-powell-comments-lead-rally-wall-street-us-commentary-2019-01-04", "https://www.nasdaq.com/articles/noteworthy-friday-option-activity-arnc-regn-crm-2019-01-04", "https://www.nasdaq.com/articles/regeneron-posting-strong-gain-upgrade-guggenheim-2019-01-04", "https://www.nasdaq.com/articles/value-investors-should-buy-teva-stock-dip-2018-12-26", "https://www.nasdaq.com/articles/biotech-stocks-made-big-progress-toward-preventing-heart-attacks-2018-2018-12-18", "https://www.nasdaq.com/articles/stocks-rallying-strong-jobs-data-powell-comments-us-commentary-2019-01-04", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-martin-zweig-12162018-2018-12-16", "https://www.nasdaq.com/articles/nasdaq-100-movers-cost-regn-2018-12-14", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-gilead-sciences-alexion-pharmaceuticals-regeneron", "https://www.nasdaq.com/articles/moderna-stock-ushers-next-wave-biotech-2018-12-11", "https://www.nasdaq.com/articles/4-biotech-stocks-investors-can-add-their-portfolio-2019-2018-12-11", "https://www.nasdaq.com/articles/noteworthy-friday-option-activity-fb-avgo-regn-2018-12-07", "https://www.nasdaq.com/articles/it-too-late-get-millionaire-maker-stock-2018-12-17", "https://www.nasdaq.com/articles/3-top-stocks-after-ash18-2018-12-06", "https://www.nasdaq.com/articles/sp-500-movers-dg-azo-2018-12-04", "https://www.nasdaq.com/articles/better-buy-vertex-pharmaceuticals-vs-regeneron-pharmaceuticals-2018-12-01", "https://www.nasdaq.com/articles/10-stocks-could-tank-according-morgan-stanley-2018-11-30", "https://www.nasdaq.com/articles/galapagos-osteoarthritis-candidate-gets-fast-track-status-2018-11-28", "https://www.nasdaq.com/articles/noteworthy-wednesday-option-activity-pypl-regn-wmt-2018-11-28", "https://www.nasdaq.com/articles/implied-analyst-12-month-target-xlv-2018-11-26", "https://www.nasdaq.com/articles/why-is-regeneron-regn-up-2.4-since-last-earnings-report-2018-12-06", "https://www.nasdaq.com/articles/glaxo-seeks-label-expansion-of-nucala-in-pediatric-patients-2018-11-20", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-martin-zweig-11182018-2018-11-18", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-peter-lynch-11182018-2018-11-18", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-petrochina-nextera-eni-dr-pepper-and-regeneron-2018-11", "https://www.nasdaq.com/articles/regeneron-regn-rides-on-eylea-and-dupixents-performance-2018-11-16", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-gilead-regeneron-present-data-cocrystal-pharma-surges-2018-11-14", "https://www.nasdaq.com/articles/7-best-stocks-buy-until-next-seismic-shift-2018-11-12", "https://www.nasdaq.com/articles/pfizer-stock-has-multiple-positive-catalysts-2018-11-21", "https://www.nasdaq.com/articles/wall-street-dives-deeper-ahead-opening-bell-veterans-day-2018-11-12", "https://www.nasdaq.com/articles/us-futures-cautiously-lower-traders-pause-veterans-day-2018-11-12", "https://www.nasdaq.com/articles/inovio-ino-q3-loss-narrower-than-expected-revenues-meet-2018-11-09", "https://www.nasdaq.com/articles/waiting-bluebird-bio-sing-ash-2018-11-09", "https://www.nasdaq.com/articles/sanofi-eczema-drug-dupixents-sbla-gets-priority-review-2018-11-07", "https://www.nasdaq.com/articles/september-jolts-report-in-spotlight-2018-11-06", "https://www.nasdaq.com/articles/regeneron-regn-q3-earnings-and-revenues-beat-estimates-2018-11-06", "https://www.nasdaq.com/articles/whats-in-the-cards-for-bayer-bayry-this-earnings-season-2018-11-12", "https://www.nasdaq.com/articles/regeneron-pharmaceuticals-inc-regn-q3-2018-earnings-conference-call-transcript-2018-11-06", "https://www.nasdaq.com/articles/will-stocks-gain-after-elections-earnings-cvs-lly-hear-2018-11-06", "https://www.nasdaq.com/articles/nasdaq-100-movers-atvi-khc-2018-11-05", "https://www.nasdaq.com/articles/why-regeneron-regn-might-surprise-this-earnings-season-2018-11-05", "https://www.nasdaq.com/articles/5-drug-biotech-stocks-set-to-trump-estimates-in-q3-earnings-2018-11-05", "https://www.nasdaq.com/articles/pre-market-earnings-report-november-6-2018-lly-cvs-bdx-emr-regn-apd-tri-adm-abc-tdg-br", "https://www.nasdaq.com/articles/biogen-stock-rebounds-after-impressive-q3-earnings-2018-11-05", "https://www.nasdaq.com/articles/regeneron-regn-q3-earnings-beat-estimates-revenues-in-line-2018-11-06", "https://www.nasdaq.com/articles/eli-lilly-lly-to-report-q3-earnings%3A-whats-in-the-cards-2018-11-01", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-gilead-sciences-amgen-vertex-pharmaceuticals-celgene", "https://www.nasdaq.com/articles/regeneron-regn-to-report-q3-earnings%3A-is-a-beat-in-store-2018-11-01", "https://www.nasdaq.com/articles/whats-in-the-cards-for-novavax-nvax-this-earnings-season-2018-10-31", "https://www.nasdaq.com/articles/sanofis-sny-q3-earnings-and-sales-surpass-estimates-2018-10-31", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-celgene-amgen-vertex-impress-in-q3-drna-soars-on-lly-deal-2018-10", "https://www.nasdaq.com/articles/whats-in-the-cards-for-abbvie-abbv-this-earnings-season-2018-10-30", "https://www.nasdaq.com/articles/bluebird-blue-q3-loss-narrower-than-expected-revenues-beat-2018-11-02", "https://www.nasdaq.com/articles/7-rising-healthcare-stocks-consider-2018-10-29", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-allergan-regeneron-pharmaceuticals-amgen-alnylam", "https://www.nasdaq.com/articles/math-shows-splg-can-go-38-2018-10-26", "https://www.nasdaq.com/articles/5-drug-biotech-stocks-likely-to-beat-estimates-in-q3-earnings-2018-10-26", "https://www.nasdaq.com/articles/can-amgen-amgn-keep-the-earnings-streak-alive-in-q3-2018-10-25", "https://www.nasdaq.com/articles/regeneron-pharmaceuticals-now-oversold-regn-2018-10-25", "https://www.nasdaq.com/articles/regn-crosses-below-key-moving-average-level-2018-10-25", "https://www.nasdaq.com/articles/should-you-invest-in-the-invesco-dynamic-biotechnology-genome-etf-pbe-2018-10-30", "https://www.nasdaq.com/articles/pfizer-succeeds-in-pain-study-forms-jv-to-make-cns-drugs-2018-10-24", "https://www.nasdaq.com/articles/is-a-beat-in-the-cards-for-allergan-agn-in-q3-earnings-2018-10-24", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-biib-tops-mack-plunges-regns-asthma-drug-gets-fda-nod-2018-10-24", "https://www.nasdaq.com/articles/noteworthy-wednesday-option-activity-regn-rmd-dish-2018-10-24", "https://www.nasdaq.com/articles/whats-in-store-for-celgene-corp.-celg-q3-earnings-2018-10-23", "https://www.nasdaq.com/articles/whats-in-store-for-anika-therapeutics-anik-in-q3-earnings-2018-10-22", "https://www.nasdaq.com/articles/will-gilead-gild-hiv-sales-offset-hcv-sales-decline-in-q3-2018-10-22", "https://www.nasdaq.com/articles/nasdaq-100-movers-algn-xlnx-2018-10-25", "https://www.nasdaq.com/articles/4-strong-stocks-buy-double-big-takeover-targets-2018-10-16", "https://www.nasdaq.com/articles/tuesday-sector-leaders-healthcare-technology-communications-2018-10-16", "https://www.nasdaq.com/articles/health-care-sector-update-10162018-regnsnyprpopstijnj-2018-10-16", "https://www.nasdaq.com/articles/5-healthcare-stocks-buy-complete-portfolio-wellness-2018-10-10", "https://www.nasdaq.com/articles/arwr-stock-sinks-after-signing-big-collaboration-deal-2018-10-09", "https://www.nasdaq.com/articles/3-top-biotech-stocks-buy-october-2018-10-08", "https://www.nasdaq.com/articles/noteworthy-monday-option-activity-regn-goog-cpb-2018-10-08", "https://www.nasdaq.com/articles/regenerons-dupixent-meets-goals-in-nasal-polyps-studies-2018-10-17", "https://www.nasdaq.com/articles/health-care-sector-update-10012018-tlrymntataroabbvregnmyl-2018-10-01", "https://www.nasdaq.com/articles/notable-friday-option-activity-evri-regn-goog-2018-09-28", "https://www.nasdaq.com/articles/is-regeneron-pharmaceuticals-regn-outperforming-other-medical-stocks-this-year-2018-09-27", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-above-8000-516-points-804197-2018-09-27", "https://www.nasdaq.com/articles/my-favorite-large-cap-biotech-stock-buy-now-2018-09-26", "https://www.nasdaq.com/articles/xbi-icpt-srpt-regn-etf-outflow-alert-2018-09-25", "https://www.nasdaq.com/articles/fda-lifts-clinical-hold-on-epizymes-lead-candidates-study-2018-09-25", "https://www.nasdaq.com/articles/sanofi-regenerons-cemiplimab-wins-fda-nod-for-skin-cancer-2018-10-01", "https://www.nasdaq.com/articles/zacks.com-featured-highlights-include%3A-regeneron-att-ametek-hershey-company-and-bgc-2018", "https://www.nasdaq.com/articles/chmp-reconfirms-negative-opinion-for-sareptas-exondys-2018-09-24", "https://www.nasdaq.com/articles/novartis-gets-positive-chmp-opinion-for-drugs-biosimilar-2018-09-24", "https://www.nasdaq.com/articles/fda-confirms-positive-safety-profile-of-acadias-nuplazid-2018-09-21", "https://www.nasdaq.com/articles/notable-friday-option-activity-gww-t-regn-2018-09-21", "https://www.nasdaq.com/articles/zacks.com-highlights%3A-g-iii-apparel-group-target-regeneron-pharmaceuticals-ametek-and", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-regeneron-pharmaceuticals-celgene-sanofi-and-gilead", "https://www.nasdaq.com/articles/fda-lifts-clinical-hold-on-sareptas-dmd-gene-therapy-program-2018-09-25", "https://www.nasdaq.com/articles/5-stocks-near-52-week-high-with-scope-for-further-upside-2018-09-19", "https://www.nasdaq.com/articles/regeneron-gains-on-eylea-dupixent-and-pipeline-progress-2018-09-18", "https://www.nasdaq.com/articles/xbi-icpt-srpt-regn-large-outflows-detected-etf-2018-09-17", "https://www.nasdaq.com/articles/regeneron-sanofi-report-data-on-dupixent-in-atopic-dermatitis-2018-09-17", "https://www.nasdaq.com/articles/time-to-focus-on-regeneron-pharmaceuticals-regn-for-strong-earnings-growth-potential-2018", "https://www.nasdaq.com/articles/notable-thursday-option-activity-regn-unh-fis-2018-09-13", "https://www.nasdaq.com/articles/3-top-value-stocks-buy-right-now-2018-09-12", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-celg-regn-present-data-vktx-soars-on-drugs-success-2018-09-19", "https://www.nasdaq.com/articles/5-stocks-near-52-week-high-with-scope-for-further-upside-2018-09-19", "https://www.nasdaq.com/articles/bluebird-bio-stock-may-have-upside-least-60-percent-2018-09-12", "https://www.nasdaq.com/articles/inovios-early-mid-stage-vaccine-pipeline-exhibits-growth-2018-09-10", "https://www.nasdaq.com/articles/inovio-initiates-dosing-in-phase-i-iia-study-on-mers-vaccine-2018-09-07", "https://www.nasdaq.com/articles/arrowhead-stock-not-done-rallying-after-its-38-jump-2018-09-07", "https://www.nasdaq.com/articles/ibb-gild-celg-regn-large-outflows-detected-etf-2018-09-06", "https://www.nasdaq.com/articles/noteworthy-wednesday-option-activity-ttd-regn-expe-2018-09-05", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-gilds-arthritis-drug-successful-in-phase-iii-prqr-soars-2018-09-12", "https://www.nasdaq.com/articles/is-regeneron-pharmaceuticals-regn-stock-outpacing-its-medical-peers-this-year-2018-08-30", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-oracle-intuit-regeneron-macys-and-deere-2018-08-29", "https://www.nasdaq.com/articles/wednesday-sector-leaders-energy-healthcare-2018-08-29", "https://www.nasdaq.com/articles/noteworthy-wednesday-option-activity-it-bkng-regn-2018-08-29", "https://www.nasdaq.com/articles/top-stock-reports-oracle-intuit-regeneron-pharmaceuticals-2018-08-28", "https://www.nasdaq.com/articles/4-biotech-stocks-investors-can-bet-post-solid-q2-earnings-2018-08-23", "https://www.nasdaq.com/articles/top-ranked-stocks-crushed-sp-500-longest-bull-run-2018-08-23", "https://www.nasdaq.com/articles/inovio-ino-initiates-phase-i-study-on-hepatitis-c-vaccine-2018-09-04", "https://www.nasdaq.com/articles/5-low-cost-biotech-stocks-with-high-levels-of-growth-2018-08-21", "https://www.nasdaq.com/articles/notable-tuesday-option-activity-c-hain-regn-2018-08-21", "https://www.nasdaq.com/articles/regenerons-eylea-gets-fda-nod-for-wet-amd-as-a-12-week-dose-2018-08-20", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-peter-lynch-8192018-2018-08-19", "https://www.nasdaq.com/articles/nasdaq-100-movers-amat-pcar-2018-08-17", "https://www.nasdaq.com/articles/regeneron-teva-announce-positive-data-on-osteoarthritis-drug-2018-08-17", "https://www.nasdaq.com/articles/inovio-pharmaceuticals-initiates-dosing-in-hiv-vaccine-study-2018-08-16", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-label-expansion-of-regenerons-eylea-vertexs-kalydeco-2018-08-22", "https://www.nasdaq.com/articles/health-care-sector-update-08162018-teva-regn-pfe-mdt-sny-2018-08-16", "https://www.nasdaq.com/articles/health-care-sector-update-08162018-tevaregnpfemdt-2018-08-16", "https://www.nasdaq.com/articles/regenerons-12-week-eylea-dose-gets-crl-from-fda-for-wet-amd-2018-08-14", "https://www.nasdaq.com/articles/time-to-focus-on-regeneron-pharmaceuticals-regn-for-strong-earnings-growth-potential-0", "https://www.nasdaq.com/articles/xbi-icpt-regn-hrtx-large-outflows-detected-etf-2018-08-13", "https://www.nasdaq.com/articles/notable-monday-option-activity-igt-syy-regn-2018-08-13", "https://www.nasdaq.com/articles/momenta-mnta-earnings-and-revenues-lag-estimates-in-q2-2018-08-10", "https://www.nasdaq.com/articles/why-warren-buffetts-still-gobbling-shares-generic-drugmaker-2018-08-16", "https://www.nasdaq.com/articles/sarepta-srpt-q2-loss-narrows-exondys-51-drives-sales-2018-08-09", "https://www.nasdaq.com/articles/inovio-ino-q2-loss-narrows-revenues-surpass-estimates-2018-08-08", "https://www.nasdaq.com/articles/nasdaq-100-movers-myl-qrtea-2018-08-08", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-regeneron-shines-blue-surges-once-plunges-2018-08-08", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-788833-467-points-2018-08-08", "https://www.nasdaq.com/articles/why-bluebird-bio-blue-stock-gaining-today-2018-08-06", "https://www.nasdaq.com/articles/morning-movers-intel-drops-qualcomm-rises-bluebird-flies-2018-08-06", "https://www.nasdaq.com/articles/carl-icahn-fires-shots-express-scripts-2018-08-09", "https://www.nasdaq.com/articles/company-news-for-aug-3-2018-2018-08-03", "https://www.nasdaq.com/articles/regeneron-pharmaceuticals-regn-jumps%3A-stock-rises-7-2018-08-03", "https://www.nasdaq.com/articles/noteworthy-friday-option-activity-ctrl-regn-med-2018-08-03", "https://www.nasdaq.com/articles/regeneron-regn-q2-earnings-beat-on-strong-dupixent-sales-2018-08-02", "https://www.nasdaq.com/articles/xbi-hrtx-icpt-regn-large-inflows-detected-etf-2018-08-02", "https://www.nasdaq.com/articles/ophthotech-opht-q2-loss-narrows-zimura-progress-on-track-2018-08-02", "https://www.nasdaq.com/articles/zoetis-zts-beats-on-q2-earnings-sales-updates-18-view-2018-08-02", "https://www.nasdaq.com/articles/t-mobile-sprint-pepsi-ceo-departs-jamie-dimons-latest-wisdom-more-free-lunch-2018-08-06", "https://www.nasdaq.com/articles/company-news-for-aug-3-2018-2018-08-03", "https://www.nasdaq.com/articles/why-sanofi-stock-should-run-higher-despite-mixed-earnings-2018-07-31", "https://www.nasdaq.com/articles/sanofis-sny-q2-earnings-surpass-estimates-sales-miss-2018-07-31", "https://www.nasdaq.com/articles/zoetis-zts-gears-up-for-q2-earnings%3A-whats-in-store-2018-07-31", "https://www.nasdaq.com/articles/regeneron-regn-to-report-q2-earnings%3A-whats-in-the-cards-2018-07-30", "https://www.nasdaq.com/articles/7-rebounding-stocks-that-are-coming-back-from-the-dead-2018-07-27", "https://www.nasdaq.com/articles/drug-stock-q2-earnings-releases-on-aug-2%3A-zts-regn-more-2018-08-01", "https://www.nasdaq.com/articles/whats-next-pfizer-stock-after-being-called-out-president-trump-2018-07-23", "https://www.nasdaq.com/articles/pfizer-lillys-pain-candidate-succeeds-in-phase-iii-study-2018-07-19", "https://www.nasdaq.com/articles/noteworthy-thursday-option-activity-idcc-fnd-regn-2018-07-19", "https://www.nasdaq.com/articles/glaxosmithkline-more-just-5-dividend-income-play-2018-07-17", "https://www.nasdaq.com/articles/better-know-biotech-regenxbio-inc-2018-07-13", "https://www.nasdaq.com/articles/notable-monday-option-activity-tdg-twtr-regn-2018-07-09", "https://www.nasdaq.com/articles/5-pharmaceutical-and-biotech-stocks-to-consider-for-july-2018-07-06", "https://www.nasdaq.com/articles/noteworthy-friday-option-activity-jnj-stz-regn-2018-07-27", "https://www.nasdaq.com/articles/bullish-two-hundred-day-moving-average-cross-regn-2018-07-05", "https://www.nasdaq.com/articles/3-big-stock-charts-for-friday%3A-sherwin-williams-regeneron-and-allstate-2018-06-29", "https://www.nasdaq.com/articles/notable-friday-option-activity-regn-jack-ssys-2018-06-29", "https://www.nasdaq.com/articles/nasdaq-100-movers-ctrp-regn-2018-06-27", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-744509-down-11654-points-2018-06-27", "https://www.nasdaq.com/articles/amgens-repatha-reduces-bad-cholestrol-in-type-ii-diabetes-2018-06-25", "https://www.nasdaq.com/articles/venture-capital-deals-week-tencent-bets-online-education-2018-06-23", "https://www.nasdaq.com/articles/3-top-biotech-stocks-buy-july-2018-07-06", "https://www.nasdaq.com/articles/bullish-two-hundred-day-moving-average-cross-regn-2018-07-05", "https://www.nasdaq.com/articles/notable-thursday-option-activity-agio-pbyi-regn-2018-06-14", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-axon-soars-amgen-drugs-get-fda-ec-nod-2018-06-13", "https://www.nasdaq.com/articles/should-crispr-stock-investors-worry-about-cancer-2018-06-13", "https://www.nasdaq.com/articles/alnylam-reports-positive-data-on-lumasiran-in-renal-disease-2018-06-11", "https://www.nasdaq.com/articles/bull-case-regeneron-pharmaceuticals-inc-couldnt-be-more-clear-2018-06-07", "https://www.nasdaq.com/articles/noteworthy-friday-option-activity-gpc-kmx-regn-2018-06-22", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-regeneron-celgene-amgen-impress-at-asco-2018-06-06", "https://www.nasdaq.com/articles/mylan-myl-gets-fda-approval-for-biosimilar-of-neulasta-2018-06-05", "https://www.nasdaq.com/articles/why-is-regeneron-pharmaceuticals-regn-up-2.7-since-its-last-earnings-report-2018-06-04", "https://www.nasdaq.com/articles/regn-july-13th-options-begin-trading-2018-05-31", "https://www.nasdaq.com/articles/noteworthy-wednesday-option-activity-box-igt-regn-2018-05-30", "https://www.nasdaq.com/articles/genome-editing-next-biotech-breakthrough-2018-05-24", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-fda-gives-nod-to-amgens-drugs-eu-approves-exelixis-cabometyx-2018", "https://www.nasdaq.com/articles/noteworthy-thursday-option-activity-regn-qcom-cme-2018-06-07", "https://www.nasdaq.com/articles/amgens-amgn-repatha-gains-eu-nod-to-include-outcomes-data-2018-05-17", "https://www.nasdaq.com/articles/sanofi-eczema-drug-dupixent-succeeds-in-adolescents-study-2018-05-16", "https://www.nasdaq.com/articles/nasdaq-100-movers-idxx-mu-2018-05-16", "https://www.nasdaq.com/articles/better-buy-amgen-inc-vs-biogen-inc-2018-05-15", "https://www.nasdaq.com/articles/will-trumps-surprise-drug-pricing-plan-boost-pharma-stocks-2018-05-14", "https://www.nasdaq.com/articles/sp-500-movers-symc-regn-2018-05-11", "https://www.nasdaq.com/articles/nasdaq-100-movers-symc-regn-2018-05-11", "https://www.nasdaq.com/articles/noteworthy-friday-option-activity-regn-trox-cb-2018-05-18", "https://www.nasdaq.com/articles/why-trade-desk-noodles-co-and-regeneron-pharmaceuticals-jumped-today-2018-05-11", "https://www.nasdaq.com/articles/friday-sector-leaders-utilities-healthcare-2018-05-11", "https://www.nasdaq.com/articles/notable-friday-option-activity-bkng-hd-regn-2018-05-11", "https://www.nasdaq.com/articles/fridays-etf-movers-pjp-cibr-2018-05-11", "https://www.nasdaq.com/articles/inovios-ino-q1-loss-wider-than-expected-shares-down-2018-05-10", "https://www.nasdaq.com/articles/ophthotechs-opht-q1-loss-narrows-y-y-zimura-in-focus-2018-05-10", "https://www.nasdaq.com/articles/esperion-therapeutics-inc-buy-dip-2018-05-08", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-740288-down-209-points-2018-05-11", "https://www.nasdaq.com/articles/why-trade-desk-noodles-co-and-regeneron-pharmaceuticals-jumped-today-2018-05-11", "https://www.nasdaq.com/articles/2-beaten-down-biotech-stocks-look-bargains-now-2018-05-05", "https://www.nasdaq.com/articles/are-these-disappointing-drugs-back-track-billions-2018-05-05", "https://www.nasdaq.com/articles/clinical-stage-biotechs-tackling-huge-health-issue-it-has-overcome-pessimistic-investors", "https://www.nasdaq.com/articles/regeneron-regn-q1-earnings-top-sales-lag-updates-view-2018-05-03", "https://www.nasdaq.com/articles/pfizer-inc-stuck-trading-range-now-2018-05-03", "https://www.nasdaq.com/articles/regeneron-regn-beats-q1-earnings-2018-05-03", "https://www.nasdaq.com/articles/oversold-conditions-regeneron-pharmaceuticals-regn-2018-05-07", "https://www.nasdaq.com/articles/health-care-sector-update-05032018-cahtdocregnakao-2018-05-03", "https://www.nasdaq.com/articles/health-care-sector-update-05032018-tdocregnakao-2018-05-03", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-alxn-vrtx-post-solid-results-gild-disappoints-in-q1-2018-05-02", "https://www.nasdaq.com/articles/pre-market-earnings-report-may-3-2018-bdx-cnq-ice-ci-bce-regn-pcg-k-ppl-cah-ggp-gpn-2018", "https://www.nasdaq.com/articles/is-a-beat-in-store-for-adverum-advm-this-earnings-season-2018-05-01", "https://www.nasdaq.com/articles/allergan-plc-stock-becomes-buy-it-bottoms-out-2018-05-01", "https://www.nasdaq.com/articles/whats-in-the-offing-for-regeneron-regn-in-q1-earnings-2018-04-30", "https://www.nasdaq.com/articles/notable-thursday-option-activity-pah-regn-odfl-2018-05-03", "https://www.nasdaq.com/articles/nasdaq-100-movers-chtr-expe-2018-04-27", "https://www.nasdaq.com/articles/sp-500-movers-chtr-sivb-2018-04-27", "https://www.nasdaq.com/articles/friday-sector-leaders-healthcare-financial-2018-04-27", "https://www.nasdaq.com/articles/notable-thursday-option-activity-bkng-evhc-regn-2018-04-26", "https://www.nasdaq.com/articles/amgen-amgn-earnings-beat-estimates-in-q1-revenues-up-y-y-2018-04-25", "https://www.nasdaq.com/articles/first-week-june-2019-options-trading-regeneron-pharmaceuticals-regn-2018-04-25", "https://www.nasdaq.com/articles/abbvie-inc-clear-value-play-biotech-stocks-2018-04-17", "https://www.nasdaq.com/articles/sanofis-sny-earnings-beat-estimates-in-q1-sales-miss-mark-2018-04-27", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-martin-zweig-4152018-2018-04-15", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-peter-lynch-4152018-2018-04-15", "https://www.nasdaq.com/articles/fda-restricts-sale-of-bayers-essure-birth-control-device-2018-04-10", "https://www.nasdaq.com/articles/fda-okays-label-expansion-of-paciras-exparels-stock-up-2018-04-09", "https://www.nasdaq.com/articles/sonoma-up-on-fda-approval-of-antimicrobial-post-therapy-gel-2018-04-06", "https://www.nasdaq.com/articles/emergent-ebs-gains-86.1-in-a-years-time%3A-heres-why-2018-04-06", "https://www.nasdaq.com/articles/novo-nordisk-obtains-licence-for-sickle-cell-disease-program-2018-04-06", "https://www.nasdaq.com/articles/noteworthy-tuesday-option-activity-amwd-pypl-regn-2018-04-17", "https://www.nasdaq.com/articles/catalyst-cprx-up-on-new-drug-application-for-firdapse-2018-04-05", "https://www.nasdaq.com/articles/thursday-sector-laggards-technology-communications-healthcare-2018-04-05", "https://www.nasdaq.com/articles/bio-path-leukemia-combo-study-shows-positive-early-data-2018-04-04", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-edge-falls-alks-down-fda-oks-amgn-drug-label-expansion-2018-04-04", "https://www.nasdaq.com/articles/rigel-rigl-sinks-on-failure-of-mid-stage-study-on-lead-drug-2018-04-04", "https://www.nasdaq.com/articles/celgene-celg-president-and-coo-to-step-down%3A-whats-ahead-2018-04-03", "https://www.nasdaq.com/articles/ema-accepts-regeneron-sanofis-application-for-dupixent-2018-04-03", "https://www.nasdaq.com/articles/notable-friday-option-activity-incy-nflx-regn-2018-04-06", "https://www.nasdaq.com/articles/sanofis-sny-skin-cancer-candidate-filing-accepted-in-eu-2018-04-03", "https://www.nasdaq.com/articles/alkermes-sinks-as-fda-refuses-depression-drug-review-2018-04-03", "https://www.nasdaq.com/articles/edge-therapeutics-loses-edge-on-failure-of-late-stage-study-2018-04-02", "https://www.nasdaq.com/articles/alnylam-falls-on-pfizers-rare-disease-drug-success-2018-04-02", "https://www.nasdaq.com/articles/monday-sector-laggards-energy-healthcare-2018-04-02", "https://www.nasdaq.com/articles/celgene-celg-up-on-deal-with-bluebird-for-car-t-candidate-2018-03-29", "https://www.nasdaq.com/articles/biomarins-maa-for-phenylketonuria-candidate-gains-eu-nod-2018-03-29", "https://www.nasdaq.com/articles/amgens-amgn-xgeva-gets-eu-approval-for-expanded-label-2018-04-03", "https://www.nasdaq.com/articles/noteworthy-thursday-option-activity-jpm-cat-regn-2018-03-29", "https://www.nasdaq.com/articles/celgene-loses-17.8-in-3-months%3A-time-to-reshuffle-portfolio-2018-03-28", "https://www.nasdaq.com/articles/tread-very-carefully-when-investing-anaptysbio-inc-2018-03-28", "https://www.nasdaq.com/articles/wall-street-has-given-these-3-stocks-and-thats-huge-mistake-2018-03-27", "https://www.nasdaq.com/articles/results-renew-optimism-esperion-therapeutics-2018-03-27", "https://www.nasdaq.com/articles/amgens-repatha-gains-chmp-nod-to-include-outcomes-data-2018-03-26", "https://www.nasdaq.com/articles/exelixis-cabometyx-gets-positive-chmp-opinion-in-europe-2018-03-26", "https://www.nasdaq.com/articles/regeneron-pharmaceuticals-inc-buy-2018-03-29", "https://www.nasdaq.com/articles/gilead-sciences-investors-better-watch-regeneron-alnylam-deal-2018-03-24", "https://www.nasdaq.com/articles/expect-slow-and-steady-climb-ahead-mylan-nv-2018-03-23", "https://www.nasdaq.com/articles/celgene-corporation-looks-cheap-considering-its-potential-2018-03-23", "https://www.nasdaq.com/articles/radius-health-down-on-negative-chmp-opinion-for-lead-drug-2018-03-23", "https://www.nasdaq.com/articles/regeneron-collaborates-with-alnylam-to-develop-nash-treatment-2018-03-22", "https://www.nasdaq.com/articles/roches-rhhby-lucentis-0.3-mg-pfs-receives-fda-approval-2018-03-22", "https://www.nasdaq.com/articles/valeant-vrx-stock-declines-21-ytd%3A-what-lies-ahead-2018-03-22", "https://www.nasdaq.com/articles/roches-tecentriq-combo-study-meets-co-primary-endpoint-2018-03-26", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-alxn-arna-up-on-study-data-prta-teams-up-with-celgene-2018-03-21", "https://www.nasdaq.com/articles/novo-nordisk-poised-on-strong-pipeline-amid-competition-2018-03-21", "https://www.nasdaq.com/articles/prothena-rallies-on-multi-year-collaboration-with-celgene-2018-03-21", "https://www.nasdaq.com/articles/ignore-trumps-pricing-rhetoric-these-5-biotech-picks-2018-03-21", "https://www.nasdaq.com/articles/regeneron-eylea-hits-24-week-primary-endpoint-in-study-2018-03-20", "https://www.nasdaq.com/articles/roche-tecentriq-phase-iii-combo-study-meets-primary-endpoint-2018-03-20", "https://www.nasdaq.com/articles/arena-pharmaceuticals-arna-in-focus%3A-stock-moves-10.7-higher-2018-03-22", "https://www.nasdaq.com/articles/health-care-sector-update-03192018-mdwd-regn-cdtx-gern-2018-03-19", "https://www.nasdaq.com/articles/3-top-biotech-stocks-buy-right-now-2018-03-19", "https://www.nasdaq.com/articles/health-care-sector-update-03192018-cdtxmdwdgernregn-2018-03-19", "https://www.nasdaq.com/articles/health-care-sector-update-03192018-mdwdgernregn-2018-03-19", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-martin-zweig-3182018-2018-03-18", "https://www.nasdaq.com/articles/agenus-agen-q4-loss-wider-than-expected-revenues-miss-2018-03-16", "https://www.nasdaq.com/articles/alexion-alxn-gains-on-positive-date-from-lead-candidate-2018-03-16", "https://www.nasdaq.com/articles/radius-health-announces-positive-data-on-lead-drug-tymlos-2018-03-19", "https://www.nasdaq.com/articles/catalyst-cprx-posts-in-line-q4-loss-pipeline-in-progress-2018-03-15", "https://www.nasdaq.com/articles/immune-design-imdz-posts-narrower-than-expected-loss-in-q4-2018-03-15", "https://www.nasdaq.com/articles/inovios-ino-q4-loss-narrower-than-expected-revenues-beat-2018-03-15", "https://www.nasdaq.com/articles/arena-pharmaceuticals-arna-q4-earnings-beat-sales-down-y-y-2018-03-15", "https://www.nasdaq.com/articles/solid-biosciences-sldb-hit-by-clinical-hold-on-lead-drug-2018-03-15", "https://www.nasdaq.com/articles/why-intellia-therapeutics-plunging-today-2018-03-14", "https://www.nasdaq.com/articles/epizyme-epzm-reports-narrower-than-expected-loss-in-q4-2018-03-14", "https://www.nasdaq.com/articles/infinity-infi-reports-narrower-than-expected-loss-in-q4-2018-03-16", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-regn-cuts-praluent-price-orex-to-file-for-bankruptcy-2018-03-14", "https://www.nasdaq.com/articles/ibb-amgn-gild-regn-etf-outflow-alert-2018-03-14", "https://www.nasdaq.com/articles/regeneron-pharmaceuticals-caesarstone-qualcomm-broadcom-and-exxon-mobil-highlighted-as", "https://www.nasdaq.com/articles/bull-day-regeneron-regn-2018-03-14", "https://www.nasdaq.com/articles/sarepta-to-seek-rapid-approval-for-second-dmd-drug-stock-up-2018-03-13", "https://www.nasdaq.com/articles/3-biotech-stocks-with-rising-earnings-estimates-post-q4-2018-03-13", "https://www.nasdaq.com/articles/merrimack-mack-incurs-narrower-than-expected-loss-in-q4-2018-03-13", "https://www.nasdaq.com/articles/abbvies-uterine-fibroids-candidate-succeeds-in-phase-iii-2018-03-14", "https://www.nasdaq.com/articles/wall-street-stays-buoyant-after-uplifting-february-jobs-report-2018-03-12", "https://www.nasdaq.com/articles/regeneron-takes-aim-amgen-and-esperion-therapeutics-2018-03-12", "https://www.nasdaq.com/articles/regeneron-and-sanofi-announce-positive-data-on-praluent-2018-03-12", "https://www.nasdaq.com/articles/health-care-sector-update-03122018-svra-srpt-alny-regn-sny-biib-pfe-2018-03-12", "https://www.nasdaq.com/articles/pfizer-gets-fda-panel-backing-for-new-indication-for-xeljanz-2018-03-09", "https://www.nasdaq.com/articles/notable-friday-option-activity-prty-pay-regn-2018-03-09", "https://www.nasdaq.com/articles/conatus-cnat-loss-narrower-than-expected-in-q4-sales-miss-2018-03-08", "https://www.nasdaq.com/articles/aradigm-files-maa-for-bronchiectasis-candidate-in-the-eu-2018-03-12", "https://www.nasdaq.com/articles/how-pieces-add-qqew-targets-68-2018-03-08", "https://www.nasdaq.com/articles/biotech-stock-round-up%3A-regeneron-submits-sbla-biogen-to-withdraw-zinbryta-2018-03-08", "https://www.nasdaq.com/articles/corcept-plans-korlym-label-expansion-pipeline-in-progress-2018-03-08", "https://www.nasdaq.com/articles/bristol-myers-opdivo-gets-fda-nod-for-every-four-week-dosing-2018-03-08", "https://www.nasdaq.com/articles/lilly-boehringer-to-expand-jardiance-heart-failure-program-2018-03-08", "https://www.nasdaq.com/articles/bayer-basf-in-talks-for-vegetable-seeds-business-sell-off-2018-03-08", "https://www.nasdaq.com/articles/ma-innovation-new-drugs-to-drive-pharma-stocks-2018-03-08", "https://www.nasdaq.com/articles/looking-for-a-growth-stock-why-it-is-time-to-focus-on-regeneron-regn-2018-03-08", "https://www.nasdaq.com/articles/dermiras-acne-candidate-fails-in-pivotal-trials-shares-sink-2018-03-06", "https://www.nasdaq.com/articles/whats-in-the-cards-for-inovio-ino-this-earnings-season-2018-03-06", "https://www.nasdaq.com/articles/gilead-announces-positive-data-on-new-hiv-therapy-biktarvy-2018-03-06", "https://www.nasdaq.com/articles/astrazenecas-forxiga-label-expansion-filing-accepted-in-eu-2018-03-06", "https://www.nasdaq.com/articles/heres-what-weighed-regeneron-pharmaceuticals-inc-down-february-2018-03-06", "https://www.nasdaq.com/articles/why-clearside-biomedical-jumped-higher-today-2018-03-06", "https://www.nasdaq.com/articles/spectrum-sppi-q4-loss-widens-y-y-sales-miss-stock-falls-2018-03-07", "https://www.nasdaq.com/articles/valeant-vrx-down-on-q4-earnings-miss-issues-drab-18-view-2018-03-05", "https://www.nasdaq.com/articles/fda-accepts-regeneron-sanofis-dupixent-sbla-for-asthma-2018-03-05", "https://www.nasdaq.com/articles/perrigo-prgo-surpassed-earnings-in-q4-revenues-down-y-y-2018-03-02", "https://www.nasdaq.com/articles/puma-pbyi-q4-loss-narrower-than-expected-shares-down-2018-03-02", "https://www.nasdaq.com/articles/radius-rdus-q4-loss-wider-than-expected-on-higher-expenses-2018-03-02", "https://www.nasdaq.com/articles/impax-ipxl-q4-earnings-revenues-miss-estimates-fall-y-y-2018-03-02", "https://www.nasdaq.com/articles/pacira-pcrx-posts-earnings-in-q4-revenues-in-line-2018-03-02", "https://www.nasdaq.com/articles/aduro-adro-q4-loss-narrower-than-expected-revenues-miss-2018-03-05", "https://www.nasdaq.com/articles/bayer-bayry-q4-earnings-beat-estimates-sales-down-y-y-2018-03-01", "https://www.nasdaq.com/articles/endo-endp-surpasses-earnings-revenue-estimates-in-q4-2018-02-28", "https://www.nasdaq.com/articles/ibb-regn-vrtx-alxn-large-outflows-detected-etf-2018-02-28", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-jazz-q4-earnings-miss-sales-up-y-y-2018-02-28", "https://www.nasdaq.com/articles/theravance-biopharma-tbph-q4-loss-wider-sales-drop-y-y-2018-02-28", "https://www.nasdaq.com/articles/amag-pharma-amag-beats-on-q4-earnings-misses-on-revenues-2018-02-28", "https://www.nasdaq.com/articles/ophthotech-opht-q4-earnings-beat-gene-therapy-in-focus-2018-02-28", "https://www.nasdaq.com/articles/sarepta-srpt-narrows-q4-loss-exondys-51-sales-impress-2018-03-02", "https://www.nasdaq.com/articles/perrigo-prgo-postpones-q4-earnings-results-shares-down-2018-02-27", "https://www.nasdaq.com/articles/endocyte-ecyt-reports-wider-than-estimated-loss-in-q4-2018-02-27", "https://www.nasdaq.com/articles/is-a-beat-in-store-for-adverum-advm-this-earnings-season-2018-02-26", "https://www.nasdaq.com/articles/biomarin-bmrn-q4-loss-wider-than-expected-sales-beat-2018-02-23", "https://www.nasdaq.com/articles/corcepts-cort-earnings-and-sales-meet-estimates-in-q4-2018-02-23", "https://www.nasdaq.com/articles/ibb-biib-celg-regn-etf-inflow-alert-2018-02-20", "https://www.nasdaq.com/articles/novavax-nvax-in-focus%3A-stock-moves-8.3-higher-2018-02-20", "https://www.nasdaq.com/articles/mallinckrodt-mnk-up-on-earnings-and-revenues-beat-in-q4-2018-02-28", "https://www.nasdaq.com/articles/top-research-reports-novo-nordisk-tjx-companies-cigna-2018-02-16", "https://www.nasdaq.com/articles/notable-friday-option-activity-qcom-regn-wynn-2018-02-16", "https://www.nasdaq.com/articles/nasdaq-100-movers-regn-bidu-2018-02-14", "https://www.nasdaq.com/articles/heres-what-pushed-intellia-therapeutics-inc-337-january-2018-02-08", "https://www.nasdaq.com/articles/regeneron-regn-q4-earnings-revenues-top-eylea-sales-grow-2018-02-08", "https://www.nasdaq.com/articles/ishares-nasdaq-biotechnology-etf-experiences-big-outflow-2018-02-08", "https://www.nasdaq.com/articles/regeneron-regn-tops-q4-earnings-sales-2018-02-08", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-nordisk-tjx-cigna-regeneron-and-arcelormittal-2018-02", "https://www.nasdaq.com/articles/commit-buy-regeneron-pharmaceuticals-200-earn-45-using-options-2018-02-08", "https://www.nasdaq.com/articles/sanofi-sny-q4-earnings-lag-on-weak-diabetes-vaccines-sales-2018-02-07", "https://www.nasdaq.com/articles/regn-vs.-alxn%3A-which-stock-is-poised-for-better-q4-earnings-2018-02-07", "https://www.nasdaq.com/articles/heres-why-anaptysbio-inc-stock-surged-wednesday-2018-02-07", "https://www.nasdaq.com/articles/pre-market-earnings-report-february-8-2018-pm-cvs-tmus-bce-regn-tri-yum-alxn-k-tsn-tu-wltw", "https://www.nasdaq.com/articles/10-stocks-to-ride-out-the-market-storm-2018-02-06", "https://www.nasdaq.com/articles/will-regeneron-regn-disappoint-investors-in-q4-earnings-2018-02-05", "https://www.nasdaq.com/articles/noteworthy-thursday-option-activity-regn-ttwo-nyld-2018-02-08", "https://www.nasdaq.com/articles/noteworthy-thursday-option-activity-bby-regn-px-2018-02-01", "https://www.nasdaq.com/articles/ishares-nasdaq-biotechnology-etf-experiences-big-outflow-2018-01-31", "https://www.nasdaq.com/articles/vertex-vrtx-other-drug-stocks-fda-catalysts-february-2018-01-31", "https://www.nasdaq.com/articles/regenerons-dupixent-receives-mhlw-nod-for-label-expansion-2018-01-23", "https://www.nasdaq.com/articles/notable-tuesday-option-activity-mlm-adbe-regn-2018-01-23", "https://www.nasdaq.com/articles/why-2017-was-year-forget-regeneron-pharmaceuticals-inc-2018-01-22", "https://www.nasdaq.com/articles/ophthotech-begins-phase-ii-zimura-study-in-stargardt-disease-2018-01-17", "https://www.nasdaq.com/articles/how-pieces-add-qqq-targets-181-2018-02-05", "https://www.nasdaq.com/articles/noteworthy-thursday-option-activity-bby-regn-px-2018-02-01", "https://www.nasdaq.com/articles/can-biotech-keep-last-years-momentum-alive-in-2018-2018-01-11", "https://www.nasdaq.com/articles/notable-etf-outflow-detected-ibb-regn-vrtx-ilmn-2018-01-10", "https://www.nasdaq.com/articles/biotech-stock-roundup-celgene-acquire-impact-jp-morgan-healthcare-conference-focus-2018-01", "https://www.nasdaq.com/articles/regeneron-sanofi-expand-investment-in-cemiplimab-dupilumab-2018-01-09", "https://www.nasdaq.com/articles/fda-approvals-surge-2017-heres-look-numbers-2018-01-09", "https://www.nasdaq.com/articles/abbvies-upadacitinib-gains-breakthrough-therapy-designation-2018-01-09", "https://www.nasdaq.com/articles/validea-martin-zweig-strategy-daily-upgrade-report-1172018-2018-01-17", "https://www.nasdaq.com/articles/why-former-biotech-winner-now-short-sale-opportunity-2018-01-08", "https://www.nasdaq.com/articles/monday-sector-laggards-healthcare-services-2018-01-08", "https://www.nasdaq.com/articles/momenta-mylan-to-initiate-trial-on-biosimilar-of-eylea-2018-01-04", "https://www.nasdaq.com/articles/generalists-biotech-sidelines-tax-reform-sweeps-us-2018-01-03", "https://www.nasdaq.com/articles/us-novel-drug-approvals-rocket-higher-overall-numbers-slide-2018-01-02", "https://www.nasdaq.com/articles/analysts-expect-xlv-will-reach-91-2018-01-01", "https://www.nasdaq.com/articles/3-top-value-stocks-buy-2018-2017-12-31", "https://www.nasdaq.com/articles/momenta-reports-positive-top-line-data-on-antibody-m281-2018-01-08", "https://www.nasdaq.com/articles/does-regeneron-pharma-have-potential-blockbuster-2018-2017-12-28", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-693625-down-2371-points-2017-12-26", "https://www.nasdaq.com/articles/biotech-stock-roundup-label-expansion-exelixiss-cabometyx-fda-nod-sparks-gene-therapy-2017", "https://www.nasdaq.com/articles/regeneron-in-strategic-immuno-oncology-collaboration-with-isa-2017-12-19", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-disney-kraft-heinz-caterpillar-humana-and-regeneron", "https://www.nasdaq.com/articles/top-research-reports-disney-kraft-heinz-caterpillar-2017-12-18", "https://www.nasdaq.com/articles/beware-price-wars-big-pharma-biotech-companies-horizon-2017-12-15", "https://www.nasdaq.com/articles/ishares-nasdaq-biotechnology-etf-experiences-big-outflow-2017-12-29", "https://www.nasdaq.com/articles/will-drug-kick-start-regeneron-pharmaceuticals-shares-2017-12-13", "https://www.nasdaq.com/articles/biotech-stock-roundup-ash-data-focus-gilead-buy-cell-design-labs-2017-12-13", "https://www.nasdaq.com/articles/regeneron-sanofi-report-positive-top-line-skin-cancer-data-2017-12-13", "https://www.nasdaq.com/articles/regenerons-sbla-for-eylea-accepted-by-fda-action-date-set-2017-12-12", "https://www.nasdaq.com/articles/fda-accepts-regenerons-supplemental-biologics-license-application-eylea-shares-edge-lower", "https://www.nasdaq.com/articles/regeneron-regn-down-8.3-since-earnings-report%3A-can-it-rebound-2017-12-11", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-netflix-stamps.com-constellation-brands-and-regeneron", "https://www.nasdaq.com/articles/cancer-space-update%3A-roche-pfizer-regeneron-make-data-presentations-2017-12-15", "https://www.nasdaq.com/articles/biotech-stock-roundup-fda-nod-amgen-pcsk9-inhibitor-revance-rt002-data-2017-12-06", "https://www.nasdaq.com/articles/double-whammy-caused-regeneron-pharmaceuticals-inc-fall-10-november-2017-12-06", "https://www.nasdaq.com/articles/amgens-pcsk9-inhibitor-gets-fda-nod-for-stroke-prevention-2017-12-04", "https://www.nasdaq.com/articles/amgen-regeneron-prep-battle-2018-over-cholesterol-drugs-2017-12-04", "https://www.nasdaq.com/articles/nasdaq-100-movers-ulta-myl-2017-12-01", "https://www.nasdaq.com/articles/heres-whats-unusual-about-regeneron-pharmaceuticals-latest-deal-2017-11-30", "https://www.nasdaq.com/articles/biotech-stock-roundup-regeneron-down-eylea-data-biogen-alkermes-ms-deal-2017-11-29", "https://www.nasdaq.com/articles/notable-friday-option-activity-regn-mon-pzza-2017-12-08", "https://www.nasdaq.com/articles/how-parts-add-xlv-headed-90-2017-11-27", "https://www.nasdaq.com/articles/notable-monday-option-activity-hum-dvn-regn-2017-11-27", "https://www.nasdaq.com/articles/regeneron-dips-7-month-low-after-drug-combo-bayer-fails-2017-11-27", "https://www.nasdaq.com/articles/regeneron-pharmaceuticals-now-oversold-regn-2017-11-20", "https://www.nasdaq.com/articles/lagoda-investment-management-lp-buys-cimarex-energy-co-tesla-inc-t2-biosystems-inc-sells", "https://www.nasdaq.com/articles/noteworthy-thursday-option-activity-ulta-regn-sjm-2017-11-16", "https://www.nasdaq.com/articles/nasdaq-100-movers-disca-has-2017-11-13", "https://www.nasdaq.com/articles/regenerons-stock-falls-as-mid-stage-eye-disease-studies-fail-2017-11-28", "https://www.nasdaq.com/articles/inovio-ino-q3-loss-wider-than-expected-revenues-miss-2017-11-09", "https://www.nasdaq.com/articles/ophthotech-opht-q3-earnings-sales-beat-zimura-in-focus-2017-11-09", "https://www.nasdaq.com/articles/biotech-stock-roundup-regeneron-delivers-strong-q3-results-cellectis-clinical-hold-lifted", "https://www.nasdaq.com/articles/regeneron-regn-beats-on-q3-earnings-sales-shares-up-2017-11-08", "https://www.nasdaq.com/articles/nasdaq-100-movers-ctxs-atvi-2017-11-08", "https://www.nasdaq.com/articles/sp-500-movers-dva-regn-2017-11-08", "https://www.nasdaq.com/articles/regeneron-jumps-after-issuing-street-topping-revenue-earnings-2017-11-08", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-675760-666-points-2017-11-13", "https://www.nasdaq.com/articles/heres-why-regeneron-pharmaceuticals-inc-slipped-10-october-2017-11-07", "https://www.nasdaq.com/articles/pre-market-earnings-report-november-8-2017-regn-hum-rok-mgm-gib-eca-hii-br-see-ver-stwd", "https://www.nasdaq.com/articles/inovio-ino-q3-earnings%3A-is-a-beat-in-store-for-the-stock-2017-11-06", "https://www.nasdaq.com/articles/chart-school-using-regenerons-five-year-rally-study-support-2017-11-03", "https://www.nasdaq.com/articles/will-regeneron-pharma-regn-disappoint-in-q3-earnings-2017-11-03", "https://www.nasdaq.com/articles/whats-in-the-cards-for-adverum-advm-this-earnings-season-2017-11-03", "https://www.nasdaq.com/articles/sanofi-sny-q3-earnings-in-line-sales-lag-diabetes-weak-2017-11-02", "https://www.nasdaq.com/articles/regeneron-regn-q3-earnings-beat-estimates-2017-11-08", "https://www.nasdaq.com/articles/relative-strength-alert-regeneron-pharmaceuticals-2017-10-26", "https://www.nasdaq.com/articles/amgen-amgn-q3-earnings-top-sales-decline-y-y-stock-falls-2017-10-26", "https://www.nasdaq.com/articles/analysts-see-11-gains-ahead-qqew-2017-10-26", "https://www.nasdaq.com/articles/notable-wednesday-option-activity-agn-regn-bk-2017-10-25", "https://www.nasdaq.com/articles/regeneron-pharmaceuticals-inc-stock-buy-2017-10-24", "https://www.nasdaq.com/articles/regn-crosses-below-key-moving-average-level-2017-10-20", "https://www.nasdaq.com/articles/nasdaq-100-movers-celg-pypl-2017-10-20", "https://www.nasdaq.com/articles/noteworthy-wednesday-option-activity-seas-tsla-regn-2017-11-01", "https://www.nasdaq.com/articles/notable-wednesday-option-activity-agn-regn-abbv-2017-10-18", "https://www.nasdaq.com/articles/sanofi-regenerons-dupixent-succeeds-in-phase-ii-study-2017-10-17", "https://www.nasdaq.com/articles/ibd-biotech-innovator-awards-2017-10-16", "https://www.nasdaq.com/articles/6-top-biotech-companies-innovation-earn-recognition-new-awards-2017-10-16", "https://www.nasdaq.com/articles/regeneron-advances-science-attack-arthritis-eye-disease-more-2017-10-16", "https://www.nasdaq.com/articles/health-care-sector-update-10162017-aimiregnsnyexeltgtx-2017-10-16", "https://www.nasdaq.com/articles/why-these-biotech-players-look-poised-crush-earnings-views-2017-10-13", "https://www.nasdaq.com/articles/biotech-stock-roundup-exelixis-soars-priority-review-fda-panel-supports-spark-drug-2017-10", "https://www.nasdaq.com/articles/dows-merck-bails-cholesterol-drug-prodding-shares-down-2017-10-11", "https://www.nasdaq.com/articles/notable-wednesday-option-activity-abbv-agn-regn-2017-10-11", "https://www.nasdaq.com/articles/biotech-hit-record-high-could-undercut-regeneron-eczema-2017-10-10", "https://www.nasdaq.com/articles/regeneron-and-sanofi-get-favorable-ruling-against-amgen-2017-10-06", "https://www.nasdaq.com/articles/why-regenerons-patent-win-worse-amgen-you-think-2017-10-06", "https://www.nasdaq.com/articles/regeneron-pops-after-judge-tosses-ban-amgen-rivaling-med-2017-10-05", "https://www.nasdaq.com/articles/why-regeneron-pharmaceuticals-dropped-113-september-2017-10-05", "https://www.nasdaq.com/articles/biotech-stock-roundup-amgens-imlygic-data-promising-regeneron-scores-win-pcsk9-lawsuit", "https://www.nasdaq.com/articles/mallinckrodt-neuroprotexeon-team-up-for-inhalation-therapy-2017-10-03", "https://www.nasdaq.com/articles/allergans-snda-for-anti-infective-avycaz-accepted-by-fda-2017-10-03", "https://www.nasdaq.com/articles/seattle-genetics-adcetris-gets-breakthrough-therapy-status-2017-10-03", "https://www.nasdaq.com/articles/3-top-ranked-big-biotech-stocks-to-buy-now-2017-10-03", "https://www.nasdaq.com/articles/fda-accepts-roches-rhhby-application-for-adjuvant-perjeta-2017-10-03", "https://www.nasdaq.com/articles/endocyte-inks-deal-for-prostate-cancer-candidate-shares-up-2017-10-03", "https://www.nasdaq.com/articles/novo-nordisks-fiasp-gets-fda-nod-for-diabetes-in-adults-2017-10-02", "https://www.nasdaq.com/articles/biotech-stock-roundup-endocyte-shoots-deal-amgen-abbvie-settle-humira-litigation-2017-10", "https://www.nasdaq.com/articles/mallinckrodt-neuroprotexeon-team-up-for-inhalation-therapy-2017-10-03", "https://www.nasdaq.com/articles/4-biotech-stocks-and-1-etf-to-buy-as-they-bolt-higher-2017-10-02", "https://www.nasdaq.com/articles/notable-monday-option-activity-tsla-regn-gww-2017-10-02", "https://www.nasdaq.com/articles/friday-sector-leaders-healthcare-consumer-products-2017-09-29", "https://www.nasdaq.com/articles/3-stocks-turned-7000-130200-2017-09-28", "https://www.nasdaq.com/articles/galapagos-pops-after-eczema-drug-shows-promise-vs-regeneron-2017-09-27", "https://www.nasdaq.com/articles/infinity-bristol-myers-adds-tnbc-patients-to-clinical-deal-2017-09-26", "https://www.nasdaq.com/articles/lilly-lly-makes-leadership-changes-to-executive-positions-2017-10-02", "https://www.nasdaq.com/articles/notable-monday-option-activity-regn-whr-qrvo-2017-09-25", "https://www.nasdaq.com/articles/the-medicines-co.-continues-to-focus-on-pipeline-development-2017-09-22", "https://www.nasdaq.com/articles/bayer-bayry-focuses-on-pipeline-development-acquisitions-2017-09-22", "https://www.nasdaq.com/articles/alnylam-sanofis-rnai-drug-meets-endpoint-in-study-stock-up-2017-09-21", "https://www.nasdaq.com/articles/how-is-the-age-related-macular-degeneration-space-faring-now-2017-09-21", "https://www.nasdaq.com/articles/5-top-stocks-with-impressive-sales-growth-worth-betting-on-2017-09-21", "https://www.nasdaq.com/articles/teva-nuvelution-to-speed-up-development-of-austedo-in-us-2017-09-20", "https://www.nasdaq.com/articles/abbvie-bristol-myers-inks-deal-to-develop-therapeutic-cancer-2017-09-25", "https://www.nasdaq.com/articles/alkermes-aristada-shows-better-results-to-treat-schizophrenia-2017-09-19", "https://www.nasdaq.com/articles/pluristems-ischemia-candidate-gets-fast-track-designation-2017-09-19", "https://www.nasdaq.com/articles/zacks.com-featured-highlights-include-include-hasbro-regeneron-pharmaceuticals-applied", "https://www.nasdaq.com/articles/glaxos-triple-therapy-copd-inhaler-gets-chmp-nod-in-the-eu-2017-09-18", "https://www.nasdaq.com/articles/5-top-stocks-with-impressive-sales-growth-worth-betting-on-2017-09-18", "https://www.nasdaq.com/articles/notable-monday-option-activity-jpm-noc-regn-2017-09-18", "https://www.nasdaq.com/articles/ibb-biib-regn-alxn-etf-inflow-alert-2017-09-15", "https://www.nasdaq.com/articles/proqrs-genetic-disorder-candidate-gets-orphan-drug-status-2017-09-20", "https://www.nasdaq.com/articles/lilly-incytes-baricitinib-meets-endpoint-in-eczema-study-2017-09-15", "https://www.nasdaq.com/articles/glaxos-shingles-candidate-gets-positive-fda-committee-vote-2017-09-14", "https://www.nasdaq.com/articles/3-high-risk-high-reward-naked-puts-2017-09-14", "https://www.nasdaq.com/articles/alexion-alxn-reports-interim-results-for-soliris-study-2017-09-14", "https://www.nasdaq.com/articles/oversold-conditions-regeneron-pharmaceuticals-regn-2017-09-13", "https://www.nasdaq.com/articles/biotech-stock-roundup-alexion-cut-jobs-streamline-operations-kura-cancer-data-2017-09-13", "https://www.nasdaq.com/articles/regenerons-dupixent-takes-another-step-toward-blockbuster-status-2017-09-13", "https://www.nasdaq.com/articles/pfizer-xtandi-succeeds-in-early-stage-prostate-cancer-study-2017-09-15", "https://www.nasdaq.com/articles/achillions-hcv-partnership-with-jj-terminated-stock-falls-2017-09-12", "https://www.nasdaq.com/articles/astrazenecas-asthma-candidate-shows-promising-results-2017-09-12", "https://www.nasdaq.com/articles/pfizer-lung-cancer-drugs-overall-survival-data-unfavorable-2017-09-12", "https://www.nasdaq.com/articles/3-soaring-healthcare-stocks-with-very-bullish-news-sentiment-2017-09-12", "https://www.nasdaq.com/articles/5-things-regenerons-ceo-said-biotech-stock-sank-2017-09-12", "https://www.nasdaq.com/articles/top-ranked-momentum-stocks-to-buy-for-september-11th-2017-09-11", "https://www.nasdaq.com/articles/nasdaq-100-movers-regn-meli-2017-09-11", "https://www.nasdaq.com/articles/alexion-to-restructure-operations-to-lower-headcount-by-20-2017-09-13", "https://www.nasdaq.com/articles/roches-ophthalmology-drug-fails-to-meet-primary-endpoint-2017-09-11", "https://www.nasdaq.com/articles/5-top-ranked-biotech-stocks-buy-right-now-2017-09-11", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-643226-7207-points-2017-09-11", "https://www.nasdaq.com/articles/why-equifax-regeneron-pharmaceuticals-and-anglogold-ashanti-slumped-today-2017-09-11", "https://www.nasdaq.com/articles/astrazenecas-lung-cancer-study-data-promising-shares-spike-2017-09-11", "https://www.nasdaq.com/articles/regeneron-sanofis-dupixent-asthma-study-meets-endpoints-2017-09-11", "https://www.nasdaq.com/articles/lilly-to-cut-3500-jobs-to-invest-in-new-drugs-and-growth-2017-09-08", "https://www.nasdaq.com/articles/sp-500-movers-regn-re-2017-09-11", "https://www.nasdaq.com/articles/regenerons-cemiplimab-gains-breakthrough-therapy-status-2017-09-08", "https://www.nasdaq.com/articles/noteworthy-friday-option-activity-regn-fnhc-axon-2017-09-08", "https://www.nasdaq.com/articles/4-biotech-stocks-to-improve-your-portfolios-health-2017-09-08", "https://www.nasdaq.com/articles/nasdaq-100-movers-regn-cern-2017-09-07", "https://www.nasdaq.com/articles/astrazenecas-copd-candidate-duaklir-reports-positive-data-2017-09-07", "https://www.nasdaq.com/articles/sp-500-movers-leg-ma-2017-09-07", "https://www.nasdaq.com/articles/regn-crosses-above-average-analyst-target-2017-09-07", "https://www.nasdaq.com/articles/abbvies-upadacitinib-meets-primary-endpoint-in-phase-iib-2017-09-08", "https://www.nasdaq.com/articles/nasdaq-100-biotechnology-beyond-pure-tech-still-pure-innovation-2017-09-06", "https://www.nasdaq.com/articles/why-regeneron-regn-could-be-positioned-for-a-surge-2017-09-06", "https://www.nasdaq.com/articles/proqrs-qrx-421-gets-orphan-drug-designation-from-fda-and-ema-2017-09-06", "https://www.nasdaq.com/articles/vivus-gives-rights-to-alvogen-in-korea-for-anti-obesity-drug-2017-09-06", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-regeneron-pharmaceuticals-activision-blizzard-intuit", "https://www.nasdaq.com/articles/biotech-stocks-back-favor-will-rally-continue-2017-09-05", "https://www.nasdaq.com/articles/4-biotech-stocks-to-improve-your-portfolios-health-2017-09-05", "https://www.nasdaq.com/articles/abbvie-scores-2-wins-1-threatens-regeneron-2017-09-07", "https://www.nasdaq.com/articles/nasdaq-100-biotechnology-beyond-pure-tech-still-pure-innovation-2017-09-06", "https://www.nasdaq.com/articles/5-winning-stocks-beat-september-blues-2017-09-01", "https://www.nasdaq.com/articles/amags-filing-for-ferahemes-label-expansion-accepted-by-fda-2017-09-01", "https://www.nasdaq.com/articles/teva-austedo-gets-fda-nod-for-label-expansion-in-dyskinesia-2017-08-31", "https://www.nasdaq.com/articles/lilly-incyte-to-re-file-baricitinib-nda-faster-than-expected-2017-08-31", "https://www.nasdaq.com/articles/roches-rhhby-actemra-gets-fda-nod-for-label-expansion-2017-08-31", "https://www.nasdaq.com/articles/biomarins-pegvaliase-bla-granted-priority-review-by-the-fda-2017-08-30", "https://www.nasdaq.com/articles/why-is-regeneron-regn-up-7.9-since-the-last-earnings-report-2017-09-04", "https://www.nasdaq.com/articles/amgen-presents-new-repatha-analysis-from-fourier-study-2017-08-29", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-toyota-motor-nvidia-and-regeneron-2017-08-29", "https://www.nasdaq.com/articles/strength-seen-in-adaptimmune-therapeutics-adap%3A-stock-soars-15.2-2017-08-29", "https://www.nasdaq.com/articles/advanced-accelerator-gets-action-date-for-lutathera-from-fda-2017-08-29", "https://www.nasdaq.com/articles/novo-nordisks-tresiba-gets-canadian-nod-2017-08-29", "https://www.nasdaq.com/articles/kamada-kmda-gets-fda-approval-for-rabies-vaccine-2017-08-28", "https://www.nasdaq.com/articles/time-facts-global-week-ahead-2017-08-28", "https://www.nasdaq.com/articles/5-biotech-stocks-that-are-breaking-higher-2017-08-30", "https://www.nasdaq.com/articles/amgen-presents-new-repatha-analysis-from-fourier-study-2017-08-29", "https://www.nasdaq.com/articles/vertexs-cystic-fibrosis-combo-gets-priority-review-in-u.s.-2017-08-25", "https://www.nasdaq.com/articles/will-endo-endp-continue-to-disappoint-investors-in-2017-2017-08-25", "https://www.nasdaq.com/articles/pfizers-ibrance-in-first-line-combo-breast-cancer-study-2017-08-23", "https://www.nasdaq.com/articles/are-glaxos-successful-new-drugs-enough-to-drive-growth-2017-08-23", "https://www.nasdaq.com/articles/alkermes-initiates-rolling-submission-of-depression-drug-2017-08-22", "https://www.nasdaq.com/articles/4-biotech-stocks-add-your-portfolio-post-q2-earnings-2017-08-22", "https://www.nasdaq.com/articles/astrazenecas-faslodex-gets-fda-nod-in-first-line-setting-2017-08-28", "https://www.nasdaq.com/articles/why-regeneron-pharmaceuticals-inc.-regn-might-be-a-diamond-in-the-rough-2017-08-22", "https://www.nasdaq.com/articles/whats-most-important-drug-regeneron-pharmaceuticals-pipeline-2017-08-22", "https://www.nasdaq.com/articles/what-will-drive-regeneron-pharmaceuticals-growth-higher-here-2017-08-22", "https://www.nasdaq.com/articles/why-eylea-still-regeneron-pharmaceuticals-most-important-drug-2017-08-22", "https://www.nasdaq.com/articles/3-large-cap-biotech-stocks-to-scrape-from-the-selloff-2017-08-21", "https://www.nasdaq.com/articles/pfizers-pfe-besponsa-gets-fda-nod-with-a-boxed-warning-2017-08-18", "https://www.nasdaq.com/articles/regeneron-pharmaceuticals-best-biotech-stock-buy-2017-08-17", "https://www.nasdaq.com/articles/alexions-alxn-soliris-label-expansion-approved-in-europe-2017-08-22", "https://www.nasdaq.com/articles/why-regeneron-pharmaceuticals-inc.-regn-might-be-a-diamond-in-the-rough-2017-08-22", "https://www.nasdaq.com/articles/ophthotechs-fovista-combo-regimen-disappoints-in-phase-iii-2017-08-16", "https://www.nasdaq.com/articles/biotech-stock-roundup-regeneron-drops-rsv-antibody-gilead-hiv-drug-gets-priority-review", "https://www.nasdaq.com/articles/regenerons-regn-rsv-drug-suptavumab-fails-nursery-trial-2017-08-16", "https://www.nasdaq.com/articles/spectrum-sppi-initiates-phase-ii-study-for-cancer-drug-2017-08-16", "https://www.nasdaq.com/articles/3-stocks-could-make-you-rich-2017-08-15", "https://www.nasdaq.com/articles/regeneron-vs-alexion-which-stock-better-pick-post-q2-earnings-2017-08-14", "https://www.nasdaq.com/articles/seattle-genetics-adcetris-granted-priority-review-by-fda-2017-08-17", "https://www.nasdaq.com/articles/puma-pbyi-q2-loss-narrower-than-expected-nerlynx-in-focus-2017-08-10", "https://www.nasdaq.com/articles/geron-gern-q2-loss-narrows-sales-miss-estimates-stock-up-2017-08-10", "https://www.nasdaq.com/articles/inovio-ino-q2-loss-narrower-than-expected-revenues-beat-2017-08-09", "https://www.nasdaq.com/articles/biotech-stock-roundup-q2-earnings-regeneron-kite-more-fibrogen-ipf-data-2017-08-09", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-exxonmobil-mastercard-shell-regeneron-and-bp-2017-08-08", "https://www.nasdaq.com/articles/ray-gerald-l-associates-ltd-buys-norfolk-southern-corp-splunk-inc-oneok-inc-sells-2017-08", "https://www.nasdaq.com/articles/top-research-reports-exxonmobil-mastercard-shell-2017-08-07", "https://www.nasdaq.com/articles/forget-teva-teva-buy-these-4-drug-stocks-instead-2017-08-11", "https://www.nasdaq.com/articles/puma-pbyi-q2-loss-narrower-than-expected-nerlynx-in-focus-2017-08-10", "https://www.nasdaq.com/articles/regeneron-regn-q2-earnings-beat-estimates-2017-08-03", "https://www.nasdaq.com/articles/regeneron-regn-beats-on-q2-earnings-sales-raises-view-2017-08-03", "https://www.nasdaq.com/articles/pre-market-earnings-report-august-3-2017-agn-duk-epd-aet-shpg-regn-bdx-bce-ctsh-ice-enb", "https://www.nasdaq.com/articles/notable-tuesday-option-activity-cia-regn-tsla-2017-08-01", "https://www.nasdaq.com/articles/whats-in-the-cards-for-adverum-advm-this-earnings-season-2017-08-01", "https://www.nasdaq.com/articles/sanofi-sny-q2-earnings-in-line-sales-lag17-view-raised-2017-07-31", "https://www.nasdaq.com/articles/vertex-pharmaceuticals-vs-regeneron-pharmaceuticals-which-company-reported-better-earnings", "https://www.nasdaq.com/articles/regeneron-pharmaceuticals-reaches-analyst-target-price-2017-08-03", "https://www.nasdaq.com/articles/can-regeneron-pharma-regn-pull-a-surprise-in-q2-earnings-2017-07-26", "https://www.nasdaq.com/articles/3-large-cap-biotech-stocks-to-buy-now-2017-07-24", "https://www.nasdaq.com/articles/notable-monday-option-activity-vc-regn-ryam-2017-07-24", "https://www.nasdaq.com/articles/tesla-moves-market-cap-rank-passing-regeneron-pharmaceuticals-2017-07-21", "https://www.nasdaq.com/articles/3-big-stock-charts-for-thursday%3A-tripadvisor-inc-trip-regeneron-pharmaceuticals-inc-regn", "https://www.nasdaq.com/articles/7-stocks-to-buy-that-wall-street-analysts-hate-2017-07-20", "https://www.nasdaq.com/articles/agree-buy-regeneron-pharmaceuticals-370-earn-64-using-options-2017-07-28", "https://www.nasdaq.com/articles/5-top-multibagger-biotech-stocks-buy-2nd-half-2017-07-11", "https://www.nasdaq.com/articles/bib-biib-regn-vrtx-etf-outflow-alert-2017-07-10", "https://www.nasdaq.com/articles/sanofi-versus-astrazeneca%3A-large-cap-pharma-stock-faceoff-2017-07-06", "https://www.nasdaq.com/articles/noteworthy-thursday-option-activity-cdns-regn-bac-2017-07-06", "https://www.nasdaq.com/articles/3-best-fidelity-funds-to-finish-2017-2017-07-06", "https://www.nasdaq.com/articles/tech-takes-leadbut-how-long-2017-07-06", "https://www.nasdaq.com/articles/thursday-sector-leaders-healthcare-utilities-2017-07-20", "https://www.nasdaq.com/articles/apple-ceo-tim-cook-blows-away-other-ceos-2016-salary-2017-07-05", "https://www.nasdaq.com/articles/biomarin-files-bla-for-phenylketonuria-candidate-pegvaliase-2017-07-03", "https://www.nasdaq.com/articles/roche-rhhby-launches-cobas-test-for-bacterial-infections-2017-07-03", "https://www.nasdaq.com/articles/marinus-mrns-ganaxolone-gets-orphan-drug-status-in-us-2017-06-30", "https://www.nasdaq.com/articles/amgens-colorectal-cancer-drug-gets-fda-nod-to-expand-label-2017-06-30", "https://www.nasdaq.com/articles/acorda-files-nda-for-parkinsons-disease-candidate-inbrija-2017-06-30", "https://www.nasdaq.com/articles/zacks.com-featured-highlights%3A-principal-financial-group-regeneron-pharmaceuticals-zebra", "https://www.nasdaq.com/articles/apples-tim-cook-earns-%24145m-in-2016-tops-sp-500-ceos-2017-07-05", "https://www.nasdaq.com/articles/apple-ceo-tim-cook-blows-away-other-ceos-2016-salary-2017-07-05", "https://www.nasdaq.com/articles/sarepta-appoints-ex-allergan-executive-as-ceo-and-president-2017-06-29", "https://www.nasdaq.com/articles/robust-1h-for-pharma-biotech-sector-3-big-stocks-to-buy-2017-06-29", "https://www.nasdaq.com/articles/biotech-stock-roundup-eu-nod-regeneron-ra-drug-portola-soars-fda-nod-2017-06-29", "https://www.nasdaq.com/articles/5-top-ranked-stocks-with-impressive-sales-growth-to-buy-now-2017-06-29", "https://www.nasdaq.com/articles/noteworthy-thursday-option-activity-sig-met-regn-2017-06-29", "https://www.nasdaq.com/articles/esperions-combo-cholesterol-candidate-enters-phase-iii-2017-06-28", "https://www.nasdaq.com/articles/health-care-sector-update-06302017-regnsnysklncara-2017-06-30", "https://www.nasdaq.com/articles/strongbridge-sbbp-shows-strength%3A-stock-moves-up-10.1-2017-06-28", "https://www.nasdaq.com/articles/neothetics-fat-reduction-candidate-fails-in-phase-ii-study-2017-06-28", "https://www.nasdaq.com/articles/5-biomedical-stocks-are-expected-surge-2017-06-27", "https://www.nasdaq.com/articles/agios-celgenes-leukemia-candidate-positive-in-phase-i-ii-2017-06-27", "https://www.nasdaq.com/articles/sanofi-regenerons-kevzara-gets-marketing-approval-in-eu-2017-06-27", "https://www.nasdaq.com/articles/amgen-gets-positive-chmp-opinion-for-mimpara-label-expansion-2017-06-27", "https://www.nasdaq.com/articles/conatuss-psc-candidate-gets-orphan-designation-in-the-u.s.-2017-06-27", "https://www.nasdaq.com/articles/teva-xenon-nerve-pain-candidate-fails-in-phase-ii-study-2017-06-28", "https://www.nasdaq.com/articles/novartis-cardiovascular-drug-positive-nsclc-drug-approved-2017-06-26", "https://www.nasdaq.com/articles/mid-day-market-update-bed-bath-beyond-drops-following-disappointing-earnings-synchronoss", "https://www.nasdaq.com/articles/nasdaq-100-movers-regn-mnst-2017-06-23", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-mostly-flat-blackberry-sales-miss-views-2017-06-23", "https://www.nasdaq.com/articles/kamada-withdraws-inhaled-aat-marketing-application-in-eu-2017-06-23", "https://www.nasdaq.com/articles/heres-why-investors-are-glued-to-vertex-pharma-vrtx-stock-2017-06-23", "https://www.nasdaq.com/articles/regeneron-regn-stock-on-fire%3A-whats-behind-the-surge-2017-06-23", "https://www.nasdaq.com/articles/will-abbvie-outsmart-biosimilars-and-can-clovis-win-parp-race-2017-06-27", "https://www.nasdaq.com/articles/2-key-stock-index-plays-buy-range-biotechs-surge-again-2017-06-22", "https://www.nasdaq.com/articles/heres-why-geron-gern-is-a-good-stock-to-invest-in-now-2017-06-22", "https://www.nasdaq.com/articles/nasdaq-100-movers-ca-regn-2017-06-22", "https://www.nasdaq.com/articles/biodelivery-inks-new-contract-with-cvs-caremark-shares-up-2017-06-22", "https://www.nasdaq.com/articles/indivors-opioid-use-disorder-drug-meets-primary-endpoint-2017-06-22", "https://www.nasdaq.com/articles/avexis-avxs-jumps%3A-stock-rises-7.1-2017-06-22", "https://www.nasdaq.com/articles/strength-seen-in-arena-pharmaceuticals-arna%3A-stock-up-5.4-2017-06-22", "https://www.nasdaq.com/articles/friday-sector-laggards-services-healthcare-2017-06-23", "https://www.nasdaq.com/articles/novartis-migraine-drug-accepted-amd-positive-in-phase-iii-2017-06-21", "https://www.nasdaq.com/articles/fresh-capital-be-injected-biotech-stocks-5-must-buys-2017-06-21", "https://www.nasdaq.com/articles/vanda-pharmaceuticals-vnda-worth-a-look%3A-stock-jumps-8-2017-06-21", "https://www.nasdaq.com/articles/biotech-stock-roundup-clovis-soars-rubraca-data-seattle-hit-study-halt-2017-06-21", "https://www.nasdaq.com/articles/5-biotech-stocks-that-are-roaring-back-to-life-2017-06-21", "https://www.nasdaq.com/articles/wednesday-sector-leaders-healthcare-technology-communications-2017-06-21", "https://www.nasdaq.com/articles/jj-abbvies-imbruvica-positive-in-follow-up-lymphoma-study-2017-06-20", "https://www.nasdaq.com/articles/if-esperion-wants-market-next-big-cholesterol-drug-it-will-take-strategy-2017-06-22", "https://www.nasdaq.com/articles/amgens-xgeva-myeloma-label-expansion-sbla-accepted-by-fda-2017-06-20", "https://www.nasdaq.com/articles/merrimack-completes-enrollment-in-phase-ii-study-for-mm-141-2017-06-20", "https://www.nasdaq.com/articles/nasdaq-100-movers-lila-regn-2017-06-20", "https://www.nasdaq.com/articles/cai-international-kroger-broadcom-regeneron-and-vodafone-group-highlighted-as-zacks-bull", "https://www.nasdaq.com/articles/market-close-report-nasdaq-trading-volume-joins-top-ten-ranking-year-nasdaq-composite-19", "https://www.nasdaq.com/articles/novartis-takes-aim-regeneron-pharmaceuticals-eylea-2017-06-20", "https://www.nasdaq.com/articles/regeneron-pharmaceuticals-inc-regn-stock-looks-good-despite-the-backdrop-2017-06-20", "https://www.nasdaq.com/articles/rigel-pharmaceuticals-nda-for-tavalisse-accepted-by-fda-2017-06-20", "https://www.nasdaq.com/articles/glaxosmithklines-benlysta-positive-in-continuation-trial-2017-06-19", "https://www.nasdaq.com/articles/lazy-unfocused-summer-here-global-week-ahead-2017-06-19", "https://www.nasdaq.com/articles/3-biotech-trades-to-diversify-your-portfolio-2017-06-16", "https://www.nasdaq.com/articles/pfizer-lilly-get-fast-track-designation-for-pain-candidate-2017-06-14", "https://www.nasdaq.com/articles/zacks.com-featured-highlights%3A-regeneron-pharmaceuticals-raymond-james-financial-dollar", "https://www.nasdaq.com/articles/notable-wednesday-option-activity-isrg-unh-regn-2017-06-14", "https://www.nasdaq.com/articles/gtxs-gtxi-enobosarm-positive-in-phase-ii-study-shares-up-2017-06-13", "https://www.nasdaq.com/articles/tuesdays-etf-unusual-volume-urth-2017-06-20", "https://www.nasdaq.com/articles/lilly-plans-new-outcomes-study-to-expand-jardiance-label-2017-06-13", "https://www.nasdaq.com/articles/sanofi-regenerons-praluent-cuts-bad-cholesterol-in-studies-2017-06-12", "https://www.nasdaq.com/articles/jj-announces-eu-regulatory-approval-for-actelion-deal-2017-06-12", "https://www.nasdaq.com/articles/midday-update-averages-set-record-highs-after-event-risk-fades-2017-06-09", "https://www.nasdaq.com/articles/regeneron-regn-up-7.3-since-earnings-report%3A-can-it-continue-2017-06-09", "https://www.nasdaq.com/articles/astrazeneca-azn-divests-migraine-drug-rights-beyond-japan-2017-06-08", "https://www.nasdaq.com/articles/pfizers-pfe-tafamidis-gets-fast-track-status-in-the-u.s.-2017-06-07", "https://www.nasdaq.com/articles/5-stocks-with-solid-sales-growth-catching-eyeballs-2017-06-13", "https://www.nasdaq.com/articles/amgen-files-for-repatha-in-the-u.s.-eu-for-expanded-use-2017-06-06", "https://www.nasdaq.com/articles/notable-tuesday-option-activity-ksu-regn-mon-2017-06-06", "https://www.nasdaq.com/articles/regeneron-announces-positive-data-on-carcinoma-candidate-2017-06-05", "https://www.nasdaq.com/articles/dont-be-rip-van-winkle-global-week-ahead-2017-06-05", "https://www.nasdaq.com/articles/why-regeneron-quickly-becoming-my-top-biotech-stock-pick-2017-06-05", "https://www.nasdaq.com/articles/3-biotech-stocks-buy-if-youve-never-bought-biotech-stock-2017-06-04", "https://www.nasdaq.com/articles/biomarins-bmrn-brineura-approved-by-european-commission-2017-06-02", "https://www.nasdaq.com/articles/acorda-presents-phase-iii-data-on-pd-candidate-cvt-301-2017-06-07", "https://www.nasdaq.com/articles/universal-display-hewlett-packard-regeneron-pharmaceuticals-sangamo-therapeutics-and-puma", "https://www.nasdaq.com/articles/whats-behind-regenerons-big-15-bounce-may-2017-06-02", "https://www.nasdaq.com/articles/friday-sector-leaders-healthcare-industrial-2017-06-02", "https://www.nasdaq.com/articles/noteworthy-etf-outflows-xbi-vrtx-exas-regn-2017-06-01", "https://www.nasdaq.com/articles/3-hot-biotech-stocks-buy-june-2017-06-01", "https://www.nasdaq.com/articles/tevas-migraine-candidate-tev-48125-positive-in-phase-iii-2017-06-01", "https://www.nasdaq.com/articles/eli-lillys-lly-cancer-drug-cyramza-positive-in-phase-iii-2017-06-01", "https://www.nasdaq.com/articles/sds-pbe-big-etf-inflows-2017-06-02", "https://www.nasdaq.com/articles/universal-display-hewlett-packard-regeneron-pharmaceuticals-sangamo-therapeutics-and-puma", "https://www.nasdaq.com/articles/whats-behind-regenerons-big-15-bounce-may-2017-06-02", "https://www.nasdaq.com/articles/how-regeneron-pharmaceuticals-inc-makes-most-its-money-2017-05-31", "https://www.nasdaq.com/articles/will-regenerons-regn-newly-approved-drugs-drive-growth-2017-05-30", "https://www.nasdaq.com/articles/sanofi-sny-stock-continues-to-gain-on-key-drug-approvals-2017-05-30", "https://www.nasdaq.com/articles/noteworthy-tuesday-option-activity-adi-regn-wdc-2017-05-30", "https://www.nasdaq.com/articles/regeneron-presents-positive-phase-ii-data-on-hofh-candidate-2017-05-25", "https://www.nasdaq.com/articles/pfizers-trumenba-vaccine-approved-by-european-commission-2017-05-31", "https://www.nasdaq.com/articles/theravance-mylan-presents-phase-iii-data-on-copd-candidate-2017-05-24", "https://www.nasdaq.com/articles/biotech-stock-roundup-fda-nod-regeneron-ra-drug-amgen-hit-study-data-2017-05-24", "https://www.nasdaq.com/articles/sanofi-regenerons-kevzara-gets-fda-approval-for-arthritis-2017-05-23", "https://www.nasdaq.com/articles/merck-presents-phase-ii-data-on-chronic-cough-candidate-2017-05-23", "https://www.nasdaq.com/articles/mercks-hiv-drug-gets-positive-chmp-opinion-for-higher-dose-2017-05-22", "https://www.nasdaq.com/articles/compugen-cgen-worth-a-look%3A-stock-adds-10.4-in-session-2017-05-22", "https://www.nasdaq.com/articles/xbi-vrtx-regn-exas-large-inflows-detected-etf-2017-05-19", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-regeneron-amgen-and-celgene-2017-05-25", "https://www.nasdaq.com/articles/biotech-stock-roundup-biogen-inks-deal-boost-pipeline-sangamo-soars-pfizer-deal-2017-05-17", "https://www.nasdaq.com/articles/bull-day-regeneron-regn-2017-05-17", "https://www.nasdaq.com/articles/transenterix-trxc-reports-wider-than-expected-loss-in-q1-2017-05-15", "https://www.nasdaq.com/articles/bear-day-amag-pharmaceuticals-amag-2017-05-15", "https://www.nasdaq.com/articles/notable-monday-option-activity-xon-regn-nflx-2017-05-15", "https://www.nasdaq.com/articles/wsfs-capital-management-llc-buys-regeneron-pharmaceuticals-inc-williams-inc-bbt-corp-2017", "https://www.nasdaq.com/articles/regeneron-pharmaceuticals-stock-still-buy-after-its-big-bounce-2017-05-12", "https://www.nasdaq.com/articles/regeneron-nuance-communications-waste-management-waste-connections-and-republic-services", "https://www.nasdaq.com/articles/biotech-stock-roundup-biogen-inks-deal-boost-pipeline-sangamo-soars-pfizer-deal-2017-05-17", "https://www.nasdaq.com/articles/steris-ste-grapples-with-headwinds%3A-should-you-dump-2017-05-12", "https://www.nasdaq.com/articles/hologic-holx-tops-q2-earnings-sales-raises-2017-view-2017-05-11", "https://www.nasdaq.com/articles/genomic-health-ghdx-misses-q1-earnings-sales-estimates-2017-05-11", "https://www.nasdaq.com/articles/dull-q1-earnings-tough-industry-spell-trouble-for-bioscrip-2017-05-11", "https://www.nasdaq.com/articles/inovio-ino-q1-loss-narrower-than-expected-revenues-beat-2017-05-11", "https://www.nasdaq.com/articles/biotech-stock-roundup-regeneron-biomarin-report-q1-kite-down-patient-death-2017-05-10", "https://www.nasdaq.com/articles/masimo-masi-beats-on-q1-earnings-and-revenues-guides-up-2017-05-12", "https://www.nasdaq.com/articles/regeneron-pharmaceuticals-regn-shares-march-higher-can-it-continue-2017-05-09", "https://www.nasdaq.com/articles/7-stocks-to-buy-now-for-big-summer-outperformance-2017-05-09", "https://www.nasdaq.com/articles/regeneron-pharmaceuticals-reaches-analyst-target-price-2017-05-05", "https://www.nasdaq.com/articles/zacks-investment-ideas-feature-highlights%3A-regeneron-edwards-lifesciences-alexion", "https://www.nasdaq.com/articles/go-long-regeneron-pharmaceuticals-inc-regn-stock-at-a-discount-2017-05-04", "https://www.nasdaq.com/articles/nasdaq-100-movers-tsla-regn-2017-05-04", "https://www.nasdaq.com/articles/ophthotech-opht-q1-loss-narrower-than-expected-sales-miss-2017-05-04", "https://www.nasdaq.com/articles/i-still-cant-believe-gilead-sciences-inc-spent-148-billion-shareholder-rewards-2017-05-09", "https://www.nasdaq.com/articles/5-healthcare-innovators-im-still-buying-2017-05-04", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-607534-279-points-2017-05-04", "https://www.nasdaq.com/articles/regeneron-regn-q1-earnings-miss-revenues-beat-estimates-2017-05-04", "https://www.nasdaq.com/articles/thursday-sector-leaders-healthcare-consumer-products-2017-05-04", "https://www.nasdaq.com/articles/4-biotech-stocks-that-could-be-rocked-and-rolled-this-month-2017-05-04", "https://www.nasdaq.com/articles/drug-stock-q1-earnings-releases-on-may-4%3A-zts-regn-more-2017-05-03", "https://www.nasdaq.com/articles/biotech-stock-roundup-amgen-gilead-celgene-q1-earnings-sunesis-down-vosaroxin-update-2017", "https://www.nasdaq.com/articles/regeneron-regn-q1-earnings-misses-estimates-2017-05-04", "https://www.nasdaq.com/articles/pre-market-earnings-report-may-4-2017-d-oxy-regn-cnq-zts-ppl-k-incy-apa-cce-wltw-abc-2017", "https://www.nasdaq.com/articles/after-gilead-earnings-buy-these-biotech-stocks-2017-05-03", "https://www.nasdaq.com/articles/notable-etf-outflow-detected-bib-biib-regn-ilmn-2017-05-02", "https://www.nasdaq.com/articles/6-fda-events-watch-out-may-2017-2017-05-01", "https://www.nasdaq.com/articles/5-big-drugmakers-important-catalysts-may-2017-04-30", "https://www.nasdaq.com/articles/regeneron-finally-getting-back-track-2017-04-29", "https://www.nasdaq.com/articles/regeneron-pharmaceuticals-breaks-above-200-day-moving-average-bullish-regn-2017-04-28", "https://www.nasdaq.com/articles/whats-in-store-for-adverum-advm-in-q1-earnings-2017-05-03", "https://www.nasdaq.com/articles/nasdaq-100-movers-bidu-cern-2017-04-28", "https://www.nasdaq.com/articles/seattle-genetics-sgen-q1-loss-widens-sales-top-estimates-2017-04-28", "https://www.nasdaq.com/articles/sanofi-sny-q1-earnings-top-sales-rise-y-y-shares-up-2017-04-28", "https://www.nasdaq.com/articles/regeneron-regn-to-post-q1-earnings%3A-whats-in-the-cards-2017-04-28", "https://www.nasdaq.com/articles/noteworthy-friday-option-activity-regn-ambc-lsi-2017-04-28", "https://www.nasdaq.com/articles/friday-sector-leaders-healthcare-energy-2017-04-28", "https://www.nasdaq.com/articles/amgen-amgn-q1-earnings-top-sales-miss-shares-decline-2017-04-27", "https://www.nasdaq.com/articles/sarepta-srpt-q1-loss-narrows-exondys-51-sales-pick-up-2017-04-28", "https://www.nasdaq.com/articles/biotech-stock-roundup-biogen-gains-strong-q1-nash-data-gilead-drug-2017-04-26", "https://www.nasdaq.com/articles/agree-buy-regeneron-pharmaceuticals-270-earn-72-using-options-2017-04-24", "https://www.nasdaq.com/articles/noteworthy-friday-option-activity-bac-regn-mhk-2017-04-21", "https://www.nasdaq.com/articles/lilly-and-incytes-loss-abbvie-and-regenerons-gain-2017-04-17", "https://www.nasdaq.com/articles/3-big-reasons-be-bullish-biotech-stocks-2017-04-16", "https://www.nasdaq.com/articles/analysts-predict-11-gains-ahead-holdings-iyh-2017-04-12", "https://www.nasdaq.com/articles/5-reasons-why-sanofi-sny-is-a-good-stock-to-buy-now-2017-04-12", "https://www.nasdaq.com/articles/amgens-q1-results-highlight-need-acquisition-2017-04-27", "https://www.nasdaq.com/articles/notable-monday-option-activity-expe-regn-swft-2017-04-10", "https://www.nasdaq.com/articles/3-big-biotech-stocks-big-time-catalysts-2017-04-08", "https://www.nasdaq.com/articles/regenerons-evinacumab-gets-breakthrough-therapy-by-fda-2017-04-07", "https://www.nasdaq.com/articles/regn-makes-notable-cross-below-critical-moving-average-2017-04-04", "https://www.nasdaq.com/articles/4-fda-decisions-watch-out-apr-2017-2017-04-03", "https://www.nasdaq.com/articles/could-pfizer-buy-esperion-therapeutics-2017-03-31", "https://www.nasdaq.com/articles/regenerons-game-changing-new-eczema-drug-could-be-blockbuster-2017-03-30", "https://www.nasdaq.com/articles/biotech-stock-roundup-geron-gains-interim-data-oncomed-slumps-pipeline-setback-2017-04-12", "https://www.nasdaq.com/articles/nasdaq-100-movers-biib-vrtx-2017-03-29", "https://www.nasdaq.com/articles/regeneron-sanofis-atopic-dermatitis-drug-gets-fda-nod-2017-03-29", "https://www.nasdaq.com/articles/biotech-stock-roundup-regeneron-tesaro-drugs-approved-vertex-scores-big-study-2017-03-29", "https://www.nasdaq.com/articles/noteworthy-tuesday-option-activity-kmx-regn-dri-2017-03-28", "https://www.nasdaq.com/articles/3-top-biotech-stocks-buy-2017-2017-03-26", "https://www.nasdaq.com/articles/how-company-taking-amgen-2017-03-23", "https://www.nasdaq.com/articles/biotech-stock-roundup-amgen-down-repatha-data-nektar-surges-pain-results-2017-03-22", "https://www.nasdaq.com/articles/3-best-cholesterol-drug-stocks-buy-2017-2017-03-30", "https://www.nasdaq.com/articles/nasdaq-100-movers-amgn-adbe-2017-03-17", "https://www.nasdaq.com/articles/sp-500-movers-amgn-adbe-2017-03-17", "https://www.nasdaq.com/articles/what-are-sanofis-sny-strengths-and-challenges-in-2017-2017-03-17", "https://www.nasdaq.com/articles/noteworthy-etf-outflows-ibb-biib-regn-incy-2017-03-16", "https://www.nasdaq.com/articles/biotech-stock-roundup-amgens-data-repatha-catalyst-soars-firdapse-data-2017-03-16", "https://www.nasdaq.com/articles/amgens-repatha-meets-primary-endpoint-in-phase-iii-study-2017-03-14", "https://www.nasdaq.com/articles/3-growth-stocks-id-buy-right-now-2017-03-11", "https://www.nasdaq.com/articles/amgen-amgn%3A-repatha-outcomes-data-disappoint-shares-drop-2017-03-20", "https://www.nasdaq.com/articles/noteworthy-friday-option-activity-alb-ph-regn-2017-03-10", "https://www.nasdaq.com/articles/regn-crosses-above-key-moving-average-level-2017-03-09", "https://www.nasdaq.com/articles/nasdaq-100-movers-stx-regn-2017-03-09", "https://www.nasdaq.com/articles/trip-8-year-bull-run-whats-whats-down-2017-03-09", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-583881-126-points-2017-03-09", "https://www.nasdaq.com/articles/thursday-sector-leaders-healthcare-utilities-2017-03-09", "https://www.nasdaq.com/articles/stock-market-news-for-march-08-2017-2017-03-08", "https://www.nasdaq.com/articles/why-amgen-amgn-stock-rallied-after-q4-earnings-release-2017-03-10", "https://www.nasdaq.com/articles/5-fda-decisions-watch-out-mar-2017-2017-03-06", "https://www.nasdaq.com/articles/analysts-expect-bbh-will-reach-134-2017-03-02", "https://www.nasdaq.com/articles/noteworthy-thursday-option-activity-lgnd-lxrx-regn-2017-03-02", "https://www.nasdaq.com/articles/ophthotech-opht-q4-loss-wider-than-expected-sales-miss-2017-03-01", "https://www.nasdaq.com/articles/ibb-regn-ilmn-alxn-large-outflows-detected-etf-2017-02-27", "https://www.nasdaq.com/articles/adverum-advm-to-post-q4-earnings%3A-whats-in-the-cards-2017-02-27", "https://www.nasdaq.com/articles/notable-thursday-option-activity-cmg-regn-lvlt-2017-02-23", "https://www.nasdaq.com/articles/better-buy-regeneron-pharmaceuticals-inc-vs-novartis-2017-03-07", "https://www.nasdaq.com/articles/drug-stocks-q4-earnings-slated-for-feb-16%3A-alxn-zts-more-2017-02-15", "https://www.nasdaq.com/articles/amgen-looking-to-broaden-leukemia-drug-blincytos-label-2017-02-15", "https://www.nasdaq.com/articles/biotech-stock-roundup-regenerons-praluent-remain-market-now-gild-presents-hiv-data-2017-02", "https://www.nasdaq.com/articles/bullish-two-hundred-day-moving-average-cross-regn-2017-02-15", "https://www.nasdaq.com/articles/bib-biib-regn-ilmn-large-outflows-detected-etf-2017-02-13", "https://www.nasdaq.com/articles/nasdaq-100-movers-tmus-tsla-2017-02-13", "https://www.nasdaq.com/articles/market-close-report-historical-high-reached-nasdaq-composite-index-closes-576396-2017-02", "https://www.nasdaq.com/articles/why-amgens-becoming-one-my-top-dividend-stocks-buy-2017-02-16", "https://www.nasdaq.com/articles/regeneron-regn-misses-on-q4-earnings-sales-view-bleak-2017-02-09", "https://www.nasdaq.com/articles/regeneron-regn-q4-earnings-misses-estimates-2017-02-09", "https://www.nasdaq.com/articles/sanofi-sny-q4-earnings-in-line-can-sell-praulent-for-now-2017-02-09", "https://www.nasdaq.com/articles/biotech-stock-roundup-amgen-gilead-report-4q-results-ariad-seeks-eu-nod-brigatinib-2017-02", "https://www.nasdaq.com/articles/regeneron-regn-q4-earnings%3A-will-the-stock-disappoint-2017-02-08", "https://www.nasdaq.com/articles/pre-market-earnings-report-february-9-2017-ko-cvs-oxy-mfc-regn-k-cmi-yum-tu-rop-dte-wltw", "https://www.nasdaq.com/articles/7-high-risk-high-reward-stocks-to-buy-now-2017-02-08", "https://www.nasdaq.com/articles/3-beaten-down-stocks-ready-bounce-back-2017-02-10", "https://www.nasdaq.com/articles/why-morgan-stanley-amgen-and-tableau-software-jumped-today-2017-02-03", "https://www.nasdaq.com/articles/biotech-stock-roundup-celgene-biogen-abbv-post-q4-results-catabasis-falls-dmd-data-2017-02", "https://www.nasdaq.com/articles/amgen-inc.-amgn-q4-earnings-preview-2017-02-01", "https://www.nasdaq.com/articles/sanofiregeneron-sarilumab-approved-in-canada-for-arthritis-2017-02-01", "https://www.nasdaq.com/articles/nasdaq-100-movers-pcar-myl-2017-01-31", "https://www.nasdaq.com/articles/analysts-forecast-15-upside-holdings-xlv-2017-01-30", "https://www.nasdaq.com/articles/amgen-inc.-amgn-stock-is-a-bet-on-fatter-yields-2017-01-27", "https://www.nasdaq.com/articles/amgen-amgn-q4-earnings-top-repatha-positive-in-cv-study-2017-02-03", "https://www.nasdaq.com/articles/biotech-stock-roundup-synergy-drug-gets-fda-nod-abbvie-gild-hcv-drugs-under-eu-review-2017", "https://www.nasdaq.com/articles/lagoda-investment-management-lp-buys-texas-pacific-land-trust-microsoft-corp-coca-cola-co", "https://www.nasdaq.com/articles/top-biotech-stocks-buy-2017-2017-01-22", "https://www.nasdaq.com/articles/proshares-ultrapro-qqq-experiences-big-outflow-2017-01-20", "https://www.nasdaq.com/articles/5-biotech-stocks-youll-want-watch-1st-quarter-2017-01-18", "https://www.nasdaq.com/articles/noteworthy-wednesday-option-activity-jpm-regn-afsi-2017-01-18", "https://www.nasdaq.com/articles/key-fda-events-to-watch-out-for-in-q1-2017-01-17", "https://www.nasdaq.com/articles/3-top-biotech-stocks-you-can-still-buy-dow-20000-2017-01-26", "https://www.nasdaq.com/articles/stock-market-news-for-january-11-2017-2017-01-11", "https://www.nasdaq.com/articles/should-you-buy-amgen-inc.-amgn-stock-3-pros-3-cons-2017-01-11", "https://www.nasdaq.com/articles/biotech-stock-roundup-ariad-be-acquired-52b-vertex-outlook-falls-short-2017-01-11", "https://www.nasdaq.com/articles/notable-etf-inflow-detected-ibb-regn-alxn-incy-2017-01-10", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-clovis-oncology-pfizer-roches-sanofi-and-regeneron-2017", "https://www.nasdaq.com/articles/amgen-inks-multiple-deals-offers-update-on-repatha-lawsuit-2017-01-10", "https://www.nasdaq.com/articles/biotech-resolutions-more-innovation-better-execution-and-fewer-price-hikes-2017-01-10", "https://www.nasdaq.com/articles/why-regeneron-pharmaceuticals-inc-stock-slipped-324-2016-2017-01-15", "https://www.nasdaq.com/articles/company-news-for-january-09-2017-2017-01-09", "https://www.nasdaq.com/articles/fda-approved-fewer-drugs-2016-heres-why-2017-01-09", "https://www.nasdaq.com/articles/2-top-stocks-biotech-2017-01-09", "https://www.nasdaq.com/articles/10-worst-stocks-nasdaq-2016-2017-01-09", "https://www.nasdaq.com/articles/the-3-best-mutual-funds-for-a-january-correction-2017-01-09", "https://www.nasdaq.com/articles/noteworthy-monday-option-activity-regn-goog-antm-2017-01-09", "https://www.nasdaq.com/articles/why-biotech-titans-are-clashing-over-cholesterol-2017-01-08", "https://www.nasdaq.com/articles/nasdaq-100-movers-vod-incy-2017-01-09", "https://www.nasdaq.com/articles/better-buy-regeneron-pharmaceuticals-inc-vs-pfizer-2017-01-07", "https://www.nasdaq.com/articles/nasdaq-100-movers-regn-amgn-2017-01-06", "https://www.nasdaq.com/articles/sp-500-movers-regn-amgn-2017-01-06", "https://www.nasdaq.com/articles/health-care-sector-update-01062017-mdco-sny-regn-jnj-pfe-abt-mrk-amgn-2017-01-06", "https://www.nasdaq.com/articles/pre-market-most-active-jan-6-2017-jcp-nok-teva-bac-sum-fcau-tlt-tvix-orex-qqq-xiv-regn", "https://www.nasdaq.com/articles/amgens-repatha-wins-over-sanofi-regenerons-praluent-2017-01-06", "https://www.nasdaq.com/articles/why-regeneron-pharmaceuticals-sears-holdings-and-shake-shack-slumped-today-2017-01-06", "https://www.nasdaq.com/articles/top-stocks-buy-2017-2017-01-07", "https://www.nasdaq.com/articles/roches-rhhby-lucentis-gets-fda-nod-for-fifth-indication-2017-01-06", "https://www.nasdaq.com/articles/healthcare-stocks-buy-2017-less-risky-more-risky-and-most-risky-2017-01-05", "https://www.nasdaq.com/articles/3-stocks-to-watch-on-wednesday%3A-tesla-motors-inc-tsla-agile-therapeutics-inc-agrx-and", "https://www.nasdaq.com/articles/health-care-sector-update-01042017-snyamgnregncbayagrx-2017-01-04", "https://www.nasdaq.com/articles/biotech-stocks-what-watch-2017-2017-01-01", "https://www.nasdaq.com/articles/notable-friday-option-activity-feye-regn-fdx-2016-12-30", "https://www.nasdaq.com/articles/regeneron-vs-vertex-which-stock-better-pick-2016-12-29", "https://www.nasdaq.com/articles/market-close-report-historical-high-reached-nasdaq-composite-index-closes-552106-2017-01", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-alexion-pharmaceuticals-celgene-incyte-eli-lilly", "https://www.nasdaq.com/articles/stock-market-news-for-december-27-2016-2016-12-27", "https://www.nasdaq.com/articles/forget-alexion-alxn-buy-these-3-biotech-stocks-instead-2016-12-27", "https://www.nasdaq.com/articles/bad-news-bashes-biotech-investors-again-2016-12-21", "https://www.nasdaq.com/articles/5-steps-buying-biotech-stocks-2016-12-21", "https://www.nasdaq.com/articles/fovista-flops-whats-next-2016-12-19", "https://www.nasdaq.com/articles/noteworthy-etf-inflows-ibb-regn-myl-alxn-2016-12-19", "https://www.nasdaq.com/articles/4-biotech-stocks-with-bright-prospects-in-2017-2016-12-29", "https://www.nasdaq.com/articles/7-top-stocks-were-excited-about-headed-2017-2016-12-19", "https://www.nasdaq.com/articles/7-stocks-to-buy-with-impressive-interest-coverage-ratio-2016-12-16", "https://www.nasdaq.com/articles/4-growth-stocks-to-buy-amid-obamacare-repeal-talks-2016-12-15", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-celgene-regeneron-pharmaceuticals-ophthotech-and", "https://www.nasdaq.com/articles/biotech-stock-roundup-ophthotech-slumps-fovista-results-achaogen-skyrockets-data-2016-12", "https://www.nasdaq.com/articles/ophthotech-hits-52-week-low-on-unfavorable-fovista-data-2016-12-13", "https://www.nasdaq.com/articles/3-great-stocks-beat-biotech-blues-2016-12-13", "https://www.nasdaq.com/articles/zacks.com-featured-highlights%3A-enersys-monarch-casino-resort-grand-canyon-education", "https://www.nasdaq.com/articles/regn-crosses-above-key-moving-average-level-2016-12-12", "https://www.nasdaq.com/articles/nasdaq-100-movers-alxn-regn-2016-12-12", "https://www.nasdaq.com/articles/sp-500-movers-alxn-regn-2016-12-12", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-541254-down-3196-points-2016-12-12", "https://www.nasdaq.com/articles/mondays-etf-unusual-volume-spyg-2016-12-12", "https://www.nasdaq.com/articles/verizon-communications-inc.-vz-stock-is-a-keeper-2016-12-12", "https://www.nasdaq.com/articles/the-boost-in-basic-materials-is-just-the-beginning-2016-12-12", "https://www.nasdaq.com/articles/regeneron-pharmaceuticals-inc-regn-stock-gains-on-opthotechs-loss-2016-12-12", "https://www.nasdaq.com/articles/cohens-point72-bets-big-ahead-ophthotech-corp-trial-results-2016-12-09", "https://www.nasdaq.com/articles/should-biotech-investors-worry-about-donald-trump-2016-12-08", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-booz-allen-hamilton-holding-mcdonalds-regions-financial", "https://www.nasdaq.com/articles/play-trump-factor-these-4-large-cap-stocks-2016-12-06", "https://www.nasdaq.com/articles/buy-7-stocks-with-impressive-interest-coverage-ratio-2016-12-01", "https://www.nasdaq.com/articles/5-top-performing-biotechnology-stocks-of-november-2016-12-01", "https://www.nasdaq.com/articles/nvidia-sothebys-holdings-celgene-regeneron-pharmaceuticals-and-sanofi-highlighted-as-zacks", "https://www.nasdaq.com/articles/think-sanofi-sa-adr-sny-stock-when-you-think-big-pharma-2016-12-09", "https://www.nasdaq.com/articles/biotech-stock-roundup-acorda-stops-ampyra-pswd-development-crl-spectrums-qapzola-2016-11", "https://www.nasdaq.com/articles/3-biotechs-dont-pay-dividends-could-2016-11-22", "https://www.nasdaq.com/articles/attention-biotech-investors-black-friday-already-here-2016-11-21", "https://www.nasdaq.com/articles/buy-regeneron-pharmaceuticals-inc-regn-now-dont-fold-2016-11-18", "https://www.nasdaq.com/articles/regeneron-sanofis-praluent-cv-outcomes-study-to-continue-2016-11-18", "https://www.nasdaq.com/articles/sanofi-regeneron-present-sarilumab-data-at-acr-meeting-2016-11-18", "https://www.nasdaq.com/articles/aegerions-juxtapid-gets-pricing-authorization-in-japan-2016-11-18", "https://www.nasdaq.com/articles/celgene-vs-regeneron-which-stock-better-pick-2016-11-29", "https://www.nasdaq.com/articles/nasdaq-100-movers-csco-ntap-2016-11-17", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-edge-higher-wal-mart-posts-mixed-q3-results-2016-11-17", "https://www.nasdaq.com/articles/biotech-stock-roundup-biotech-stocks-soar-election-results-gilead-hbv-drug-approved-2016", "https://www.nasdaq.com/articles/ibb-regn-alxn-vrtx-etf-inflow-alert-2016-11-15", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-527562-5722-points-2016-11-15", "https://www.nasdaq.com/articles/notable-monday-option-activity-pbyi-ocul-regn-2016-11-14", "https://www.nasdaq.com/articles/3-biotech-stocks-you-must-buy-for-donald-trumps-presidency-2016-11-10", "https://www.nasdaq.com/articles/better-buy-regeneron-pharmaceuticals-inc-vs-novartis-2016-11-18", "https://www.nasdaq.com/articles/nasdaq-100-movers-csco-ntap-2016-11-17", "https://www.nasdaq.com/articles/this-unlucky-biotech-stock-has-entered-the-value-buy-zone-opht-2016-11-09", "https://www.nasdaq.com/articles/biotech-stock-roundup-ionis-soars-spinraza-data-regenerons-q3-results-mixed-2016-11-09", "https://www.nasdaq.com/articles/nasdaq-composite-index-closes-2732-points-week-rising-3rd-straight-day-2016-11-09", "https://www.nasdaq.com/articles/regeneron-pharmaceuticals-breaks-above-200-day-moving-average-bullish-regn-2016-11-09", "https://www.nasdaq.com/articles/adverum-advm-q3-earnings-preview%3A-whats-in-the-cards-2016-11-08", "https://www.nasdaq.com/articles/regeneron-pharmaceuticals-inc-dropped-143-october-heres-why-2016-11-08", "https://www.nasdaq.com/articles/drug-stocks-surge-trump-win-5-stocks-buy-now-2016-11-10", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-516617-11980-points-2016-11-07", "https://www.nasdaq.com/articles/regeneron-pharmaceuticals-inc-regn-stock-pops-on-mixed-q3-results-2016-11-04", "https://www.nasdaq.com/articles/spy-etf-tests-key-level-every-sp-sector-posts-weekly-loss-2016-11-04", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-allergan-gilead-sciences-pfizer-regeneron", "https://www.nasdaq.com/articles/regeneron-regn-q3-earnings-top-estimates-sales-miss-2016-11-04", "https://www.nasdaq.com/articles/notable-friday-option-activity-regn-wifi-dnkn-2016-11-04", "https://www.nasdaq.com/articles/3-things-you-really-need-know-about-regeneron-pharmaceuticals-q3-results-2016-11-04", "https://www.nasdaq.com/articles/top-research-reports-exxon-duke-gilead-2016-11-07", "https://www.nasdaq.com/articles/biotech-stock-roundup-amgen-down-enbrel-sales-regenerons-sarilumab-faces-delay-2016-11-03", "https://www.nasdaq.com/articles/pre-market-earnings-report-november-4-2016-duk-regn-pcg-hum-tu-wltw-fe-xray-aee-cnp-bip", "https://www.nasdaq.com/articles/pfizers-surprising-news-upends-market-next-gen-cholesterol-busters-2016-11-01", "https://www.nasdaq.com/articles/10-best-stocks-bull-market-2016-11-01", "https://www.nasdaq.com/articles/regeneron-regn-q3-earnings%3A-will-the-stock-surprise-2016-11-01", "https://www.nasdaq.com/articles/3-things-you-really-need-know-about-pfizers-q3-results-2016-11-01", "https://www.nasdaq.com/articles/nasdaq-100-movers-shpg-chkp-2016-10-31", "https://www.nasdaq.com/articles/drug-stocks-to-watch-for-earnings-on-nov-4-regn-more-2016-11-03", "https://www.nasdaq.com/articles/will-trend-cost-biotech-stock-investors-lots-money-2016-10-30", "https://www.nasdaq.com/articles/3-big-money-naked-puts-to-trade%3A-amzn-regn-googl-2016-10-27", "https://www.nasdaq.com/articles/exactly-how-bad-regenerons-latest-news-2016-10-26", "https://www.nasdaq.com/articles/3-key-questions-amgen-inc-q3-2016-10-25", "https://www.nasdaq.com/articles/ishares-nasdaq-biotechnology-etf-experiences-big-outflow-2016-10-24", "https://www.nasdaq.com/articles/biotech-stock-roundup-ariad-down-drug-pricing-tweet-regeneron-study-clinical-hold-2016-10", "https://www.nasdaq.com/articles/regeneron-teva-hit-by-clinical-hold-on-chronic-pain-study-2016-10-18", "https://www.nasdaq.com/articles/sanofi-sny-beats-earnings-revenues-rise-y-y-ups-view-2016-10-31", "https://www.nasdaq.com/articles/midday-update-wall-street-spooked-downbeat-chinese-trade-data-2016-10-13", "https://www.nasdaq.com/articles/mid-day-market-update-ocular-therapeutix-surges-following-collaboration-deal-regeneron", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-open-lower-delta-air-lines-profit-beats-estimates-2016", "https://www.nasdaq.com/articles/stock-futures-turn-defensive-china-trade-disappoints-initial-claims-fall-43-year-low-2016", "https://www.nasdaq.com/articles/close-update-downbeat-chinese-trade-data-weighs-wall-street-2016-10-13", "https://www.nasdaq.com/articles/mid-afternoon-market-update-lindsay-gains-following-q4-results-fluidigm-shares-drop-2016", "https://www.nasdaq.com/articles/better-buy-regeneron-pharmaceuticals-inc-vs-roche-holding-ag-2016-10-12", "https://www.nasdaq.com/articles/oculars-ocul-stock-jumps-on-collaboration-with-regeneron-2016-10-14", "https://www.nasdaq.com/articles/sanofi-vaccines-unit-riding-high-on-barda-zika-funding-2016-10-11", "https://www.nasdaq.com/articles/another-blockbuster-drug-way-regeneron-pharmaceuticals-inc-2016-10-10", "https://www.nasdaq.com/articles/10-hot-stocks-that-made-millionaires-in-10-years-2016-10-10", "https://www.nasdaq.com/articles/noteworthy-monday-option-activity-pvh-regn-eqix-2016-10-10", "https://www.nasdaq.com/articles/big-reason-you-shouldnt-give-big-cap-biotech-2016-10-08", "https://www.nasdaq.com/articles/heres-why-ophtotech-corporation-dropped-165-september-2016-10-08", "https://www.nasdaq.com/articles/biotech-stock-roundup-summit-soars-sarepta-deal-regeneron-presents-data-2016-10-05", "https://www.nasdaq.com/articles/wednesday-sector-laggards-healthcare-energy-2016-10-12", "https://www.nasdaq.com/articles/regenerons-eylea-rinucumab-combination-data-disappoints-2016-10-03", "https://www.nasdaq.com/articles/marketplace-roundtable-state-biotech-2016-10-01", "https://www.nasdaq.com/articles/heres-why-ophthotech-corporation-dropping-today-2016-09-30", "https://www.nasdaq.com/articles/nasdaq-100-movers-ctsh-nxpi-2016-09-30", "https://www.nasdaq.com/articles/exelixis-inc.-exel-crushed-on-cabonivo-drug-trial-results-2016-09-30", "https://www.nasdaq.com/articles/a-dont-blink-opportunity-in-regeneron-pharmaceuticals-inc-regn-2016-09-30", "https://www.nasdaq.com/articles/why-cognizant-technology-solutions-pier-1-imports-and-ophthotech-slumped-today-2016-09-30", "https://www.nasdaq.com/articles/your-40s-3-stocks-you-should-consider-buying-2016-10-05", "https://www.nasdaq.com/articles/regenerons-eylea-rinucumab-combination-data-disappoints-2016-10-03", "https://www.nasdaq.com/articles/marketplace-roundtable-state-biotech-2016-10-01", "https://www.nasdaq.com/articles/zacks.com-featured-highlights%3A-regeneron-pharmaceuticals-nordstrom-intel-nu-skin", "https://www.nasdaq.com/articles/3-critical-fda-decisions-you-cant-afford-miss-2016-09-27", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-530571-4822-points-2016-09-27", "https://www.nasdaq.com/articles/5-stocks-with-impressive-sales-growth-to-bet-on-2016-09-26", "https://www.nasdaq.com/articles/regeneron-sanofi-skin-disease-drug-under-priority-review-2016-09-26", "https://www.nasdaq.com/articles/why-investors-are-paying-premium-regeneron-pharmaceuticals-inc-2016-09-29", "https://www.nasdaq.com/articles/regeneron-pharmaceuticals-breaks-above-200-day-moving-average-bullish-regn-2016-09-23", "https://www.nasdaq.com/articles/biotech-stock-roundup-tobira-soars-acquisition-deal-fda-says-yes-sarepta-dmd-drug-2016-09", "https://www.nasdaq.com/articles/regeneron-teva-collaborate-to-develop-chronic-pain-drug-2016-09-21", "https://www.nasdaq.com/articles/this-crazy-stock-market-is-creating-crazy-discounts-2016-09-14", "https://www.nasdaq.com/articles/notable-etf-outflow-detected-pbe-incy-bmrn-regn-2016-09-08", "https://www.nasdaq.com/articles/3-large-cap-stocks-buy-september-2016-09-02", "https://www.nasdaq.com/articles/3-biotech-stocks-buy-september-2016-09-02", "https://www.nasdaq.com/articles/3-growth-stocks-you-can-buy-cheap-right-now-2016-09-26", "https://www.nasdaq.com/articles/the-medicines-co.-offers-update-on-dyslipidemia-programs-2016-08-31", "https://www.nasdaq.com/articles/3-beaten-biotech-stocks-are-they-bargains-2016-08-31", "https://www.nasdaq.com/articles/regeneron-sanofi-present-positive-phase-iii-praluent-data-2016-08-29", "https://www.nasdaq.com/articles/these-next-generation-cholesterol-drugs-could-raise-us-healthcare-costs-119-billion-year", "https://www.nasdaq.com/articles/buy-chesapeake-energy-corporation-chk-if-youve-got-some-guts-2016-08-24", "https://www.nasdaq.com/articles/merck-co.-inc.-mrk-preps-for-a-healthy-breakout-2016-08-24", "https://www.nasdaq.com/articles/biotech-stock-roundup-gilead-patent-infringement-lawsuit-enbrel-biosimilar-approved-2016", "https://www.nasdaq.com/articles/why-barrick-gold-corporation-usa-abx-express-inc.-expr-and-garmin-ltd.-grmn-are-3-of", "https://www.nasdaq.com/articles/biotech-stock-roundup-medivation-pfizer-clovis-priority-review-2016-08-24", "https://www.nasdaq.com/articles/regeneron-stock-up-on-barda-deal-for-mers-antibodies-2016-08-23", "https://www.nasdaq.com/articles/sp-500-movers-mro-regn-2016-08-22", "https://www.nasdaq.com/articles/jj-jnj-remicade-patent-invalid-pfizer-launch-inflectra-2016-08-18", "https://www.nasdaq.com/articles/another-endorsement-biotech-etfs-2016-08-16", "https://www.nasdaq.com/articles/regeneron-pharmaceuticals-inc-profit-regn-stocks-pullback-2016-08-15", "https://www.nasdaq.com/articles/regeneron-pharmaceuticals-inc-regn-just-reached-a-critical-fork-in-the-road-2016-08-24", "https://www.nasdaq.com/articles/adverum-advm-reports-narrower-than-expected-q2-loss-2016-08-11", "https://www.nasdaq.com/articles/biotech-stock-roundup-earnings-focus-abbvie-takes-steps-block-humira-copycat-2016-08-11", "https://www.nasdaq.com/articles/regeneron-pharmaceuticals-incs-q2-earnings-its-still-all-about-eylea-not-too-much-longer", "https://www.nasdaq.com/articles/whats-in-store-for-adverum-advm-this-earnings-season-2016-08-08", "https://www.nasdaq.com/articles/regeneron-regn-tops-q2-earnings-keeps-16-eylea-view-2016-08-04", "https://www.nasdaq.com/articles/regeneron-regn-beats-on-q2-earnings-retains-eylea-view-2016-08-04", "https://www.nasdaq.com/articles/3-frank-sands-top-5-transactions-2nd-quarter-were-reductions-2016-08-14", "https://www.nasdaq.com/articles/health-care-sector-update-08042016-regncheksgmo-2016-08-04", "https://www.nasdaq.com/articles/3-big-stock-charts-for-wednesday%3A-regeneron-pharmaceuticals-inc-regn-biogen-inc-biib-and", "https://www.nasdaq.com/articles/ibb-significantly-overbought-sharp-declines-imminent-2016-08-03", "https://www.nasdaq.com/articles/5-drug-stocks-to-watch-for-earnings-on-aug-4%3A-bmrn-more-2016-08-03", "https://www.nasdaq.com/articles/pre-market-earnings-report-august-4-2016-pcln-duk-regn-eog-bce-bdx-cnq-mnst-k-sre-apa-ph", "https://www.nasdaq.com/articles/regeneron-regn-q2-earnings%3A-can-the-stock-surprise-2016-08-01", "https://www.nasdaq.com/articles/better-buy-regeneron-pharmaceuticals-vs-pfizer-2016-07-29", "https://www.nasdaq.com/articles/earnings-reaction-history-regeneron-pharmaceuticals-182-follow-through-indicator-32", "https://www.nasdaq.com/articles/noteworthy-etf-outflows-bib-biib-regn-myl-2016-07-21", "https://www.nasdaq.com/articles/why-i-bought-shares-regeneron-pharmaceuticals-inc-last-week-2016-07-20", "https://www.nasdaq.com/articles/3-biotech-stocks-buy-and-hold-2016-07-19", "https://www.nasdaq.com/articles/noteworthy-monday-option-activity-mac-gpc-regn-2016-07-18", "https://www.nasdaq.com/articles/pfizer-publishes-final-data-from-atopic-dermatitis-studies-2016-07-14", "https://www.nasdaq.com/articles/heres-why-regeneron-pharmaceuticals-inc-dropped-another-12-june-2016-07-13", "https://www.nasdaq.com/articles/amgens-repatha-gains-fda-approval-for-new-dosing-option-2016-07-12", "https://www.nasdaq.com/articles/notable-wednesday-option-activity-ftk-regn-hes-2016-07-27", "https://www.nasdaq.com/articles/stock-market-news-for-july-07-2016-2016-07-07", "https://www.nasdaq.com/articles/sanofi-starts-olipudase-alfa-study-praluent-okd-in-japan-2016-07-07", "https://www.nasdaq.com/articles/3-top-healthcare-stocks-buy-now-2016-07-04", "https://www.nasdaq.com/articles/heres-why-regeneron-pharmaceuticals-inc-down-35-year-2016-07-01", "https://www.nasdaq.com/articles/pfizers-pcsk9-inhibitor-tops-two-additional-phase-iii-studies-2016-06-29", "https://www.nasdaq.com/articles/esperion-therapeutics-inc-sinks-after-fda-says-ask-us-2019-2016-06-29", "https://www.nasdaq.com/articles/instant-analysis-amgens-latest-approval-raises-bar-yet-again-regeneron-pharmaceuticals-inc", "https://www.nasdaq.com/articles/company-news-for-june-23-2016-2016-06-23", "https://www.nasdaq.com/articles/warren-buffetts-favorite-high-yield-dividend-stock-2016-06-22", "https://www.nasdaq.com/articles/3-biotech-stocks-to-buy-now%3A-celg-regn-and-biib-2016-06-21", "https://www.nasdaq.com/articles/3-biotech-stocks-buy-if-market-crashes-2016-06-14", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-ishares-nasdaq-biotechnology-biogen-alexion-pharma", "https://www.nasdaq.com/articles/5-top-stocks-buy-june-2016-06-13", "https://www.nasdaq.com/articles/4-stocks-crushed-biotechnology-etf-ibb-week-2016-06-10", "https://www.nasdaq.com/articles/3-biotech-stocks-buy-now-long-haul-2016-06-25", "https://www.nasdaq.com/articles/biotech-stock-roundup-biogen-slips-ms-results-asco-data-focus-2016-06-08", "https://www.nasdaq.com/articles/regeneron-sanofi-report-positive-dupilumab-phase-iii-data-2016-06-06", "https://www.nasdaq.com/articles/3-biotechs-expecting-market-moving-trial-results-soon-2016-06-04", "https://www.nasdaq.com/articles/regeneron-reports-interim-data-on-cholesterol-lowering-drug-2016-06-01", "https://www.nasdaq.com/articles/better-buy-regeneron-pharmaceuticals-inc-vs-roche-2016-05-27", "https://www.nasdaq.com/articles/10-highest-paid-ceos-in-2015-2016-05-27", "https://www.nasdaq.com/articles/pfizers-buyout-anacor-pharmaceuticals-52-billion-bad-move-heres-why-2016-05-24", "https://www.nasdaq.com/articles/why-ophthotech-corp-shares-soared-149-may-2016-06-09", "https://www.nasdaq.com/articles/3-bullish-stock-picks-in-a-soft-market%3A-regn-rtec-tis-2016-05-19", "https://www.nasdaq.com/articles/nasdaq-100-movers-chtr-bidu-2016-05-16", "https://www.nasdaq.com/articles/5-toxic-stocks-to-discard-from-your-portfolio-2016-05-09", "https://www.nasdaq.com/articles/avalanche-aavl-reports-wider-than-expected-q1-loss-2016-05-09", "https://www.nasdaq.com/articles/look-under-hood-csm-has-12-upside-2016-05-09", "https://www.nasdaq.com/articles/regeneron-regn-tops-q1-earnings-ups-2016-eylea-view-2016-05-05", "https://www.nasdaq.com/articles/regeneron-regn-beats-q1-earnings-and-revenues-2016-05-05", "https://www.nasdaq.com/articles/the-10-best-healthcare-stocks-to-buy-now-2016-05-24", "https://www.nasdaq.com/articles/pre-market-earnings-report-may-5-2016-mrk-baba-oxy-eog-regn-bdx-cnq-k-apa-tu-abc-mga-2016", "https://www.nasdaq.com/articles/noteworthy-wednesday-option-activity-tumi-regn-mtch-2016-05-04", "https://www.nasdaq.com/articles/biotech-stock-roundup-amgen-impresses-gilead-disappoints-q1-biogen-spin-hemophilia-2016-05", "https://www.nasdaq.com/articles/biotech-stocks-earnings-preview%3A-regn-lgnd-ecyt-more-2016-05-03", "https://www.nasdaq.com/articles/regeneron-pharmaceuticals-inc-has-lot-prove-may-5-2016-05-03", "https://www.nasdaq.com/articles/vanguard-boosts-stake-incyte-st-quarter-2016-05-03", "https://www.nasdaq.com/articles/regeneron-regn-q1-earnings%3A-stock-likely-to-disappoint-2016-05-02", "https://www.nasdaq.com/articles/regeneron-regn-misses-on-q1-earnings-beats-on-revenues-2016-05-05", "https://www.nasdaq.com/articles/pre-market-earnings-report-may-5-2016-mrk-baba-oxy-eog-regn-bdx-cnq-k-apa-tu-abc-mga-2016", "https://www.nasdaq.com/articles/biotech-stock-roundup-biogen-tops-q1-earnings-sarepta-catalyst-plunge-regulatory-news-2016", "https://www.nasdaq.com/articles/3-stocks-buy-crashing-market-2016-04-22", "https://www.nasdaq.com/articles/ibb-regn-ilmn-alxn-etf-outflow-alert-2016-04-21", "https://www.nasdaq.com/articles/nasdaq-100-movers-chkp-bmrn-2016-04-20", "https://www.nasdaq.com/articles/3-stocks-analysts-think-could-roar-25-higher-citigroup-dal-lnkd-2016-04-20", "https://www.nasdaq.com/articles/3-stocks-analysts-think-could-crater-35-gpro-u.s.-steel-mbly-2016-04-20", "https://www.nasdaq.com/articles/aside-1-eyesore-amgen-delivers-another-solid-quarter-2016-05-02", "https://www.nasdaq.com/articles/3-biotech-stocks-that-could-endure-hillary-clinton-2016-04-19", "https://www.nasdaq.com/articles/3-big-money-covered-calls-goog-pcln-regn-2016-04-14", "https://www.nasdaq.com/articles/better-buy-mannkind-corporation-vs-sanofi-2016-04-14", "https://www.nasdaq.com/articles/3-biotech-stocks-buy-april-2016-04-12", "https://www.nasdaq.com/articles/regeneron-intellia-strike-deal-for-crispr-cas-platform-2016-04-12", "https://www.nasdaq.com/articles/regenerons-bold-bet-future-medicine-2016-04-12", "https://www.nasdaq.com/articles/shares-regeneron-pharmaceuticals-inc-struggled-march-heres-why-2016-04-11", "https://www.nasdaq.com/articles/illumina-inc.-ilmn-takes-a-25-hit-what-now-2016-04-19", "https://www.nasdaq.com/articles/3-biotech-stocks-that-could-endure-hillary-clinton-2016-04-19", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-gilead-regeneron-medivation-and-intercept-2016-04-07", "https://www.nasdaq.com/articles/9-stocks-to-buy-with-rip-roaring-growth-potential-2016-04-07", "https://www.nasdaq.com/articles/biotech-stock-roundup-gileads-hiv-drug-approved-regeneron-positive-data-2016-04-06", "https://www.nasdaq.com/articles/allergan-pfizer-inc.-fall-prey-to-tax-inversion-hawks-agn-pfe-2016-04-05", "https://www.nasdaq.com/articles/general-electric-company-downgraded-who-cares-ge-2016-04-05", "https://www.nasdaq.com/articles/ibb-regn-ilmn-myl-large-inflows-detected-etf-2016-04-11", "https://www.nasdaq.com/articles/forget-regeneron-pharmaceuticals-inc-these-2-stocks-are-better-buys-2016-04-05", "https://www.nasdaq.com/articles/wall-street-hits-snag-on-strength-in-treasuries-2016-04-05", "https://www.nasdaq.com/articles/amgen-news-could-be-game-changer-its-fight-against-sanofi-and-regeneron-pharmaceuticals", "https://www.nasdaq.com/articles/3-biotech-stocks-on-the-verge-of-an-overdue-run-amgn-gild-regn-2016-04-04", "https://www.nasdaq.com/articles/better-buy-regeneron-pharmaceuticals-inc-vs-amgen-2016-04-04", "https://www.nasdaq.com/articles/pfizers-pcsk9-inhibitor-positive-second-phase-iii-study-2016-04-04", "https://www.nasdaq.com/articles/regeneron-sanofi-up-eczema-drug-tops-phase-iii-studies-2016-04-04", "https://www.nasdaq.com/articles/regeneron-pharmaceuticals-inc-is-the-biotech-stock-to-buy-regn-2016-04-05", "https://www.nasdaq.com/articles/sp-500-movers-crc-regn-2016-04-01", "https://www.nasdaq.com/articles/why-regeneron-pharmaceuticals-tronox-and-office-depot-jumped-today-2016-04-01", "https://www.nasdaq.com/articles/regeneron-pharmaceuticals-inc-jumps-positive-clinical-data-2016-04-01", "https://www.nasdaq.com/articles/regeneron-delivers-blockbuster-win-eczema-2016-04-01", "https://www.nasdaq.com/articles/friday-sector-leaders-healthcare-financial-2016-04-01", "https://www.nasdaq.com/articles/mid-afternoon-market-update-crude-oil-down-35-tesla-shares-rise-following-model-3-launch", "https://www.nasdaq.com/articles/fridays-etf-movers-ibb-fxn-2016-04-01", "https://www.nasdaq.com/articles/nasdaq-100-movers-mar-tsla-2016-04-01", "https://www.nasdaq.com/articles/sp-500-movers-crc-regn-2016-04-01", "https://www.nasdaq.com/articles/gilead-biogens-patent-woes-amgen-scores-win-patent-litigation-2016-03-24", "https://www.nasdaq.com/articles/amgen-inc-amgn-stock-looking-break-out-2016-03-18", "https://www.nasdaq.com/articles/do-you-own-any-these-top-sector-funds-2016-03-18", "https://www.nasdaq.com/articles/3-biotech-stocks-buy-march-2016-03-18", "https://www.nasdaq.com/articles/winners-and-losers-5-stocks-you-can-buy-now-2016-03-18", "https://www.nasdaq.com/articles/friday-sector-leaders-drugs-biotechnology-stocks-2016-04-01", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-gilead-amgen-regeneron-ionis-and-biogen-2016-03-28", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-gw-pharma-orexigen-gilead-and-regeneron-2016-03-17", "https://www.nasdaq.com/articles/amgen-wins-pcsk9-lawsuit-sanofi-and-regeneron-to-appeal-2016-03-17", "https://www.nasdaq.com/articles/biotech-stock-roundup-gw-pharma-soars-epidiolex-data-gileads-zydelig-trouble-2016-03-16", "https://www.nasdaq.com/articles/why-investors-should-sell-these-biotech-stocks-buy-gilead-instead-2016-03-15", "https://www.nasdaq.com/articles/regeneron-sanofi-report-positive-sarilumab-phase-iii-data-2016-03-14", "https://www.nasdaq.com/articles/instant-analysis-regeneron-pharmaceuticals-and-sanofis-experimental-drug-bests-abbvie", "https://www.nasdaq.com/articles/3-biotech-stocks-that-are-ripe-for-a-fall-2016-03-17", "https://www.nasdaq.com/articles/nasdaq-100-movers-regn-wdc-2016-03-09", "https://www.nasdaq.com/articles/regeneron-pharmaceuticals-inc-regn-suffers-amid-biotech-rout-2016-03-09", "https://www.nasdaq.com/articles/biotech-stock-roundup-abbvies-imbruvica-label-expanded-celldex-slumps-study-update-2016-03", "https://www.nasdaq.com/articles/3-stocks-own-next-10-years-2016-03-08", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-valeant-pharmaceuticals-international-gilead-sciences", "https://www.nasdaq.com/articles/4-top-stocks-were-excited-about-2016-03-06", "https://www.nasdaq.com/articles/repligen-corporation-jumped-146-february-heres-why-2016-03-06", "https://www.nasdaq.com/articles/biotech-investing-guide-3-stocks-buy-and-3-avoid-2016-03-11", "https://www.nasdaq.com/articles/avalanche-aavl-reports-wider-than-expected-loss-in-q4-2016-03-04", "https://www.nasdaq.com/articles/these-3-biotechs-are-growing-fast-which-best-buy-today-2016-03-03", "https://www.nasdaq.com/articles/whats-in-store-for-avalanche-aavl-this-earnings-season-2016-03-02", "https://www.nasdaq.com/articles/5-must-see-comments-amgens-top-executives-2016-02-23", "https://www.nasdaq.com/articles/better-buy-regeneron-pharmaceuticals-inc-vs-pfizer-2016-02-22", "https://www.nasdaq.com/articles/can-biotech-stocks-bounce-back-2016-02-19", "https://www.nasdaq.com/articles/4-funds-to-buy-on-healthy-medical-sector-earnings-2016-02-18", "https://www.nasdaq.com/articles/what-does-trumps-healthcare-plan-mean-investors-2016-03-04", "https://www.nasdaq.com/articles/bouncing-biotech-here-are-3-stocks-buy-2016-02-17", "https://www.nasdaq.com/articles/eyleas-slowing-sales-growth-sends-regeneron-pharmaceutical-incs-shares-lower-2016-02-12", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-regeneron-alexion-cti-biopharma-biocryst-and-sarepta", "https://www.nasdaq.com/articles/sanofi-tops-q4-earnings-revenues-fall-y-y-gives-2016-view-2016-02-10", "https://www.nasdaq.com/articles/biotech-stock-roundup-alexion-regeneron-miss-estimates-setback-cti-biopharma-2016-02-10", "https://www.nasdaq.com/articles/regeneron-q4-earnings-lag-gives-2016-view-for-eylea-sales-2016-02-09", "https://www.nasdaq.com/articles/noteworthy-tuesday-option-activity-cers-regn-ctct-2016-02-09", "https://www.nasdaq.com/articles/biotech-stock-roundup-incyte-down-jakafi-update-intercept-buyout-target-2016-02-17", "https://www.nasdaq.com/articles/pre-market-earnings-report-february-9-2016-ko-cvs-regn-omc-hcp-fis-viab-ir-agu-tdg-sny-mas", "https://www.nasdaq.com/articles/why-ophthotech-corporation-shares-tumbled-31-january-2016-02-06", "https://www.nasdaq.com/articles/ewt-pth-big-etf-outflows-2016-02-05", "https://www.nasdaq.com/articles/3-things-look-regeneron-pharmaceuticals-incs-earnings-2016-02-05", "https://www.nasdaq.com/articles/regeneron-regn-to-report-q4-earnings%3A-whats-in-store-2016-02-05", "https://www.nasdaq.com/articles/biotech-stock-roundup-biogen-amgen-top-estimates-zika-virus-grabs-attention-2016-02-03", "https://www.nasdaq.com/articles/ignore-regeneron-pharmaceuticals-inc-here-are-3-better-buys-right-now-2016-02-02", "https://www.nasdaq.com/articles/regeneron-regn-misses-on-q4-earnings-and-revenues-2016-02-09", "https://www.nasdaq.com/articles/avalanche-aavl-set-to-acquire-annapurna-therapeutics-2016-02-02", "https://www.nasdaq.com/articles/nasdaq-100-movers-incy-sbac-2016-01-26", "https://www.nasdaq.com/articles/regeneron-pharmaceuticals-inc-stock-bargain-or-rip-2016-01-21", "https://www.nasdaq.com/articles/health-care-sector-update-01202016-oncy-regn-2016-01-20", "https://www.nasdaq.com/articles/best-healthcare-stocks-2016-2016-01-15", "https://www.nasdaq.com/articles/5-slides-tell-you-everything-you-need-know-about-amgen-2016-01-13", "https://www.nasdaq.com/articles/biotech-stock-roundup-baxalta-shire-combine-jpm-healthcare-conference-focus-2016-01-13", "https://www.nasdaq.com/articles/why-regeneron-pharmaceuticals-shares-fell-23-january-2016-02-02", "https://www.nasdaq.com/articles/nasdaq-100-movers-regn-akam-2016-01-12", "https://www.nasdaq.com/articles/sanofi-inks-multiple-deals-sarilumab-under-fda-review-2016-01-11", "https://www.nasdaq.com/articles/why-opthotech-corporation-shares-skyrocketed-75-2015-2016-01-10", "https://www.nasdaq.com/articles/why-regeneron-pharmaceuticals-shares-jumped-32-2015-2016-01-09", "https://www.nasdaq.com/articles/will-2016-be-regeneron-pharmaceuticals-incs-best-year-yet-2016-01-06", "https://www.nasdaq.com/articles/biotech-stock-roundup-mannkind-tanks-deal-termination-speedy-review-gilead-drug-2016-01-06", "https://www.nasdaq.com/articles/doctorx-positions-2016-my-no-1-risk-factor-flood-money-biotech-2016-01-06", "https://www.nasdaq.com/articles/biotech-etfs-snap-back-after-undercutting-sept-lows-2016-01-12", "https://www.nasdaq.com/articles/agree-purchase-regeneron-pharmaceuticals-380-earn-92-using-options-2015-12-31", "https://www.nasdaq.com/articles/will-amgen-inc-raise-its-dividend-2016-2015-12-31", "https://www.nasdaq.com/articles/5-companies-we-wish-wed-bought-2015-2015-12-30", "https://www.nasdaq.com/articles/what-happened-biotech-2015-2015-12-28", "https://www.nasdaq.com/articles/worst-regeneron-pharmaceuticals-inc-headlines-2015-2015-12-26", "https://www.nasdaq.com/articles/biotech-industry-could-offer-early-profit-2016-2015-12-24", "https://www.nasdaq.com/articles/best-3-biotech-stocks-2016-2015-12-22", "https://www.nasdaq.com/articles/3-stocks-buy-market-crash-2016-01-04", "https://www.nasdaq.com/articles/agree-purchase-regeneron-pharmaceuticals-380-earn-92-using-options-2015-12-31", "https://www.nasdaq.com/articles/best-amgen-inc-headlines-2015-2015-12-17", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-amgen-ariad-clovis-oncology-regeneron-and-akebia", "https://www.nasdaq.com/articles/big-biotech-amgen-facing-pivotal-year-2016-2015-12-17", "https://www.nasdaq.com/articles/biotech-stock-roundup-amgen-hikes-first-quarter-dividend-ariad-lowers-iclusig-outlook-2015", "https://www.nasdaq.com/articles/did-cvs-health-just-make-huge-mistake-2015-12-15", "https://www.nasdaq.com/articles/may-be-fastest-growing-biotech-stock-next-year-hint-its-not-gilead-sciences-2015-12-14", "https://www.nasdaq.com/articles/why-aegerion-pharmaceuticals-stock-bolted-higher-today-2015-12-21", "https://www.nasdaq.com/articles/ibb-amgn-regn-biib-large-outflows-detected-etf-2015-12-11", "https://www.nasdaq.com/articles/aegerion-pharmaceuticals-lost-third-its-value-november-time-buy-2015-12-09", "https://www.nasdaq.com/articles/why-ophthotech-corporation-shares-soared-higher-last-month-2015-12-04", "https://www.nasdaq.com/articles/noteworthy-friday-option-activity-kmi-cvx-regn-2015-12-04", "https://www.nasdaq.com/articles/noteworthy-etf-outflows-ibb-regn-biib-alxn-2015-12-03", "https://www.nasdaq.com/articles/stock-market-news-for-december-01-2015-2015-12-01", "https://www.nasdaq.com/articles/cvs-health-plays-favorites-new-cholesterol-drugs-2015-12-01", "https://www.nasdaq.com/articles/top-fda-drug-approvals-2015-high-cholesterol-2015-12-12", "https://www.nasdaq.com/articles/3-stocks-buy-and-hold-next-decade-2015-11-23", "https://www.nasdaq.com/articles/5-things-amgen-inc-wants-you-know-2015-11-21", "https://www.nasdaq.com/articles/sanofi-and-regeneron-hit-another-bullseye-2015-11-18", "https://www.nasdaq.com/articles/these-2-companies-could-revolutionize-heart-disease-prevention-2015-11-14", "https://www.nasdaq.com/articles/ibb-regn-amgn-celg-etf-outflow-alert-2015-11-13", "https://www.nasdaq.com/articles/why-aegerion-pharmaceuticals-crashing-today-2015-11-10", "https://www.nasdaq.com/articles/avalanche-aavl-reports-wider-than-expected-loss-in-q3-2015-11-10", "https://www.nasdaq.com/articles/monday-sector-laggards-healthcare-services-2015-11-30", "https://www.nasdaq.com/articles/health-care-sector-update-11042015-crl-scmp-regn-2015-11-04", "https://www.nasdaq.com/articles/regeneron-regn-misses-on-q3-earnings-revenues-in-line-2015-11-04", "https://www.nasdaq.com/articles/earnings-reaction-history-regeneron-pharmaceuticals-300-follow-through-indicator-27", "https://www.nasdaq.com/articles/regeneron-misses-on-q3-earnings-eylea-2015-view-upped-2015-11-04", "https://www.nasdaq.com/articles/5-exciting-biotech-stocks-to-buy-on-november-upswing-2015-11-03", "https://www.nasdaq.com/articles/pre-market-earnings-report-november-4-2015-agn-twx-regn-ctsh-foxa-bdx-fox-se-wec-hsic-sep", "https://www.nasdaq.com/articles/zoetis-tops-q3-earnings-ups-2015-bottom-line-guidance-2015-11-03", "https://www.nasdaq.com/articles/ibb-celg-regn-amgn-large-inflows-detected-etf-2015-11-05", "https://www.nasdaq.com/articles/noteworthy-etf-inflows-ibb-amgn-celg-regn-2015-10-29", "https://www.nasdaq.com/articles/aegerion-aegr-q3-earnings-preview%3A-whats-in-the-cards-2015-10-27", "https://www.nasdaq.com/articles/will-express-scripts-esrx-surprise-q3-earnings-estimates-2015-10-26", "https://www.nasdaq.com/articles/stock-market-news-for-october-21-2015-2015-10-21", "https://www.nasdaq.com/articles/stock-market-news-for-october-20-2015-2015-10-20", "https://www.nasdaq.com/articles/eli-lillys-failure-success-these-companies-2015-10-19", "https://www.nasdaq.com/articles/3-biotechs-growing-faster-apple-2015-10-18", "https://www.nasdaq.com/articles/whats-store-regeneron-regn-earnings-season-2015-11-02", "https://www.nasdaq.com/articles/nasdaq-100-movers-incy-regn-2015-10-12", "https://www.nasdaq.com/articles/sp-500-movers-lly-regn-2015-10-12", "https://www.nasdaq.com/articles/winners-and-losers-eli-lillys-cetp-drug-failure-2015-10-12", "https://www.nasdaq.com/articles/stock-market-news-for-october-08-2015-2015-10-08", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-amgen-regeneron-acorda-amicus-and-abbvie-2015-10-08", "https://www.nasdaq.com/articles/cholesterol-busters-will-be-cheaper-remain-top-sellers-2015-10-07", "https://www.nasdaq.com/articles/stock-market-news-for-october-14-2015-2015-10-14", "https://www.nasdaq.com/articles/nasdaq-100-movers-adbe-wynn-2015-10-07", "https://www.nasdaq.com/articles/stock-market-news-for-october-07-2015-2015-10-07", "https://www.nasdaq.com/articles/express-scripts-includes-praluent-and-repatha-in-formulary-2015-10-07", "https://www.nasdaq.com/articles/biotech-stock-roundup-pbm-lists-both-amgen-regeneron-pcsk9-inhibitors-fold-plunges-nda", "https://www.nasdaq.com/articles/illumina-ilmn-shares-tumble-on-weak-outlook-for-sales-2015-10-06", "https://www.nasdaq.com/articles/would-ebola-vaccine-move-regeneron-pharmaceuticals-bottom-line-2015-10-06", "https://www.nasdaq.com/articles/mercks-mrk-keytruda-gains-fda-nod-for-label-expansion-2015-10-05", "https://www.nasdaq.com/articles/commit-buy-regeneron-pharmaceuticals-320-earn-66-using-options-2015-10-07", "https://www.nasdaq.com/articles/illumina-poised-on-product-innovation-global-expansion-2015-10-05", "https://www.nasdaq.com/articles/dbv-technologies-reveals-positive-data-on-viaskin-peanut-2015-10-05", "https://www.nasdaq.com/articles/sanofi-opts-into-alnylams-aln-at3-hemophilia-program-2015-10-02", "https://www.nasdaq.com/articles/biomarin-bmrn-to-acquire-rights-to-phenylketonuria-drugs-2015-10-02", "https://www.nasdaq.com/articles/bristol-myers-melanoma-combo-opdivo-yervoy-gets-fda-nod-2015-10-02", "https://www.nasdaq.com/articles/sarepta-unveils-new-phase-iib-eteplirsen-data-shares-soar-2015-10-02", "https://www.nasdaq.com/articles/illumina-downgraded-by-leerink-shares-plummet-over-10-2015-10-02", "https://www.nasdaq.com/articles/gileads-letairis-gets-fda-nod-in-combination-with-adcirca-2015-10-05", "https://www.nasdaq.com/articles/jazzs-defibrotide-under-fda-priority-review-shares-up-2015-10-01", "https://www.nasdaq.com/articles/stock-market-news-for-october-01-2015-2015-10-01", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-regeneron-vertex-gilead-biogen-and-celgene-2015-10-01", "https://www.nasdaq.com/articles/chiasma-chma-jumps%3A-stock-adds-5.6-in-session-2015-10-01", "https://www.nasdaq.com/articles/infinity-infi-up-set-to-get-duvelisib-milestone-payment-2015-10-01", "https://www.nasdaq.com/articles/revances-botulinum-toxin-type-a-in-cervical-dystonia-study-2015-09-30", "https://www.nasdaq.com/articles/oxigene-oxgn-to-initiate-two-phase-ii-iii-studies-on-ca4p-2015-09-30", "https://www.nasdaq.com/articles/integra-iart-hopeful-on-spine-spin-off-amid-global-woes-2015-10-02", "https://www.nasdaq.com/articles/clovis-rociletinib-under-review-in-u.s.-eu-for-lung-cancer-2015-09-30", "https://www.nasdaq.com/articles/novavaxs-respiratory-vaccine-study-data-fail-to-impress-2015-09-30", "https://www.nasdaq.com/articles/regeneron-pharmaceuticals-and-sanofi-grab-another-important-win-2015-09-29", "https://www.nasdaq.com/articles/sanofi-eli-lilly-agree-to-settle-lantus-patent-litigation-2015-09-29", "https://www.nasdaq.com/articles/endo-completes-%248.05b-par-pharma-acquisition-updates-view-2015-09-29", "https://www.nasdaq.com/articles/alnylams-extension-study-on-patisiran-reveals-positive-data-2015-09-29", "https://www.nasdaq.com/articles/esperion-plunges-on-fda-advice-for-cardiovascular-study-2015-09-30", "https://www.nasdaq.com/articles/regeneron-pharmaceuticals-regn-shares-cross-below-200-dma-2015-09-28", "https://www.nasdaq.com/articles/stock-market-news-for-september-28-2015-2015-09-28", "https://www.nasdaq.com/articles/regeneron-sanofis-pcsk9-inhibitor-praluent-approved-in-eu-2015-09-28", "https://www.nasdaq.com/articles/price-war-new-cholesterol-drugs-heating-2015-09-25", "https://www.nasdaq.com/articles/stock-market-news-for-september-25-2015-2015-09-25", "https://www.nasdaq.com/articles/kempharm-kmph-updates-on-abuse-deterrent-opioid-drug-2015-09-25", "https://www.nasdaq.com/articles/bellerophon-presents-positive-interim-data-on-inopulse-2015-09-25", "https://www.nasdaq.com/articles/allergan-agn-projects-revenues-to-surpass-%248b-in-2h15-2015-09-29", "https://www.nasdaq.com/articles/orexigen-receives-%2422m-milestone-payment-for-contrave-2015-09-24", "https://www.nasdaq.com/articles/conatus-reports-promising-phase-ii-data-on-emricasan-2015-09-24", "https://www.nasdaq.com/articles/biotech-stock-roundup-clintons-tweet-shakes-biotech-stocks-amgen-pipeline-boosting-deals", "https://www.nasdaq.com/articles/herons-hrtx-post-operative-pain-candidate-encourages-2015-09-23", "https://www.nasdaq.com/articles/acelrxs-pain-treatment-drug-zalviso-approved-in-europe-2015-09-23", "https://www.nasdaq.com/articles/pfizers-xeljanz-tops-phase-iii-ulcerative-colitis-studies-2015-09-22", "https://www.nasdaq.com/articles/inovio-gets-grant-for-ebola-drugs-regeneron-inks-deal-2015-09-22", "https://www.nasdaq.com/articles/biomed-realty-trust-reit-looks-buyer-2015-09-24", "https://www.nasdaq.com/articles/5-biotech-stocks-hit-hard-hillary-clintons-tweet-2015-09-22", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-medivation-gilead-sciences-regeneron-pharmaceuticals", "https://www.nasdaq.com/articles/merck-reports-encouraging-phase-iii-data-on-bezlotoxumab-2015-09-21", "https://www.nasdaq.com/articles/trevena-hits-a-52-week-high-on-positive-phase-ii-data-2015-09-21", "https://www.nasdaq.com/articles/tracon-skyrockets-on-positive-choriocarcinoma-study-data-2015-09-21", "https://www.nasdaq.com/articles/biodelivery-up-opioid-dependence-treatments-in-focus-2015-09-21", "https://www.nasdaq.com/articles/biomarin-dr.-reddys-agree-to-settle-kuvan-patent-litigation-2015-09-21", "https://www.nasdaq.com/articles/gilead-unveils-encouraging-hcv-data-on-sovaldi-velpatasvir-2015-09-22", "https://www.nasdaq.com/articles/yellen-doesnt-raise-rates%3A-4-biotech-stocks-to-buy-2015-09-18", "https://www.nasdaq.com/articles/allergan-gedeons-vraylar-gets-fda-nod-for-mental-disorders-2015-09-18", "https://www.nasdaq.com/articles/inovio-presents-positive-data-on-cervical-neoplasia-drug-2015-09-18", "https://www.nasdaq.com/articles/aerie-reported-positive-phase-iii-data-on-rhopressa-2015-09-17", "https://www.nasdaq.com/articles/novo-nordisks-victoza-fares-better-than-sanofis-lyxumia-2015-09-17", "https://www.nasdaq.com/articles/intra-cellular-up-on-positive-data-from-schizophrenia-study-2015-09-17", "https://www.nasdaq.com/articles/xenoport-hits-52-week-low-on-preliminary-psoriasis-data-2015-09-17", "https://www.nasdaq.com/articles/3-stocks-battling-heart-disease-2-buy-1-sell-2015-09-20", "https://www.nasdaq.com/articles/illumina-in-partnership-with-memorial-sloan-to-develop-ctdna-2015-09-17", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-vivus-regeneron-pharmaceuticals-gilead-sciences", "https://www.nasdaq.com/articles/alnylam-reports-positive-initial-phase-i-data-on-aln-as1-2015-09-16", "https://www.nasdaq.com/articles/insite-vision-terminates-qlt-deal-in-favor-of-sun-pharma-2015-09-16", "https://www.nasdaq.com/articles/gw-pharmaceuticals-up-on-encouraging-schizophrenia-data-2015-09-16", "https://www.nasdaq.com/articles/biotech-poised-rebound-5-growth-picks-2015-09-15", "https://www.nasdaq.com/articles/raptor-crushed-by-liver-disease-data-hits-52-week-low-2015-09-15", "https://www.nasdaq.com/articles/bristol-myers-up-opdivo-gets-breakthrough-therapy-status-2015-09-17", "https://www.nasdaq.com/articles/amgen-seeks-fda-approval-for-repathas-new-dosing-option-2015-09-14", "https://www.nasdaq.com/articles/sanofis-sny-lixilan-positive-in-phase-iii-diabetes-study-2015-09-14", "https://www.nasdaq.com/articles/better-buy-amgen-inc-or-regeneron-pharmaceuticals-inc-2015-09-11", "https://www.nasdaq.com/articles/abbvies-humira-gains-fda-approval-for-label-expansion-2015-09-11", "https://www.nasdaq.com/articles/why-is-gilead-gild-raising-a-whopping-%2410-billion-2015-09-11", "https://www.nasdaq.com/articles/revances-botulinum-toxin-type-a-gel-in-phase-ii-study-2015-09-11", "https://www.nasdaq.com/articles/biogen-biib-autoimmune-disease-deal-worth-544m-2015-09-10", "https://www.nasdaq.com/articles/collegiums-xtampza-supported-for-approval-by-fda-panels-2015-09-14", "https://www.nasdaq.com/articles/marinus-end-of-phase-ii-meeting-positive-for-ganaxolone-2015-09-10", "https://www.nasdaq.com/articles/protalixs-phase-i-ii-fabry-disease-study-interim-data-positive-2015-09-10", "https://www.nasdaq.com/articles/integra-faces-multiple-headwinds-seaspine-spin-off-strong-2015-09-10", "https://www.nasdaq.com/articles/biotech-stock-roundup-biosimilar-competition-amgen-tetraphase-hit-disappointing-data-2015", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-gilead-regeneron-pharmaceuticals-thermo-fisher", "https://www.nasdaq.com/articles/impax-hayward-facility-gets-fda-clearance-shares-rise-2015-09-09", "https://www.nasdaq.com/articles/biodelivery-up-on-striking-deal-with-tenncare-for-bunavail-2015-09-09", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-solaredge-technologies-comfort-systems-usa-universal", "https://www.nasdaq.com/articles/nasdaq-100-movers-gmcr-jd-2015-09-08", "https://www.nasdaq.com/articles/healthcare-boom-a-bubble-4-stocks-to-buy-anyway-2015-09-08", "https://www.nasdaq.com/articles/bristol-myers-opdivo-encourages-in-lung-cancer-study-2015-09-08", "https://www.nasdaq.com/articles/is-another-amendment-of-qlt-insite-vision-deal-coming-up-2015-09-08", "https://www.nasdaq.com/articles/alexions-kanuma-fda-action-date-delayed-by-three-months-2015-09-07", "https://www.nasdaq.com/articles/astrazeneca-starpharma-ink-drug-delivery-technology-deal-2015-09-07", "https://www.nasdaq.com/articles/4-low-volatility-stocks-to-sail-through-market-mayhem-2015-09-04", "https://www.nasdaq.com/articles/5-low-debt-stocks-to-brave-the-impact-of-rate-hike-2015-09-09", "https://www.nasdaq.com/articles/roches-hemophilia-a-drug-gets-breakthrough-status-in-u.s.-2015-09-04", "https://www.nasdaq.com/articles/allergan-agn-to-buy-eye-care-device-company-aquesys-2015-09-04", "https://www.nasdaq.com/articles/astrazenecas-brilinta-gains-fda-nod-for-label-expansion-2015-09-04", "https://www.nasdaq.com/articles/dicerna-files-ind-application-for-primary-hyperoxaluria-drug-2015-09-04", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-google-gilead-sciences-regeneron-pharmaceuticals", "https://www.nasdaq.com/articles/why-regeneron-pharmaceuticals-regn-could-be-a-potential-winner-2015-09-03", "https://www.nasdaq.com/articles/3-stocks-were-watching-third-quarter-2015-09-03", "https://www.nasdaq.com/articles/pcsk9-drugs-are-here-and-way-over-there-2015-09-04", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-amazon.com-skyworks-solutions-regeneron-pharmaceuticals", "https://www.nasdaq.com/articles/amgens-next-generation-cholesterol-drug-approved-pricing-huge-concern-2015-09-02", "https://www.nasdaq.com/articles/regeneron-and-sanofi-present-encouraging-praluent-data-2015-09-02", "https://www.nasdaq.com/articles/illumina-acquires-genologics-boosts-genomic-sequencing-2015-09-02", "https://www.nasdaq.com/articles/4-winning-stocks-with-the-potential-to-beat-the-market-2015-09-01", "https://www.nasdaq.com/articles/intercepts-icpt-oca-under-priority-review-in-the-u.s.-2015-09-01", "https://www.nasdaq.com/articles/amicus-fold-signs-agreement-to-acquire-scioderm-2015-09-01", "https://www.nasdaq.com/articles/4-google-beating-stocks-that-still-hold-promise-2015-09-02", "https://www.nasdaq.com/articles/applied-genetic-meets-enrolment-milestone-in-xlrs-study-2015-08-31", "https://www.nasdaq.com/articles/noteworthy-etf-inflows-ixj-mck-regn-antm-2015-08-28", "https://www.nasdaq.com/articles/amgens-pcsk9-inhibitor-repatha-approved-us-2015-08-28", "https://www.nasdaq.com/articles/pfizer-pfe-gains-on-label-expansion-efforts-for-ibrance-2015-08-28", "https://www.nasdaq.com/articles/exelixis-up-on-swiss-approval-of-advanced-melanoma-drug-2015-08-28", "https://www.nasdaq.com/articles/oncolytics-reolysin-phase-ii-lung-cancer-study-enrolled-2015-08-27", "https://www.nasdaq.com/articles/jj-to-sell-sugar-substitute-splenda-to-heartland-food-2015-08-26", "https://www.nasdaq.com/articles/trevenas-postoperative-pain-drug-positive-in-phase-iib-study-2015-09-01", "https://www.nasdaq.com/articles/bouncing-biotech-3-stocks-buy-2015-08-25", "https://www.nasdaq.com/articles/seres-mcrb-up-on-orphan-drug-status-for-lead-candidate-2015-08-24", "https://www.nasdaq.com/articles/alkermes-alks-aristada-review-date-postponed-by-fda-2015-08-24", "https://www.nasdaq.com/articles/bull-or-bear-biotechs-post-earnings-buys-and-sells-2015-08-23", "https://www.nasdaq.com/articles/vascular-vblt-starts-patient-dosing-in-glioblastoma-study-2015-08-21", "https://www.nasdaq.com/articles/pfizers-pfe-breast-cancer-drug-ibrance-under-eu-review-2015-08-21", "https://www.nasdaq.com/articles/raptor-rptp-to-buy-quinsair-boost-rare-disease-portfolio-2015-08-21", "https://www.nasdaq.com/articles/sareptas-dmd-drug-eteplirsen-gains-fda-priority-review-2015-08-26", "https://www.nasdaq.com/articles/concern-amgen-investors-shouldnt-take-lightly-2015-08-20", "https://www.nasdaq.com/articles/googles-11-year-dream-run%3A-from-ipo-to-alphabet-2015-08-20", "https://www.nasdaq.com/articles/esperion-updates-on-its-cholesterol-management-candidate-2015-08-19", "https://www.nasdaq.com/articles/walgreens-boots-plans-to-eliminate-370-employees-to-cut-cost-2015-08-19", "https://www.nasdaq.com/articles/esperions-good-news-actually-bad-2015-08-19", "https://www.nasdaq.com/articles/kite-pharma-provides-update-death-not-related-kte-c19-2015-08-18", "https://www.nasdaq.com/articles/biolinerx-up-on-phase-iib-study-initiation-on-leukemia-drug-2015-08-18", "https://www.nasdaq.com/articles/why-eli-lilly-lly-was-bright-spot-market-thursday-2015-08-21", "https://www.nasdaq.com/articles/cvs-health-draws-line-sand-2015-08-15", "https://www.nasdaq.com/articles/avalanche-biotechnologies-aavl-q2-loss-narrows-y-y-2015-08-14", "https://www.nasdaq.com/articles/closing-update-afternoon-recovery-erases-early-decline-following-above-consensus-rise", "https://www.nasdaq.com/articles/health-care-sector-update-08142015-ontx-pbmd-ebio-nvs-regn-2015-08-14", "https://www.nasdaq.com/articles/emergent-biosolutions-gets-%2444m-cdc-contract-for-vigiv-2015-08-14", "https://www.nasdaq.com/articles/juno-therapeutics-posts-line-2q-loss-pipeline-focus-2015-08-13", "https://www.nasdaq.com/articles/looking-for-a-top-growth-stock-3-reasons-why-regeneron-pharmaceuticals-regn-is-an", "https://www.nasdaq.com/articles/are-3-best-performing-big-cap-biotech-stocks-2015-still-worth-buying-2015-08-17", "https://www.nasdaq.com/articles/cvs-health-draws-line-sand-2015-08-15", "https://www.nasdaq.com/articles/regeneron-pharmaceuticals-oshkosh-amgen-and-caterpillar-highlighted-as-zacks-bull-and-bear", "https://www.nasdaq.com/articles/bull-day-regeneron-pharma-regn-2015-08-12", "https://www.nasdaq.com/articles/pluristem-psti-provides-update-on-plx-pad-cells-in-japan-2015-08-12", "https://www.nasdaq.com/articles/repros-incurs-narrower-y-y-loss-in-q2-pipeline-in-focus-analyst-blog-2015-08-11", "https://www.nasdaq.com/articles/trovagene-q2-loss-widens-on-higher-expenses-shares-fall-analyst-blog-2015-08-11", "https://www.nasdaq.com/articles/sanofi-inks-deals-diabetes-and-immuno-oncology-in-focus-analyst-blog-2015-08-10", "https://www.nasdaq.com/articles/tevas-chorea-in-huntington-disease-treatment-under-review-2015-08-13", "https://www.nasdaq.com/articles/cvs-healths-anti-tobacco-strategy-paying-2015-08-08", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-amgen-vertex-regeneron-baxalta-and-vivus-press-releases", "https://www.nasdaq.com/articles/aegerions-loss-narrower-than-expected-view-maintained-analyst-blog-2015-08-06", "https://www.nasdaq.com/articles/biotech-stock-roundup-baxalta-rejects-shire-bid-amgens-beat-raise-quarter-analyst-blog", "https://www.nasdaq.com/articles/will-regenerons-new-drug-break-bank-2015-08-05", "https://www.nasdaq.com/articles/top-rated-stock-picks-and-most-read-stories-nasdaqcom-july-26-august-1-2015-08-04", "https://www.nasdaq.com/articles/nasdaq-100-movers-avgo-regn-2015-08-04", "https://www.nasdaq.com/articles/3-top-biotech-stocks-high-risk-investors-2015-08-08", "https://www.nasdaq.com/articles/health-care-sector-update-08042015-elgx-cphr-regn-2015-08-04", "https://www.nasdaq.com/articles/regeneron-regn-beats-on-q2-earnings-updates-2015-view-tale-of-the-tape-2015-08-04", "https://www.nasdaq.com/articles/top-mutual-funds-pile-celgene-other-leading-stocks-2015-08-04", "https://www.nasdaq.com/articles/regenerons-knock-out-quarter-could-be-just-beginning-2015-08-04", "https://www.nasdaq.com/articles/pre-market-earnings-report-august-4-2015-cvs-regn-aet-emr-adm-sre-zts-hcn-k-chtr-incy-hcp", "https://www.nasdaq.com/articles/sanofi-tops-q2-earnings-revenues-grow-y-y-maintains-view-analyst-blog-2015-07-31", "https://www.nasdaq.com/articles/sp-500-movers-all-bxlt-2015-08-04", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-biogen-abbvie-regeneron-amgen-and-xoma-press-releases", "https://www.nasdaq.com/articles/biotech-stock-roundup-biogen-down-tecfidera-issues-regenerons-praluent-gets-fda-nod", "https://www.nasdaq.com/articles/sanofi-regeneron-enter-immuno-oncology-collaboration-analyst-blog-2015-07-29", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-biogen-ligand-pharmaceuticals-bluebird-bio-regeneron", "https://www.nasdaq.com/articles/forget-biogen-buy-these-promising-biotech-stocks-instead-analyst-blog-2015-07-27", "https://www.nasdaq.com/articles/stock-market-news-for-july-27-2015-market-news-2015-07-27", "https://www.nasdaq.com/articles/regeneron-pharmaceuticals-and-sanofi-grab-blockbuster-fda-approval-2015-07-27", "https://www.nasdaq.com/articles/will-regeneron-regn-earnings-surprise-on-eylea-sales-analyst-blog-2015-07-31", "https://www.nasdaq.com/articles/biotech-stock-roundup-amgen-pcsk9-inhibitor-first-gain-approval-exelixis-positive-data", "https://www.nasdaq.com/articles/amgens-repatha-gains-eu-nod-first-pcsk9-drug-approved-analyst-blog-2015-07-22", "https://www.nasdaq.com/articles/mondays-etf-movers-pdp-gdx-2015-07-20", "https://www.nasdaq.com/articles/notable-monday-option-activity-esrx-whr-regn-2015-07-20", "https://www.nasdaq.com/articles/8-biotech-stocks-buy-2015-07-16", "https://www.nasdaq.com/articles/ohr-pharmaceutical-jumps-on-positive-eye-drug-study-data-analyst-blog-2015-07-16", "https://www.nasdaq.com/articles/sanofi-unveils-restructuring-plans-prunes-business-units-analyst-blog-2015-07-16", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-amgen-exelixis-regeneron-five-prime-therapeutics-and", "https://www.nasdaq.com/articles/notable-monday-option-activity-vlo-cbs-regn-2015-07-13", "https://www.nasdaq.com/articles/why-july-will-be-exciting-month-regeneron-pharmaceuticals-2015-07-11", "https://www.nasdaq.com/articles/regeneron-and-sanofi-report-positive-data-on-praluent-analyst-blog-2015-07-09", "https://www.nasdaq.com/articles/health-care-sector-update-07092015-myl-regn-azn-2015-07-09", "https://www.nasdaq.com/articles/commit-buy-regeneron-pharmaceuticals-370-earn-62-using-options-2015-07-08", "https://www.nasdaq.com/articles/ibb-celg-amgn-regn-large-inflows-detected-etf-2015-07-02", "https://www.nasdaq.com/articles/what-beyond-vision-loss-blockbuster-regeneron-2015-07-01", "https://www.nasdaq.com/articles/anacor-hits-52-week-high-on-positive-atopic-dermatitis-data-analyst-blog-2015-07-14", "https://www.nasdaq.com/articles/stock-market-news-for-june-19-2015-market-news-2015-06-19", "https://www.nasdaq.com/articles/why-avalanche-biotechnologies-inc-stock-collapsed-today-2015-06-16", "https://www.nasdaq.com/articles/health-care-sector-update-06152015-regn-innl-orpn-2015-06-15", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-regeneron-vertex-celgene-seattle-genetics-and-sage", "https://www.nasdaq.com/articles/how-big-impact-could-praluent-have-regeneron-pharmaceuticals-inc-2015-06-10", "https://www.nasdaq.com/articles/cholesterol-drug-blues-why-esperion-therapeutics-stock-getting-crushed-today-2015-06-10", "https://www.nasdaq.com/articles/biotech-stock-roundup-fda-panel-recommends-regenerons-praluent-sage-gains-data-analyst", "https://www.nasdaq.com/articles/regeneron-bayers-eylea-gets-label-expansion-in-japan-analyst-blog-2015-06-29", "https://www.nasdaq.com/articles/sp-500-movers-regn-tln-2015-06-10", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-open-higher-oxford-industries-beats-q1-expectations-2015", "https://www.nasdaq.com/articles/regeneron-sanofis-praluent-gets-positive-fda-panel-vote-analyst-blog-2015-06-10", "https://www.nasdaq.com/articles/mid-day-market-update-sigma-designs-surges-upbeat-results-boulder-brands-shares-drop-2015", "https://www.nasdaq.com/articles/amgens-repatha-briefing-document-gives-mixed-review-analyst-blog-2015-06-09", "https://www.nasdaq.com/articles/regeneron-sanofis-pcsk9-drug-praluent-set-for-fda-panel-analyst-blog-2015-06-08", "https://www.nasdaq.com/articles/stock-market-news-for-june-08-2015-market-news-2015-06-08", "https://www.nasdaq.com/articles/nasdaq-100-movers-regn-nflx-2015-06-10", "https://www.nasdaq.com/articles/biotech-stock-roundup-immunogen-soars-asco-data-amgen-collaborates-roche-analyst-blog-2015", "https://www.nasdaq.com/articles/top-mutual-funds-add-medical-holdings-2015-06-02", "https://www.nasdaq.com/articles/highest-paid-ceos-biotech-2015-05-30", "https://www.nasdaq.com/articles/amgens-pcsk9-inhibitor-step-closer-eu-approval-analyst-blog-2015-05-25", "https://www.nasdaq.com/articles/ampio-pharmaceuticals-shoots-up-on-positive-optina-data-analyst-blog-2015-05-22", "https://www.nasdaq.com/articles/regeneron-sanofis-sarilumab-meets-endpoints-in-phase-iii-analyst-blog-2015-05-21", "https://www.nasdaq.com/articles/stock-market-news-for-may-21-2015-market-news-2015-05-21", "https://www.nasdaq.com/articles/cholesterol-drugs-3-stocks-watch-week-2015-06-08", "https://www.nasdaq.com/articles/biotech-stock-roundup-eleven-bio-slumps-eye-drug-data-achillion-signs-deal-jj-analyst-blog", "https://www.nasdaq.com/articles/stock-market-news-for-may-19-2015-market-news-2015-05-19", "https://www.nasdaq.com/articles/regeneron-sanofi-announce-positive-data-on-dupilumab-analyst-blog-2015-05-19", "https://www.nasdaq.com/articles/regeneron-earnings-shine-all-eyes-are-pipeline-2015-05-08", "https://www.nasdaq.com/articles/regeneron-regn-beats-on-q1-earnings-updates-2015-view-tale-of-the-tape-2015-05-07", "https://www.nasdaq.com/articles/regeneron-beats-on-q1-earnings-eylea-2015-view-upped-analyst-blog-2015-05-07", "https://www.nasdaq.com/articles/pre-market-earnings-report-may-7-2015-pcln-regn-cnq-mfc-bdx-apa-mga-ppl-tu-sial-tap-cpg", "https://www.nasdaq.com/articles/health-care-sector-update-05212015-cala-drna-regn-2015-05-21", "https://www.nasdaq.com/articles/beyond-pharma-3-healthcare-choices-analyst-blog-2015-05-05", "https://www.nasdaq.com/articles/will-eylea-sales-drive-regeneron-regn-q1-earnings-analyst-blog-2015-05-05", "https://www.nasdaq.com/articles/3-best-stocks-investing-cholesterol-drugs-2015-04-18", "https://www.nasdaq.com/articles/3-potential-blockbuster-drugs-could-be-approved-years-end-2015-04-16", "https://www.nasdaq.com/articles/nasdaq-100-movers-viab-regn-2015-04-07", "https://www.nasdaq.com/articles/following-gilead-sciences-inc-which-biotech-will-pay-dividend-next-2015-04-04", "https://www.nasdaq.com/articles/stock-market-news-for-april-01-2015-market-news-2015-04-01", "https://www.nasdaq.com/articles/nasdaq-100-movers-vrtx-nflx-2015-05-05", "https://www.nasdaq.com/articles/ohr-pharmaceutical-crashes-on-disappointing-eye-drug-data-analyst-blog-2015-03-30", "https://www.nasdaq.com/articles/regenerons-eylea-gets-fda-approval-for-label-expansion-analyst-blog-2015-03-26", "https://www.nasdaq.com/articles/biotech-stock-roundup-biogen-soars-alzheimers-data-gilead-hcv-drugs-label-update-analyst", "https://www.nasdaq.com/articles/biotech-etf-performance-shows-rally-not-fluke-2015-03-20", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-amgen-regeneron-nektar-acadia-and-pharmacyclics-press", "https://www.nasdaq.com/articles/regeneron-hits-a-52-week-high-on-positive-praluent-data-analyst-blog-2015-03-18", "https://www.nasdaq.com/articles/biotech-stock-roundup-amgen-regeneron-shine-acc-nektar-drug-disappoints-analyst-blog-2015", "https://www.nasdaq.com/articles/biotech-stock-roundup-horizon-buy-hyperion-conatus-liver-disease-data-analyst-blog-2015-04", "https://www.nasdaq.com/articles/regeneron-sanofis-pcsk9-drug-praluent-data-published-analyst-blog-2015-03-16", "https://www.nasdaq.com/articles/amgen-presents-encouraging-pcsk9-inhibitor-repatha-data-analyst-blog-2015-03-16", "https://www.nasdaq.com/articles/bayer-seeks-eylea-label-expansion-in-the-eu-provides-view-analyst-blog-2015-03-12", "https://www.nasdaq.com/articles/biotech-stock-roundup-abbvie-buy-pharmacyclics-fda-approves-first-biosimilar-analyst-blog", "https://www.nasdaq.com/articles/nasdaq-100-movers-wynn-mnst-2015-03-09", "https://www.nasdaq.com/articles/biotech-stock-roundup-pharmacyclics-buyout-rumors-celgene-drug-label-expanded-analyst-blog", "https://www.nasdaq.com/articles/billions-line-next-drug-pricing-war-2015-02-24", "https://www.nasdaq.com/articles/esperion-soars-on-positive-phase-iib-data-on-etc-1002-analyst-blog-2015-03-18", "https://www.nasdaq.com/articles/thursdays-etf-movers-pbe-icf-2015-02-19", "https://www.nasdaq.com/articles/nasdaq-100-movers-vip-pcln-2015-02-19", "https://www.nasdaq.com/articles/3-upcoming-fda-decisions-were-most-excited-about-2015-02-16", "https://www.nasdaq.com/articles/forget-gilead-sciences-here-are-3-better-biotech-stocks-2015-02-12", "https://www.nasdaq.com/articles/biotech-stock-roundup-achillion-impresses-hcv-data-regeneron-4q-results-top-estimates", "https://www.nasdaq.com/articles/health-care-sector-update-02112015-cvs-casm-regn-2015-02-11", "https://www.nasdaq.com/articles/regeneron-pharmaceuticals-inc-earnings-all-eyes-eylea-2015-02-10", "https://www.nasdaq.com/articles/regenerons-eylea-tops-diabetic-macular-edema-study-analyst-blog-2015-02-19", "https://www.nasdaq.com/articles/regeneron-beats-on-q4-earnings-driven-by-eylea-sales-analyst-blog-2015-02-10", "https://www.nasdaq.com/articles/health-care-sector-update-02102015-mrge-isis-regn-2015-02-10", "https://www.nasdaq.com/articles/regeneron-regn-beats-on-q4-earnings-provides-2015-view-tale-of-the-tape-2015-02-10", "https://www.nasdaq.com/articles/roches-lucentis-gets-fda-nod-for-diabetic-retinopathy-analyst-blog-2015-02-09", "https://www.nasdaq.com/articles/pre-market-earnings-report-february-10-2015-ko-cvs-regn-rai-pcg-hcp-omc-hot-tap-kkr-wyn", "https://www.nasdaq.com/articles/will-regeneron-regn-beat-q4-earnings-on-eylea-sales-analyst-blog-2015-02-09", "https://www.nasdaq.com/articles/will-avalanche-aavl-miss-this-earnings-on-higher-costs-analyst-blog-2015-02-09", "https://www.nasdaq.com/articles/stock-market-news-for-february-10-2015-market-news-2015-02-10", "https://www.nasdaq.com/articles/biotech-stock-roundup-biogen-impresses-4q-results-gilead-abbvie-hcv-drugs-focus-analyst", "https://www.nasdaq.com/articles/nasdaq-100-movers-aal-spls-2015-02-03", "https://www.nasdaq.com/articles/energy-stocks-lead-mutual-funds-dive-red-jan-2015-02-03", "https://www.nasdaq.com/articles/will-perrigo-prgo-disappoint-this-earnings-season-analyst-blog-2015-02-03", "https://www.nasdaq.com/articles/will-teva-teva-earnings-surprise-on-higher-sales-analyst-blog-2015-02-03", "https://www.nasdaq.com/articles/tiny-biotech-hopes-capture-share-6-billion-market-2015-02-02", "https://www.nasdaq.com/articles/will-pacific-biosciences-pacb-surprise-on-earnings-in-q4-analyst-blog-2015-02-02", "https://www.nasdaq.com/articles/sanofi-misses-on-q4-earnings-maintains-diabetes-guidance-analyst-blog-2015-02-06", "https://www.nasdaq.com/articles/regeneron-sanofis-pcsk9-drug-gets-fda-priority-review-analyst-blog-2015-01-27", "https://www.nasdaq.com/articles/can-celgene-celg-beat-earnings-on-strong-product-sales-analyst-blog-2015-01-27", "https://www.nasdaq.com/articles/will-alexions-alxn-soliris-drive-q4-earnings-beat-analyst-blog-2015-01-27", "https://www.nasdaq.com/articles/health-care-sector-update-01232015-regn-aspx-celg-2015-01-23", "https://www.nasdaq.com/articles/biotech-stock-roundup-shire-acquire-npsp-celgene-pharmacyclics-give-strong-outlook-analyst", "https://www.nasdaq.com/articles/aegerion-reveals-preliminary-2014-results-and-2015-outlook-analyst-blog-2015-01-13", "https://www.nasdaq.com/articles/nasdaq-100-movers-sndk-celg-2015-01-12", "https://www.nasdaq.com/articles/will-gw-pharmaceuticals-gwph-miss-this-earnings-season-analyst-blog-2015-02-02", "https://www.nasdaq.com/articles/agree-purchase-regeneron-pharmaceuticals-240-earn-63-using-options-2015-01-09", "https://www.nasdaq.com/articles/sp-500-movers-dnr-luv-2014-12-31", "https://www.nasdaq.com/articles/nasdaq-100-movers-vip-regn-2014-12-31", "https://www.nasdaq.com/articles/doctorx-positions-2015-i-have-cut-back-my-exposure-all-biotech-substantially-2014-12-30", "https://www.nasdaq.com/articles/nasdaq-100-movers-regn-gild-2014-12-29", "https://www.nasdaq.com/articles/ibb-gild-regn-bmrn-large-inflows-detected-etf-2014-12-29", "https://www.nasdaq.com/articles/nasdaq-100-movers-celg-wynn-2014-12-23", "https://www.nasdaq.com/articles/regeneron-sanofi-seek-pcsk9-drug-praluent-approval-in-eu-analyst-blog-2015-01-12", "https://www.nasdaq.com/articles/best-healthcare-stocks-2014-which-our-favorite-2015-2014-12-19", "https://www.nasdaq.com/articles/top-healthcare-stocks-2014-2014-12-14", "https://www.nasdaq.com/articles/billionaires-are-dumping-these-3-stocks-2014-12-13", "https://www.nasdaq.com/articles/can-pfizers-cholesterol-drug-catch-competition-2014-12-11", "https://www.nasdaq.com/articles/3-biotech-stocks-buy-december-2014-12-10", "https://www.nasdaq.com/articles/5-biotech-stocks-buy-2015-2014-12-09", "https://www.nasdaq.com/articles/regeneron-at-52-week-high-on-eylea-priority-review-status-analyst-blog-2014-12-04", "https://www.nasdaq.com/articles/nasdaq-100-movers-gild-vip-2014-12-22", "https://www.nasdaq.com/articles/stock-market-news-for-december-03-2014-market-news-2014-12-03", "https://www.nasdaq.com/articles/regeneron-bayers-eylea-to-be-reviewed-on-a-priority-basis-analyst-blog-2014-12-02", "https://www.nasdaq.com/articles/gilead-sciences-inc-just-paid-125-million-something-it-cant-use-year-2014-11-24", "https://www.nasdaq.com/articles/can-new-launches-offset-sanofis-soft-diabetes-business-analyst-blog-2014-11-21", "https://www.nasdaq.com/articles/regeneron-sanofi-present-positive-data-on-pcsk9-drug-analyst-blog-2014-11-20", "https://www.nasdaq.com/articles/gilead-to-buy-knight-therapeutics-priority-review-voucher-analyst-blog-2014-11-20", "https://www.nasdaq.com/articles/biotech-stock-roundup-geron-soars-935m-jj-deal-gileads-harvoni-approved-eu-analyst-blog", "https://www.nasdaq.com/articles/biotech-stock-roundup-avanir-be-acquired-japanese-firm-biogen-scores-alzheimers-study", "https://www.nasdaq.com/articles/nasdaq-100-movers-vip-myl-2014-11-17", "https://www.nasdaq.com/articles/biotech-and-yet-weve-just-begun-2014-11-14", "https://www.nasdaq.com/articles/why-novartis-and-regeneron-care-about-tiny-biotech-stock-2014-11-14", "https://www.nasdaq.com/articles/regeneron-sanofi-announce-positive-dupilumab-study-data-analyst-blog-2014-11-12", "https://www.nasdaq.com/articles/biotech-stock-roundup-gilead-abbvie-score-liver-meeting-dendreon-files-bankruptcy-analyst", "https://www.nasdaq.com/articles/3-crashing-stocks-1-buy-2014-11-09", "https://www.nasdaq.com/articles/biotech-stock-roundup-regenerons-eylea-stumbles-geron-lifting-clinical-hold-analyst-blog", "https://www.nasdaq.com/articles/merck-improves-it-causing-these-biotechs-stock-prices-improve-too-2014-11-18", "https://www.nasdaq.com/articles/sector-update-health-care-2014-11-04-0", "https://www.nasdaq.com/articles/regeneron-pharmaceuticals-inc-earnings-eyleas-roller-coaster-ride-2014-11-04", "https://www.nasdaq.com/articles/regeneron-q3-earnings-up-y-y-narrows-eylea-guidance-analyst-blog-2014-11-04", "https://www.nasdaq.com/articles/pre-market-earnings-report-november-4-2014-cvs-pcln-eog-emr-regn-trp-adm-sre-vlo-bdx-ice", "https://www.nasdaq.com/articles/aegerion-q3-loss-wider-than-expected-2014-view-lowered-analyst-blog-2014-10-31", "https://www.nasdaq.com/articles/will-regeneron-regn-q3-earnings-be-hit-by-higher-costs-analyst-blog-2014-10-30", "https://www.nasdaq.com/articles/alnylam-pharmaceuticals-inc-has-ratio-right-2014-11-05", "https://www.nasdaq.com/articles/astrazenecas-lynparza-a-step-closer-to-european-approval-analyst-blog-2014-10-27", "https://www.nasdaq.com/articles/biotech-stock-roundup-abbvie-calls-shire-acquisition-will-amgen-consider-breakup-analyst", "https://www.nasdaq.com/articles/regeneron-pharmaceuticals-regn-jumps%3A-stock-up-8.5-tale-of-the-tape-2014-10-20", "https://www.nasdaq.com/articles/sanofi-and-regeneron-dose-patients-in-dupilumab-study-analyst-blog-2014-10-20", "https://www.nasdaq.com/articles/amgen-sues-sanofi-and-regeneron-over-pcsk9-candidate-analyst-blog-2014-10-20", "https://www.nasdaq.com/articles/nasdaq-100-movers-nflx-xlnx-2014-10-17", "https://www.nasdaq.com/articles/sanofi-beats-on-q3-earnings-but-lantus-outlook-disappoints-analyst-blog-2014-10-30", "https://www.nasdaq.com/articles/fridays-etf-movers-bbh-gdx-2014-10-17", "https://www.nasdaq.com/articles/sp-500-analyst-moves-regn-2014-10-17", "https://www.nasdaq.com/articles/ohr-pharmaceuticals-ohr-102-to-enter-phase-iii-in-1h15-analyst-blog-2014-10-16", "https://www.nasdaq.com/articles/bristol-myers-collaborates-for-opdivo-imbruvica-combo-analyst-blog-2014-10-14", "https://www.nasdaq.com/articles/celgenes-otezla-encourages-in-plaque-psoriasis-at-eadv-analyst-blog-2014-10-13", "https://www.nasdaq.com/articles/amgens-data-on-evolocumab-published-in-the-lancet-analyst-blog-2014-10-08", "https://www.nasdaq.com/articles/biotech-stock-roundup-sunesis-tanks-study-results-chimerix-ebola-update-analyst-blog-2014", "https://www.nasdaq.com/articles/pharmacyclics-roche-ink-deal-for-cancer-combo-therapy-analyst-blog-2014-10-17", "https://www.nasdaq.com/articles/should-pfizer-inc-buy-surprisingly-competitive-biotech-stock-2014-10-07", "https://www.nasdaq.com/articles/regenerons-eye-drug-eylea-wins-another-fda-approval-analyst-blog-2014-10-07", "https://www.nasdaq.com/articles/regeneron-sanofis-dupilumab-meets-all-endpoints-analyst-blog-2014-10-03", "https://www.nasdaq.com/articles/sector-update-health-care-shares-mixed-pre-market-2014-10-01", "https://www.nasdaq.com/articles/sector-update-health-care-2014-10-01", "https://www.nasdaq.com/articles/sector-update-health-care-shares-flat-pre-market-trade-2014-09-30", "https://www.nasdaq.com/articles/sector-update-health-care-2014-09-30-1", "https://www.nasdaq.com/articles/bristol-myers-gives-up-on-us-approval-of-2-drug-hcv-combo-analyst-blog-2014-10-08", "https://www.nasdaq.com/articles/regeneron-pharmaceuticals-inc-stock-racks-another-win-2014-09-23", "https://www.nasdaq.com/articles/anacors-kerydin-launched-in-the-us-for-onychomycosis-analyst-blog-2014-09-23", "https://www.nasdaq.com/articles/bayer-regeneron-successfully-expand-eylea-label-in-japan-analyst-blog-2014-09-23", "https://www.nasdaq.com/articles/sector-update-health-care-shares-mixed-pre-market-2014-09-22", "https://www.nasdaq.com/articles/sector-update-health-care-2014-09-22", "https://www.nasdaq.com/articles/regeneron-gets-breakthrough-therapy-status-for-eylea-analyst-blog-2014-09-17", "https://www.nasdaq.com/articles/why-id-avoid-pfizer-inc-stock-despite-dividend-2014-09-11", "https://www.nasdaq.com/articles/biotech-stock-roundup-auxilium-acquisition-target-amgen-submits-another-bla-analyst-blog", "https://www.nasdaq.com/articles/3-reasons-sanofis-stock-could-fall-2014-09-08", "https://www.nasdaq.com/articles/bayer-regeneron-looking-for-eylea-label-expansion-in-japan-analyst-blog-2014-09-08", "https://www.nasdaq.com/articles/nasdaq-100-movers-spls-fast-2014-09-04", "https://www.nasdaq.com/articles/5-stocks-buy-september-2014-09-04", "https://www.nasdaq.com/articles/amgen-seeks-eu-approval-for-pcsk9-inhibitor-evolocumab-analyst-blog-2014-09-04", "https://www.nasdaq.com/articles/biotech-stock-roundup-united-therapeutics-court-ruling-amgen-files-pcsk9-inhibitor-analyst", "https://www.nasdaq.com/articles/sp-500-movers-wynn-spls-2014-09-02", "https://www.nasdaq.com/articles/nasdaq-100-movers-regn-yhoo-2014-09-08", "https://www.nasdaq.com/articles/great-cholesterol-drug-data-regeneron-pharmaceuticals-inc-and-sanofi-sa-read-fine-pri-2014", "https://www.nasdaq.com/articles/regeneron-sanofi-presents-encouraging-alirocumab-data-analyst-blog-2014-09-02", "https://www.nasdaq.com/articles/regeneron-pharmaceuticals-pipeline-progress-raises-costs-analyst-blog-2014-08-29", "https://www.nasdaq.com/articles/amgen-submits-regulatory-application-for-pcsk9-inhibitor-analyst-blog-2014-08-29", "https://www.nasdaq.com/articles/regeneron-regn-is-in-overbought-territory%3A-whats-next-tale-of-the-tape-2014-08-27", "https://www.nasdaq.com/articles/7-things-regeneron-pharmaceuticals-incs-management-wants-you-know-2014-08-26", "https://www.nasdaq.com/articles/nasdaq-100-movers-intu-gild-2014-08-25", "https://www.nasdaq.com/articles/nasdaq-100-movers-wynn-spls-2014-09-02", "https://www.nasdaq.com/articles/biotech-stock-roundup-amgen-plans-job-cuts-regenerons-eylea-continues-impress-analyst-blog", "https://www.nasdaq.com/articles/nasdaq-100-movers-expd-wfm-2014-08-05", "https://www.nasdaq.com/articles/sector-update-health-care-stocks-weighed-pre-market-trade-2014-08-05", "https://www.nasdaq.com/articles/sector-update-health-care-2014-08-05-1", "https://www.nasdaq.com/articles/regeneron-misses-on-earnings-in-q2-eylea-drives-sales-beat-analyst-blog-2014-08-05", "https://www.nasdaq.com/articles/pre-market-earnings-report-august-5-2014-cvs-emr-act-regn-adm-hcp-mmp-zts-msi-fe-mgm-iep", "https://www.nasdaq.com/articles/biomarin-q2-loss-narrower-than-expected-revenue-guidance-up-analyst-blog-2014-07-31", "https://www.nasdaq.com/articles/regenerons-eye-drug-eylea-cleared-in-the-eu-for-dme-analyst-blog-2014-08-12", "https://www.nasdaq.com/articles/nasdaq-100-movers-grmn-regn-2014-07-30", "https://www.nasdaq.com/articles/regenerons-eylea-gets-fda-nod-for-diabetic-macular-edema-analyst-blog-2014-07-30", "https://www.nasdaq.com/articles/bayer-regeneron-continue-to-progress-with-eylea-analyst-blog-2014-07-22", "https://www.nasdaq.com/articles/sector-update-health-care-shares-mixed-pre-market-2014-07-18", "https://www.nasdaq.com/articles/sector-update-health-care-2014-07-18-1", "https://www.nasdaq.com/articles/notable-two-hundred-day-moving-average-cross-regn-2014-07-17", "https://www.nasdaq.com/articles/biotech-stock-roundup-abbvie-woos-shire-revised-offer-sarepta-slips-eteplirsen-data", "https://www.nasdaq.com/articles/sp-500-movers-gnw-ew-2014-07-30", "https://www.nasdaq.com/articles/anacors-kerydin-gets-fda-nod-for-onychomycosis-analyst-blog-2014-07-09", "https://www.nasdaq.com/articles/nasdaq-100-movers-grmn-orly-2014-07-09", "https://www.nasdaq.com/articles/biotech-stock-roundup-regado-plunges-study-update-jazz-gains-product-acquisition-deal", "https://www.nasdaq.com/articles/sanofi-buys-big-chunk-regeneron-shares-2014-07-09", "https://www.nasdaq.com/articles/nasdaq-100-movers-bidu-stx-2014-07-08", "https://www.nasdaq.com/articles/glaxo-theravance-drug-gets-japanese-approval-analyst-blog-2014-07-07", "https://www.nasdaq.com/articles/nasdaq-100-movers-wynn-regn-2014-07-07", "https://www.nasdaq.com/articles/sanofi-regeneron-announce-encouraging-dupilumab-data-analyst-blog-2014-07-10", "https://www.nasdaq.com/articles/regado-slumps-on-revolixys-study-halt-analyst-blog-2014-07-07", "https://www.nasdaq.com/articles/spectrum-pharmaceuticals-gains-u.s.-approval-of-beleodaq-analyst-blog-2014-07-07", "https://www.nasdaq.com/articles/insys-therapeutics-epilepsy-therapy-gains-fda-orphan-drug-status-analyst-blog-2014-07-03", "https://www.nasdaq.com/articles/redhill-acquires-mesupron-from-wilex-analyst-blog-2014-07-03", "https://www.nasdaq.com/articles/nasdaq-100-movers-payx-lmca-2014-07-02", "https://www.nasdaq.com/articles/roche-acquires-seragon-pharma-analyst-blog-2014-07-02", "https://www.nasdaq.com/articles/regeneron-shares-jump-as-sanofi-increases-stake-analyst-blog-2014-07-02", "https://www.nasdaq.com/articles/hospira-completes-orchid-facility-buy-analyst-blog-2014-07-07", "https://www.nasdaq.com/articles/glycomimetics-up-on-fda-agreement-on-rivipansel-study-analyst-blog-2014-07-02", "https://www.nasdaq.com/articles/roche-launches-cobas-6500-testing-system-analyst-blog-2014-07-01", "https://www.nasdaq.com/articles/sp-500-movers-urbn-nflx-2014-07-01", "https://www.nasdaq.com/articles/glaxo-theravance-seek-to-expand-breo-elliptas-label-analyst-blog-2014-07-01", "https://www.nasdaq.com/articles/nps-pharmaceuticals-gattex-gets-updated-label-analyst-blog-2014-07-01", "https://www.nasdaq.com/articles/amicus-up-on-migalastat-study-update-analyst-blog-2014-07-01", "https://www.nasdaq.com/articles/allergan-slides-as-migraine-drug-fails-to-win-approval-analyst-blog-2014-07-01", "https://www.nasdaq.com/articles/biotech-stock-roundup-vertex-jumps-phase-iii-data-mannkind-scores-fda-approval-analyst", "https://www.nasdaq.com/articles/nasdaq-100-movers-sbac-nflx-2014-07-01", "https://www.nasdaq.com/articles/chmp-positive-on-bristol-myers-pfizers-eliquis-for-new-indication-analyst-blog-2014-06-30", "https://www.nasdaq.com/articles/amerisourcebergen-acquires-minority-stake-in-profarma-analyst-blog-2014-06-30", "https://www.nasdaq.com/articles/glaxos-label-expansion-plans-marred-as-arzerra-disappoints-analyst-blog-2014-06-30", "https://www.nasdaq.com/articles/gilead-seeks-japanese-approval-for-sovaldi-analyst-blog-2014-06-30", "https://www.nasdaq.com/articles/roches-avastin-receives-positive-opinion-from-chmp-analyst-blog-2014-06-30", "https://www.nasdaq.com/articles/abbvies-oncology-candidate-progresses-analyst-blog-2014-06-30", "https://www.nasdaq.com/articles/synagevas-sebelipase-alfa-meets-primary-endpoint-in-arise-analyst-blog-2014-07-01", "https://www.nasdaq.com/articles/mannkinds-afrezza-approval-a-key-milestone-analyst-blog-2014-06-30", "https://www.nasdaq.com/articles/eli-lilly-boehringers-insulin-copy-gets-positive-eu-opinion-analyst-blog-2014-06-30", "https://www.nasdaq.com/articles/vertex-pharmaceuticals-kalydeco-wins-positive-eu-opinion-analyst-blog-2014-06-30", "https://www.nasdaq.com/articles/nasdaq-100-movers-regn-gmcr-2014-06-27", "https://www.nasdaq.com/articles/coronado-falls-on-tso-study-results-analyst-blog-2014-06-27", "https://www.nasdaq.com/articles/biodelivery-progresses-with-clonidine-late-stage-study-analyst-blog-2014-06-27", "https://www.nasdaq.com/articles/astrazenecas-olaparib-fails-to-impress-fda-panel-analyst-blog-2014-06-26", "https://www.nasdaq.com/articles/bayer-drugs-get-positive-chmp-recommendation-analyst-blog-2014-06-30", "https://www.nasdaq.com/articles/mckesson-reiterates-fy15-earnings-guidance-analyst-blog-2014-06-26", "https://www.nasdaq.com/articles/hyperions-ravicti-submission-accepted-in-eu-analyst-blog-2014-06-26", "https://www.nasdaq.com/articles/auxilium-sobis-xiapex-filed-for-label-expansion-analyst-blog-2014-06-26", "https://www.nasdaq.com/articles/shire-snubs-abbvie-offer-again-favorable-ruling-for-vyvanse-analyst-blog-2014-06-26", "https://www.nasdaq.com/articles/vertex-pharma-skyrockets-on-cystic-fibrosis-drug-trial-results-analyst-blog-2014-06-25", "https://www.nasdaq.com/articles/bayer-inks-hemophilia-deal-with-dimension-therapeutics-analyst-blog-2014-06-25", "https://www.nasdaq.com/articles/clovis-oncology-initiates-study-on-co-1686-analyst-blog-2014-06-24", "https://www.nasdaq.com/articles/bristol-myers-up-on-nivolumab-news-analyst-blog-2014-06-26", "https://www.nasdaq.com/articles/xenoports-xp23829-in-phase-ii-study-analyst-blog-2014-06-24", "https://www.nasdaq.com/articles/abbvie-raises-outlook-amidst-shire-takeover-attempts-analyst-blog-2014-06-24", "https://www.nasdaq.com/articles/regenerx-and-lees-pharmaceutical-dry-eye-drug-progresses-analyst-blog-2014-06-23", "https://www.nasdaq.com/articles/perrigo-settles-patent-dispute-with-teva-analyst-blog-2014-06-23", "https://www.nasdaq.com/articles/merrimack-falls-steeply-as-sanofi-returns-oncology-drug-rights-analyst-blog-2014-06-23", "https://www.nasdaq.com/articles/nasdaq-100-movers-wfm-dish-2014-06-20", "https://www.nasdaq.com/articles/celgene-rises-on-yet-another-stock-split-analyst-blog-2014-06-20", "https://www.nasdaq.com/articles/forest-laboratories-reports-positive-data-on-viibryd-analyst-blog-2014-06-24", "https://www.nasdaq.com/articles/alnylam-tap-collaborate-for-aat-candidate-analyst-blog-2014-06-20", "https://www.nasdaq.com/articles/alkermes-aripiprazole-lauroxil-looks-promising-analyst-blog-2014-06-19", "https://www.nasdaq.com/articles/biolinerx-to-commence-bl-8040-study-analyst-blog-2014-06-19", "https://www.nasdaq.com/articles/insmed-soars-on-arikayces-breakthrough-designation-analyst-blog-2014-06-19", "https://www.nasdaq.com/articles/alexions-soliris-gets-orphan-drug-status-for-new-indication-analyst-blog-2014-06-18", "https://www.nasdaq.com/articles/vertex-pharmaceuticals-crumbles-on-analyst-worries-analyst-blog-2014-06-17", "https://www.nasdaq.com/articles/celgenes-pomalyst-data-at-european-hematology-association-shows-promise-analyst-blog-2014", "https://www.nasdaq.com/articles/cubist-gets-priority-review-from-fda-for-antibiotic-candidate-analyst-blog-2014-06-20", "https://www.nasdaq.com/articles/celgenes-vidaza-disappoints-in-phase-iii-study-analyst-blog-2014-06-16", "https://www.nasdaq.com/articles/bristol-myers-suffers-a-legal-setback-analyst-blog-2014-06-13", "https://www.nasdaq.com/articles/sanofi-regeneron-present-postive-data-on-sarilumab-analyst-blog-2014-06-13", "https://www.nasdaq.com/articles/exelon-moves-market-cap-rank-passing-regeneron-pharmaceuticals-2014-06-13", "https://www.nasdaq.com/articles/vertex-pharmaceuticals-new-kalydeco-data-out-analyst-blog-2014-06-13", "https://www.nasdaq.com/articles/geron-gains-as-fda-lifts-partial-hold-on-imetelstat-study-analyst-blog-2014-06-13", "https://www.nasdaq.com/articles/encouraging-long-term-data-on-celgenes-otezla-analyst-blog-2014-06-12", "https://www.nasdaq.com/articles/gileads-hcv-combination-therapy-data-looks-promising-analyst-blog-2014-06-16", "https://www.nasdaq.com/articles/eli-lillys-cyramza-misses-primary-goal-liver-cancer-study-analyst-blog-2014-06-12", "https://www.nasdaq.com/articles/bayer-looking-to-expand-eyleas-label-analyst-blog-2014-06-12", "https://www.nasdaq.com/articles/alkermes-progresses-with-its-late-stage-candidate-analyst-blog-2014-06-11", "https://www.nasdaq.com/articles/nps-pharmas-natpara-likely-to-be-reviewed-in-september-analyst-blog-2014-06-11", "https://www.nasdaq.com/articles/immunomedics-immu-132-gets-orphan-drug-status-analyst-blog-2014-06-10", "https://www.nasdaq.com/articles/cubist-pharmas-antibiotics-portfolio-holds-promise-analyst-blog-2014-06-10", "https://www.nasdaq.com/articles/gw-pharma-gets-fast-track-designation-for-epidiolex-analyst-blog-2014-06-09", "https://www.nasdaq.com/articles/orexigen-slumps-as-obesity-drug-approval-delayed-analyst-blog-2014-06-12", "https://www.nasdaq.com/articles/biogens-eloctate-approved-in-the-u.s.-analyst-blog-2014-06-09", "https://www.nasdaq.com/articles/regn-makes-notable-cross-below-critical-moving-average-2014-05-21", "https://www.nasdaq.com/articles/xlf-pth-big-etf-outflows-2014-05-16", "https://www.nasdaq.com/articles/nasdaq-100-movers-regn-gmcr-2014-05-13", "https://www.nasdaq.com/articles/earnings-up-at-jazz-pharma-guidance-reiterated-analyst-blog-2014-05-09", "https://www.nasdaq.com/articles/regeneron-beats-on-earnings-revenues-in-q1-analyst-blog-2014-05-08", "https://www.nasdaq.com/articles/will-regeneron-regn-disappoint-in-q1-earnings-analyst-blog-2014-05-07", "https://www.nasdaq.com/articles/orexigens-upcoming-pipeline-catalyst-analyst-blog-2014-06-09", "https://www.nasdaq.com/articles/regeneron-inks-ophthalmology-deal-analyst-blog-2014-05-06", "https://www.nasdaq.com/articles/sanofi-misses-on-q1-earnings-lackluster-revs-analyst-blog-2014-04-30", "https://www.nasdaq.com/articles/amicus-therapeutics-fold-jumps%3A-stock-up-20.7-tale-of-the-tape-2014-04-30", "https://www.nasdaq.com/articles/gtx-inc.-gtxi-jumps%3A-stock-up-14.4-tale-of-the-tape-2014-04-30", "https://www.nasdaq.com/articles/amicus-up-on-positive-data-analyst-blog-2014-04-30", "https://www.nasdaq.com/articles/regeneron-pharmaceuticals-regn-shares-cross-above-200-dma-2014-04-29", "https://www.nasdaq.com/articles/hyperion-set-to-acquire-andromeda-analyst-blog-2014-04-29", "https://www.nasdaq.com/articles/pre-market-earnings-report-may-8-2014-pcln-vrx-pcp-apa-regn-mga-mpel-hcn-ice-dish-lmca", "https://www.nasdaq.com/articles/progenics-finishes-patient-enrollment-analyst-blog-2014-04-25", "https://www.nasdaq.com/articles/johnson-johnson-boosts-dividend-6.1-analyst-blog-2014-04-25", "https://www.nasdaq.com/articles/emergents-biothrax-gets-orphan-drug-status-analyst-blog-2014-04-24", "https://www.nasdaq.com/articles/alexion-posts-strong-earnings-in-q1-analyst-blog-2014-04-24", "https://www.nasdaq.com/articles/celgene-earnings-grow-year-over-year-in-q1-analyst-blog-2014-04-24", "https://www.nasdaq.com/articles/strong-q1-earnings-at-gilead-on-stellar-sovaldi-sales-analyst-blog-2014-04-23", "https://www.nasdaq.com/articles/cubist-pharma-posts-weak-earnings-on-soft-cubicin-sales-analyst-blog-2014-04-23", "https://www.nasdaq.com/articles/wider-than-expected-q1-loss-at-amag-analyst-blog-2014-04-25", "https://www.nasdaq.com/articles/biogens-q1-earnings-soar-y-y-on-tecfidera-sales-analyst-blog-2014-04-23", "https://www.nasdaq.com/articles/sarepta-soars-on-eteplirsen-submission-plans-analyst-blog-2014-04-22", "https://www.nasdaq.com/articles/nasdaq-100-movers-lltc-yhoo-2014-04-16", "https://www.nasdaq.com/articles/ambit-biosciences-slumps%3A-ambi-falls-13.0-in-session-tale-of-the-tape-2014-04-15", "https://www.nasdaq.com/articles/good-news-for-biomarin-analyst-blog-2014-04-15", "https://www.nasdaq.com/articles/bristol-myers-seeks-approval-for-hiv-combo-drug-analyst-blog-2014-04-15", "https://www.nasdaq.com/articles/repros-completes-enrollment-for-androxal-study-analyst-blog-2014-04-15", "https://www.nasdaq.com/articles/bristol-myers-samsung-biologics-extend-ties-analyst-blog-2014-04-23", "https://www.nasdaq.com/articles/fda-nod-for-mercks-grastek-analyst-blog-2014-04-15", "https://www.nasdaq.com/articles/portolas-betrixaban-study-design-published-analyst-blog-2014-04-15", "https://www.nasdaq.com/articles/another-earnings-beat-from-jj-view-up-analyst-blog-2014-04-15", "https://www.nasdaq.com/articles/nasdaq-100-movers-isrg-regn-2014-04-09", "https://www.nasdaq.com/articles/regn-makes-notable-cross-below-critical-moving-average-2014-04-07", "https://www.nasdaq.com/articles/anacor-enrolls-first-patient-in-study-analyst-blog-2014-03-31", "https://www.nasdaq.com/articles/aegerion-pharmaceuticals-viability-threatened-regulatory-legal-and-market-forces-close", "https://www.nasdaq.com/articles/encouraging-results-from-lexicon-candidate-analyst-blog-2014-04-15", "https://www.nasdaq.com/articles/fda-nod-for-mercks-grastek-analyst-blog-2014-04-15", "https://www.nasdaq.com/articles/ibb-biib-amgn-regn-etf-outflow-alert-2014-03-10", "https://www.nasdaq.com/articles/healthcare-stocks-slipping-near-final-bell-regeneron-sanofi-sink-after-warning-fda-probe", "https://www.nasdaq.com/articles/sector-update-healthcare-2014-03-07-1", "https://www.nasdaq.com/articles/update-on-bayer-regenerons-eylea-analyst-blog-2014-03-05", "https://www.nasdaq.com/articles/sp-500-movers-dri-nem-2014-03-03", "https://www.nasdaq.com/articles/nasdaq-100-movers-vip-regn-2014-03-03", "https://www.nasdaq.com/articles/ibb-biib-amgn-regn-etf-outflow-alert-2014-03-26", "https://www.nasdaq.com/articles/sanofi-ardelyx-ink-deal-analyst-blog-2014-02-25", "https://www.nasdaq.com/articles/nasdaq-100-movers-chtr-intu-2014-02-21", "https://www.nasdaq.com/articles/regeneron-pharmaceuticals-inc-regn-new-analyst-report-zacks-equity-research-zacks-equity", "https://www.nasdaq.com/articles/weekly-insider-sells-highlight-msft-regn-atvi-maa-2014-02-17", "https://www.nasdaq.com/articles/sector-update-healthcare-shares-flat-pre-market-regeneron-rises-2-q4-beat-2014-02-11", "https://www.nasdaq.com/articles/sector-update-healthcare-2014-02-11-0", "https://www.nasdaq.com/articles/market-wrap-february-11-yellen-re-assures-markets-wakes-sleeping-bulls-2014-02-11", "https://www.nasdaq.com/articles/no-looking-back-for-regenerons-eylea-analyst-blog-2014-02-25", "https://www.nasdaq.com/articles/sector-update-healthcare-shares-flat-pre-market-regeneron-rises-4-phase-3-trial-eylea-2014", "https://www.nasdaq.com/articles/sector-update-healthcare-2014-02-10-1", "https://www.nasdaq.com/articles/will-regeneron-regn-disappoint-in-q4-analyst-blog-2014-02-10", "https://www.nasdaq.com/articles/pre-market-earnings-report-february-11-2014-cvs-s-regn-rai-mmc-omc-pcg-hcp-ir-ice-etr-hsic", "https://www.nasdaq.com/articles/healthcare-stocks-still-adding-late-gains-regeneron-pharma-rises-after-positive-2-year", "https://www.nasdaq.com/articles/sector-update-healthcare-2014-02-10-0", "https://www.nasdaq.com/articles/sanofis-q4-earnings-beat-overcast-by-weak-guidance-analyst-blog-2014-02-07", "https://www.nasdaq.com/articles/regeneron-beats-on-earnings-revenues-analyst-blog-2014-02-11", "https://www.nasdaq.com/articles/regeneron-rises-on-upbeat-eylea-q4-outlook-analyst-blog-2014-01-15", "https://www.nasdaq.com/articles/update-on-sanofi-regns-alirocumab-analyst-blog-2013-12-23", "https://www.nasdaq.com/articles/update-on-eylea-analyst-blog-2013-12-23", "https://www.nasdaq.com/articles/bayer-files-for-another-eylea-indication-analyst-blog-2013-11-29", "https://www.nasdaq.com/articles/bayer-progresses-with-eylea-analyst-blog-2013-11-26", "https://www.nasdaq.com/articles/positive-data-on-sanofi-regns-sarilumab-analyst-blog-2013-11-25", "https://www.nasdaq.com/articles/european-shares-mostly-advance-after-strong-german-business-confidence-data-2013-11-22", "https://www.nasdaq.com/articles/linkedin-tripadvisor-google-top-managers-ideas-2014-02-04", "https://www.nasdaq.com/articles/sector-update-healthcare-2013-11-22-0", "https://www.nasdaq.com/articles/bayers-eye-drug-impresses-analyst-blog-2013-11-20", "https://www.nasdaq.com/articles/sector-update-healthcare-shares-flat-pre-market-regeneron-1-q3-earnings-2013-11-05", "https://www.nasdaq.com/articles/sector-update-healthcare-2013-11-05-0", "https://www.nasdaq.com/articles/trade-earnings-regeneron-pharmaceuticals-2013-11-05", "https://www.nasdaq.com/articles/regeneron-beats-both-earnings-and-revs-analyst-blog-2013-11-05", "https://www.nasdaq.com/articles/pre-market-earnings-report-november-5-2013-cvs-emr-d-dtv-trp-regn-ctsh-sre-hca-bdx-hcn", "https://www.nasdaq.com/articles/sector-update-healthcare-shares-mixed-pre-market-isis-1-plans-investigate-muscular-atrophy", "https://www.nasdaq.com/articles/will-amerisourcebergen-abc-disappoint-on-earnings-analyst-blog-2013-10-30", "https://www.nasdaq.com/articles/is-mylan-myl-poised-to-beat-earnings-estimates-analyst-blog-2013-10-29", "https://www.nasdaq.com/articles/will-gilead-gild-disappoint-in-q3-analyst-blog-2013-10-28", "https://www.nasdaq.com/articles/psivida-thoughts-aftermath-complete-response-letter-iluvien-2013-10-20", "https://www.nasdaq.com/articles/positive-data-on-regn-sanofis-drug-analyst-blog-2013-10-16", "https://www.nasdaq.com/articles/top-biotechnology-etf-in-focus%3A-pbe-etf-news-and-commentary-2013-10-04", "https://www.nasdaq.com/articles/new-stock-coverage-exciting-new-chapter-facebook-2013-09-19", "https://www.nasdaq.com/articles/sanofi-misses-on-q3-earnings-analyst-blog-2013-10-31", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-372218-621-points-2013-09-13", "https://www.nasdaq.com/articles/orphan-drug-status-for-aegrs-juxtapid-in-japan-analyst-blog-2013-09-10", "https://www.nasdaq.com/articles/new-stock-coverage-bill-still-come-due-jc-penney-2013-09-04", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-361261-2274-points-2013-09-03", "https://www.nasdaq.com/articles/sector-update-healthcare-shares-higher-pharmacyclics-get-75-mln-milestone-payment-2013-08", "https://www.nasdaq.com/articles/sector-update-healthcare-2013-08-29-1", "https://www.nasdaq.com/articles/good-news-for-regeneron-on-eylea-analyst-blog-2013-08-29", "https://www.nasdaq.com/articles/stock-upgrades-tillys-teenage-dream-2013-09-18", "https://www.nasdaq.com/articles/earnings-beat-at-regeneron-in-q2-analyst-blog-2013-08-06", "https://www.nasdaq.com/articles/earnings-down-outlook-lowered-at-sanofi-analyst-blog-2013-08-06", "https://www.nasdaq.com/articles/sector-update-healthcare-shares-flat-pre-market-endo-healths-q2-earnings-top-street", "https://www.nasdaq.com/articles/sector-update-healthcare-2013-08-06-1", "https://www.nasdaq.com/articles/pre-market-earnings-report-august-6-2013-cvs-emr-d-regn-adm-se-ctsh-sre-hcn-fe-ph-kors", "https://www.nasdaq.com/articles/best-stocks-isis-gilead-celgene-and-regeneron-take-over-top-ranks-2013-07-29", "https://www.nasdaq.com/articles/will-amgen-amgn-beat-earnings-analyst-blog-2013-07-29", "https://www.nasdaq.com/articles/merrimack-undervalued-because-misunderstanding-and-miscommunication-2013-08-15", "https://www.nasdaq.com/articles/evenly-poised-on-regeneron-analyst-blog-2013-06-25", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-344320-down-3898-points-2013-06-19", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-348218-3005-points-2013-06-18", "https://www.nasdaq.com/articles/stock-upgrades-france-likes-what-it-sees-lululemon-2013-06-07", "https://www.nasdaq.com/articles/positive-data-on-bayer-regns-eye-drug-analyst-blog-2013-06-07", "https://www.nasdaq.com/articles/opko-looks-lucrative-acquired-hgh-ctp-moves-phase-iii-trials-2013-06-06", "https://www.nasdaq.com/articles/biogen-idec-inc-biib-todays-most-compelling-stock-buy-2013-07-11", "https://www.nasdaq.com/articles/weekly-top-insider-sells-regn-2013-05-27", "https://www.nasdaq.com/articles/panic-button-when-hit-it-and-why-2013-05-24", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-345942-down-388-points-2013-05-23", "https://www.nasdaq.com/articles/sanofi-regns-dupilumab-data-published-analyst-blog-2013-05-22", "https://www.nasdaq.com/articles/sanofi-regn-commence-enrollment-analyst-blog-2013-05-15", "https://www.nasdaq.com/articles/stock-upgrades-make-mint-julep-jim-beam-ahead-kentucky-derby-2013-05-03", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-337863-3801-points-2013-05-03", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-342405-2257-points-2013-06-06", "https://www.nasdaq.com/articles/ecb-cuts-rates-jobless-claims-hit-new-five-year-low-2013-05-02", "https://www.nasdaq.com/articles/pre-market-earnings-report-may-3-2013-duk-adp-regn-se-mco-hst-swn-iep-nwl-pnw-bpl-lnt-2013", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-329913-down-2966-points-2013-05-01", "https://www.nasdaq.com/articles/market-wrap-wednesday-may-1-stocks-fall-employment-data-weakens-april-2013-05-01", "https://www.nasdaq.com/articles/after-hours-most-active-apr-30-2013-pcs-regn-orcl-fran-qqq-exp-s-msft-vod-bac-ddr-ge-2013", "https://www.nasdaq.com/articles/minyanvilles-t3-morning-market-call-bulls-and-bears-both-have-valid-arguments-2013-04-23", "https://www.nasdaq.com/articles/eylea-drives-earnings-at-regeneron-analyst-blog-2013-05-03", "https://www.nasdaq.com/articles/regeneron-touches-52-week-high-analyst-blog-2013-04-11", "https://www.nasdaq.com/articles/regeneron-rated-neutral-again-analyst-blog-2013-04-10", "https://www.nasdaq.com/articles/regeneron-aims-hq-expansion-analyst-blog-2013-04-08", "https://www.nasdaq.com/articles/regeneron-pharmaceuticals-inc-regn-todays-most-compelling-buy-2013-03-14", "https://www.nasdaq.com/articles/regeneron-to-earn-more-royalty-analyst-blog-2013-03-05", "https://www.nasdaq.com/articles/sanofi-regn-present-dupilumab-data-analyst-blog-2013-03-04", "https://www.nasdaq.com/articles/sanofis-vaccine-backed-by-chmp-analyst-blog-2013-02-26", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-326463-4814-points-2013-04-16", "https://www.nasdaq.com/articles/eylea-drives-regeneron-analyst-blog-2013-02-15", "https://www.nasdaq.com/articles/pre-market-earnings-report-february-14-2013-pep-gm-apa-abx-dtv-cve-ppl-alxn-slf-wm-regn", "https://www.nasdaq.com/articles/sanofi-shows-interest-in-regeneron-analyst-blog-2013-02-12", "https://www.nasdaq.com/articles/sanofis-diabetes-drug-gets-eu-nod-analyst-blog-2013-02-07", "https://www.nasdaq.com/articles/sny-regns-zaltrap-approved-in-eu-analyst-blog-2013-02-06", "https://www.nasdaq.com/articles/safety-data-on-omeros-oms302-analyst-blog-2013-01-23", "https://www.nasdaq.com/articles/regn-predicts-eylea-growth-in-2013-analyst-blog-2013-01-09", "https://www.nasdaq.com/articles/pipeline-progress-at-bayer-regeneron-analyst-blog-2013-02-19", "https://www.nasdaq.com/articles/stock-market-teaches-bad-behavior-2012-12-06", "https://www.nasdaq.com/articles/european-approval-for-eye-drug-eylea-analyst-blog-2012-12-04", "https://www.nasdaq.com/articles/weekly-top-insider-sells-goog-isrg-dg-and-aapl-2012-12-03", "https://www.nasdaq.com/articles/chmp-in-favor-of-sanofis-zaltrap-analyst-blog-2012-11-20", "https://www.nasdaq.com/articles/italy-lifts-ban-on-novartis-vaccines-analyst-blog-2012-11-16", "https://www.nasdaq.com/articles/edward-owens-vanguard-health-care-fund-does-more-shedding-adding-third-quarter-2012-11-01", "https://www.nasdaq.com/articles/allergan-beats-on-eps-updates-view-analyst-blog-2012-10-30", "https://www.nasdaq.com/articles/back-to-neutral-on-bayer-analyst-blog-2012-12-26", "https://www.nasdaq.com/articles/back-to-neutral-on-regeneron-analyst-blog-2012-10-11", "https://www.nasdaq.com/articles/detailed-data-on-sanofis-zaltrap-analyst-blog-2012-10-10", "https://www.nasdaq.com/articles/active-investment-management-2012-09-27", "https://www.nasdaq.com/articles/regeneron-pharma-on-a-high-analyst-blog-2012-09-24", "https://www.nasdaq.com/articles/52-week-high-companies-zmh-cvx-v-regn-dfs-2012-09-10", "https://www.nasdaq.com/articles/regeneron-pharmaceuticals-continuous-loss-making-company-delivers-2-year-600-gain-share", "https://www.nasdaq.com/articles/disciplined-columbia-fund-rallies-mediocre-2011-2012-09-05", "https://www.nasdaq.com/articles/strong-quarter-at-regeneron-analyst-blog-2012-10-29", "https://www.nasdaq.com/articles/back-to-neutral-on-regeneron-analyst-blog-2012-10-11", "https://www.nasdaq.com/articles/good-news-for-regeneron-sanofi-analyst-blog-2012-08-06", "https://www.nasdaq.com/articles/top-performing-funds-latch-biotech-and-discount-retail-stocks-2012-08-02", "https://www.nasdaq.com/articles/regeneron-gets-crl-analyst-blog-2012-07-31", "https://www.nasdaq.com/articles/biotechs-motion-new-drug-pipeline-brims-2012-07-27", "https://www.nasdaq.com/articles/regeneron-tops-lifts-eylea-view-analyst-blog-2012-07-26", "https://www.nasdaq.com/articles/allergan-molecular-extend-contracts-analyst-blog-2012-08-23", "https://www.nasdaq.com/articles/52-week-high-companies-bam-regn-trv-wfc-2012-08-20", "https://www.nasdaq.com/articles/sp-not-all-mid-cap-etfs-created-equal-mdy-vo-2012-07-05", "https://www.nasdaq.com/articles/eylea-drives-regeneron-to-profit-analyst-blog-2012-04-27-0", "https://www.nasdaq.com/articles/priority-review-for-zaltrap-analyst-blog-2012-04-05", "https://www.nasdaq.com/articles/still-neutral-on-ardea-biosciences-analyst-blog-2012-04-04", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-regeneron-pharmaceuticals-sanofi-pfizer-bayer-and", "https://www.nasdaq.com/articles/pipeline-progress-at-regeneron-analyst-blog-2012-03-29", "https://www.nasdaq.com/articles/regeneron-pharmaceuticals-regn-bull-of-the-day-2012-07-24", "https://www.nasdaq.com/articles/encouraging-data-on-amgen-candidate-analyst-blog-2012-03-27", "https://www.nasdaq.com/articles/australian-clearance-for-eye-drug-eylea-analyst-blog-2012-03-09", "https://www.nasdaq.com/articles/regeneron-treads-the-neutral-path-analyst-blog-2012-02-22", "https://www.nasdaq.com/articles/look-mid-caps-market-beating-returns-2012-02-20", "https://www.nasdaq.com/articles/regn-projects-strong-q4-eylea-sales-analyst-blog-2012-01-13", "https://www.nasdaq.com/articles/regeneron-settles-dispute-analyst-blog-2012-01-04", "https://www.nasdaq.com/articles/regenerons-eylea-data-unimpressive-analyst-blog-2011-12-07", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-amgen-sanofi-regeneron-alnylam-and-coach-press-releases", "https://www.nasdaq.com/articles/regeneron-bayer-initiate-study-analyst-blog-2011-11-28", "https://www.nasdaq.com/articles/regeneron-seeks-label-expansion-analyst-blog-2011-11-25", "https://www.nasdaq.com/articles/regeneron-drug-cleared-in-the-us-analyst-blog-2011-11-21", "https://www.nasdaq.com/articles/investing-101-momentum-stocks-insider-buying-2011-09-20", "https://www.nasdaq.com/articles/fda-watch-6-biotechs-awaiting-fda-drug-approvals-2011-2011-09-08", "https://www.nasdaq.com/articles/hearty-profits-companies-racing-develop-next-big-cholesterol-drug-2011-08-30", "https://www.nasdaq.com/articles/investing-101-finding-rallying-stocks-still-undervalued-analyst-estimates-2011-08-17", "https://www.nasdaq.com/articles/company-news-for-december-6-2011-corporate-summary-2011-12-06", "https://www.nasdaq.com/articles/reporting-week-billion-dollar-companies-insider-buying-2011-07-26", "https://www.nasdaq.com/articles/how-regeneron-trade-provides-protection-2011-07-25", "https://www.nasdaq.com/articles/5-rallying-biotech-stocks-being-snapped-insiders-2011-02-24", "https://www.nasdaq.com/articles/us-stock-indexes-lower-chinas-surprise-interest-rate-hike-east-coast-storm-snarls-air", "https://www.nasdaq.com/articles/mid-day-update-stocks-lower-chinas-interest-rate-move-east-coast-blizzard-drive-lackluster", "https://www.nasdaq.com/articles/stocks-mixed-mid-day-investors-seek-direction-shortened-trading-week-2010-12-20", "https://www.nasdaq.com/articles/mid-day-update-stocks-mixed-optimism-tax-cut-fades-euro-debt-weighs-2010-12-20", "https://www.nasdaq.com/articles/top-10-list-unusual-option-activity-2011-08-16", "https://www.nasdaq.com/articles/mid-day-update-stocks-trending-lower-ireland-remains-investor-focus-through-sessions-first", "https://www.nasdaq.com/articles/amgen-celgene-and-novartis-fight-against-pancreatic-cancer-2010-10-26", "https://www.nasdaq.com/articles/bull-extends-regeneron-position-2010-10-26", "https://www.nasdaq.com/articles/stocks-lower-ireland-worries-wall-street-insider-trading-probe-2010-11-22"], "Content": []}